heart failure ( class l - lll ),C0018801;C0018802;C4554158,0/10465
duration of hypertension  n ( % ),C0449238;C0449238;C2926735;C2926735,1/10465
type nmbr diabetes 一 no . ( % ),,2/10465
tofacitinib nmbr mg bid [n = nmbr |,C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696,3/10465
high - density lipoprotein cholesterol mean ( mg / dl ± sd ),,4/10465
temporary discontinuation of study drug,C0205374;C0205374;C0205374;C1548539;C1548539;C1548539;C3245481;C3245481;C3245481,5/10465
death  mi  idr  st  or any timi bleeding,C0011065;C1306577;C4082313;C4552775,6/10465
race and ss at baseline,C0034510;C1706779;C3853635,7/10465
high intensity,C4081854,8/10465
prior percutaneous coronary intervention  n ( % ),C0332152;C2826257,9/10465
pre - randomization pci,C0332152;C0740175;C2257086;C3669034,10/10465
p  subgroup *,C0369773;C2603361,11/10465
hosji fcrhypoglycemia,,12/10465
apixaban vs . placebo,C1831808,13/10465
medication use — no . ( % ),,14/10465
second prior mi,C0205436;C0205436;C0457385;C0457385;C0565930;C0565930;C1561503;C1561503;C1705190;C1705190,15/10465
subarachnoid hemorrhage,C0038525,16/10465
total invasive cancer,C0439175;C0439810,17/10465
acute stent thrombosis,C0205178,18/10465
alteplase ( n = nmbr ),C0032143,19/10465
relative decrease > nmbr %,C0080103;C0080103;C0205345;C0205345;C1547039;C1547039,20/10465
nmbrth - nmbrth percentiles,C1264641,21/10465
number of ( % ) females,C0237753;C0449788,22/10465
emphysema ( % ),C0013990;C0034067,23/10465
argentina,C0003761;C1504311,24/10465
ccq score § §,,25/10465
vents / patients,C0030705,26/10465
number of patients with,C2360800,27/10465
concomitant mtx —,,28/10465
europe / lsrael,C0015176,29/10465
thromboaspiration — no . ( % ),,30/10465
cardiac - biomarker status — no . / total no . ( % ) $,,31/10465
receiving insulin therapy,C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756;C1514756,32/10465
pulmonary embolism ± deep vein thrombosis,,33/10465
abdominal or perianal fistula at baseline  n ( % ),C0000726,34/10465
cyclosporine ( n = nmbr ),C0010592;C0010594,35/10465
geographic region - europe,C0017446,36/10465
indian ( indian subcontinent ),C1524069,37/10465
percutaneous coronary intervention,C1532338,38/10465
antiplatelet or anticoagulant therapy,,39/10465
lesion length  mean ( sd )  mm,C0221198;C0221198;C1546698;C1546698,40/10465
non - q wave,C1518422;C1518422,41/10465
continued thienopyridine n = nmbr subjects,C0549178,42/10465
weight ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0005910;C0043100;C1305866;C1705104,43/10465
left ventricular ejection fraction  % af history,C0428772;C0488728,44/10465
single - vessel disease  n ( % ),C0037179;C0087136;C0205171,45/10465
geographic region — no . ( % ),,46/10465
pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657,47/10465
bmi > nmbr kg / mnmbr ( % ),C0578022,48/10465
total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439175;C0439810;C0439810,49/10465
fatigue,C0015672;C3463815;C4050243;C4554645,50/10465
nmbr to < nmbr kg / mnmbr,C0053917;C1334884,51/10465
st - elevation mi,C0520886,52/10465
azathioprine ( n = nmbr ),C0004482,53/10465
serum uric acid ( mg / dl ),C0455272;C0700634,54/10465
baseline mean ( sd )  % [mmol / mol],C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,55/10465
cv death  ml  or stroke,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,56/10465
atenolol ( « = nmbr nmbr ),,57/10465
previous antiarrhythmic treatment — no . ( % ),,58/10465
drugs used in diabetes  n ( % ),C0013227;C3687832,59/10465
after pci,C4049621,60/10465
secukinumab,C3179547,61/10465
mean a ± sem ( % ),,62/10465
ppi but no aspirin,C0358591;C0871125;C3811894,63/10465
nmbr mg / kg ( n = nmbr ),C0053917;C1334884,64/10465
family history of cad ( diagnosed at < nmbr yr of age ) — no . ( % ) cigarette smoker — no . ( % ),,65/10465
trend / het . test,C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C1521798;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533;C4554533,66/10465
cv death + hf hospitalization,C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503,67/10465
mepolizumab  nmbr mg ( n = nmbr ),C0969324,68/10465
medical therapy only ( n = nmbr ),C0418981;C0418981,69/10465
caucasian ethnicity,C0007457;C0007457;C0043157;C0043157,70/10465
crcl at baseline < nmbr ml / min,C1846718;C1846718,71/10465
elevated hscrp > nmbr mg / l  n ( % ),C0205250;C3163633,72/10465
seizure types reported during baseline  n ( % ) a,C0036572;C1959629;C4553401,73/10465
median total cholesterol  mmol / l,C0549183;C0549183;C0876920;C0876920;C2347635;C2347635;C2348144;C2348144;C2939193;C2939193,74/10465
mean ± sd bmi  kg / mnmbr,,75/10465
first mace,C0205435;C0205435;C0205435;C1279901;C1279901;C1279901,76/10465
disease duration nmbr to bnmbr years ( n = nmbr ),C0872146;C0872146,77/10465
history of amputation — no . ( % ),,78/10465
lipid - lowering medication ( % ),C0023779;C0023779;C0023779;C0023779;C0023779;C0023779,79/10465
previous hf hospitalization  n ( % ),C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,80/10465
mean lipid values  mg / dl,C0444504;C2347634;C2348143,81/10465
prior years taking warfarin,C0332152;C2826257,82/10465
bnp  median ( iqr )  pg / ml,C0054015;C1095989;C1417808;C2982014,83/10465
hbanmbrca  % ( mmol / mol ),,84/10465
latin america hr ( nmbr % cl ),C0023122,85/10465
current atrial fibrillation or flutter on ecg,C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,86/10465
invasive,C0205281;C1334278,87/10465
estimated glomerular filtration,C0750572,88/10465
pasi score ! * *,C4528685;C4528685,89/10465
amiodarone  n ( % ),C0002598,90/10465
american indian or alaska,C0002460,91/10465
pooled simvastatin factorial studies,C1709595;C2349200;C4522255,92/10465
implantable cardioverter - defibrillator,C0162589;C2825184,93/10465
varespladib ( n = nmbr ),C2713485,94/10465
acute coronary event,C0205178,95/10465
ntpro - cnp ( ng / ml ),C3889729,96/10465
useofmedical therapyathospitaldischarge,,97/10465
coenzyme qnmbr  ^g / ml #,C0009235,98/10465
dyspnoea - mmrc grade  n ( % ),C0013404;C0013404;C0013404;C1963100;C1963100;C1963100,99/10465
triglycerides — mmol / liter,,100/10465
baseline ecrcl,C0168634;C1442488,101/10465
cardiovascular history,C1880008,102/10465
with placebo ( n nmbr nmbr ),C0032042;C1696465;C1706408,103/10465
cardiovascular medications,C0007220,104/10465
after bronchodilation,C1371299;C3537072,105/10465
mean nmbrmwd *  m ( sd ),C0444504;C2347634;C2348143,106/10465
angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C2757044,107/10465
medication taken alone or in combination,C0013227;C3244316;C4284232,108/10465
etoricoxib dose,C0972314;C0972314;C0972314,109/10465
ischemic cerebrovascular disease  n ( % ),C0475224,110/10465
bare metal stent  n ( % ),C2825200,111/10465
mean age ( years ) ( s . d . ),C0444504;C2347634;C2348143,112/10465
dasnmbr ( esr )  mean ( sd ),,113/10465
absolute  litres,C0205344,114/10465
wml load at follow - up mri,C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715,115/10465
clopidogrel ( n = nmbr  nmbr ),C0070166,116/10465
ancestry ( % ) f,,117/10465
no p - blocker intake at randomisation ( n = nmbr ),C0369773;C2603361,118/10465
valsartan / hctz  n / n ( % ),C0216784,119/10465
> nmbr oral agents,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,120/10465
total chol  mg / dl,C0439175;C0439810,121/10465
calcium channel blockers  n ( % ),C0006684;C2757014,122/10465
bsa > nmbr %  n ( % ) t,,123/10465
benralizumab nmbr mg qnmbrw ( n = nmbr ),C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078;C2982078,124/10465
blood pressure  mean ( sd ) [range]  mm hg,C0005823;C1271104;C1272641,125/10465
atenolol n = nmbr,C0004147,126/10465
type of mi ( % ),C0332307;C1547052,127/10465
mtx + non - mtx,C0025677;C1417487,128/10465
concomitant corticosteroid use  n ( % ),C0521115,129/10465
estimated glomerular filtration rate ( mdrd )  ml / min / nmbr . nmbrmnmbr,C3811844,130/10465
mild impairment ( nmbr to < nmbr ),C2945599;C2945599,131/10465
years since menopause,C0439234,132/10465
major cvd /,C0205082;C0205164;C4318856;C4521762,133/10465
medical therapy ( n = nmbr ),C0418981,134/10465
no . of tnfi among non - tnfi naive,,135/10465
use of ace inhibitor,C1524063;C1524063,136/10465
haemorrhagic,C0333275,137/10465
stroke ( vs tia ),C0038454;C4554100,138/10465
detemir / insulin glargine  %,C0537270,139/10465
screening prebronchodilator fevnmbr  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,140/10465
stent plus placebo,C0038257;C0038257;C0038257,141/10465
coronary revascularization nmbr days after randomization,C0877341;C0877341,142/10465
sacubitril / valsartan,C4033631,143/10465
no . of prior bdmards,,144/10465
mean prebronchodilator fevnmbr ( sd )  % predicted,C0444504;C2347634;C2348143,145/10465
paracetamol,C0000970,146/10465
aspirin / other antiplatelet agents  n ( % ),C0004057,147/10465
randomized to receive beta carotene,C0034656;C3815594,148/10465
bsa  % *,,149/10465
erosion score,C0333307;C0333307;C1880549;C1880549;C1959609;C1959609;C3887524;C3887524,150/10465
peripheral arterial disease  n ( % ),C0085096;C1704436,151/10465
primary end point  no . of events / total no . ( % ),C2986535,152/10465
lvdd ( mm ),,153/10465
draining cutaneous fistula at baseline  n ( % ),C0013103;C0180499;C4265177,154/10465
tg < nmbr  hdl > nmbr ( n = nmbr ),C0337445,155/10465
comorbidities other than diabetes,C0009488;C0009488,156/10465
toast classification of qualifying stroke,C1710306;C1710306;C4521230;C4521230,157/10465
rasagiline  nmbr mg / day,C0525678,158/10465
metabolic syndromenmbr baseline lipids  mg / dl,C0311400;C0311400;C1524026;C1524026;C2707259;C2707259,159/10465
crude analysis  n ( % ),C0002778;C0936012;C1524024,160/10465
bypass surgery,C1536078,161/10465
missing — number / n ( % ),,162/10465
cholesterol  ( . nmbr . nmbr mmol / l )  n ( % ),C0008377,163/10465
right coronary,C0225808,164/10465
health habits,C0679786,165/10465
blood pressure,C0005823;C1271104;C1272641,166/10465
homa . % b  median ( ql  qnmbr )  %,,167/10465
severity of copd  ( gold nmbr )  %,C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,168/10465
prior myocardial infarction,C0155668,169/10465
both ptca and cabg,C2936173,170/10465
major cerebrovascular,C0205082;C0205164;C4318856;C4521762,171/10465
hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr  nmbr . nmbr ),C2985465,172/10465
diastolic blood pressure ( mm hg ) medications,C0428883;C1305849,173/10465
iglar dose at randomization ( u / day ),C0178602;C0869039;C1114758,174/10465
prior cv event at randomization !,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,175/10465
mean ± sd waist circumference  cm,,176/10465
risk of bleeding,C3251812,177/10465
cv medication  % of patients,C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503,178/10465
total updrs score ( range  nmbr - nmbr ) 卞,,179/10465
atrial fibrillation  duration — no . ( % ),,180/10465
known duration of diabetes  yr,C0205309;C0205309;C0205309;C0205309,181/10465
nmbr % < hbanmbrc < = nmbr %,C0053917;C1334884,182/10465
dactylitis count,C0239161;C0239161,183/10465
previous disease :,C0205156;C1552607,184/10465
previous dmards use  n ( % ),C0205156;C1552607,185/10465
gly nmbr . nmbr gg b . i . d n / n ( % ),C1415124;C1415124;C1415124;C1415124,186/10465
previous percutaneous coronary intervention,C0205156;C1552607,187/10465
unfractionated heparin before randomisation,C0019134;C2825026,188/10465
oad plus insulin,C0021641;C1533581;C1579433;C3714501,189/10465
diabetes with target organ disease *,C0011847;C0011847;C0011849;C0011849,190/10465
unknown type,C0439673;C0439673;C3541433;C3541433;C4050014;C4050014,191/10465
beta - blocker — no . ( % ),,192/10465
cognitive functioning,C0392334;C0392335,193/10465
( % ) nmbr - nmbr,,194/10465
history of hyperlipidemia ( % ),C4695788,195/10465
evenls per nmbr  nmbr palienl - years,C0053917;C1334884,196/10465
fasting free fatty acids ( ^mol / liter ),C0015663,197/10465
treatment after admission,C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,198/10465
rarertd antocagibtcn before andorrtzafon,,199/10465
intestinal area involved  n ( % ) $,C0021853;C0021853,200/10465
ethnicity ( % ),C0015031;C0243103,201/10465
all cardiovascular,C0007226;C3887460,202/10465
smoking in the past year,C0037369;C0453996;C1881674,203/10465
diskus only  n,C1553480;C1553480,204/10465
jsn score  mean nmbr sd,C0449820;C4050231,205/10465
number omega - nmbr number placeb fatty acid,C0237753;C0237753;C0449788;C0449788,206/10465
high - intensity statin vs medium - or low - intensity statin at randomization,C4081854,207/10465
score on nih stroke scale — median ( iqr ),,208/10465
initiation of insulin,C0589507;C0589507;C0589507;C0589507;C1158830;C1158830;C1158830;C1158830;C1704686;C1704686;C1704686;C1704686,209/10465
nmbrnd > nmbr . nmbr / < nmbr . nmbr,,210/10465
cad and abi < nmbr - nmbr §,,211/10465
pioglitazone events / n ( % ),C0071097;C0071097,212/10465
acecoumarol  no . ( % ),,213/10465
cigarette users,C0677453;C1704760;C3890423,214/10465
gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr ),C0017654;C1424601,215/10465
bmi ( kg / mnmbr ) cardiac parameters,C0578022,216/10465
ace inhibitor or arb at last follow - up,C0003015;C4541021,217/10465
blood urea nitrogen ( mg / dl ),C0005845;C0600137,218/10465
grip strength ( kg ),C0429271;C2598165,219/10465
current smoker — no . of patients ( % ),,220/10465
one - third radius,C0205447;C0205447,221/10465
psychosocial risk factors,C0033963;C0033963;C0542298;C0542298;C1458132;C1458132,222/10465
bursitis,C0006444,223/10465
non - hdl - c in nmbr classes,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,224/10465
family history ol diabetes ?,C1313937,225/10465
age ( years ) : nmbr - < nmbr,C0001779,226/10465
digital clubbing  n ( % ),C0009080;C0149651,227/10465
death or myocardial infarction,C0011065;C1306577;C4082313;C4552775,228/10465
risk reduction  %,C1137094,229/10465
a mini - mental state examination  omega - nmbr fatty acids vs placebo,C0451306,230/10465
pain vas  nmbr - nmbr mm,C0042815,231/10465
smoking : ex - smoker,C0037369;C0453996;C1881674,232/10465
statin treatment,C0360714;C0360714;C0360714;C0360714;C0360714;C0360714;C0360714,233/10465
pre - bronchodilator fevnmbr / fvc ratio *,C2599602;C2599602,234/10465
prior stroke or transient ischemic attack,C0332152;C0332152;C2826257;C2826257,235/10465
czp nmbr mg ( n nmbr nmbr ),C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,236/10465
microvascular eye diseased,C0443258;C0443258,237/10465
extent of disease  %,C0449279;C4553144,238/10465
mean ( nmbr % ci ) difference vs saxa + dapa + met,C0444504;C2347634;C2348143,239/10465
urgent coronary revascularization,C0439609;C3272275,240/10465
caucasian simva,C0007457;C0043157,241/10465
full analysis set,C0443225;C0443225;C0443225;C0443225;C0443225;C0443225;C0443225;C0443225;C0443225,242/10465
serious ae,C0205404,243/10465
smoking history ( ever ),C1519384,244/10465
uncodable,,245/10465
no pah therapy,C0030123;C0030123;C0030123;C3203102;C3203102;C3203102;C4284467;C4284467;C4284467,246/10465
standard ( n = nmbr ),C1442989;C2828392,247/10465
patent foramen ovale,C0016522;C0344724,248/10465
laboratory values,C0022877;C3244292;C4283904,249/10465
years  mean ( sd ),C0439234,250/10465
hscrp < nmbr . nmbr mga . nmbr ( nmbr . nmbrxnmbr ( nmbr . nmbr ),,251/10465
physician ' s judgment that vka,C0031831;C0804815,252/10465
calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885,253/10465
left ventricular hypertrophy ( % ),C0149721;C3484363,254/10465
randomized to aspirin use,C0034656;C0034656;C0034656;C3815594;C3815594;C3815594,255/10465
antihypertensive  antianginal  and other cardiovascular medications,C0003364;C0003364,256/10465
glp - nmbr receptor agonist ( other than study drug ),C0018301;C0018301;C1422069;C1422069;C1425391;C1425391;C1539338;C1539338;C2350813;C2350813,257/10465
primary renal endpoint or death,C2986535,258/10465
metabolic syndrome characteristics  n ( % ),C0524620,259/10465
mean duration of disease  years,C0444504;C2347634;C2348143,260/10465
other oral hypoglycemic drug ( s ),C0359086,261/10465
> nmbr additional cv risk factorsnmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,262/10465
pancolitis,C0868908,263/10465
death from any cause,C0007465,264/10465
high - density lipoprotein cholesterol  mg / l,C0023822,265/10465
diabetes mellitus status,C1317301,266/10465
fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),C0016017;C0016017;C0016017;C1305868;C1305868;C1305868,267/10465
stool frequency subscore,C0015733;C0015733;C0015733;C0015733;C0015733;C0015733;C0015733;C0183622;C0183622;C0183622;C0183622;C0183622;C0183622;C0183622,268/10465
psap - b ( ng / ml ),C1418975;C1420002;C1425004,269/10465
no use of nmbr - asa compounds,C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063,270/10465
visit nmbr ldl cholesterol strata,C0545082;C0545082;C0545082;C0545082;C1512346;C1512346;C1512346;C1512346;C2826704;C2826704;C2826704;C2826704,271/10465
endothelin nmbr ( pg / ml ),C0079284;C0079284,272/10465
normal ( egfr > nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972,273/10465
py = nmbr . nmbr ),C0030428;C3538810,274/10465
fibrinogen,C0016006;C1167394;C2587184;C3540039,275/10465
total haq  nmbr - nmbr,C0439175;C0439175;C0439810;C0439810,276/10465
mean baseline ibdq score ( sd ) § crp concentration  mg / l,,277/10465
dipyridamole,C0012582,278/10465
aspirin and other antiplatelet,C0004057,279/10465
positive,C0439178;C1446409;C1514241;C2825490;C3812269,280/10465
age [years] ( interaction : p = nmbr . nmbr ),C0001779,281/10465
decreased appetite,C0232462,282/10465
beta - blocker ( except sotalol ),C0001645,283/10465
geometric mean crp concentration ( mg / l ),C2986759;C2986759;C2986759;C2986759;C2986759;C2986759,284/10465
duration of morning,C0449238;C2926735,285/10465
hr ( enl vs lcz ) ( nmbr % cl ),,286/10465
rf positive — number ( % ),,287/10465
selected medications — no . ( % ),,288/10465
no peripheral revascularization ( n = nmbr  nmbr ),C0205100,289/10465
white / european,C0007457;C0007457;C0043157;C0043157;C0220938;C0220938,290/10465
at least nmbr flare,C0053917;C0053917;C1334884;C1334884,291/10465
time to admission  min,C3854258;C3854259,292/10465
octave sustain,,293/10465
lm bifurcation not treated,C1261082;C1261082;C1551056;C1551056,294/10465
radial access,C0442038;C0442038;C0920847;C0920847,295/10465
history of peripheral artery disease,C0683519;C0730226;C0850708;C0944983,296/10465
baseline fev  ( l ),C0168634;C1442488,297/10465
combined trials,C0205195,298/10465
negative,C0205160;C1513916;C2825415;C2825491;C3853545,299/10465
severe dysfunction,C3274777,300/10465
fasting c - peptide  ng / ml,C0015663,301/10465
aggressive ( n = nmbr ),C0001807;C0580822,302/10465
aldosterone blocker  %,C0002006,303/10465
management of event — no . ( % ),,304/10465
> nmbrmg / dl chd status,C3642216;C3642216,305/10465
serum albumin  g nmbr nmbr,C0036773;C0728877,306/10465
intraperitoneal,C0442120,307/10465
headache,C0018681;C4553197,308/10465
left main artery,C0205091;C0205091;C0205091;C0205091;C0443246;C0443246;C0443246;C0443246;C1552822;C1552822;C1552822;C1552822,309/10465
> nmbr to < nmbr egfr  ml / min / nmbr . nmbr mnmbr a,C0053917;C1334884,310/10465
established,C0443211;C1272684,311/10465
gender ( % ) male / female,C0079399;C1522384,312/10465
chondroitin sulfate ( n = nmbr ),C0008466,313/10465
unstable angina ( biomarker negative ),C0002965,314/10465
american indian or native alaskan,C0002460,315/10465
symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878,316/10465
age ( years ) [median ( nmbrth to nmbrth percentile ) ],C0001779,317/10465
formoterol nmbr gg bid,C0060657;C0060657;C0060657;C0060657,318/10465
race or ethnic group ( % ),C0034510;C1706779;C3853635,319/10465
dihydropyridine,C0012315;C0220821,320/10465
canakinumab,C2718773,321/10465
lev status  n ( % ),C0023556,322/10465
steroids § §,,323/10465
normal / mild ckd,C0205307;C0231683;C0439166;C2347086;C4553972,324/10465
number of stent = nmbr,C0237753;C0449788,325/10465
previous medications  n ( % ),C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,326/10465
nyha class nmbr - nmbr : no { n = llll ),C1882083;C1882083,327/10465
tofacitinib nmbr mg twice daily n = nmbr,C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696,328/10465
verapamil sr n = nmbr no . ( % ),C1527129,329/10465
no prior ml or stroke,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,330/10465
stent length per lesion  mm,C0038257;C0038257;C0038257;C0038257,331/10465
chf history,C0018802;C0018802;C0018802;C0018802;C0018802;C0018802,332/10465
anti - ccp antibody positive,C4318437,333/10465
oral medications,C0304289,334/10465
no antidiabetic drug,C0935929,335/10465
tofacitinib nmbr mg two times a day,C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696,336/10465
no . of nmbr - mg acetaminophen tablets / day,,337/10465
acpa positive  %,C1525410;C1525410;C1525410;C1525410;C1525410;C1706063;C1706063;C1706063;C1706063;C1706063,338/10465
timi major / minor,C4441842,339/10465
severity of airflow limitation ( gold nmbr - nmbr )  n ( % ),C0439793;C0439793;C0522510;C0522510,340/10465
pooled simva,C1709595;C2349200;C4522255,341/10465
timi risk score — no . ( % ) : t,,342/10465
baseline dyspnea index  mean total score,C1511069,343/10465
number ( % ) of patients with event,C0237753;C0449788,344/10465
atrial fibrillation onset,C0004238;C0004238;C0344434;C0344434;C1963067;C1963067,345/10465
infarct characteristics,C0021308,346/10465
caucasian simva ( „ = nmbr },,347/10465
ticagrelor nmbr mg nmbr yr km %,C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375,348/10465
galectin - nmbr ( ng / ml ),C0607430;C0607430,349/10465
hctz = hydrochlorothiazide . * based on wilcoxon nmbr - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / nmbr tests for categorical variables . t data were missing for some patients .,C0020261,350/10465
nmbr mg clopidogrel load,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,351/10465
intravenous dobutamine,C0348016,352/10465
family history of diabetes — no . ( % ),,353/10465
primary prevention subgroup,C0033144;C0033144,354/10465
telmisartan ( n = nmbr  nmbr ),C0248719,355/10465
ppi use ( p = nmbr - nmbrt ),C0358591;C0358591;C0358591;C0871125;C0871125;C0871125;C3811894;C3811894;C3811894,356/10465
large mi,C0549177,357/10465
never / rarely,C2003901,358/10465
medication adherence,C2364172,359/10465
no concomitant cortcosteroid use,C0521115;C0521115;C0521115,360/10465
severity of hypertensionb,C0439793;C0522510,361/10465
clopidogrel  %,C0070166,362/10465
fevnmbr percent predicted ( sd ),C0439165,363/10465
antidiabetic medication | |,C0935929,364/10465
gad positive — no . ( % ) ^,,365/10465
intravenous vasodilators ( % ),C0443081,366/10465
european trial,C0239307;C1535514,367/10465
systemic corticosteroid use,C4053960;C4053960;C4053960;C0205373,368/10465
weight  median ( interquartile range )  kg,C0005910;C0043100;C1305866;C1705104,369/10465
indacaterol nmbr ug versus placebo,C1722260;C1722260;C1722260;C1722260,370/10465
crohn ’ s disease related surgery,,371/10465
peripheral arterial disease — no . ( % ) §,,372/10465
mases ( nmbr - nmbr )  mean ( sd ),,373/10465
duration of coronary artery disease — yr,,374/10465
hbanmbrc  mean ( sd )  % [mmol / mol],,375/10465
total cholesterol ( week nmbr ),C0201950;C0543421,376/10465
at least nmbr severe flare,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,377/10465
baseline / concomitant therapies,C0168634;C1442488,378/10465
chd eze / simva ( n = nmbr],C0280604;C3542407,379/10465
heart failure criteria met,C0018801;C0018802;C4554158,380/10465
left atrial diameter,C0225860;C0225861,381/10465
pulmonary function tests  % of predicted,C0024119;C2598152,382/10465
other nsaids,C0003211,383/10465
rheumatic heart disease,C0035439,384/10465
coronary angiography and intervention,C0085532;C1548829,385/10465
time of qualifying ecg to balloon inflation ( hrs ),C0040223;C3541383,386/10465
time from symptoms to treatment,C0040223;C0040223;C3541383;C3541383,387/10465
ratio fp / sal : sal ( nmbr % ci ),C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C0456603;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037;C1547037,388/10465
coexisting conditions — no . ( % ),,389/10465
clopidogrel  ticlopidine  or prasugrel,C0070166,390/10465
crp ( mg / dl ) < nmbr . nmbr,C3890735;C4048285,391/10465
mean ± s . d . duration of diabetes  years,,392/10465
russia / georgia ( n = nmbr ),C0035970;C0035970,393/10465
fatal and nonfatal ml,C1302234;C1705232,394/10465
hypertension ( n 二 nmbr ),,395/10465
cv event  years,C3538987;C3538987;C4048877;C4048877;C4318503;C4318503,396/10465
oxidative stress,C0242606,397/10465
age ( yrs ) < nmbr,C0001779,398/10465
no . of previous anti - tnf drugs — no . ( % ),,399/10465
< nmbr . nmbr mmol / liter apob : apoa - l ratio,C0053917;C0053917;C1334884;C1334884,400/10465
former smoker  n ( % ),C0337671,401/10465
less than nmbr %,C0439092;C0439092,402/10465
hispanic ( n = nmbr ),C0086409,403/10465
ischemic tvr,C0475224,404/10465
any albuminuria — no . ( % ),,405/10465
baseline ics use  n ( % ),C0168634;C0168634;C1442488;C1442488,406/10465
bosentan ( n = nmbr ),C0252643,407/10465
nitrates ( oral or topical ),C0028125,408/10465
left - sided disease only,C3842976,409/10465
third heart sound  n ( % ),C0232237;C0232278,410/10465
other antiarrhythmics^,C0003195,411/10465
psa duration  years,C3810537;C3810537;C3813209;C3813209,412/10465
low molecular weight ( lmw ) heparin before randomisation,C0019139;C3536766,413/10465
interval study drug to pci,C1272706;C1552654;C1552713,414/10465
atrial fibrillation / atrial flutter  %,C0155709,415/10465
anmbr + ez n = nmbr,C0206578,416/10465
initial aspirin — no . ( % ),,417/10465
symbol digit score,C0679214;C0679214;C0679214;C0679214;C1698987;C1698987;C1698987;C1698987,418/10465
time from qualifying event to randomization,C0040223;C0040223;C3541383;C3541383,419/10465
serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472,420/10465
pav  mean ( nmbr % ci ),C0058890,421/10465
events treatment ( nmbr ),C0441471;C0441471;C0441471;C0441471;C0441471;C0441471;C0441471;C3541888;C3541888;C3541888;C3541888;C3541888;C3541888;C3541888,422/10465
annt or bnnh ( nmbr % ci ),,423/10465
geographic region  %,C0017446,424/10465
drug - related teaesnmbr,C0013227;C0013227;C1254351;C1254351,425/10465
atorvastatin dose,C0286651;C0286651;C0286651,426/10465
ldl - cihdl - c  mean ( sd ),,427/10465
prior biologic therapy ( including anti - tnfs ),C0278947,428/10465
left ventricular ejection fraction within previous nmbr mo |,C0428772;C0428772;C0428772;C0428772;C0428772;C0428772;C0428772;C0428772;C0488728;C0488728;C0488728;C0488728;C0488728;C0488728;C0488728;C0488728,429/10465
cabg or pci,C0010055,430/10465
ace inhibitor monotherapy,C0003015;C4541021,431/10465
treated with cabg — no . / total no . ( % ),,432/10465
psoriatic arthritis pain],C4317006;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872;C0003872,433/10465
erythrocyte sedimentation rate — mm / hr | |,,434/10465
dose of aspirin,C4696290,435/10465
p - val . ( nmbr ),C0369773;C0369773;C2603361;C2603361,436/10465
small - artery occlusion ( lacune ),C0226001;C0226001;C0226001;C0226001;C0226001;C0226001;C0700321,437/10465
atorvastatin  n ( % ),C0286651,438/10465
baseline heart rate,C0168634;C1442488,439/10465
apo b ( mg / dl ) - mean ± sd,,440/10465
peak procedural act — sec,,441/10465
extended - duration enoxaparin  n / n ( % ),C0231448;C0231449;C0439792,442/10465
total stent length,C0439175;C0439175;C0439810;C0439810,443/10465
triglycerides  median ( range ),C0041004,444/10465
efficacy,C1280519;C1707887,445/10465
non - stemi,C3537184,446/10465
mri substudy ( n = nmbr ),C0024485;C1824234;C3890166,447/10465
lv mass index ( g / mnmbr - nmbr ),C0455825;C0455825;C0455825;C0455825;C0455825,448/10465
all with coenzyme qnmbr ( n = nmbr  nmbr ),C0009235,449/10465
serum total cholesterol  mmol / l ( sd ),C0587184;C1287371,450/10465
visits nmbrenmbr,C0545082;C1512346,451/10465
week nmbr ( itt population ),C0332174;C0332174;C0439230;C0439230,452/10465
puerperium,C0034042;C0086839;C1879329,453/10465
gold group d — no . ( % ) | |,,454/10465
atv nmbr mg study protocol,C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862,455/10465
aml / val nmbr / nmbr mg,C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023465;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467;C0023467,456/10465
median albumin / creatinine ratio ( g / mg ),C0549183;C0549183;C0876920;C0876920;C2347635;C2347635;C2348144;C2348144;C2939193;C2939193,457/10465
smoking ( a ),C0037369;C0453996;C1881674,458/10465
tirofiban ( n = nmbr ),C0247025,459/10465
time from acs to randomization ( median  iqr ),C0040223;C0040223;C3541383;C3541383,460/10465
smoking pack - years,C0037369;C0453996;C1881674,461/10465
serum creatinine > nmbr mmol / l  n ( % ),C0201976;C0600061,462/10465
nonaspirin antiplatelet agent,C0722138,463/10465
use of concomitant lipid - modifying therapy,C1524063,464/10465
% stenosis  as assessed by investigator,C0678234;C1261287;C2632116,465/10465
parenteral anticoagulalion before randomization,C0030547;C4522267,466/10465
lesions bnmbr / c,C0221198;C1546698,467/10465
median fasting insulin ( iqr ) — pu per milliliter,,468/10465
death or stent thrombosis,C0011065;C1306577;C4082313;C4552775,469/10465
measured at home with automated device,C0444706;C3541902,470/10465
atenolol *,C0004147,471/10465
neuropilin ( ng / ml ),C0287275,472/10465
individuals with diabetes  n = nmbr,C0027361;C0027361;C0237401;C0237401,473/10465
basal insulin analogue : insulin,C0650607;C0205112,474/10465
mean pulse pressure  mmhg ( s . d . ) “,,475/10465
oral hypoglycemic drug,C0359086,476/10465
antihypertensive treatment,C0003364;C0003364;C0003364;C0003364;C0003364;C0003364;C0003364,477/10465
patients with > nmbr exacerbations resulting in hospital admission,C0030705,478/10465
ranolazine ( n = nmbr  nmbr ),C0073633,479/10465
final timi flow grade post - ppci,C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C0205088;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C1546485;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528;C3853528,480/10465
duration of disease  median,C0872146,481/10465
ace inhibitor or arb at enrollment,C0003015;C4541021,482/10465
psoriasis duration  yrs *,C0033860;C0033860,483/10465
nmbr to < nmbr . nmbr %,C0053917;C1334884,484/10465
simvastatin monotherapy ( n = nmbr  nmbr * ),C0074554,485/10465
timi major bleeding,C0205082;C0205164;C4318856;C4521762,486/10465
small - artery occlusion,C0226001;C0226001;C0226001;C0226001;C0226001;C0226001;C0700321,487/10465
left ventricular hypertrophy — no . ( % ),,488/10465
laboratory findings,C0587081,489/10465
crp  nmol / l  median ( range ),C3890735;C4048285,490/10465
bivariate frailty model ( statin users vs non - users ),C0424594;C0424594;C0424594;C0424594,491/10465
resection performed  %,C0015252;C0728940,492/10465
liraglutide nmbr . nmbr mg ls means ( n ),C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,493/10465
ada ifg,C1060325;C1060325;C3811629;C3811629,494/10465
median change  %,C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193,495/10465
sita nmbr + pio nmbr,C0053917;C0053917;C1334884;C1334884,496/10465
combined estimated gfr and albuminuria status,C0205195,497/10465
neoplasia,C0027651;C1882062,498/10465
venous graft,C0042449;C0042449;C0042449;C0348013;C0348013;C0348013,499/10465
mean age  y  median ( range ),C0444504;C2347634;C2348143,500/10465
body - mass index ( kg / mj ) previous diagnosis,C0005893;C0578022;C1305855,501/10465
antihyperglycemic,C0020616,502/10465
duration of ra ( time from symptom onset )  years,C0449238;C0449238;C0449238;C0449238;C2926735;C2926735;C2926735;C2926735,503/10465
grouped region,C0439745;C0439745;C4319846;C4319846,504/10465
nitrate — no . ( % ),,505/10465
shs  mean nmbr sd,,506/10465
oral antidiabetes monotherapya  n ( % ),C0442027;C4521986,507/10465
patients without ra  as  or psa ( n = nmbr  nmbr ),C0030705;C0030705,508/10465
treatmentofpulmonary embolismpriorto randomization,C0034656,509/10465
renin - angiotensin inhibitors,C2917241;C2917241;C3653375;C3653375,510/10465
fevnmbr  litres ( post - salbutamol )  mean ( sd ),,511/10465
upper respiratory tract infection nmbr ( nmbr . nmbr ),C0041912;C0041912,512/10465
age at diagnosis  y,C1828181;C3173302,513/10465
change in mtss ( mean ),C0392747;C0443172;C1705241;C4319952,514/10465
aliskiren ( n = nmbr ),C1120110,515/10465
number of exacerbations in last nmbr months ,C0237753;C0449788,516/10465
p  all vs all,C0369773;C2603361,517/10465
fasting plasma insulin — mu / liter,,518/10465
baseline albumin / creatinine ratio in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,519/10465
cvd risk factors ( age > nmbr ),C0007222;C0007222,520/10465
former smoker ( n = nmbr ),C0337671,521/10465
prior use of biologics  n ( % ),C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,522/10465
amlodipine nmbrmg / v = nmbr,C0051696;C0051696,523/10465
moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,524/10465
ethnic group — no . ( % ) ',,525/10465
any event,C0441471;C4019010,526/10465
pain in extremity,C0030196;C4553007,527/10465
hospitalized for asthma  n ( % ) *,C0701159;C0701159,528/10465
sex : male ( n = nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,529/10465
apolipoprotein b^,C0003593,530/10465
abnormal angiogram,C0205161;C0205161;C0205161;C0205161;C2347472;C2347472;C2347472;C2347472;C2699333;C2699333;C2699333;C2699333,531/10465
three or more drugs,C0205449,532/10465
data missing,C1511726;C3245479;C3714741,533/10465
heart failure nyha ii - iii,C0018801;C0018801;C0018801;C0018801;C0018802;C0018802;C0018802;C0018802;C4554158;C4554158;C4554158;C4554158,534/10465
cerebrovascular disease  n ( % ),C0007820,535/10465
western europe hr ( nmbr % cl ),C0043129,536/10465
biologic agents,C0005515,537/10465
ls mean difference ± seb,,538/10465
factor xa inhibitor,C2825027;C4553708,539/10465
mean bmi  kg / mnmbr ( s . d . ),C0444504;C2347634;C2348143,540/10465
anti - ischaemia agents *,C0040616;C0040616,541/10465
exposure,C0274281;C0332157,542/10465
mycophenolate mofetil,C0209368,543/10465
age when diabetes first diagnosed — yr,,544/10465
randomization to placebo or telmisartan,C0034656;C0034656;C0034656,545/10465
aspirin nmbr clopidogrel,C0004057;C0004057,546/10465
chd risk equivalents  n ( % ),C1282512;C1282512,547/10465
systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr ),C0488055;C0871470;C1306620,548/10465
clinical history,C0205210;C0205210;C0205210;C0205210;C0205210;C0205210,549/10465
ezetimibe + simvastatin ( n = nmbr * ),C1532737,550/10465
duration of psoriasis  years,C0449238;C2926735,551/10465
procedures for index event,C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0025664;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C0184661;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C2700391;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935;C3538935,552/10465
killip class at admission — no . / total no . ( % ),,553/10465
other lipid parameters,C0023779,554/10465
tc / hdl - c ratio,C0039411;C0039411;C0040642;C0040642;C0041405;C0041405;C0041698;C0041698;C1824670;C1824670;C3272447;C3272447;C4522122;C4522122,555/10465
ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140,556/10465
peri - or postmenopausal,C0347985,557/10465
indeterminate or unknown,C0205258,558/10465
ratet ( nmbr % cl ),,559/10465
> nmbr % stenosis of coronary  carotid  or lower extremity arteries,C0053917;C0053917;C1334884;C1334884,560/10465
atrial fibrillation / flutter  n ( % ),C0155709,561/10465
hypertension — no . ( % ) hypercholesterolemia — no . ( % ),,562/10465
pulmonary disease,C0024115,563/10465
region of enrollment  n ( % ) +,C0017446;C0017446;C0017446;C0205147;C0205147;C0205147,564/10465
baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr,C0168634;C0168634;C1442488;C1442488,565/10465
statin + ezetimibe  n ( % ),C0360714,566/10465
ldl - c ( calculated ) *,,567/10465
evaluable for acrnmbr at week nmbr  n,C1516986,568/10465
tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,C0053917;C1334884,569/10465
ez / simva n = nmbr n ( % ),C0206578,570/10465
event rates  %,C0441471;C0441471;C4019010;C4019010,571/10465
baseline nmbr - h ppg ,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,572/10465
nontrial ppi,C0358591;C0871125;C3811894,573/10465
cardiac resynchronization therapy,C1167956,574/10465
nyha class iii or iv ( n = nmbr ),C1882086,575/10465
oral agents use,C0442027;C0442027;C0442027;C4521986;C4521986;C4521986,576/10465
recurrent ischemia - urgent revascularization,C1455761;C1455761;C1455761;C1455761;C2945760;C2945760;C2945760;C2945760,577/10465
rheumatoid factor positive §  n ( % ),,578/10465
serum pnmbrnp ( ^g / liter ),C0229671;C1546774;C1550100,579/10465
investigator - reported hypoglycaemia *,C0035173;C0035173;C0035173;C0035173;C0035173;C0035173,580/10465
diuretic — no . / total no . ( % ),,581/10465
interleukin - nmbr ( ng / l ),C0021764;C0021764;C1527200;C1527200,582/10465
non - caucasian eze / simva ( „ = nmbr },,583/10465
median ( qnmbr : qnmbr ) tgs,C0549183;C0876920;C2347635;C2348144;C2939193,584/10465
indacaterol nmbr ug versus indacaterol nmbr ug,C1722260;C1722260;C1722260;C1722260,585/10465
score of > nmbr . nmbr — %,,586/10465
weight  median ( nmbrth — nmbrth percentiles )  kg,,587/10465
nmbr - nmbr ( n = nmbr  nmbr ),C0053917;C1334884,588/10465
anti - cholinergics ( short - acting ) a,C0242896,589/10465
north america n z nmbr,C0028405;C0028405,590/10465
diabetes durationa < median,C0011847;C0011849,591/10465
discontinuations,C0457454,592/10465
available baseline blood specimen n,C0470187;C0470187,593/10465
quicki,,594/10465
ratio of women to men — %,,595/10465
randomization to arterial sheath insertion,C0034656;C0034656;C0034656;C0034656;C0034656;C0034656;C0034656;C0034656,596/10465
p value versus placebo,C1709380,597/10465
history of cardiac arrhythmia,C3494593,598/10465
n analysed,C0369718;C0441922,599/10465
body mass  kg,C0518010,600/10465
mean cdai score,C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,601/10465
placebo plus aspirin,C0032042;C1696465;C1706408,602/10465
ii - iv ( % ),C1710602;C1710602;C4082587;C4082587,603/10465
previous bowel resection performed — no . of patients ( % ),,604/10465
left anterior descending  n ( % ),C0441998;C0441998,605/10465
postmenopausal hormone use,C0232970;C0232970;C0232970;C0232970;C0232970;C0232970,606/10465
femoral neck,C0015815,607/10465
standard control ( n = nmbr ) no . of patients ( percent ),C1442989;C1442989;C1442989;C1442989;C1442989;C1442989;C2828392;C2828392;C2828392;C2828392;C2828392;C2828392,608/10465
other asian,C0078988,609/10465
measurements,C0242485,610/10465
antithrombotic / coagulant,C0009117,611/10465
myocardial infarction within the previous nmbr yr,C0027051;C0027051;C0027051;C0027051;C0428953;C0428953;C0428953;C0428953;C2926063;C2926063;C2926063;C2926063;C3810814;C3810814;C3810814;C3810814;C4552959;C4552959;C4552959;C4552959,612/10465
receiving concomitant nsaids and / or cox - nmbr inhibitors,C1514756,613/10465
b digit symbol substitution  omega - nmbr fatty acids vs placebo,C0582802;C0582802;C0582802;C0582802;C3241971;C3241971;C3241971;C3241971,614/10465
post - bronchodilator ratio of fevnmbr to fvc — %,,615/10465
statin with niacin,C0360714;C0360714,616/10465
neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778,617/10465
anti - inflammatory drugs,C0003209,618/10465
i & ii : fevnmbr > nmbr % predicted,C0021966;C0221138,619/10465
interval clopidogrel to pci,C1272706;C1552654;C1552713,620/10465
procedure,C0184661;C2700391;C3274430;C3539779,621/10465
electrophysiological study — no . ( % ) weight — ibj,,622/10465
montelukast ( n = nmbr ),C0298130,623/10465
nmbr - h pmg ( mg / dl ),C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,624/10465
phenytoin,C0031507;C0202454,625/10465
enact - nmbr trial rerandomization to natalizumab ( n = nmbr ),,626/10465
nmbr bmi  kg / m,C0053917;C1334884,627/10465
baseline ldl cholesterol,C0168634;C0168634;C1442488;C1442488,628/10465
iglar ( insulin glargine lnmbr u ),,629/10465
llv wlalil nmbr statin,C0053917;C1334884,630/10465
number of prior csdmards  n ( % ),C0237753;C0237753;C0449788;C0449788,631/10465
efficacy and safety : net adverse clinical events *,C1280519;C1707887,632/10465
glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778,633/10465
heart disease risk factors,C0741920,634/10465
statin use at baseline,C0360714;C0360714;C0360714;C0360714;C0360714;C0360714,635/10465
current smoker : ex - smoker ( % ),C3173209;C3241966,636/10465
aspirin but no ppi,C0004057,637/10465
nsaid use — no . / total no . ( % ),,638/10465
dx at presentation  n ( % ),C3538936,639/10465
recent surgery or trauma,C0332185;C0332185;C0332185;C0332185,640/10465
left anterior descending,C0441998;C0441998,641/10465
ezetimibe nmbr mg + statin ( n = nmbr  nmbr ),C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985,642/10465
coumadin,C0699129,643/10465
device group,C1706365,644/10465
glargine,C0907402,645/10465
safety population  n ( % ),C0036043;C0036043;C1705187;C1705187,646/10465
pef  post - bronchodilator  % predicted normal,C0030771;C1518922;C1542834,647/10465
all randomized patients ( range ),C0034656;C3815594,648/10465
permanent,C0205355,649/10465
tocilizumab,C1609165,650/10465
nmbr = help needed  still independent,C0053917;C1334884,651/10465
non - metsyn,C1518422,652/10465
hemoglobin  g nmbr nmbr,C0019046,653/10465
level of renal impairment,C0441889;C0456079;C1547707;C2946261,654/10465
soe or sue,,655/10465
previous stroke ortransient ischaemic attack ( % ),C0205156;C0205156;C1552607;C1552607,656/10465
clopidogrel / ticlopidine,C0070166,657/10465
selexipag,C2000145,658/10465
mi type unknown ( % ),C3810814;C3810814,659/10465
crohn ' s disease,C0010346,660/10465
high - sensitivity crp — mg / liter | |,,661/10465
prior coronary revascularization,C0332152;C2826257,662/10465
severe teaes,C0205082;C4050465;C4050466,663/10465
any statin + other llt,C0360714,664/10465
arb at last follow - up,C3888198;C3888198;C3888198;C3888198,665/10465
ml without st - segment elevation !,C0439526;C1705224;C3887665,666/10465
hydralazine,C0020223,667/10465
multivessel pci,C4049621,668/10465
oral anticoagulant — no . / total no . ( % ),,669/10465
notable abnormalities,C4288581;C4288581,670/10465
contrast nephropathy risk score,C0009924;C0009924;C0009924;C0009924;C1979874;C1979874;C1979874;C1979874,671/10465
aspirin at last follow - up,C0004057;C0004057;C0004057;C0004057,672/10465
physical component,C0031809;C0031809;C0205485;C0205485;C1509143;C1509143,673/10465
indacaterol nmbr gg qd,C1722260;C1722260;C1722260;C1722260,674/10465
elderly ( > nmbr years ),C0001792;C1999167,675/10465
odds ratio versus placebo ( nmbr % ci ),C0028873,676/10465
geographic region - north america,C0017446,677/10465
all patients with fistulas ( n = nmbr ),C0030705,678/10465
fevnmbr / fvc ( post - albuterol ),C3714541,679/10465
prior medications,C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,680/10465
location of ml,C0450429;C0450429;C0450429;C1515974;C1515974;C1515974;C4284930;C4284930;C4284930;C4284931;C4284931;C4284931,681/10465
use of hormone replacement therapy ( a ),C1524063,682/10465
versus tiotropium nmbr . nmbr pg,,683/10465
prior coronary revascularization  n ( % ),C0332152;C2826257,684/10465
duration of infusion — hr,,685/10465
beta - blocker at last follow - up |,C0001645;C0001645;C0001645;C0001645,686/10465
rentrop score,C0449820;C4050231,687/10465
randomisation visit ( baseline ),C0034656;C0034656;C0034656,688/10465
gastrointestinal area involved — no . / total no . ( % ),,689/10465
baseline pulmonary medication  n ( % ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,690/10465
median serum periostin  ng / mla,C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193,691/10465
multiple tnfi *,C0439064,692/10465
diet + pravastatin ( n = nmbr ),C0012155;C0012159;C1519433;C2983588;C3668949,693/10465
prior coronary artery bypass graft surgery,C0332152;C2826257,694/10465
c - peptide  median ( ql  qnmbr )  nmol / l,C0006558,695/10465
enoxaparin,C0206460,696/10465
vorapaxar placebo nmbr - yr %,C2974521;C2974521;C2974521;C2974521;C2974521;C2974521,697/10465
missing data,C4684714,698/10465
risk reduction ( %  nmbr % ci ),C1137094,699/10465
fastest third,C0015663;C0456962;C2985769,700/10465
gemfibrozil,C0017245,701/10465
chanmbrdsnmbr - vasc,,702/10465
ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr ),C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737;C1532737,703/10465
( nmbr % ci] nmbr,C0053917;C0053917;C1334884;C1334884,704/10465
triglycerides mean ( mg / dl ± sd ),,705/10465
incidence rate,C1708485,706/10465
urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C1318330,707/10465
minimum stent diameter,C4054490,708/10465
nt - probnp pg / mla ( iqr ),C0669479;C0669479;C0669479;C0754710;C0754710;C0754710,709/10465
body mass index ( bmi )  kg / mnmbr,C0005893;C0578022;C1305855,710/10465
diet plus pravastatin group ( n = nmbr ),C0012155;C0012155;C0012155;C0012155;C0012155;C0012155;C0012159;C0012159;C0012159;C0012159;C0012159;C0012159;C1519433;C1519433;C1519433;C1519433;C1519433;C1519433;C2983588;C2983588;C2983588;C2983588;C2983588;C2983588;C3668949;C3668949;C3668949;C3668949;C3668949;C3668949,711/10465
duration of clopidogrel pretreatment 一 hr median,,712/10465
family history of coronary artery disease,C2317524,713/10465
sex  n ( % ) male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,714/10465
cv risk factor - no . ( % ),C3538987;C4048877;C4318503,715/10465
valvular disease ( % ),C3258293,716/10465
no corticosteroid + no imm  n,C0001617;C3536709,717/10465
antimalarials only,C0003374;C0003374,718/10465
tnl ultrapositive > nmbr . nmbr pg / l  nmbr = nmbr,C1540071,719/10465
dactylitis count ( nmbr - nmbr )  mean ( sd ),C0239161;C0239161,720/10465
nasal polyps,C0027430,721/10465
verapamil sr n = nmbr,C1527129,722/10465
continued thienopyridine n ( % ),C0549178,723/10465
disease - progression composite outcome !,C0679250;C0679250;C0679250;C0679250;C3542417;C3542417;C3542417;C3542417;C0242656;C0242656;C1335499;C1335499;C1947900;C1947900;C4552808;C4552808,724/10465
egfrmdrd < nmbr ml - min - nmbr - nmbr . nmbr m - nmbr  n ( % ),,725/10465
diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317,726/10465
uric acid ( mg / dl ),C0041980,727/10465
pasi score  mean ± sd,,728/10465
theophylline compound,C0039771;C0039771,729/10465
heterogeneity / trend test,C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960,730/10465
disease,C0012634,731/10465
hispanic / latin american,C0019576,732/10465
isolated pulmonary embolism,C0205409;C1548221,733/10465
middle tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),,734/10465
total cholesterol ( mg / dl )  mean + sd  available for nmbr patients,C0201950;C0543421,735/10465
geometric mean of baseline,C2986759;C2986759,736/10465
baseline fvc  l,C0168634;C1442488,737/10465
csf nmbrs - hydroxy -,C3540512;C3540512;C3889436;C3889436,738/10465
mean annualized exacerbation rate,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,739/10465
placebo no . / total ( % ),C0032042;C1696465;C1706408,740/10465
not reported / unknown,C1518422,741/10465
prior therapy with tnf antagonist  n ( % ),C1514463;C0332152;C2826257,742/10465
difference from baselinea,C1705241;C1705242,743/10465
age at randomization ( years ),C0001779,744/10465
never used lev,C2003901,745/10465
single vessel coronary artery disease *,C0581374,746/10465
non - sulfonylurea secretagogues,C1518422;C1518422,747/10465
index event asymptomatic or unconfirmed,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,748/10465
baseline medical therapy,C0168634;C1442488,749/10465
prior corticosteroid failure only,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,750/10465
one or more blood pressure medications  n ( % ),C0205447,751/10465
evomab ( n = nmbr ),,752/10465
baseline post - bronchodilator % predicted fev  < nmbr %,C0168634;C0168634;C1442488;C1442488,753/10465
cardiovascular hospitalization,C0007226;C3887460,754/10465
crohn ' s disease activity index score],C0451071;C0451071,755/10465
prior use of biologic agents,C0332152;C2826257,756/10465
relative risk reduction ( nmbr % cl ),C0242492;C0242492;C0242492;C0242492;C0080103;C0205345;C1547039,757/10465
hbanmbrc distribution,C0520511;C1704711,758/10465
diuretic agent,C0012798;C0012798;C0012798,759/10465
patients treated with insulin,C0030705,760/10465
estimated gfr ( ml / min / nmbr . nmbr mnmbr ) ^ |,C0750572;C0750572,761/10465
nmbr - aminosalicylic compounds — no . ( % ),,762/10465
iwqol - lite physical score ( arbitrary units ),C4483112,763/10465
bdi total score ( baseline ),C0006448;C0451022;C3714938;C3889415,764/10465
estimated * creatinine clearance < nmbr mlvmin  %,C0750572,765/10465
low - density lipoprotein cholesterol  %,C0023824,766/10465
education  high school or higher,C0013621;C0013622;C0013658;C0039401,767/10465
partial mayo clinic scored,C0728938;C0728938;C0728938;C0728938;C1550516;C1550516;C1550516;C1550516,768/10465
prior lipid - modifying therapy,C1514463,769/10465
cv risk factor,C3538987;C4048877;C4318503,770/10465
mets w / o tnmbrdm,C0812270;C1705694;C2939420,771/10465
other countries,C0454664,772/10465
smoking history — no . ( % ),,773/10465
other vascular disease — no . ( % ),,774/10465
mean — g / dl,,775/10465
outcome,C1274040,776/10465
ccbs  ( % ),C0006684,777/10465
sfc nmbr / nmbr | ig bid n = nmbr,C4521536;C4521536;C4521536;C4521536;C4521536;C4521536,778/10465
cangrelor  %,C1121991,779/10465
losartan n = nmbr,C0126174,780/10465
laba + ics,C0815320;C4551720,781/10465
short - acting anticholinergics,C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002,782/10465
> nmbr vessels with > nmbr % stenosis,C0053917;C1334884,783/10465
concomitant antihyperglycaemic drugs  n ( % ),C0521115;C0521115,784/10465
losmapimod,C3272847,785/10465
history of myocardial infarction ( % ),C1275835,786/10465
nmbr - nmbr with cv disease ( n = nmbr ),C0053917;C1334884,787/10465
severely impaired,C0205082,788/10465
estimated creatinine clearance < nmbr ml / min *,C0750572,789/10465
anticyclic citrullinated peptide positive^  n ( % ),C1320283;C1320283;C1320283;C1320283;C1320283,790/10465
wrist fracture,C0435630;C4553927,791/10465
mtx exposure ( mg / week ),C0025677;C0025677;C1417487;C1417487,792/10465
ischaemic  n ( % ),C0475224,793/10465
atenolol n = nmbr no . ( % ),C0004147,794/10465
vascular disordersb,C0005847;C1558950;C1801960,795/10465
adjusted mean change from baseline ( nmbr % ci )  % [mmol / mol],C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081,796/10465
< nmbr . nmbr mmol / liter triglyceride level,C0053917;C1334884,797/10465
previous myocardial infarction — no . ( % ),,798/10465
time since diagnosis of diabetesa  n ( % ),C0040223;C3541383,799/10465
fevnmbr / fvc  %  mean ( sd ) nmbr,C3714541,800/10465
> nmbr . nmbrmmol / l ( n = nmbr ),C0053917;C1334884,801/10465
serum albumin  g / dl,C0036773;C0728877,802/10465
classification of af  no . ( % ),C0008902;C0008902;C0008903;C0008903;C0678229;C0678229,803/10465
age at screening,C0001779;C0001779;C0001779;C0001779;C0001779;C0001779;C0001779,804/10465
change in sbp ( nmbr months ),C0392747;C0443172;C1705241;C4319952,805/10465
bronchitis,C0006277,806/10465
left ventricular ef  mean ( sd )  %,C0225897,807/10465
pdenmbr inhibitor monotherapy,C1999216,808/10465
ischemic heart disease  %,C0010054;C0151744,809/10465
neither pbo + statin eze + statin,C0031962,810/10465
impaired fasting glucose level ( n = nmbr ),C1272092;C1272092;C1272092;C1272092;C0221099,811/10465
cancer ( n = nmbr ),C0006826;C0998265;C1306459,812/10465
selected clinical characteristics  n ( % ),C1707391,813/10465
lumbar spine,C0024091;C3887615,814/10465
reversibility of fevnmbr ( % ),C0449261,815/10465
missing data — no . / total no . ( % ),,816/10465
insulin ( pmol / l ) t vital signs,C0021641;C1533581;C1579433;C3714501,817/10465
glucose - lowering therapies,C0017725;C0017725,818/10465
baseline heart failure severity nyha class i,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,819/10465
selected baseline medications,C1707391;C1707391;C1707391;C1707391;C1707391;C1707391;C1707391;C1707391,820/10465
endovascular — no . ( % ),,821/10465
aspirin - erdp ( n = nmbr  nmbr ),C0004057,822/10465
previous treatment with tnf antagonist — no . ( % ) §,,823/10465
zotarolimus - eluting,C1700035,824/10465
change in nt - probnp at nmbr months ( log - transformed ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,825/10465
low - molecular - weight,C0041667;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223,826/10465
heart rate ( b . p . m . )  mean ± sd,,827/10465
vorapaxar group ( n = nmbr ),C2974521;C2974521;C2974521;C2974521;C2974521;C2974521,828/10465
glucose test,C0337438;C0595310,829/10465
number of concomitant aeds  n ( % ),C0237753;C0449788,830/10465
mean number of exacerbations ( per patient - year [nmbr % ci] ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,831/10465
use nmbr - asa compounds,C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944,832/10465
glycemic drugs,C0005802;C0005802,833/10465
balloon angioplasty — no . ( % ),,834/10465
prior history of cardiovascular disease  n ( % ),C0332152;C2826257,835/10465
accp bleeding risk at inclusion  no . ( % ) f,C3251812;C3251812,836/10465
angina pectoris — no . ( % ),,837/10465
history of systemic hypertension,C0455527,838/10465
angiography — no . ( % ),,839/10465
prasugrel,C1620287,840/10465
cardiovascular disease,C0007222,841/10465
prior congestive heart failure,C0332152;C2826257,842/10465
post - bronchodilator reversibility fevnmbr ( % ) mean ( sd ),C2599594,843/10465
diabetes therapy  n ( % ),C3274787;C3539002,844/10465
low - dose aspirin use at baseline yes,C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320;C2608320,845/10465
medication at enrollment — no . ( % ),,846/10465
age  yrs  median ( nmbrth  nmbrth ),C0001779,847/10465
no . of predictors of cardiovascular risk,,848/10465
mean ( s . d . ) free pcsknmbr  ng / ml,C0444504;C2347634;C2348143,849/10465
enrollment in lmwh,C1516879;C1516879;C1696073;C1696073;C3888021;C3888021,850/10465
coronary angiography during the index hospital stay,C0085532;C0085532;C0085532;C0085532;C0085532;C1548829;C1548829;C1548829;C1548829;C1548829;C0428776,851/10465
primary pci ( n = nmbr ),C0205225;C0439612;C0439631,852/10465
versus tiotropium + olodaterol nmbr . nmbr / nmbr pg,,853/10465
long - acting or short - acting nitrates,C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317,854/10465
cardiovascular and respiratory,C0007226;C3887460,855/10465
hispanic ethnic group — no . ( % ) f,,856/10465
placebo  n ( rate ),C0032042;C1696465;C1706408,857/10465
calcium antagonists  n ( % ),C0006684,858/10465
egfr  ml / min / mnmbr,C1739039;C3811844;C3812682,859/10465
lipid lowering medication use,C0023779;C0023779,860/10465
opg  ( ng / ml ),C1262886;C1336645;C1412836;C1710303,861/10465
final timi flow,C0205088;C1546485;C3853528,862/10465
patient ' s global assessment of disease activity  mean ( sd ),C4054228,863/10465
with revascularisation,C0581603,864/10465
antihypertensive medication or,C0003364,865/10465
level nmbr immobility § | |,,866/10465
serum creatinine  limo nmbr nmbr,C0201976;C0600061,867/10465
central / eastern europe / russia,C0682369;C0205099;C1879652,868/10465
role physical,C0035820;C0035820;C0035820;C1705810;C1705810;C1705810;C3871154;C3871154;C3871154,869/10465
hbanmbrc category  n ( % ),C0683312;C3889287,870/10465
not reported in ecrf,C1518422,871/10465
beta - blockers ( all )  n ( % ),C0001645,872/10465
laba users,C1706077,873/10465
creatinine clearance at admission ( ml / min ),C0812399;C0812399,874/10465
egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr  nmbr ),C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,875/10465
other anticoagulant,C0003280;C0848112;C3536711,876/10465
severe impairment ( < nmbr ),C0205082;C0205082;C4050465;C4050465;C4050466;C4050466,877/10465
pre - bronchodilator fevnmbr ( % predicted normal ),C2599602,878/10465
insulin + oad,C0021641;C1533581;C1579433;C3714501,879/10465
clopidogrel ( n = nmbr ),C0070166,880/10465
first - generation stentt,C0205435;C0205435;C1279901;C1279901,881/10465
crp  mg / l : median ( range ),C3890735;C4048285,882/10465
least square mean ( se ),C0023189;C0023189;C0023189,883/10465
preoperative heart rate ( beats per minute ),C0445204,884/10465
angiography during index hospitalization,C0002978;C0002978;C0002978;C0002978;C0002978,885/10465
allhat - llt,C2347090,886/10465
prior cardiovascular event — no . ( % ) - j -,,887/10465
baseline killip class,C0168634;C1442488,888/10465
score on modified rankin scale — no . ( % ) §,,889/10465
energy / fatigue,C0424589;C0424589;C0424589;C0424589;C0542479;C0542479;C0542479;C0542479;C1442080;C1442080;C1442080;C1442080;C4330907;C4330907;C4330907;C4330907,890/10465
atrial flutter,C0004239;C0344423;C1963068,891/10465
subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811,892/10465
active a,C0205177;C3853793;C3888249,893/10465
rec . ischemia leading to hasp,C1424025;C1424025;C2606415;C2606415,894/10465
history of cabg surgery  n ( % ),C0455610,895/10465
western europe and other,C0043129,896/10465
qualifying mi type,C1514624;C1514624,897/10465
potassium - sparing at last follow - up,C0032821;C0032821;C0032821;C0032821;C0202194;C0202194;C0202194;C0202194;C0304475;C0304475;C0304475;C0304475;C0597277;C0597277;C0597277;C0597277;C3714637;C3714637;C3714637;C3714637,898/10465
congestive heart failure  n ( % ),C0018802,899/10465
score distribution : < nmbr,C0449820;C0449820;C4050231;C4050231,900/10465
candesartan nmbr / nmbr,C0717550;C0717550,901/10465
planned treatment strategy,C0599880,902/10465
/ ’ - valuenmbr ’,,903/10465
parental history of myocardial infarction before nmbr yr of age ( % ),C0030551,904/10465
hbanmbrc distribution at baseline  n ( % ),C0520511;C0520511;C1704711;C1704711,905/10465
change in haq - di ( mean ) t,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,906/10465
normoalbuminuria at baseline ( nmbr % of patients treated ),C0168634;C1442488,907/10465
previous deep - vein thrombosis or pulmonary embolism,C0205156;C1552607,908/10465
placebo mean ( n ),C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408,909/10465
previous coronary revascularization — no . ( % ),,910/10465
medical history and risk factors — no . ( % ),,911/10465
rankin grade,C0441800;C0919553;C3244287,912/10465
previous heart failure,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,913/10465
ptca or pci,C2936173,914/10465
inflammatory disease,C1290884,915/10465
exacerbations,C4086268,916/10465
statin ( open ),C0360714,917/10465
glyburide ( n = nmbr ),C0017628,918/10465
history of cardiovascular disease — no . ( % ) ^ |,,919/10465
heart failure — no . ( % ),,920/10465
normoglycemicnmbr,,921/10465
fevi  % predicted  mean ( sd ) nmbr,C0849974;C1561566;C4528367,922/10465
cardiac failure  n ( % ),C0018801;C0018802,923/10465
previous vascular disease,C0205156;C1552607,924/10465
ethnic origin  n ( % ),C0015031,925/10465
abatacept monotherapy ( n = nmbr ),C1619966,926/10465
calcium channel antagonists  n ( % ),C0006684;C2757014,927/10465
high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,928/10465
ra symptom duration — year,,929/10465
previous myocardial infarction ( % ),C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607,930/10465
post - bronchodilator fvc ( l ) a,C2599594,931/10465
moderate risk,C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,932/10465
< nmbr . nmbr mm hg diastolic blood pressure,C0053917;C0053917;C1334884;C1334884,933/10465
nmbr mg cohort,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,934/10465
exercise times per week  ( minimum,C0015259;C1522704,935/10465
other ( nmbr . nmbr % ) t,,936/10465
medical conditions  no . ( % ),C0199168;C0199168;C0199168;C0199168;C0205476;C0205476;C0205476;C0205476,937/10465
smoking status at screening  n ( % ),C1519386;C1519386;C1519386;C1519386;C1519386;C1519386;C1519386;C0037369;C0453996;C1881674,938/10465
low - dose rivaroxaban + aspirin ( n / n ),C2608320,939/10465
revascularization,C0581603,940/10465
hoehn and yahr stage ( range  nmbr - nmbr ),C0205390;C1300072;C1306673,941/10465
blood leukocyte count ( nmbr cells per l ),C0023508;C0023516;C0427512,942/10465
low risk and fewer symptoms ( group a ),C3272281;C3538919,943/10465
alt and / or ast > nmbr times uln consecutive #,C1266129;C4553172,944/10465
nmbr yr km % ( n ),C0053917;C1334884,945/10465
history of symptomatic,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,946/10465
time of symptom onset to balloon inflation ( hrs ),C1320528,947/10465
statin potency stratum  n ( % ),C0360714,948/10465
no dysglycaemia or mets,C1960636,949/10465
weight $ nmbr . nmbr kg  < nmbr . nmbr kg  n,C0005910;C0005910;C0005910;C0005910;C0005910;C0005910;C0043100;C0043100;C0043100;C0043100;C0043100;C0043100;C1305866;C1305866;C1305866;C1305866;C1305866;C1305866;C1705104;C1705104;C1705104;C1705104;C1705104;C1705104,950/10465
race or ethnic group,C0034510;C1706779;C3853635,951/10465
moderate impairment ( nmbr to < nmbr ),C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,952/10465
ascvd including tia,C3665365,953/10465
receiving concomitant corticosteroids,C1514756,954/10465
laba + ics ( free or fixed - dose combination ),C0815320;C4551720,955/10465
fc - ldl - c  friedewald - calculated,C2983605,956/10465
egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ),C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,957/10465
receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0597357,958/10465
hyperkalemia ( > nmbr . nmbr meq / l ),C0020461;C4552983,959/10465
region of enrollment  no . ( % ),C0017446;C0017446;C0017446;C0205147;C0205147;C0205147,960/10465
mean score on haq - di §,,961/10465
medications at randomization,C0013227;C0802604;C2598133;C4284232,962/10465
nmbr  nmbr / nmbr  nmbr ( nmbr . nmbr ),C0053917;C1334884,963/10465
history of cardiovascular disease,C0455539,964/10465
> nmbr yr warfarin experience,C0053917;C0053917;C1334884;C1334884,965/10465
intervention in complex lesions,C1292781,966/10465
peak creatine kinase - mb  u / l,C0444505;C0444505,967/10465
secondary ( change in total updrs score from baseline to final visit in phase nmbr ),C0027627;C0175668;C0205436,968/10465
leflunomide ( mean dose : nmbr . nmbr mg / day ),C0063041,969/10465
antithrombotic agents  n ( % ),C1704311,970/10465
leisure,C0086542,971/10465
angiotensin receptor blocker and / or ace,C0034787;C1622222,972/10465
type of treatment  n ( % ),C0455708,973/10465
pancreatic cancer,C0235974;C0346647;C2984259,974/10465
mean iglar dose ± sd ( u / day ),,975/10465
int . p *,C3272375,976/10465
hawaiian / pacific,C0337920,977/10465
aspirin at any dose,C4696290,978/10465
baseline fpg ,C0168634;C1442488,979/10465
crp ( mg / l ) : < nmbr,C3890735;C4048285,980/10465
large - artery atherosclerosis,C0226003;C0226003,981/10465
antihyperglycemic medication usage,C0020616;C0020616;C0020616,982/10465
carotid,C0741968,983/10465
western european includinq australia  israel  and south africa,C0043128;C0043128;C0239312,984/10465
low density lipoprotein cholesterol  mg / dl * *,C0023824,985/10465
blood eosinophil count ( nmbr cells per l ),C0014467;C0014467;C0005767;C0005767;C0005768;C0005768;C0229664;C0229664,986/10465
egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd ),C1739039;C3811844;C3812682,987/10465
placebo n = nmbr subjects,C0032042;C1696465;C1706408,988/10465
treatment with candesartan,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,989/10465
hbanmbrc nmbr - < = nmbr %,C0053917;C1334884,990/10465
eze / simva nmbr / nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,991/10465
pulmonary rales,C0034642,992/10465
loop at last follow - up,C0445022;C0445022;C0445022;C0445022,993/10465
modified rankin scale score,C2984908;C2984908;C3854213;C3854213,994/10465
qualifying event — no . ( % ),,995/10465
claudication ( fontaine class > nmbr ),C0021775;C0311395;C1456822,996/10465
steroid use at baseline  n ( % ),C0281991;C0281991,997/10465
metabolic syndrome ( > nmbr of nmbr characteristics ),C0524620,998/10465
killip class,C1881332,999/10465
respiratory medication ( % ),C0418986,1000/10465
concomitant lipid - lowering therapy  n ( % ),C0521115,1001/10465
duration of tnmbrdm,C0449238;C2926735,1002/10465
egfr  ml min nmbr nmbr . nmbr m nmbr,C1739039;C3811844;C3812682,1003/10465
smoking status ( % ),C1519386,1004/10465
bare - metal stent — no . ( % ),,1005/10465
rate / nmbr patient - years,C0871208;C0871208;C1521828;C1521828,1006/10465
> nmbr servings / wk ( n = nmbr ),C0053917;C0053917;C1334884;C1334884,1007/10465
key secondary end point : st,C4528314,1008/10465
no . of risk factors ( % ) | |,,1009/10465
prior antihypertensive medication  n ( % ),C0332152;C2826257,1010/10465
mean yearly decline,C0444504;C2347634;C2348143,1011/10465
standard therapy,C2936643,1012/10465
phosphorus  mmol nmbr nmbr,C0031705;C0080014;C3714498,1013/10465
lipid levels — mg / dl,,1014/10465
smoking habit  n ( % ),C4505437,1015/10465
open triple ( n = nmbr ),C0175566,1016/10465
no prior hf hospitalization ( n = nmbr  nmbr ),C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,1017/10465
glyburide,C0017628,1018/10465
mean ( sd ) extent of exposure  days,C0444504;C2347634;C2348143,1019/10465
triple therapy use at screening  n ( % ),C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174;C0205174,1020/10465
europe nmbr ( n = nmbr ),C0015176;C0015176,1021/10465
ankle - brachial index < nmbr . nmbr — no . ( % ),,1022/10465
number of subjects,C0237753;C0237753;C0237753;C0237753;C0237753;C0449788;C0449788;C0449788;C0449788;C0449788,1023/10465
fasting insulin,C0015663;C0015663;C0015663;C0015663,1024/10465
ace - i or arb use,C1452534;C1452534;C4284014;C4284014,1025/10465
pfo closure group ( n = nmbr ),C0185003;C0185003;C0185003;C0185003;C0185003;C0185003;C1521802;C1521802;C1521802;C1521802;C1521802;C1521802,1026/10465
median ( qnmbr : qnmbr ) duration of insulin use  years,C0549183;C0876920;C2347635;C2348144;C2939193,1027/10465
control group ( n = nmbr ),C0009932,1028/10465
normal troponin,C0205307;C0231683;C0439166;C2347086;C4553972,1029/10465
ind / glynmbr / nmbr pg o . d . n = nmbr,C4049864;C4049864,1030/10465
traditional chinese medicine for respiratory disease — no . ( % ),,1031/10465
baseline copd exacerbation history  * n ( % ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,1032/10465
european union,C0015179,1033/10465
blood pressure - lowering treatment,C0596197;C0596197;C0596197;C0596197;C0596197;C0596197;C0596197;C0596197;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641,1034/10465
ezetimibe,C1142985,1035/10465
fish oil,C0016157,1036/10465
cardiovascular inclusion criteriat,C0007226;C0007226;C3887460;C3887460,1037/10465
median duration of study - drug administration,C0549183;C0876920;C2347635;C2348144;C2939193,1038/10465
psoriasis body surface area > nmbr %,C0033860,1039/10465
exenatide,C0167117,1040/10465
cardiovascular risk factors — no . / total no . ( % ),,1041/10465
( nmbr % ci ) p value,C0053917;C0053917;C1334884;C1334884,1042/10465
time from symptom onset to randomization,C0040223;C3541383;C1457887;C3854129,1043/10465
percentage difference ( nmbr % cl ),C0439165;C0439165;C1549488;C1549488;C1561533;C1561533,1044/10465
fpg ( mmol / l )  mean ( sd ) 、,,1045/10465
apo anmbr ( g / l ),,1046/10465
fibrinolysis ( n = nmbr ),C0016017;C1305868,1047/10465
ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375,1048/10465
combined n = nmbr,C0205195,1049/10465
simplified disease activity index,C3869582,1050/10465
ratio of ldl to hdl,C0456603;C1547037,1051/10465
st ( arc definite only ),C0036056;C0036056;C0036056;C0036056;C3272372;C3272372;C3272372;C3272372,1052/10465
duration of diabetes mellitus  y,C0449238;C2926735,1053/10465
sex  male / female  %,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,1054/10465
total study population ( n = nmbr  nmbr ),C3258257;C3258257;C0439175;C0439810,1055/10465
sita / pio nmbr / nmbr,C0030800;C0030800;C2347712;C2347712,1056/10465
blood eosinophils count,C0014467,1057/10465
who / idf ifg,C1334085;C1708411,1058/10465
cardiovascular history 一 no . ( % ),,1059/10465
ace inhibitor at last follow - up,C0003015;C0003015;C0003015;C0003015;C4541021;C4541021;C4541021;C4541021,1060/10465
prior cardiac surgery  n ( % ),C0455610;C0455610;C0332152;C0332152;C2826257;C2826257,1061/10465
ischemic aetiology  n ( % ),C0475224;C0475224;C0475224,1062/10465
placebo nmbr year km ( % ),C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408,1063/10465
vorapaxar n = nmbr,C2974521,1064/10465
postmenopausal  never or past hormone therapy use,C0232970,1065/10465
difference vs placebo  % [nmbr % cl]  p,C1705241;C1705242,1066/10465
urinary albumin - to - creatinine ratio^,C0455271;C1318330,1067/10465
percent change,C0439165;C0439165;C0439165;C0439165,1068/10465
standard care ( n = nmbr ),C1442989;C2828392,1069/10465
cerebrovascular disorders  n ( % ),C0007820,1070/10465
ace inhibitor — no . ( % ),,1071/10465
location of treatment center,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,1072/10465
indacaterol nmbr ug ( n = nmbr ),C1722260;C1722260;C1722260;C1722260,1073/10465
history of peripheral arterial disease ( % ),C0683519;C0683519;C0730226;C0730226;C0850708;C0850708;C0944983;C0944983,1074/10465
creatinine  mean ( sd )  mg / dl,C0010294;C1561535,1075/10465
sfnmbr - pcs,C1864389;C1882368,1076/10465
randomization groups nmbr and nmbr,C0034656,1077/10465
presence of honeycombing  nmbr n ( % ),C0150312;C0150312;C0392148;C0392148;C3854307;C3854307,1078/10465
very severe n z nmbr,C3641272;C3641272;C4050419;C4050419,1079/10465
years since pah diagnosis,C0439234,1080/10465
partial mayo score $ | |,C0728938;C0728938;C0728938;C0728938;C1550516;C1550516;C1550516;C1550516,1081/10465
rosuvastain + fenofibric acid nmbr = nmbr,C0060179;C0060179,1082/10465
severity n ( % ),C0439793;C0522510,1083/10465
history of hypercholesterolemia,C1533076,1084/10465
> nmbr years education,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,1085/10465
angiographic complications  site - reported — no . / total no . ( % ),,1086/10465
acute coronary syndrome nmbr,C0948089;C0948089,1087/10465
asastoppedat randomization  n,C0034656,1088/10465
mean blood pressure  mmhg ( s . d . j,C0428886;C0488053,1089/10465
baseline lipids  mean ± sd ( mmol / l ),,1090/10465
philippines,C0031529,1091/10465
active cancer at randomization  n ( % ),C0205177;C0205177;C0205177;C3853793;C3853793;C3853793;C3888249;C3888249;C3888249,1092/10465
current (  nmbr cigs / day ),C0521116;C1705970,1093/10465
aspirin and ppi,C0004057,1094/10465
screening % reversibility fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,1095/10465
prior pci or cabg surgery,C0332152;C2826257,1096/10465
lower - limb arterial — no . ( % ),,1097/10465
baseline disease and quality - of - life scores,C0168634;C1442488,1098/10465
index event  %,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,1099/10465
endoscopy subscore,C0014245,1100/10465
intended clopidogrel dose nmbr mg,C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357,1101/10465
placebo + mtx,C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,1102/10465
celecoxib ( n = nmbr ),C0538927,1103/10465
oral hypoglycemic agent,C0359086,1104/10465
death  mi  idr  or st,C0011065;C1306577;C4082313;C4552775,1105/10465
unacceptable adverse events,C1883420;C1883420,1106/10465
tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424,1107/10465
median ( days ),C0549183;C0876920;C2347635;C2348144;C2939193,1108/10465
ldl particle size ( week nmbr ),C3641256,1109/10465
gold nmbr groups,C0018026;C0018026;C1304897;C1304897,1110/10465
parameter,C0549193;C1704769;C2350001,1111/10465
vascular intervention,C0005847;C0005847;C0005847;C1558950;C1558950;C1558950;C1801960;C1801960;C1801960,1112/10465
anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr ),,1113/10465
amlodipine / vaisartan ( n = nmbr ),C0051696,1114/10465
ldl cholesterol — mg / dl | |,,1115/10465
week nmbr ( geometric mean  cv ),C0332174;C0332174;C0439230;C0439230,1116/10465
triglycerides ( week nmbr ) a,C0041004,1117/10465
cause of heart failure,C0015127;C0015127;C0015127;C1524003;C1524003;C1524003,1118/10465
copd or asthma,C0024117;C1412502;C3714496,1119/10465
latin and north america,,1120/10465
comorbid diseasesa diabetesb,C0009488,1121/10465
cardiac rhythm,C0232187,1122/10465
proactive intervention ( n = nmbra ),C0184661;C0886296;C1273869,1123/10465
nmbr = minor symptoms  no limitations,C0053917;C1334884,1124/10465
patients ' characteristics age ( years )  mean + sd,C4698447;C0815172,1125/10465
history of hypercholesterolemia  n ( % ),C1533076,1126/10465
acc / aha lesion class bnmbr or c  n ( % ),C4072694;C4072694;C4072694;C4072694;C4072694;C4072694,1127/10465
enact - nmbr trial,,1128/10465
fasting insulin — / tiu / ml §,,1129/10465
biomarker low ( periostin < nmbr ng / ml or blood eosinophils < nmbr cells per pl )  na,C0005516,1130/10465
age  mean years  [sd],C0001779,1131/10465
lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C1096202;C1439335,1132/10465
any pulmonary medication,C0024109;C0024109;C0024109;C2707265;C2707265;C2707265;C2709248;C2709248;C2709248;C4522268;C4522268;C4522268,1133/10465
non - study ppi use,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,1134/10465
> nmbr : obese class iii,C0053917;C1334884,1135/10465
acute dvt study,C0205178;C0205178;C0205178;C0205178;C0205178;C0205178,1136/10465
high subgroup,C0205250;C0205250;C1299351;C1299351;C2700149;C2700149;C3887512;C3887512;C3889660;C3889660;C4321237;C4321237;C4522209;C4522209,1137/10465
mean ( sd ) body mass index  kg / mnmbr,C0444504;C2347634;C2348143,1138/10465
diuretic drugs,C0012798;C0012798,1139/10465
gallbladder - related aes,C0016976;C0016976;C0016976;C0016976,1140/10465
rivastigmine ( n = nmbr ),C0649350,1141/10465
vitamin e,C0042874;C3714803,1142/10465
jvp > nmbrcm,,1143/10465
family history of venous thromboembolism ( % ),C0241889;C0015576;C0015576;C1704727;C1704727,1144/10465
post - bronchodilator fevnmbr ( % predicted * ),C2599594,1145/10465
creatinine clearance by c - g ( ml / min ),C0439267,1146/10465
associated with hiv infection,C0332281,1147/10465
muscle spasms,C0037763,1148/10465
copd severity ( gold stage ),C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,1149/10465
rivaroxaban nmbr mg,C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768;C1739768,1150/10465
baseline cardiac biomarkers elevated,C0168634;C0168634;C1442488;C1442488,1151/10465
mental component score ( mcs ),C0229992;C0229992;C0229992;C0229992,1152/10465
combined end points,C0205195,1153/10465
death  large mi,C0011065;C1306577;C4082313;C4552775,1154/10465
race  white  n ( % ),C0034510;C1706779;C3853635,1155/10465
elevated tg,C0205250;C3163633,1156/10465
baseline scales  median ( range ),C0168634;C0168634;C1442488;C1442488,1157/10465
formal education  years,C0681344,1158/10465
tiotropium nmbr gg qd,C0213771;C0213771;C0213771;C0213771,1159/10465
thrombocytopenia,C0040034;C0392386,1160/10465
presence of mets,C0150312;C0150312;C0150312;C0392148;C0392148;C0392148;C3854307;C3854307;C3854307,1161/10465
treatment at randomization — no . ( % ),,1162/10465
other biologic agent,C0005515,1163/10465
hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) for men / women,C3715113,1164/10465
baseline systolic bp,C0168634;C1442488,1165/10465
angina class iii or iv prior myocardial infarction,C0264677,1166/10465
mucolytic agent,C0026698,1167/10465
acenocoumaroi,,1168/10465
multiple,C0439064,1169/10465
emotional well - being,C2984554;C3641833,1170/10465
nmbr ( fevnmbr < nmbr % pred ),C0053917;C1334884,1171/10465
rec . ischemia due worsening angina,C1424025;C1424025;C1424025;C1424025;C2606415;C2606415;C2606415;C2606415,1172/10465
current ( nmbr + cigs / day ),C0521116;C1705970,1173/10465
prior surgery : no,C0455610,1174/10465
carotid stenosis,C0007282,1175/10465
smoking history  pack - years  mean ( sd ),C1519384,1176/10465
ever smoked ( current / former ),,1177/10465
estimated gfr  ml min - nmbr nmbr . nmbr m - nmbr ( sd ) a,C0750572;C0750572,1178/10465
isolated systolic hypertension  n ( % ) “,,1179/10465
feno placebo ( lsm ),C0032042;C1696465;C1706408,1180/10465
no . of prior tnfi,,1181/10465
non - fatal myocardial infarction,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,1182/10465
involved intestinal area  n ( % ),C1879646,1183/10465
normal fasting glucose level ( n = nmbr ),C0522082;C0205307;C0231683;C0439166;C2347086;C4553972,1184/10465
saxa + dapa + met n = nmbr,,1185/10465
joint damage outcomes ( mitt population ),C0022417;C0022417;C0392905;C0392905;C1706309;C1706309,1186/10465
discontinuations teaes,C0457454,1187/10465
aldosterone inhibitor,C0002007,1188/10465
adverse outcome,C1274040,1189/10465
etoricoxib nmbr mg n = nmbr n ( % ),C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314,1190/10465
asia - pacific hr ( nmbr % cl ),C0003980,1191/10465
left bundle - branch block,C0023211;C0344420;C2828132,1192/10465
any prior anti - tnf treatment failure,C1514463;C1514463;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,1193/10465
pioglitazone pts / n ( % ),C0071097;C0071097,1194/10465
central / eastern europe and russia hr ( nmbr % cl ),C0682369;C0205099;C1879652,1195/10465
copd - rosuvastatin ( n = nmbr ),C0024117;C1412502;C3714496,1196/10465
abatacept / open - label abatacept,C1619966,1197/10465
nonblack race — no . ( % ) - j -,,1198/10465
prior ischemic stroke,C0332152;C2826257,1199/10465
ff / vi nmbr / nmbr gg ( n = nmbr  nmbr ),C4554348;C4554348;C4554348;C4554348,1200/10465
baseline nihss score ( % ) #,C0168634;C0168634;C1442488;C1442488,1201/10465
free fatty acids ( mmol / l ),C0015688,1202/10465
laba or lama ’ versus ind / gly lsm difference ( nmbr % cl ),,1203/10465
change from baseline in hbanmbrc ( % ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,1204/10465
aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0004057;C0004057;C0004057;C0004057;C0004057;C0004057,1205/10465
angiogenin ( ng / ml ),C0051844;C1367482,1206/10465
weight  mean ± sd ( kg ),,1207/10465
race / ethnicity  %,C0034510;C0034510;C1706779;C1706779;C3853635;C3853635,1208/10465
etanercept ( n = nmbr ),C0717758,1209/10465
serum creatinine — pmol / liter,,1210/10465
prior carotid intervention,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,1211/10465
abx - facil . pci,C4049621,1212/10465
antiplatelet — no . / total no . ( % ),,1213/10465
other lipid - modifying drug use at study entry  n ( % ),C0023779;C0023779;C0023779;C0023779;C0023779;C0023779;C0023779,1214/10465
without dm ( n = nmbrinmbr * ),C0011816;C3250443,1215/10465
potassium,C0032821;C0202194;C0304475;C0597277;C3714637,1216/10465
difference ( tiotropium - placebo ) ml ( nmbr % ci ),C1705241;C1705242,1217/10465
any relevant infarct,C2347946,1218/10465
baricitinib  nmbr mg daily ( n = nmbr ),C4044947,1219/10465
ls mean % change from baseline _ se,C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668,1220/10465
established ascvd or > nmbr cv risk factors,C0443211;C1272684,1221/10465
fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0015663,1222/10465
enmbr + anmbr -,,1223/10465
filtration rate nmbr - nmbr,C0016107;C0016107;C0016107;C0016107,1224/10465
placebo secukinumab nmbr mg,C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408,1225/10465
sf - nmbr physical component summaryjj,C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712;C0037712,1226/10465
angiographic data,C0002978;C0002978;C0002978,1227/10465
community hospital ( % ),C0020003,1228/10465
death or absolute fvc decrease > nmbr %,C0011065;C1306577;C4082313;C4552775,1229/10465
indacaterol nmbr mg[n z nmbr],C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260,1230/10465
other statin,C0360714,1231/10465
median ( iqr ) age  years,C0549183;C0876920;C2347635;C2348144;C2939193,1232/10465
estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr : i : §,,1233/10465
homa_ % b tx difference vs pbo  median change from baseline ( se ) nmbr,C0041403;C0041403,1234/10465
tim nmbr nsk score,C1313407;C1313407;C1313407;C1313407;C3541335;C3541335;C3541335;C3541335;C3711667;C3711667;C3711667;C3711667;C3827754;C3827754;C3827754;C3827754;C3890185;C3890185;C3890185;C3890185;C4319633;C4319633;C4319633;C4319633,1235/10465
indication for pci,C0392360;C3146298,1236/10465
percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C1532338,1237/10465
nmbr - aminosalicylates ’ i " i ‘,,1238/10465
native latin,C0302891,1239/10465
left atrial diameter  mm ( sd ),C0225860;C0225861,1240/10465
patient history of disease,C0030705;C0030705;C0030705;C0030705,1241/10465
copd severity : severe / very severe,C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,1242/10465
mean platelet volume  fl,C0200665;C0344388,1243/10465
in ibdq total score at week nmbr  mean [se],C2964552;C2964552;C2964552;C2964552,1244/10465
baseline ezetimibe usec,C0168634;C1442488,1245/10465
ics use at screening  n ( % ),C0815320;C4551720,1246/10465
mdi / hfa  n,C0993596;C1839839;C4049613,1247/10465
moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,1248/10465
mixed chronic bronchitis and emphysema,C0205430;C3160715,1249/10465
triple - vessel disease  n ( % ),C0856738,1250/10465
mean ( sd ) crp  mg / l *,C0444504;C2347634;C2348143,1251/10465
epa / aa ratio,C0282379;C0282379;C1235746;C1235746;C1882141;C1882141;C4554792;C4554792,1252/10465
one or more requiring hospitalization in nmbr mo before screening — no . ( % ) nmbr,,1253/10465
health state index score  uk algorithm,C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314;C0683314,1254/10465
time from onset of pain to randomization  median ( iqr )  h,C0449244;C0449244;C0449244;C0449244;C0449244;C0449244;C0449244;C0449244;C0449244,1255/10465
homajr tx difference vs pbo  median change from baseline ( se ) nmbr lipid parameters,C0041403;C0041403,1256/10465
ticagrelor  nmbr mg ( n = nmbr ),C1999375,1257/10465
dpp - nmbr inhibitor therapy,C1414174;C1414174;C1414174;C1414174;C1414174;C1414174,1258/10465
median cardiac troponin t ( iqr ) — pg / ml,,1259/10465
> nmbr ( ml ) additional angiography,C0053917;C1334884,1260/10465
sbp < nmbr mmhg and dbp < nmbr mmhg,C0085805,1261/10465
insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501,1262/10465
other antiplatelet,,1263/10465
use of ics,C1524063;C1524063,1264/10465
mean hscrp  mg / l ( sd ),C0444504;C2347634;C2348143,1265/10465
carotid revascularization,C0741968,1266/10465
time from onset to randomization  h  mean ± sd,,1267/10465
beta - adrenergic blocker,C0001645;C2757061;C3536830,1268/10465
class l / ll heart failure,C0456387;C1518526;C1705943,1269/10465
rerandomization to placebo ( n = nmbr ) f,C0032042;C1696465;C1706408,1270/10465
triglycerides > nmbr mg / dl,C0041004,1271/10465
history of cabg surgery,C0455610,1272/10465
vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769,1273/10465
thoracic cage fractures,C0222762,1274/10465
baseline sgrq score,C0168634;C1442488,1275/10465
usa and canada,C0041703,1276/10465
obesity ( body mass index > nmbr kg / mnmbr ),C0028754;C1963185,1277/10465
clopidogrel plus aspirin ( n = nmbr ),C0070166,1278/10465
intent of early invasive strategy  %,C0162425;C0162425;C1283828;C1283828;C1550453;C1550453,1279/10465
mean fevnmbr  l ( sd ),C0444504;C2347634;C2348143,1280/10465
heavy calcification,C0439539;C0439539;C0439539;C0439539;C0439539;C0439539,1281/10465
cardiovascular medications  %,C0007220,1282/10465
only peripheral artery disease,C0205171;C0205171;C1720467;C1720467,1283/10465
inhaled anticholinergic §,,1284/10465
nmbr - h plasma glucose during ogtt ( mmol / l ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,1285/10465
uacra  mg / g  n ( % ),,1286/10465
western europe and israel,C0043129,1287/10465
sglt - nmbr inhibitors^,C3665045;C3665045,1288/10465
myocardial infarction — no . ( % ),,1289/10465
united states,C0041703,1290/10465
number of antidiabetes drugs at screening  n ( % ),C0237753;C0237753;C0449788;C0449788,1291/10465
any type  according to daily dose * *,C0332307;C1547052,1292/10465
glucocorticoids plus immunosuppressive agents,C0017710;C3540777;C3540778,1293/10465
left anterior descending artery  n ( % ),C0226032,1294/10465
albuterol reversibility  %,C0001927,1295/10465
rivaroxaban + aspirin,C1739768,1296/10465
anyantianginal agent,C0450442;C1254351;C1521826,1297/10465
patients with diabetic nephropathy,C0030705;C0030705,1298/10465
hbanmbrc in patients with baseline hbanmbrc > nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol )  % [mmol / mol]  la  n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se ),C0030705,1299/10465
health - related quality of life,C4279947,1300/10465
risk factors  %,C0035648;C1553898,1301/10465
concomitant therapy  no . ( % ),C1707479,1302/10465
any cardiovascular disease history  n ( % ),C1880008;C0007222;C0007222;C0007222;C0007222;C0007222;C0007222;C0007226;C3887460,1303/10465
cardiac history  %,C0018787;C0018787;C0018787;C0018787;C0018787;C0018787;C1522601;C1522601;C1522601;C1522601;C1522601;C1522601,1304/10465
subgroup by treatment interaction p - value,C1079230;C1079230;C1079230;C1079230;C1079230;C1079230;C1079230;C1515021;C1515021;C1515021;C1515021;C1515021;C1515021;C1515021,1305/10465
anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ),,1306/10465
dpi ( other than diskus )  n,,1307/10465
previous copd treatment  n ( % ) *,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,1308/10465
body mass index ( kg / mnmbr ) - mean ± sd,,1309/10465
positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,,1310/10465
psoriasis duration  mean ± sd  years,,1311/10465
fevi  l *,C0849974;C1561566;C4528367,1312/10465
ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0023824;C0202117;C0202117,1313/10465
black race,C0005680,1314/10465
lp ( a )  mean ( sd ),C0065058;C1439335;C4553379,1315/10465
previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,1316/10465
calculated ldl - c in nmbr classes,C0444686;C0444686;C0444686;C0444686;C0444686;C0444686;C0444686;C0444686;C1441506;C1441506;C1441506;C1441506;C1441506;C1441506;C1441506;C1441506,1317/10465
rosiglitazone,C0289313,1318/10465
without revascularsation,,1319/10465
odds ratio,C0028873,1320/10465
body mass index  kg / mnmbr  median ( qnmbr  qnmbr ),C0005893;C0578022;C1305855,1321/10465
exenatide n = nmbr,C0167117,1322/10465
total score on the sgrq - c  i ,C2964552,1323/10465
elevated creatinine ( > nmbr pmol / l ),C0151578;C0700225,1324/10465
valsartan / hctz,C0216784,1325/10465
baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr or < nmbr . nmbr meq / l,C0168634;C1442488,1326/10465
history of currently treated hypertension  n ( % ),C0455527,1327/10465
tg  mmol / l [mg / dl],C0337445,1328/10465
terminal ileum,C0227327,1329/10465
dasnmbr - esr lda,C3811131,1330/10465
prior tnfi  n ( % ),C0332152;C2826257,1331/10465
liraglutide nmbr . nmbr mg / day ( n = nmbr ),C1456408;C1456408,1332/10465
established ascvd,C0443211;C1272684,1333/10465
depressed and low perceived social support,C0344315;C0549249,1334/10465
limb ( sd ),C0015385,1335/10465
emergent / urgent surgery,C0750573,1336/10465
laboratory measurements,C0681902,1337/10465
simva n = nmbr n ( % ),,1338/10465
czp nmbr mg  % ( n / n ),C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,1339/10465
fibrinogen ( pmol / l ) c,C0016006;C1167394;C2587184;C3540039,1340/10465
frailty status,C0424594,1341/10465
basal insulin dose at run - in ( u / day ),C0650607;C0650607;C0650607;C0205112,1342/10465
worsening angina,C0002965,1343/10465
use of parenteral antithrombotic,C1524063;C1524063,1344/10465
cvd or mi,C0007222,1345/10465
screening bmi ( kg / mnmbr ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,1346/10465
atherosclerosis^  n ( % ),C0003850;C0004153,1347/10465
none ( cdmard - naive or past use at baseline ),,1348/10465
tender joint count ( nmbr - nmbr ),C0451530,1349/10465
hbanmbrc  %  n ( % ) b,,1350/10465
ldl - c < nmbr . nmbr mmol / l,,1351/10465
duration of last qualifying episode of atrial fibrillation > nmbr days,C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,1352/10465
saxagliptin nmbr . nmbr mg ( n = nmbr  nmbr ),C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,1353/10465
years [range],C0439234,1354/10465
potassium - sparing at enrollment,C0032821;C0032821;C0032821;C0202194;C0202194;C0202194;C0304475;C0304475;C0304475;C0597277;C0597277;C0597277;C3714637;C3714637;C3714637,1355/10465
body mass index > nmbr kg / mnmbr  n ( % ),C0005893;C0578022;C1305855,1356/10465
modmy al randcnxzaton,C0202311,1357/10465
additional investigations,C2359834,1358/10465
peri - op amiodarone : no ( n = nmbr ),C0347985,1359/10465
ejection fraction  % nyha class  n ( % ),C0489482;C2700378,1360/10465
class i or iii aad use in nmbr months before enrollment,C0441885;C1319793;C2698967,1361/10465
intravenous anticoagulant during hospitalization,C0348016;C0348016;C0348016,1362/10465
high density lipoprotein cholesterol  mg / dl^,C0023822,1363/10465
functional assessment of chronic illness,C0278372,1364/10465
hormonal status,C0458083,1365/10465
postmenopausal  current hormone,C0232970;C0232970;C0232970;C0232970,1366/10465
spironolactone ( n = nmbr ),C0037982,1367/10465
any disease,C0012634,1368/10465
endothelin - receptor antagonists plus phosphodiesterase type nmbr inhibitors,C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C1134681;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875;C2266875,1369/10465
bolus administered — no . ( % ),,1370/10465
tofacitinib  nmbr mg ( n = nmbr ),C2930696,1371/10465
medical history — no . / total no . ( % ),,1372/10465
tobacco use ( % ),C0040335;C0543414;C0841002;C3853727,1373/10465
infliximab - naive ( n = nmbr ),C0666743,1374/10465
week nmbr mean 士 sd,,1375/10465
hr ( nmbr % ci ) p value for interaction *,,1376/10465
history of congestive heart failure,C0455531,1377/10465
events  no .,C0441471;C3541888,1378/10465
event / total,C0441471;C0441471;C4019010;C4019010,1379/10465
serum cholesterol — mmol / liter,,1380/10465
pooled empagliflozin ( n = nmbr ),C1709595;C2349200;C4522255,1381/10465
statin monotherapy,C0360714,1382/10465
total comparators  patients with events / total patients,C0439175;C0439175;C0439175;C0439810;C0439810;C0439810,1383/10465
( % ) control ( nmbr ),,1384/10465
hypertension : no ( n = nmbr ),C0020538;C1963138,1385/10465
angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021,1386/10465
bdmard - ir,C0022065;C0022071;C1448132,1387/10465
estimated glomerular filtration rate,C3811844,1388/10465
periprocedural medications — no . / total no . ( % ),,1389/10465
proportion of predicted normal fevnmbr value   §,,1390/10465
mellitus,,1391/10465
amiodarone,C0002598,1392/10465
permanently stopped study drug because of adverse events,C1272691;C1272691,1393/10465
median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol,C0549183;C0876920;C2347635;C2348144;C2939193,1394/10465
apolipoproiein anmbr ( tng / nmbr ),,1395/10465
metformin dose  mg,C0025598;C0025598;C0025598,1396/10465
placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408,1397/10465
hbanmbrc nmbr % - < nmbr % ( n - nmbr ),C0053917;C1334884,1398/10465
hypoglycaemic agents,C0020616,1399/10465
apremilast nmbr mg bid n = nmbr,C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805;C1678805,1400/10465
duration  mean ( sd )  years,C0449238;C2926735,1401/10465
patient global assessment of disease activity ( vas nmbr - nmbr mm ),C4054228,1402/10465
intermittent claudication,C0021775,1403/10465
myocardial ischaemia,C0010054;C0151744,1404/10465
arb at enrollment,C3888198;C3888198;C3888198,1405/10465
rosuvastatin of patients ( rate ),C0965129,1406/10465
recent cardioversion ( within nmbr days before randomization ) —,,1407/10465
denosumab ( n = nmbr ),C1690432,1408/10465
genotyping,C1285573,1409/10465
remission  n ( % ),C0544452;C0687702,1410/10465
radius fracture,C0034628,1411/10465
clopidogrel dose on / before pci,C0070166;C0070166;C0070166,1412/10465
enoxaparin / vka,C0206460,1413/10465
sf - nmbr score,C0037712;C0037712;C0037712;C0037712,1414/10465
seropositivity,C0521143,1415/10465
interval pain onset to admission,C1272706;C1272706;C1552654;C1552654;C1552713;C1552713,1416/10465
metrex modified intention - to - treat population with an eosinophilic phenotypey,,1417/10465
number of previous anti - tnf treatments for psoriatic arthritis,C0237753;C0237753;C0449788;C0449788,1418/10465
serum creatinine  mean ( sd )  pmol / l,C0201976;C0600061,1419/10465
coronary heart disease ( % ),C0010054;C0010068;C1956346,1420/10465
bmi ( kg / mnmbr ) < nmbr,C0578022,1421/10465
abdominal aortic — no . ( % ),,1422/10465
mean weight  kg ( sd ),C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,1423/10465
severe hyperkalemiac,C0205082;C4050465;C4050466,1424/10465
history of bone disease ( predefined )  n ( % ),C0683519;C0730226;C0850708;C0944983;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,1425/10465
abrupt vessel closure,C1276802;C1276802,1426/10465
/ j - valuc ! l,,1427/10465
> nmbr days warfarin,C0053917;C1334884,1428/10465
non - hdl - c ( mmol / l  mean ),C1518422,1429/10465
yes  non - insulin - treated,C1549445;C1705108;C1710701,1430/10465
nmbr - nmbr . nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,1431/10465
baseline lp ( a ) in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,1432/10465
primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631,1433/10465
dyspepsia,C0013395;C4552968,1434/10465
south asian,C1519427,1435/10465
claudication,C0021775;C0311395;C1456822,1436/10465
anticoagulant therapy,C0150457,1437/10465
dactylitis  n ( % ),C0239161,1438/10465
prior immunnosupressive failure but no anti - tnf failure,C0332152;C0332152;C2826257;C2826257,1439/10465
sf - nmbrvnmbr domain scores  mean [sd],C0037712;C0037712;C0037712,1440/10465
reversibility ( bnmbr - agonist )  %  mean ( sd ) nmbr,C0449261,1441/10465
icd therapy vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0021122;C0021122;C0021122,1442/10465
fev  at baseline,C3714541,1443/10465
low - density lipoprotein cholesterol  mg / dl,C0023824,1444/10465
qualifying type of atherosclerosis — no . ( % ),,1445/10465
white : black : other,C0007457;C0043157;C0220938,1446/10465
placebo estimated mean,C0032042;C1696465;C1706408,1447/10465
salmeterol - fluticasone group,C0939232;C0939232;C0939232;C0939232;C0939232;C0939232,1448/10465
impaired glucose tolerance or impaired fasting glucose — no . ( % ),,1449/10465
duration of tnmbrdm ( % ),C0449238;C2926735,1450/10465
therapy ( asa nmbr  nmbr / placebo nmbr ),C0039798;C0087111;C1363945,1451/10465
antihyperglycemic oral agent therapy,C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616,1452/10465
gender  % of patients,C0079399;C1522384,1453/10465
planned thienopyridine at baseline,C1301732;C1301732,1454/10465
medical history,C0262926;C1704706,1455/10465
medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283,1456/10465
current / past,C0521116;C0521116;C1705970;C1705970,1457/10465
rosuvastatin n = nmbr,C0965129,1458/10465
pulse rate ( bpm ),C0232117,1459/10465
anti - cholinergics ( long - acting ),C0242896,1460/10465
primary + gusto severe bleeding,C0205225;C0205225;C0205225;C0439612;C0439612;C0439612;C0439631;C0439631;C0439631,1461/10465
mean age  years ( nmbr % ci ),C0444504;C2347634;C2348143,1462/10465
vertebrobasilar infarct,C0545733,1463/10465
alathosterol ( % ),,1464/10465
blood oxygenation  mean ± sd,,1465/10465
rf positive  %,C0035448;C0035448;C0035448;C0035448;C0035448;C0201660;C0201660;C0201660;C0201660;C0201660;C0748398;C0748398;C0748398;C0748398;C0748398;C1547111;C1547111;C1547111;C1547111;C1547111,1466/10465
sf - nmbr ( health transition score ),C0037712;C0037712,1467/10465
time since diagnosis of osteoarthritis — yr,,1468/10465
no . of days to homa - ir testing — median ( iqr ),,1469/10465
certolizumab group ( n = nmbr ),C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,1470/10465
nmbr - nmbr / week,C0053917;C0053917;C1334884;C1334884,1471/10465
pnmbrynmbr inhibitor,C1999216,1472/10465
previous cardiovascular disease !,C0205156;C1552607,1473/10465
acute and delayed reaction,C0205178,1474/10465
atenolol strategy,C0004147,1475/10465
nationality,C0027473,1476/10465
bl updrs : high,C0005918;C0006413;C1552663;C2827109,1477/10465
history of paroxysmal atrial fibrillation  n ( % ),C0729790,1478/10465
biomarker status,C0449442,1479/10465
nicotine pack - years,C0028040,1480/10465
congestive heart failure — no . ( % ) | |,,1481/10465
fibrin - specific,C0015982;C0015982,1482/10465
≥ nmbr . nmbr to < nmbr . nmbr years,,1483/10465
duration of hypertension ( years ),C0449238;C0449238;C2926735;C2926735,1484/10465
therapy ( asa nmbr / placebo nmbr ),C0039798;C0087111;C1363945,1485/10465
nmbr prolonged antithrombotic pretreatment ( n = nmbr ),C0053917;C1334884,1486/10465
isolated igt,C0205409;C1548221,1487/10465
pasi < nmbr *,C4528685,1488/10465
nmbr locf ),C0053917;C1334884,1489/10465
uacr ( mgg - nmbr ),,1490/10465
vorapaxar placebo nmbr - yr . km % rate,C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521;C2974521,1491/10465
change from baseline  adjusted mean ( nmbr % ci )  %,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,1492/10465
paclitaxel - eluting,C0144576,1493/10465
distal anastomosis ( % ),C0448964,1494/10465
< nmbr ml / min / nmbr . nmbr mnmbr — no . ( % ),,1495/10465
atrial fibrillation  n ( % ),C0004238;C0344434;C1963067,1496/10465
uacr  mg / mmol ( interquartile range ) b,,1497/10465
fasting glucose  mmol / l  mean ± sd,,1498/10465
coronary artery bypass surgery,C0010055,1499/10465
prior cardiovascular event — no . ( % ),,1500/10465
concomitant atorvastatin dose  mg,C0521115;C0521115;C0521115,1501/10465
n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo ),C0369718;C0441922,1502/10465
etanercept,C0717758,1503/10465
aortic stenosis  n ( % ),C0003507,1504/10465
pretreatment / concomitant treatment,C1550147;C1550147;C1550147;C1550147;C1550147;C1550147;C1550147;C2709094;C2709094;C2709094;C2709094;C2709094;C2709094;C2709094;C3539075;C3539075;C3539075;C3539075;C3539075;C3539075;C3539075;C3539076;C3539076;C3539076;C3539076;C3539076;C3539076;C3539076,1505/10465
circumflex,C1880089,1506/10465
diuretic drugs  n ( % ),C0012798;C0012798,1507/10465
baseline median ( iq range ),C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,1508/10465
serum sodium — meq / liter,,1509/10465
pacific islander,C0242191,1510/10465
hbalc > = nmbr % ( n - nmbr ),,1511/10465
hbanmbrc ( % ) all countries,,1512/10465
prior diabetes,C0332152;C0332152;C2826257;C2826257,1513/10465
number of events / patients,C4330837;C2360800;C2360800,1514/10465
coronary heart disease,C0010054;C0010068;C1956346,1515/10465
mean sgrq total score ( sd ),C3533236;C3533236;C0444504;C2347634;C2348143,1516/10465
managed medically — no . / total no . ( % ),,1517/10465
postoperative glucocorticoid use,C0032790;C0032790;C0032790,1518/10465
losartan + placebo,C0126174;C0126174;C0126174,1519/10465
geographical region ( % ),C0017446,1520/10465
serum haemoglobin anmbrc concentration ( % )  mean ( sd ),C0683149;C0229671;C0229671;C0229671;C1546774;C1546774;C1546774;C1550100;C1550100;C1550100,1521/10465
creatinine ≥ nmbr . nmbr mg / dl,,1522/10465
previous balloon angioplasty  n ( % ),C0205156;C0205156;C1552607;C1552607,1523/10465
thrombolytic treatment before randomization,C0016018;C0016018;C0016018;C0016018;C0016018;C0016018;C0016018;C0520997;C0520997;C0520997;C0520997;C0520997;C0520997;C0520997,1524/10465
apixaban,C1831808,1525/10465
urgent cor revasc,C0439609;C0439609;C3272275;C3272275,1526/10465
diabetic treatments !,C0241863,1527/10465
primary ep ( cvd / mi / ri ),C0205225;C0205225;C0439612;C0439612;C0439631;C0439631,1528/10465
cv death / mi / stroke,C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503,1529/10465
ticlopidine ( n = nmbr ),C0040207,1530/10465
alt  ast  or both > nmbrx uln,C1266129;C4553172,1531/10465
qualifying nstemi  n ( % ),C1514624;C1514624,1532/10465
baseline nihss score  median ( range ),C0168634;C1442488,1533/10465
scr  gmol / l,C1539487;C4050416,1534/10465
baseline cardiovascular medication  c n ( % ),C0168634;C1442488,1535/10465
thienopyridine drug at start of open - label period,C1120149;C1120149,1536/10465
egfr ( mumin / nmbr . nmbr mnmbr ),C1739039;C3811844;C3812682,1537/10465
median ( sd )  mg / mmol,C0549183;C0876920;C2347635;C2348144;C2939193,1538/10465
double - vessel disease  n ( % ),C0205173;C1705764;C1705765,1539/10465
lipid profile,C0023779;C0023779,1540/10465
chronic obstructive pulmonary disease,C0024117,1541/10465
treatment difference  ml,C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,1542/10465
homa - ir  median ( qnmbr  qnmbr ),C0022065;C0022071;C1448132,1543/10465
nmbr placebo n = nmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,1544/10465
concomitant mtx use  n ( % ),C0521115;C0521115;C0521115;C0521115;C0521115;C0521115,1545/10465
atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651,1546/10465
dmard | |,C0242708,1547/10465
calculated ldl cholesterol ( week nmbr ),C0444686;C0444686;C1441506;C1441506,1548/10465
median ( qnmbr : qnmbr ) total daily insulin dosenmbr,C0549183;C0876920;C2347635;C2348144;C2939193,1549/10465
hematologic,C0018943;C0205488,1550/10465
physician global assessment ( nmbr - nmbr mm vas ),C4050369,1551/10465
ipf - related,C0034069;C0034069;C1800706;C1800706,1552/10465
history of major bleeding,C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062,1553/10465
fpg  mean ( sd )  mmol / l,,1554/10465
ldl - c ( bq ) ( mg / dl ) - mean ± sd,,1555/10465
body - mass index  !  waist - to - hip ratio,C0005893;C0578022;C1305855,1556/10465
hba  % nmbrc,C0019016;C1825777;C3538758,1557/10465
current tobacco abuse  n ( % ),C0521116;C1705970,1558/10465
hormone therapy,C0279025,1559/10465
total group ( n = nmbr ),C0439175;C0439175;C0439175;C0439175;C0439175;C0439175;C0439810;C0439810;C0439810;C0439810;C0439810;C0439810,1560/10465
smoking pack year ( years ) fl,C0037369;C0453996;C1881674,1561/10465
( nmbr % ell ' ll  * non - hdl - c,C0053917;C0053917;C1334884;C1334884,1562/10465
terol  hdl - c  high - density lipoprotein cholesterol ,,1563/10465
age at first seizure  years  mean ( sd ),C0001779;C0001779;C0001779;C0001779;C0001779;C0001779,1564/10465
glomerular,C0022663;C0268731,1565/10465
median blood eosinophil count  cells per pla,C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193;C2939193,1566/10465
cv death or first hhf,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,1567/10465
balloon angioplasty plus abciximab,C0002996;C0002997,1568/10465
lipoprotein ( a )  median ( ql  qnmbr )  nmol / l,C0065058;C0125953;C1096202;C1439335,1569/10465
osteoporosis,C0029456;C4554622,1570/10465
acute rheumatic disorders,C0001314,1571/10465
intensive control,C0162425;C0162425;C0162425;C0162425;C0162425;C0162425;C0522510;C0522510;C0522510;C0522510;C0522510;C0522510;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1550453;C1550453;C1550453;C1550453;C1550453;C1550453,1572/10465
treatment duration  days,C0444921;C3259042,1573/10465
warfarin ( n = nmbr ),C0043031,1574/10465
reported hypertension *,C0684224;C0684224;C0700287;C0700287;C4319718;C4319718,1575/10465
before bronchodilation,C1371299;C3537072,1576/10465
ccv history / condition at baseline,C0683519;C0683519,1577/10465
ivabradine ( n = nmbr ),C0257190,1578/10465
bmi ( nmbr . nmbr  nmbr . nmbr ),C0578022,1579/10465
physical function ( nmbr - nmbr  short form - nmbr subscale ),C0516981;C4049916,1580/10465
prior cerebrovascular disease,C0332152;C2826257,1581/10465
reason for enrollment in active a — no . ( % ),,1582/10465
medical characteristics,C0199168;C0205476,1583/10465
medication use at baseline — no . ( % ),,1584/10465
age < nmbr years — no . ( % ),,1585/10465
planned valve surgery  n ( % ),C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732;C1301732,1586/10465
time from randomization to pci ( st - elevation mi )  min,C0040223;C3541383,1587/10465
haq - di score ( nmbr - nmbr ),C3826998;C3826998;C4321476;C4321476,1588/10465
mean ( sd ) dasnmbr - nmbr ( esr ) *,C0444504;C2347634;C2348143,1589/10465
randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,1590/10465
v alsartan / hctz  n ( % ),C0020261,1591/10465
nmbr year or more,C0053917;C0053917;C1334884;C1334884,1592/10465
crcb - ( ml / min )  mean ( s . e . ),,1593/10465
three - vessel disease,C3272265,1594/10465
st - segment depression > nmbr . nmbr mv on admission  %,C0520887,1595/10465
planned treatment duration  n ( % ),C4528394,1596/10465
z\tonastaiin,,1597/10465
inadequate response / intolerance to prior therapy  %,C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0205412;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856;C0439856,1598/10465
change from baseline in dasnmbr - esr  meannmbr sd,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,1599/10465
cause of heart failure — no . ( % ),,1600/10465
predominant type of heparin,C1542147;C1542147;C1542147;C1542147,1601/10465
western europe / australia / israel,C0043128;C0043129,1602/10465
preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0445204;C0445204;C0445204,1603/10465
glucose  mmol / l,C0017725,1604/10465
aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr,C0004057,1605/10465
retinopathy — %,,1606/10465
pulmonary embolism,C0034065,1607/10465
mild or moderate copd,C2945599,1608/10465
prior ml ( before index acs ),C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,1609/10465
diabetes duration ( known )  % of patients,C0011847;C0011847;C0011849;C0011849,1610/10465
creatinine clearance ， : : nmbr ml / min  %,,1611/10465
baseline hb < nmbr g nmbr nmbr n = nmbr,C0168634;C0168634;C1442488;C1442488,1612/10465
joint swelling,C0152031,1613/10465
nmbrmwd decrease > nmbr m,C0392756;C0547047,1614/10465
profound thrombocytopenia ( < nmbrxnmbr / l ),C0439808;C0439808,1615/10465
body mass index  median  ( nmbrth — nmbrth percentiles )  kg / mnmbr,,1616/10465
associated with connective tissue disease,C0332281,1617/10465
postbronchodilator lung function at screening,C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594,1618/10465
non – small - cell lung cancer,,1619/10465
prior anti - tnf therapy — no . ( % ),,1620/10465
all rosuva,,1621/10465
peripheral edema,C0085649,1622/10465
insulin - na ' ive,C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501,1623/10465
gender  women n  % ),C0079399;C1522384,1624/10465
mean ( sd ) swollen joint count *,C0444504;C2347634;C2348143,1625/10465
diuretic drugs ( excluding antialdosterone ),C0012798;C0012798,1626/10465
hfpef ( ef n nmbr )  ( % ),,1627/10465
extent of disease  n ( % ),C0449279;C4553144,1628/10465
tendonitis,C0039503,1629/10465
previous hypertension,C0205156;C0205156;C1552607;C1552607,1630/10465
oral contraceptives,C0009905,1631/10465
syncope — no . ( % ),,1632/10465
anatomic complexity characteristics,C0502371;C0502371,1633/10465
conventional treatment,C2945704,1634/10465
left circumflex,C0205091;C0443246;C1552822,1635/10465
amiodarone vs . placebo no . hazard ratio ( nmbr . nmbr % cl ),C0002598,1636/10465
number of pack - years,C0237753;C0449788,1637/10465
baseline cardiac biomarkers,C0168634;C0168634;C1442488;C1442488,1638/10465
type nmbr diabetes duration  mean ( sd )  years,C1320657;C1320657;C1320657;C1320657,1639/10465
oral study drug administered — no . / total no . ( % ),,1640/10465
diltiazem or verapamil,C0012373,1641/10465
major bleeding ( statin use vs non - use ),C0205082;C0205164;C4318856;C4521762,1642/10465
placebo secukinumab pooled,C0032042;C1696465;C1706408,1643/10465
bilateral disease ( % ) ' j ' ' j ',C1511113,1644/10465
pathological q waves,C0429090,1645/10465
leukocytes  nmbr / nl,C0023516,1646/10465
lipid - lowering agents ( % ),C0086440,1647/10465
history of second prior mi,C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062,1648/10465
study medication — no . ( % ),,1649/10465
laboratory data  mean ( sd ),C0022877;C0022877;C0022877;C3244292;C3244292;C3244292;C4283904;C4283904;C4283904,1650/10465
p value ( men versus women ),C1709380,1651/10465
former n z nmbr,C0205156;C0205156;C0750523;C0750523,1652/10465
insulin : glucose ratio,C0021641;C1533581;C1579433;C3714501,1653/10465
tnmbrdm duration ( years ),C0449238;C2926735,1654/10465
serum creatinine > nmbr pmol / l . n ( % ) |,C0201976;C0600061,1655/10465
kellgren and lawrence radiographic reading grade nmbr — no . ( % ),,1656/10465
data missing or no drug given,C1511726;C1511726;C1511726;C3245479;C3245479;C3245479;C3714741;C3714741;C3714741,1657/10465
gpiib / iiia receptor inhibitor,C0016011,1658/10465
ethnic origin,C0015031,1659/10465
supine after nmbr minutes change from baseline,C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846;C0038846,1660/10465
omega - nmbr fatty acid ( n = nmbr ),C1719844;C1719844,1661/10465
pulmonary rales  n ( % ),C0034642,1662/10465
< nmbr months  n ( % ),C0053917;C1334884,1663/10465
fibrinogen  g / l,C0016006;C1167394;C2587184;C3540039,1664/10465
right ventriculardysfunction atinclusion,C0205090;C0444532,1665/10465
nace ( primary endpoint ),,1666/10465
micro - / macro - albuminuria  ckd and / or retinopathy,C0085672;C1553035;C3811161;C4049106,1667/10465
interaction : treatment by psoriasis p valuenmbr,C1704675,1668/10465
score > nmbr %  % of patients,C0449820;C4050231,1669/10465
any aes  n ( % ),C1412268;C2699274,1670/10465
ace inhibitors or angiotensin ii,C0003015,1671/10465
des ( % previous stenting ),C0011702;C0011702;C0011702;C0011702;C4551552;C4551552;C4551552;C4551552,1672/10465
comparison with placebo ( mean,C1707455;C1707455;C1707455,1673/10465
mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143,1674/10465
exercise,C0015259;C1522704,1675/10465
vascular territory # nmbr,C0005847;C0005847;C0005847;C0005847;C1558950;C1558950;C1558950;C1558950;C1801960;C1801960;C1801960;C1801960,1676/10465
native hawaiian or other pacific islander,C0337920,1677/10465
control baseline ( n - nmbr ),C0243148;C0243148;C1550141;C1550141;C1882979;C1882979;C2587213;C2587213;C3274648;C3274648;C4553389;C4553389,1678/10465
rando . in na * *,,1679/10465
estimated glomerular filtration rate - ml / min  median ( iqr ) ',C3811844,1680/10465
nyha class within past month — no . / total no . ( % ),,1681/10465
aspirin group,C0004057;C0004057;C0004057;C0004057;C0004057;C0004057,1682/10465
non - hdl - c ( mg / dl ) - mean ± sd,,1683/10465
fibrinolytic for qualifying event,C0040044;C0040044,1684/10465
nmbr degree of ica stenosis 丰,,1685/10465
calcium - channel blockers ( % ),C0006684;C2757014,1686/10465
duration of ra ( years ),C0449238;C0449238;C2926735;C2926735,1687/10465
min  max,C0702093;C1524029;C3813700,1688/10465
estimated gfr  < nmbr ml min - nmbr nmbr . nmbr m - nmbr  n ( % ) a,C0750572;C0750572,1689/10465
ctn - l  ng / ml,C0917591,1690/10465
chd + cerebral infarction,C0280604;C3542407,1691/10465
fenofibric acid + moderate - dose statin,C0060179,1692/10465
highest tg tertile,C1522410,1693/10465
days of study - drug administration ( % ) * * nmbr day,C2826182;C2826182,1694/10465
emotional role,C0013987;C0013987;C0013987;C0849912;C0849912;C0849912,1695/10465
antithrombotic therapy,C0039798;C0087111;C1363945,1696/10465
periprocedural medications — no . / total no .,,1697/10465
kim nmbr ( pg / ml ),C0053917;C1334884,1698/10465
mi or cad,C3810814,1699/10465
d - dimer levelsatinclusion,C0060323,1700/10465
any immunosuppressive agent,C0021081,1701/10465
tender joint count  of nmbr,C0451530,1702/10465
increased waist circumference,C0205217;C0442805,1703/10465
cross - damp time : < l : llhrs : min ( n = nmbr ),C2828360;C2828360;C2828360;C2828360,1704/10465
aspirin only ( n = nmbr  nmbr ),C0004057;C0004057,1705/10465
high risk with atherosclerotic vascular disease *,C0332167;C3272283;C4050568;C4319571,1706/10465
metrex overall modified intention - to - treat population ? :,C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C0282416;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607;C1561607,1707/10465
basmi ( linear )  mean ( sd ),,1708/10465
cor revasc,C0018787;C0056331,1709/10465
high ( > nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,1710/10465
adl subscale ( range  nmbr - nmbr ) *,C0001288;C1420005,1711/10465
baseline statin usec,C0168634;C1442488,1712/10465
unbound pcsknmbr ( nmol / l ),,1713/10465
months from mi — median ( iqr ),,1714/10465
enthesitis count,C1282952;C1282952,1715/10465
enalapril,C0014025,1716/10465
history of alcohol use,C0551571;C0552479,1717/10465
initiation of dialysis  renal transplantation  or creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l ),C0589507;C0589507;C0589507;C0589507;C1158830;C1158830;C1158830;C1158830;C1704686;C1704686;C1704686;C1704686,1718/10465
female race / ethnicity,C0043210;C0043210;C0043210;C0043210;C0043210;C0043210;C0086287;C0086287;C0086287;C0086287;C0086287;C0086287;C1705497;C1705497;C1705497;C1705497;C1705497;C1705497;C1705498;C1705498;C1705498;C1705498;C1705498;C1705498,1719/10465
bsa affected  mean ± sd  %,,1720/10465
timing of clopidogrel loading dose,C0449243;C1704250,1721/10465
week nmbr fpg  mean ( s . e . ),C0332174;C0332174;C0439230;C0439230,1722/10465
crohn ' s disease - related medication at baseline  n ( % ),C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346;C0010346,1723/10465
post - menopausal ( a ),C0232970,1724/10465
saxagliptin nmbrmg ( n z nmbr ),C1611934,1725/10465
weight ( range ) ( kg ),C0005910;C0043100;C1305866;C1705104,1726/10465
monotherapy,,1727/10465
small vessel,C0225988,1728/10465
history of microvascular disease — no . ( % ),,1729/10465
baseline sitosterol,C0168634;C0168634;C1442488;C1442488,1730/10465
hypertension and left ventricular hypertrophy,C0020538;C1963138,1731/10465
ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,C0023668;C0023668;C0023668,1732/10465
severe n z nmbr,C0205082;C0205082;C4050465;C4050465;C4050466;C4050466,1733/10465
arthritis,C0003864;C4552845,1734/10465
concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,,1735/10465
extensive,C0205231,1736/10465
baseline corticosteroids *,C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,1737/10465
lv hypertrophy  n ( % ),C0149721,1738/10465
sex ( interaction : p = nmbr . nmbr ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,1739/10465
native hawaiian / other,C0337920,1740/10465
pain ( nmbr - nmbr mm vas ),C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132,1741/10465
randomized,C0034656;C3815594,1742/10465
nmbrbaseline mean,C0444504;C2347634;C2348143,1743/10465
fc - ldl - c  mg / dl,C2983605,1744/10465
patients with previous loss of response to and intolerance of infliximab *,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,1745/10465
other glp - nmbr receptor agonist,C0018301;C0018301;C1422069;C1422069;C1425391;C1425391;C1539338;C1539338;C2350813;C2350813,1746/10465
baseline hematocrit  median ( iqr ),C0168634;C0168634;C1442488;C1442488,1747/10465
placebo event rate ( n = nmbr )  %,C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408,1748/10465
history of amputation,C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062,1749/10465
low - dose rivaroxaban + aspirin group,C2608320;C2608320;C2608320;C2608320;C2608320;C2608320,1750/10465
documented asymptomatic cardiac ischemiac,C1301725;C1301725;C1609436;C1609436,1751/10465
seropositive ( rf + ve and / or acpa + ve ) subgroup,C0521143,1752/10465
| ? ) - blocker  %,,1753/10465
metabolizer phenotype ( % ) §,,1754/10465
disease location / type : terminal ileum,C0457464;C0457464;C0457464;C0457464,1755/10465
selexipag ( n = nmbr ),C2000145,1756/10465
clinical presentation,C2708283,1757/10465
patients not receiving corticosteroids at baseline,C0030705,1758/10465
alteplase group ( n = nmbr ),C0032143;C0032143;C0032143;C0032143;C0032143;C0032143,1759/10465
obesity  % *,C0028754;C1963185,1760/10465
cardiovascular history — no . / total no . ( % ),,1761/10465
cardiac therapy  n ( % ) d,C3654025,1762/10465
femoral access — no . / total no . ( % ),,1763/10465
laboratory data,C0022877;C0022877;C0022877;C3244292;C3244292;C3244292;C4283904;C4283904;C4283904,1764/10465
other drugs,C0013227;C3687832,1765/10465
apob : apoa - nmbr ratio,C0003593;C3252643,1766/10465
length of stay ( randomization to discharge  h ),C0023303,1767/10465
nmbr - aminosalicylates | | | |,C0053917;C1334884,1768/10465
peripheral - artery disease ( % ),C1704436;C4025272,1769/10465
severity of the disease ( gold nmbr )  n ( % ),C0521117,1770/10465
apixaban  nmbr . nmbr mg,C1831808,1771/10465
coronary bypass graft,C1260596,1772/10465
vascular disease indicator no ( n = nmbr ),C0042373;C0042373;C0042373,1773/10465
laboratory values at randomization ( median and iqr ),C0022877;C3244292;C4283904,1774/10465
acr  mg / mmol,C1412134;C1515941,1775/10465
tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,1776/10465
hbanmbrc at baseline  %,C0168634;C1442488,1777/10465
indication for stent,C0392360;C3146298,1778/10465
history of intermittent claudication and abi < nmbr - nmbr or substantial peripheral arterial stenosis > nmbr %,C2315493,1779/10465
months since ra was first diagnosed  mean ( sd ),C0439231,1780/10465
hemorrhagic stroke ( n = nmbr ),C0553692,1781/10465
mini - mental state examination,C0451306,1782/10465
number of stents implanted,C0237753;C0449788,1783/10465
risk score category ( points ),C0035647;C0035647;C0035647;C0035647;C4552904;C4552904;C4552904;C4552904,1784/10465
microvascular complications  n ( % ) ’,,1785/10465
erosion score  median ( min  max ),C0333307;C0333307;C1880549;C1880549;C1959609;C1959609;C3887524;C3887524,1786/10465
fevnmbr / fvc ( post salbutamol ),C3714541,1787/10465
type nmbr diabetes,C1320657;C1320657,1788/10465
% predicted pre - bronchodilator fevnmbr  % *,C0681842;C1882327,1789/10465
patients receiving corticosteroids at baseline,C0030705,1790/10465
odds ratio adj ( nmbr % cl ),C0028873;C0028873;C0028873;C0028873,1791/10465
no statin vs statin alone vs any statin plus other llt,C0360714,1792/10465
general and lumbar epidural,C0205246;C3812897;C3891294;C4521767,1793/10465
rf and acpa negativenmbr,C0035448;C0201660;C0748398;C1547111,1794/10465
hispanic,C0086409,1795/10465
onsetofaf  no . ( % ),,1796/10465
percentage with disease duration < nmbr years,C0439165;C1549488;C1561533,1797/10465
doubling of creatinine †,,1798/10465
diameter stenosis  mean ( sd )  %,C1301886;C1301886;C1301886,1799/10465
biologic naive,C0005515;C0205460,1800/10465
systemic corticosteroids  n ( % ) a,C4053960,1801/10465
europe ( non - eu ),C0015176,1802/10465
fasting blood glucose ( mg / dl ),C0428568;C1261430,1803/10465
fevnmbr reversibilityz ( pre / post ipratropium )  %,,1804/10465
mean eosinophil count  per ml,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,1805/10465
men  total ( n 二 nmbr ),,1806/10465
rhabdomyolysis  myopathy  or myalgia with ck elevation > nmbrx uln,C0035410;C4552660,1807/10465
rf positive  n ( % ),C0035448;C0035448;C0035448;C0035448;C0035448;C0201660;C0201660;C0201660;C0201660;C0201660;C0748398;C0748398;C0748398;C0748398;C0748398;C1547111;C1547111;C1547111;C1547111;C1547111,1808/10465
without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501,1809/10465
hospitalized for heart failure during that time period,C0701159;C0701159;C0701159,1810/10465
phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),C0031676;C0031676;C0202177;C0202177,1811/10465
clinical and laboratory measurements,C0205210,1812/10465
current medication — no . ( % ),,1813/10465
infliximab nmbr mg / kg,C0666743;C0666743,1814/10465
randomization - to -,C0034656,1815/10465
low hdl cholesterol,C0151691,1816/10465
history of chronic hf,C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062,1817/10465
race - non - white ( n = nmbr  nmbr ),C0034510;C0034510;C0034510;C1706779;C1706779;C1706779;C3853635;C3853635;C3853635,1818/10465
moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,1819/10465
sfc nmbr / nmbr mg twice daily ( n = nmbr ),C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536,1820/10465
time since diagnosis of type nmbr diabetes,C0040223;C3541383,1821/10465
riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ),C0683610;C4553947,1822/10465
disease and quality - of - life scores,C0012634,1823/10465
laba / ics use at screening  n ( % ),C0815320;C4551720,1824/10465
mean change in radiographic end points,C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,1825/10465
screening % predicted fevnmbr,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,1826/10465
lntensityd,,1827/10465
steroid use at baseline,C0281991;C0281991,1828/10465
angina class at baseline,C0002962;C0002962;C0002962;C0002962;C0002962;C0002962,1829/10465
emotional status,C0013987;C0849912,1830/10465
albuminuria ( g / g ),C0001925,1831/10465
concomitant therapy,C1707479,1832/10465
thrombophilia,C0398623,1833/10465
mean — mg / dl level — no . ( % ),,1834/10465
urine albumin - to - creatinine ratio - no . ( % ) § §,,1835/10465
mean a ± sd ( mmhg ),,1836/10465
hdl cholesterol ( week nmbr ) a,C0023822;C0392885,1837/10465
low - dose rivaroxaban plus aspirin ( n = nmbr ),C2608320,1838/10465
clinical criterianmbr,C0205210,1839/10465
abatacept ( n = nmbr * ),C1619966,1840/10465
ind nmbr gg q . d . n / n ( % ),C4049864;C4049864;C4049864;C4049864,1841/10465
lvef ( % )  mean ± sd,,1842/10465
menopausal status and use of hrt ( % ) y,C1513126,1843/10465
renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920,1844/10465
urine albumin - to - creatinine ratio,C0455271;C1318330,1845/10465
total n = nmbr n ( % ),C0439175;C0439810,1846/10465
chronic heart failure,C0018802;C0264716,1847/10465
type nmbr diabetes mellitus ’,,1848/10465
mean score on dasnmbr - nmbr ( crp ) ^,C3533236;C3533236,1849/10465
orthostatic hypotension,C0020651,1850/10465
previous oral glucose - lowering agents  % of patients,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,1851/10465
aortic stenosis,C0003507,1852/10465
no . of patients / total no . ( % ),,1853/10465
any dose reduction,C0178602;C0178602;C0178602;C0178602;C0869039;C0869039;C0869039;C0869039;C1114758;C1114758;C1114758;C1114758,1854/10465
hazard ratio for event ( nmbr % ci ),C2985465;C2985465,1855/10465
prior implantable cardiodefibrillator  n ( % ),C0332152;C2826257,1856/10465
crp ( mg / l )  median ( min  max ),C3890735;C4048285,1857/10465
gold nmbr groups  n ( % ),C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897,1858/10465
enalapril + aliskiren dm = nmbr non - dm = nmbr,C0014025;C0014025,1859/10465
ics  mg / day,C0815320;C4551720,1860/10465
psoriasis covering > nmbr % bsa  n ( % ) §,,1861/10465
antihypertensive drug  %,C0003364,1862/10465
mean ( sd ) post - bronchodilator fevnmbr reversibility  %,C0444504;C2347634;C2348143,1863/10465
nmbr - nmbr ( severe ),C0053917;C1334884,1864/10465
stroke or pvd  ( % ),C0038454;C4554100,1865/10465
cabg > nmbr month ago,C0010055,1866/10465
history of percutaneous coronary intervention,C1320647;C4554713,1867/10465
current or previous atrial fibrillation,C0521116;C1705970,1868/10465
ace - inhibitor use,C0003015;C0003015;C0003015;C4541021;C4541021;C4541021,1869/10465
anemia — no . ( % ) | |,,1870/10465
low - dose corticosteroid user,C0445550;C0445550;C0445550;C0445550;C1708745;C1708745;C1708745;C1708745,1871/10465
upper gastrointestinal,C3203348,1872/10465
cad history and risk factors  n ( % ),C1504769;C1504769;C1504769;C1504769;C1504769;C1504769;C2239547;C2239547;C2239547;C2239547;C2239547;C2239547;C3813548;C3813548;C3813548;C3813548;C3813548;C3813548;C4284121;C4284121;C4284121;C4284121;C4284121;C4284121,1873/10465
das - nmbr ( crp ) < nmbr . nmbr  n ( % ),C0051767;C0051767;C0057671;C0057671,1874/10465
repaired chd,C0205340;C0205340,1875/10465
gusto - defined bleeding,C1704788;C3539106,1876/10465
peripheral vasodilators,C0724804,1877/10465
mean ( sd ) number of albuterol per day  puff,C0444504;C2347634;C2348143,1878/10465
liraglutide ( n = nmbr  nmbr ),C1456408,1879/10465
angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534,1880/10465
perianal or anus,C0442158,1881/10465
framingham nmbr - year cv risk score,C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866;C3166866,1882/10465
native coronary - artery lesions,C0302891,1883/10465
current drinker,C0556297,1884/10465
placebo ls means ( n ),C0032042;C1696465;C1706408,1885/10465
( %  nmbr % cl ),,1886/10465
duration of disease  years,C0872146,1887/10465
musculoskeletal,C0497254;C2707260,1888/10465
severe ( gold nmbr ),C0205082;C4050465;C4050466,1889/10465
moderate thrombocytopenia ( < nmbrxnmbr / l ),C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,1890/10465
st change > nmbr mm,C0036056;C0036056;C0036056;C0036056;C3272372;C3272372;C3272372;C3272372,1891/10465
received an oral aha within nmbr weeks prior to screening,C1514756,1892/10465
stiffness subscale,C0427008,1893/10465
egfr < nmbr  n ( % ),C1739039;C3811844;C3812682,1894/10465
rec . ischemia requiring revasc,C1424025;C1424025;C2606415;C2606415,1895/10465
type of concomitant statin,C0332307;C1547052,1896/10465
bmi ( kg / mnmbr ) [median ( nmbrth to nmbrth percentile ) ],C0578022,1897/10465
moderate ( nmbr risk factor ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,1898/10465
timi risk score nmbr - nmbr,C0035647;C0035647;C0035647;C0035647;C4552904;C4552904;C4552904;C4552904,1899/10465
chronic obstructive pulmonary disease  n ( % ),C0024117,1900/10465
glycopyrronium nmbr mg ( n = nmbr ),C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772;C3814772,1901/10465
history of microvascular eye disease 本  n ( % ),,1902/10465
oral aminosalicylates,C0442027;C4521986,1903/10465
bmi kg - m - nmbr,C0578022;C0578022,1904/10465
mean ± sd triglycerides  mg / dl,,1905/10465
type of des,C0332307;C0332307;C1547052;C1547052,1906/10465
white  n ( % ),C0007457;C0043157;C0220938,1907/10465
aspirin / antiplatelet,C0004057,1908/10465
any peripheral arterial disease,C0085096;C1704436,1909/10465
ldl cholesterol mean ( mg / dl ± sd ),,1910/10465
index event — no . ( % ),,1911/10465
hospital factor # nmbr,C0019994;C0019994;C0019994;C0019994;C1510665;C1510665;C1510665;C1510665,1912/10465
baseline tobacco use,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,1913/10465
persistent anemia bsl hb < nmbrg i - nmbr  yr nmbr < nmbrg i nmbr,C0741008;C0741008;C0741008;C0741008,1914/10465
previously taken tnfi  %,,1915/10465
troponin t,C0077404;C1420827,1916/10465
exacerbations in the previous year,C4086268;C4086268;C4086268;C4086268,1917/10465
omega - nmbr fatty acid,C1719844;C1719844,1918/10465
stroke risk score,C1277291;C1277291,1919/10465
daily insulin dose  mean ( sd )  iu,C2348070;C2348070;C2348070;C2348070;C0332173,1920/10465
former or never,C0205156;C0750523,1921/10465
type nmbr diabetes duration  years,C1320657;C1320657;C1320657;C1320657,1922/10465
ccv history / condition,C0683519,1923/10465
microalbuminuria or proteinuria,C0730345,1924/10465
absolute risk difference ( ci )  % *,C1549031;C1549031;C1519101;C1519101,1925/10465
elevated at wk nmbr — no . ( % ) nmbr,,1926/10465
proctosigmoiditis,C0033252,1927/10465
mean age ( years ) race,C0444504;C2347634;C2348143,1928/10465
cat total score,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282,1929/10465
nmbr no . of events,C0053917;C1334884,1930/10465
intervention group ( n = nmbr ),C2986530,1931/10465
( nmbr % cl ) interaction,C0053917;C1334884,1932/10465
apoa - nmbr  g / l,C0003592;C0003592;C0523508;C0523508;C4553344;C4553344;C4553379;C4553379,1933/10465
yes  insulin - treated,C1549445;C1705108;C1710701,1934/10465
epa treatment ( n = nmbr ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,1935/10465
responders of three - item end point at nmbr weeks *,C0205449;C0205449;C0205449;C0205449,1936/10465
systemic glucocorticoid use at randomisation,C0205373;C0205373;C0205373,1937/10465
duration of tnmbrdm  y,C0449238;C2926735,1938/10465
ace inhibitors or angiotensin ii blockers,C0003015,1939/10465
physician ' s global assessment of dis -,C4050369;C4050369;C4050369,1940/10465
clopidogrel no . of patients % ),C0070166,1941/10465
duration of crohn ' s disease ( yrs ),C0449238;C2926735;C0010346,1942/10465
multivessel intervention  n ( % ),C0184661;C0886296;C1273869,1943/10465
tertile nmbr,C0053917;C1334884,1944/10465
cabg surgery,C0010055;C0010055;C0010055;C0010055,1945/10465
crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l )  n ( % ),C3890735;C3890735;C3890735;C4048285;C4048285;C4048285,1946/10465
fatal and nonfatal stroke,C1302234;C1705232,1947/10465
angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,,1948/10465
ace - i / arb  ( % ),C1452534;C1452534;C4284014;C4284014,1949/10465
gliclazide ( modified release ) 一 no . ( % ) ^,,1950/10465
conventional treatment ( n = nmbr ),C2945704,1951/10465
currentother ( notpredefined ) medical conditions,,1952/10465
history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,1953/10465
concomitant conventional dmard use,C0521115;C0521115;C0521115,1954/10465
dual antiplatelet,C0205173;C1554184,1955/10465
digitalis,C0012252;C0304520,1956/10465
active or previous cancer,C0205177;C3853793;C3888249,1957/10465
therapy at discharge,C0039798;C0039798;C0039798;C0087111;C0087111;C0087111;C1363945;C1363945;C1363945,1958/10465
north america hr ( nmbr % cl ),C0028405,1959/10465
intermediate ( nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205103;C1550465;C2827755;C3889971,1960/10465
male sex — no . ( % ) race — no . ( % ) ) :,,1961/10465
primary end point kaplan - meier rate  %,C2986535;C2986535,1962/10465
all ~ cause mort / hf hosp .,C0015127;C0015127;C0015127;C0015127;C1524003;C1524003;C1524003;C1524003,1963/10465
haemodynamics and lv function,C0019010;C4281788,1964/10465
duration of study - drug infusion,C0449238;C0449238;C2926735;C2926735,1965/10465
salmeterol nmbr gg bid,C0073992;C0073992;C0073992;C0073992,1966/10465
p value for adjusted hr,C1709380,1967/10465
vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235,1968/10465
a / v ( n = nmbr ),,1969/10465
unknown,C0439673;C3541433;C4050014,1970/10465
ff / vi nmbr / nmbr pg od,C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348;C4554348,1971/10465
ivabradine group,C0257190;C0257190;C0257190;C0257190;C0257190;C0257190,1972/10465
comparison with baseline ( mean,C1707455;C1707455,1973/10465
irofiban,,1974/10465
laba / lama,C0999593;C1416775,1975/10465
< nmbr years eze / simva,C0053917;C1334884,1976/10465
placebo ( dm - vs . dm + ),C0032042;C1696465;C1706408,1977/10465
o total randomized,C0483204;C0483204,1978/10465
cabgorptca,,1979/10465
total patients n = nmbr,C0439175;C0439810,1980/10465
left circumflex artery,C0226037,1981/10465
lebrikizumab ( n = nmbr ),C2981360,1982/10465
disease duration  median ( range ) years,C0872146,1983/10465
bl updrs : low,C0005918;C0006413;C1552663;C2827109,1984/10465
fevnmbr % reversibility,C0449261,1985/10465
lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0065058;C0065058;C0125953;C0125953;C1096202;C1096202;C1439335;C1439335,1986/10465
( $ nmbr mg / dl [nmbr . nmbr mmol / l] ),C0053917;C1334884,1987/10465
very high risk,C0442804;C0442804;C4321397;C4321397;C0442824;C0442824;C0442824;C0442824;C2984081;C2984081;C2984081;C2984081,1988/10465
location of crohn ' s disease  %,C0450429;C1515974;C4284930;C4284931,1989/10465
baseline diabetes,C0168634;C0168634;C1442488;C1442488,1990/10465
number of vessels disease,C0237753;C0449788,1991/10465
patient history of disease n ( % ),C0030705;C0030705;C0030705;C0030705,1992/10465
tocilizumab ( n = nmbr ),C1609165,1993/10465
mean ( sd ) duration of smoking  pack years,C0444504;C2347634;C2348143,1994/10465
difference ( a ) vs placebo ( nmbr % cl ),C1705241;C1705242,1995/10465
nmbr . nmbr - nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,1996/10465
demographic characteristics,C0683970,1997/10465
ezetimibe use,C1142985;C1142985;C1142985,1998/10465
subset of patients on metformin,C1515021,1999/10465
nmbr vessels or left main,C0053917;C1334884,2000/10465
congenital shunts,C0009678;C0009678;C0009678;C1744681;C1744681;C1744681,2001/10465
eze / simva gender,C0079399;C1522384,2002/10465
methotrexate dose at baseline,C0025677;C0025677;C0025677;C0025677;C0025677;C0025677,2003/10465
neoplasia  n ( % ),C0027651;C1882062,2004/10465
mesothelin ( ng / ml ),C0380162;C1334533,2005/10465
non - smoker ( n = nmbr  nmbr ),C0337672;C0425293;C4554605,2006/10465
amlodipine / valsartan nmbr / nmbr mg / v = nmbr,C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523,2007/10465
> nmbr . nmbr hdl cholesterol level,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,2008/10465
past or current angina pectoris,C1444637;C4284302,2009/10465
history of peripheral vascular disease,C1881056,2010/10465
group — no . ( % ),,2011/10465
number of treated vessels ( per patient ),C0237753;C0449788,2012/10465
ranolazine  n = inmbrinmbr,C0073633,2013/10465
prior failure of anti - tnf therapy — no . ( % ),,2014/10465
concomitant medications for ulcerative colitis — no . ( % ),,2015/10465
lipid - lowering therapy,C0585943,2016/10465
dlqi  nmbr - nmbr *,C3899393,2017/10465
patients treated for > nmbr weeks ( % ),C0030705,2018/10465
immunomodulatory agents,C0005525,2019/10465
endothelin - receptor antagonists,C1134681;C2266875,2020/10465
nt - probnp  median ( iqr )  pg / ml,C0669479;C0754710,2021/10465
hosp . for hf,,2022/10465
alcohol use ( > nmbr drink / wk ),C0001948,2023/10465
st - segment elevation mi,C0520886,2024/10465
history of dyspepsia,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,2025/10465
ncep risk category at study entry  n ( % ),C0035647;C0035647;C4552904;C4552904,2026/10465
treated hypertension :,C1522326;C1522326,2027/10465
presence of dactylitis  n ( % ),C0150312;C0392148;C3854307,2028/10465
placebo every nmbr weeks ( n = nmbr ),C0032042;C1696465;C1706408,2029/10465
heart rate  mean ± sd ( b . p . m . ),,2030/10465
post - bronchodilator fevnmbr  reversibility percentage of baseline value,C2599594,2031/10465
intense physical activity,C0522510;C0522510,2032/10465
concomitant drugs,C0521115;C0521115,2033/10465
cholesterol absorption inhibitor ( ezetimibe ),C0003277;C0003277;C0003277;C0003277;C0003277;C2945742,2034/10465
chanmbrdsnmbr - vasc score ( median  iqr ),C0449820;C4050231,2035/10465
serum potassium — mmol / liter,,2036/10465
nadroparin vs control,C0206232,2037/10465
type of event — no . ( % ),,2038/10465
stroke or tia — no . ( % ),,2039/10465
previous major bleeding,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,2040/10465
coexisting conditions,C0679225,2041/10465
characteristics of pulmonary embolism at inclusion,C1521970,2042/10465
time of symptom onset to randomization ( hrs ),C1320528,2043/10465
recurrent heart failure,C1455761;C1455761;C1455761;C2945760;C2945760;C2945760,2044/10465
all completers ( n nmbr nmbr ),,2045/10465
qualifying hbanmbrc ( % ),C1514624,2046/10465
medically important infectionsa,C3898777;C4084912,2047/10465
three arm,C0205449;C0205449;C0205449,2048/10465
after nmbr h,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,2049/10465
fevnmbr % pred,C0032952;C0044955,2050/10465
copd assessment test ( cat ) score,C4284282;C4284282,2051/10465
aspirin use ( > nmbr mg ),C0004057;C0004057;C0004057,2052/10465
moderate ( gold nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,2053/10465
no ascvd + additional cv risk factors  n ( % ),C3665365;C3665365;C3665365;C3665365;C3665365;C3665365,2054/10465
arb / ace,C3888198;C3888198,2055/10465
hypertension serum lipid values,C0020538;C1963138,2056/10465
measured at clinic visit with usual device,C0444706;C3541902,2057/10465
average maximum cimt ( mm ),C1510992;C1510992;C1510992;C2825518;C2825518;C2825518,2058/10465
thrombophilia  no . ( % ) e,C0398623,2059/10465
health assessment questionnaire - disability index,C4321476,2060/10465
median ( qnmbr : qnmbr ) lp ( a )  mg / dl,C0549183;C0876920;C2347635;C2348144;C2939193,2061/10465
any clinical ae,C0205210,2062/10465
mean ( sd ) feno  ppb,C0444504;C2347634;C2348143,2063/10465
cdai score §,,2064/10465
unfractionated,,2065/10465
physical and cognitive examination : ! :,C0031809;C0205485;C1509143,2066/10465
syst . bp ( mmhg ),C0037623;C1415692;C1708288;C4318478,2067/10465
medications at discharge or day nmbr  if earlier ( % ),C0806915,2068/10465
drug discontinuation not due to death,C0013227;C0013227;C0013227;C1254351;C1254351;C1254351,2069/10465
congestive heart failure ( < nmbr wk ),C0018802,2070/10465
aliskiren,C1120110,2071/10465
physician global assessment of disease activity ( vas nmbr - nmbr mm ),C4050369,2072/10465
baseline dlco . mmol kpa - ’ -,,2073/10465
role emotional,C0035820;C0035820;C1705810;C1705810;C3871154;C3871154,2074/10465
baseline ( geometric mean  cv ),C0168634;C1442488,2075/10465
pah classification,C0030123;C0030123;C0030123;C3203102;C3203102;C3203102;C4284467;C4284467;C4284467,2076/10465
days without albuterol use  * %,C0439228;C0439228;C0439228,2077/10465
simva ( % ),,2078/10465
treatment with open - label perindopril,C3640652,2079/10465
new diabetes — no . ( % ),,2080/10465
adjusted change from baseline mean ( s . e . ),C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081,2081/10465
$ nmbrand  nmbr years,,2082/10465
fpg ( range ) ( mmol / l ),,2083/10465
arterial graft,C0450140,2084/10465
any established coronary artery disease,C0443211;C0443211;C0443211;C1272684;C1272684;C1272684,2085/10465
time to treatment ( min ) t,C3494202,2086/10465
serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),C0302353;C0543465,2087/10465
hemoglobin concentration — g / liter,,2088/10465
clopidogrel + aspirin ( n = nmbr ),C0070166,2089/10465
previous metformin use  %,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,2090/10465
current ( % ),C0521116;C1705970,2091/10465
ecg findings at baseline — no . ( % ),,2092/10465
concomitant therapies n ( % ),C1707479,2093/10465
baseline therapy,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,2094/10465
hbanmbrc nmbr . nmbr to < nmbr . nmbr % ( nmbr - nmbr mmol / mol ),C0053917;C1334884,2095/10465
history of recurrent venous thromboembolism,C0455533;C0455533;C0455533;C0455533,2096/10465
magnetic resonance angiography,C0243032,2097/10465
free fatty acids — mmol / liter,,2098/10465
baseline post - bronchodilator % predicted fev  > nmbr % and no concurrent tiotropium,C0168634;C0168634;C1442488;C1442488,2099/10465
id genotype,C0009450;C0600091;C1441613,2100/10465
major coronary,C0205082;C0205164;C4318856;C4521762,2101/10465
cardiac rhythm disorders,C0264886,2102/10465
previous ischemic stroke  n ( % ),C0205156;C1552607,2103/10465
apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se ),C0003593;C0003593,2104/10465
history of macroalbuminuriat  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,2105/10465
high ( > nmbr risk factor ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,2106/10465
psoriasis affecting > nmbr % of body - surface,C0033860;C0033860,2107/10465
asthma duration ( sd )  years,C0004096;C0004096;C2984299;C2984299,2108/10465
glucose metabolism,C0596620,2109/10465
glycated hemoglobin  median ( iqr ),C0017853,2110/10465
blood pressure  mean ± sd mm hg,,2111/10465
fpi  mean ( sd )  pu / mlt,,2112/10465
secondary # nmbr,C0027627;C0027627;C0175668;C0175668;C0205436;C0205436,2113/10465
nmbr . nmbr - nmbr . nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,2114/10465
primary pci no .,C0205225;C0439612;C0439631,2115/10465
rectum and sigmoid colon only,C0034896,2116/10465
radial access — no . / total no . ( % ),,2117/10465
oral blood glucose - lowering,C0442027;C4521986,2118/10465
age nmbr + yrs,C0001779;C0001779,2119/10465
> nmbr . nmbr pmol / liter hscrp level,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,2120/10465
other ischaemic heart disease ( non - infarction ),C0010054;C0151744,2121/10465
calcium supplements,C0006675;C0006726;C2936886;C3540037;C3714611,2122/10465
a mini - mental state examination  insulin glargine vs standard care,C0451306,2123/10465
country : argentina ( n = nmbr ),C0454664;C1511538,2124/10465
estimated gfr — no . ( % ) nmbr,,2125/10465
received > nmbr prior anti - tnf therapies  n,C1514756,2126/10465
nmbr placebo ( n = nmbr nmbr ),C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,2127/10465
standard care n ( % ),C1442989;C2828392,2128/10465
interval from clopidogrel loading  h,C1272706;C1552654;C1552713,2129/10465
severity of copd *  n ( % ),C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,2130/10465
acr deciles,C1412134;C1515941,2131/10465
change at week nmbr,C0392747;C0392747;C0392747;C0392747;C0443172;C0443172;C0443172;C0443172;C1705241;C1705241;C1705241;C1705241;C4319952;C4319952;C4319952;C4319952,2132/10465
europe  israel  or australia,C0015176,2133/10465
low density lipoprotein cholesterol - mg / dltt,C0023824;C0023824;C0023824;C0023824;C0023824;C0023824;C0023824,2134/10465
other dmard use,C0242708;C0242708;C0242708,2135/10465
duration of hypercholesterolemia ( yr ),C0449238;C0449238;C2926735;C2926735,2136/10465
personal relationships,C1552027,2137/10465
heart failure or lvef < nmbr % associated with index acs event,C0018801;C0018802;C4554158,2138/10465
previous venous thromboembolism — no . ( % ),,2139/10465
prior biologic exposure,C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,2140/10465
need for urgent coronary - artery bypass grafting,C0027552;C0027552;C0686904;C0686904,2141/10465
egfr ( ml / min / nmbr - nmbr mz ),C1739039;C3811844;C3812682,2142/10465
egfr ( mdrd )  ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,2143/10465
previous stroke  n ( % ),C0205156;C0205156;C1552607;C1552607,2144/10465
alpha nmbr blockers,C0001641;C0001641,2145/10465
moderate dysfunction,C3274776,2146/10465
tnf - rnmbra ( ng / ml ),C1448177,2147/10465
jejunum,C0022378,2148/10465
neither ace - i nor arb use,C1452534;C1452534;C4284014;C4284014,2149/10465
history of vte * *,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,2150/10465
d - dimer level  mean ( sd )  ng / mld,C0060323;C0060323;C0060323;C0060323,2151/10465
gfr ( ml / min per nmbr . nmbr nr ),C0017654;C1424601,2152/10465
diastolic fmmhff ' ),C0012000,2153/10465
diabetes duration  median ( iqr )  years,C0011847;C0011847;C0011849;C0011849,2154/10465
nmbr . nmbr ( nmbr nmbr . nmbr ),C0053917;C1334884,2155/10465
plaque score ( nmbr - nmbr ),C0429153,2156/10465
prior disease,C0332152;C2826257,2157/10465
mean sd fpg  mg / dl,C0444504;C2347634;C2348143,2158/10465
serum ctx ( ng / ml ),C0229671;C0229671;C0229671;C1546774;C1546774;C1546774;C1550100;C1550100;C1550100,2159/10465
baseline triglycerides in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,2160/10465
ff / vi nmbr mg / nmbr mg ( n = nmbr ),C4554348;C4554348,2161/10465
previous anti - tnf therapy  n [ % ],C0205156;C1552607,2162/10465
dronedarone ( n = nmbr ),C0766326,2163/10465
standard ( nmbr ),C1442989;C2828392,2164/10465
age  median ( interquartile range )  y,C0001779,2165/10465
one or more copd exacerbations ( n / n [ % ] ),C0205447,2166/10465
peripheral embolism,C0205100;C0205100,2167/10465
arterial blood pressure  mm hg,C1272641,2168/10465
co - morbidities  a n ( % ),C0009488,2169/10465
oral hypoglycemic drugs only,C0359086;C0359086,2170/10465
p value ( on vs off omt ),C1709380,2171/10465
mucocutaneous,,2172/10465
any new anti - hyperglycemic rx,C0205314;C0205314;C0205314,2173/10465
metsyn with ldl > nmbr . nmbr mg / dl,,2174/10465
severe or worse airflow limitation,C0205082;C4050465;C4050466,2175/10465
periprocedural anticoagulant,C0003280;C0848112;C3536711,2176/10465
lsms difference ( nmbr % ci ) nmbr,C1705241;C1705242,2177/10465
age  y sex  no . ( % ),C0001779,2178/10465
blood eosinophil,C0014467,2179/10465
pah classification — no . ( % ),,2180/10465
short - acting bnmbr - agonists,C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1282927;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C1806781;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002;C2350002,2181/10465
fevnmbr reversibility  pre - / post - albuterol  %,C0449261,2182/10465
ischemia on cecg ( n = nmbr  nmbr ),C0022116;C4321499,2183/10465
ularitide n / n ( % ),C0077910,2184/10465
three of seven risk factors,C0205449;C0205449,2185/10465
moderately high risk without atherosclerotic vascular disease *,C0205081;C0205081;C0205081;C0205081;C1881878;C1881878;C1881878;C1881878;C4085643;C4085643;C4085643;C4085643;C4321491;C4321491;C4321491;C4321491,2186/10465
randomised to canakinumab nmbr mg,,2187/10465
ff nmbr pgod,C4554348;C4554348,2188/10465
fevnmbr post - bronchodilator  % predicted normal,C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594,2189/10465
migraine — no . ( % ) $,,2190/10465
hypertension — no . / total no . ( % ),,2191/10465
randomized to active yitamin e,C0034656;C0034656;C0034656;C3815594;C3815594;C3815594,2192/10465
low risk and more symptoms ( group b ),C3272281;C3538919,2193/10465
high risk,C0332167;C3272283;C4050568;C4319571,2194/10465
carotid artery diseaset,C0007272;C0162859,2195/10465
cholesterol — mmol / liter,,2196/10465
fasting plasma glucose,C0015663;C0015663,2197/10465
daily activities,C0871707,2198/10465
extended - duration enoxaparin ( n = nmbr ),C0231448;C0231449;C0439792,2199/10465
dasnmbr - nmbr ( esr ),C0053917;C1334884,2200/10465
associated with corrected - congenital shunts,C0332281;C0332281;C0332281;C0332281;C0332281;C0332281,2201/10465
traditional nsaid use,C3897349;C3897349,2202/10465
baseline albumin : < nmbr,C0168634;C1442488,2203/10465
high - risk cvd  n ( % ),C0332167;C3272283;C4050568;C4319571,2204/10465
pro / pro homozygotes,C1120626,2205/10465
sulfasalazine ( mean dose : nmbr . nmbr g / day ),C0036078,2206/10465
> nmbr years eze / simva baseline ldl - c,C0053917;C0053917;C1334884;C1334884,2207/10465
< nmbr % predicted arr ( n = nmbr  nmbr ),C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,2208/10465
pe associated with dvt at diagnosis,C0070939;C1880476;C4284304,2209/10465
baseline hbanmbrc,C0168634;C1442488,2210/10465
renal function < nmbr egfr  ml / min / nmbr . nmbr mnmbr,C0232804,2211/10465
blood eosinophil concentration  nmbr cells per l,C0427728;C0699870;C1313904;C0014467;C0014467;C0014467,2212/10465
less severenmbr,C0439092;C0547044,2213/10465
cardiovascular risk,C0007226;C0007226;C3887460;C3887460,2214/10465
prehospital ticagrelor ( n = nmbr ),C1999375,2215/10465
symptoms of atrial fibrillation in the nmbr months before randomiza -,C0683368;C0683368;C0683368;C1457887;C1457887;C1457887,2216/10465
perindopril,C0136123,2217/10465
tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr ),C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,2218/10465
symptom onset to hospital admission,C4086878,2219/10465
ldl - c ( measured ) *,,2220/10465
rerapamil - sr strategy ( n = nmbr ),C0753208;C1709991;C3813610;C3890900;C3891546,2221/10465
erosion score  mean nmbr sd,C0333307;C0333307;C1880549;C1880549;C1959609;C1959609;C3887524;C3887524,2222/10465
valve surgery  n ( % ),C0184252;C0184252;C0184252;C0184252;C1186983;C1186983;C1186983;C1186983;C1704414;C1704414;C1704414;C1704414;C3888056;C3888056;C3888056;C3888056,2223/10465
ticagrelor nmbr mg nmbr year km ( % ),C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375;C1999375,2224/10465
north america ( plus australia and new zealand ),C0028405,2225/10465
calcium antagonist — no . ( % ),,2226/10465
penetrating disease  %,C0205321,2227/10465
non - drug - eluting stent,C1518422,2228/10465
number of exacerbations in the past nmbr months,C0237753;C0449788,2229/10465
potassium supplement,C0304475,2230/10465
age group,C0027362;C2348001,2231/10465
congestive heart failure ( chf ) ( in past nmbr weeks ),C0018802,2232/10465
platelet count  x nmbr mmnmbr,C0032181;C1287267,2233/10465
other supraventricular tachycardia,C0039240;C1963244;C3815188,2234/10465
egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] ),C1739039;C3811844;C3812682,2235/10465
mean bmi  kg / mnmbr,C0444504;C2347634;C2348143,2236/10465
* * * unstable angina,,2237/10465
rate ratio,C0871208;C0871208;C1521828;C1521828,2238/10465
recurrent vte ( statin use vs non - use ),C1455761;C2945760,2239/10465
saxagliptin nmbr mg ( n = nmbr  nmbr ),C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,2240/10465
irregular or ulcerated ica p ) laque : [ :,C0205271,2241/10465
extreme tortuosity,C0205403;C3641272;C4085555,2242/10465
angina status — no . ( % ),,2243/10465
p value nmbr . nmbr,C1709380;C1709380,2244/10465
nonaspirin antiplatelet,C0722138,2245/10465
antihyperglycemictherapies  %,,2246/10465
geographic distribution - no . ( % ),C0681686,2247/10465
conventional synthetic dmard use at baseline,C0439858;C0439858;C0439858;C0439858;C0439858;C0439858,2248/10465
statins 一 no . ( % ),,2249/10465
at six weeks,C0205452,2250/10465
angiographic data and treatment :,C0002978;C0002978;C0002978,2251/10465
clinical indication at the index procedure  n ( % ),C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210;C0205210,2252/10465
mean bdi focal score ( sd ),C3533236;C3533236;C3533236;C3533236,2253/10465
cabg during index hospitalization,C0010055;C0010055;C0010055;C0010055;C0010055,2254/10465
pci for index event,C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621,2255/10465
concomitant drug treatment,C0521115;C0521115,2256/10465
third primary ( change in updrs score / wk  wk nmbr - nmbr ),C0205437;C0205437;C0205437,2257/10465
implanted pacemaker,C0848753,2258/10465
concomitant asthma medications  n ( % ),C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115,2259/10465
hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol ),C0053917;C1334884,2260/10465
uacr not available,,2261/10465
ret / abx - facil . pci,C0389252,2262/10465
severity of copd  airflow limitation  n ( % ),C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,2263/10465
claudication only,C0021775;C0021775;C0311395;C0311395;C1456822;C1456822,2264/10465
mean % predicted dlco * ( sd ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,2265/10465
titre ( u / ml ) t,C0475208,2266/10465
treatment before admission ( % ),C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,2267/10465
overall quality of life,C3641830,2268/10465
no baseline corticosteroids,C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,2269/10465
high on - treatment platelet reactivity *,C0205250;C0205250;C0205250;C0205250;C0205250;C0205250;C0205250;C1299351;C1299351;C1299351;C1299351;C1299351;C1299351;C1299351;C2700149;C2700149;C2700149;C2700149;C2700149;C2700149;C2700149;C3887512;C3887512;C3887512;C3887512;C3887512;C3887512;C3887512;C3889660;C3889660;C3889660;C3889660;C3889660;C3889660;C3889660;C4321237;C4321237;C4321237;C4321237;C4321237;C4321237;C4321237;C4522209;C4522209;C4522209;C4522209;C4522209;C4522209;C4522209,2270/10465
potassium ( meql )  mean + sd  available for nmbr patients,C0032821;C0202194;C0304475;C0597277;C3714637,2271/10465
all patients with opg n - nmbr,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,2272/10465
urinary albumin : creatinine ratio ( pg / mg )  median ( iqr ),C2362049,2273/10465
cardiac rhythm disorder at baseline yes,C0264886;C0264886;C0264886;C0264886;C0264886;C0264886,2274/10465
islander,,2275/10465
left circumflex coronary artery,C0226037,2276/10465
risk category ( points ),C0035647;C0035647;C4552904;C4552904,2277/10465
nihss at randomization  nmbr - nmbr,C1697238,2278/10465
cilostazol,C0055729,2279/10465
creatinine clearance category  ml / min  no . ( % ) b,C0812399;C0812399,2280/10465
tg > nmbr mg / dl  n ( ° / o ),,2281/10465
chf on losartan ( % ),C0018802,2282/10465
comorbidities  %,C0009488,2283/10465
prior lipid - lowering agent use,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,2284/10465
iwqol - lite total score ( arbitrary units ) #,C2964552,2285/10465
absolute change,C1549031,2286/10465
gusto moderate / severe,,2287/10465
ls mean difference ( se ) vs placebo,C0023668;C0023668;C0023668;C0023668;C0023668;C0023668,2288/10465
stent implanted — no . ( % ),,2289/10465
eze / simva ( „ = nmbr },,2290/10465
low eosinophil subgroup (  nmbr / ml ) ( n = nmbr ),C0205251;C0205251;C1550472;C1550472;C3890211;C3890211;C4048187;C4048187;C4321351;C4321351;C4522223;C4522223,2291/10465
alaska native,C0682125,2292/10465
| interactior nmbr p,C0053917;C1334884,2293/10465
number ( s ) of features present,C0237753;C0449788,2294/10465
extent of disease — no . / total no . ( % ) § ^ |,,2295/10465
eze / simva nmbr / nmbr mg n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,2296/10465
bivalirudin,C0168273,2297/10465
two arm,C0205448;C0205448;C0205448,2298/10465
metreo modified intention - to - treat population §,,2299/10465
any blood pressure medications ( % ),C0849164;C0849164;C0849164;C0849164;C0005823;C0005823;C0005823;C0005823;C1271104;C1271104;C1271104;C1271104;C1272641;C1272641;C1272641;C1272641,2300/10465
p  net difference,C0369773;C2603361,2301/10465
statin users ( n = nmbr ),C0360714,2302/10465
simplified disease activity index score ( nmbr - nmbr ),C3869582;C3869582,2303/10465
calcium channel,C0006685,2304/10465
level — no . ( % ),,2305/10465
no regular consumption,C0205272;C0205272,2306/10465
nmbr / nmbr  nmbr ( nmbr . nmbr ),C0053917;C1334884,2307/10465
time from randomization to pci ( non - st - elevation mi )  h,C0040223;C3541383,2308/10465
nmbre < nmbr %  n ( % ),,2309/10465
prior pacemaker  n ( % ),C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257,2310/10465
non - detectable / unknown  n ( % ),C1518422;C1518422;C1518422,2311/10465
individuals without diabetes  n = nmbr  nmbr,C0027361;C0027361;C0237401;C0237401,2312/10465
post - fibrinolysis angioplasty ( n = nmbr ),C0687676;C0687676;C0687676;C0687676;C1704687;C1704687;C1704687;C1704687;C3469826;C3469826;C3469826;C3469826,2313/10465
aerobic activity,C0001701,2314/10465
pulse pressure,C0949236,2315/10465
laboratory measures,C0022877;C3244292;C4283904,2316/10465
deep - vein thrombosis ( % ),C0149871,2317/10465
cardiovascu lar subg roup,C1419115;C3814448,2318/10465
greater than or equal to nmbr ml / min / nmbr . nmbrmnmbr,C0439093,2319/10465
statin  n ( % ),C0360714,2320/10465
location of infarction,C0450429;C1515974;C4284930;C4284931,2321/10465
infliximab - experienced ( n = nmbr ),C0666743,2322/10465
time since first copd diagnosis ( years ),C0040223;C3541383,2323/10465
potassium — mmol / liter,,2324/10465
rivaroxaban ( n = nmbr ),C1739768,2325/10465
investigator - determined myocardial infarction,C0035173;C0035173;C0035173;C0035173;C0035173,2326/10465
time from first eval,C0040223;C0040223;C0040223;C0040223;C3541383;C3541383;C3541383;C3541383,2327/10465
diagnosis of heterozygous familial hypercholester,C0011900;C0011900;C1704338;C1704338;C1704656;C1704656,2328/10465
baseline crp ( mg / dl ),C0168634;C0168634;C1442488;C1442488,2329/10465
average of maximum far wall cimt ( mm ),C1510992;C1510992;C1510992;C2825518;C2825518;C2825518,2330/10465
hispanic ethnicity,C0086409;C0086409,2331/10465
other vasodilator,C0042402;C3537240,2332/10465
maintenance dose,C3714445,2333/10465
thienopyridine type,C1120149;C1120149,2334/10465
perfusion defectsatinclusion,C0031001;C4281794,2335/10465
dasnmbr - esr remission,C3811131;C3811131,2336/10465
no . of panents . total no . nmbr % ),,2337/10465
disease activity outcomes ( itt population ) week nmbr,C0679250;C0679250;C0679250;C0679250;C0679250;C0679250;C0679250;C3542417;C3542417;C3542417;C3542417;C3542417;C3542417;C3542417;C1292728,2338/10465
fluticasone furoate and vilanterol ( n = nmbr ),C1948374,2339/10465
any infarct,C0021308,2340/10465
apolipoprotein a - i *,C0085201;C1677784,2341/10465
current smoking — no . / total no . ( % ),,2342/10465
miami k antagonist received,C1551421;C1551421,2343/10465
rivastigmine,C0649350,2344/10465
europa ( n = nmbrlnmbr ),C0242751,2345/10465
lung function  mean,C0035245,2346/10465
physician ' s global assessment of disease activity ( nmbr - nmbr mm vas )  mean ( sd ),C4050369,2347/10465
nmbr - nmbr ( very severe ),C0053917;C1334884,2348/10465
high - risk clinical features,C0332167;C3272283;C4050568;C4319571,2349/10465
second primary composite outcome,C0205436;C0205436;C0205436;C0205436;C0205436;C0205436;C0457385;C0457385;C0457385;C0457385;C0457385;C0457385;C0565930;C0565930;C0565930;C0565930;C0565930;C0565930;C1561503;C1561503;C1561503;C1561503;C1561503;C1561503;C1705190;C1705190;C1705190;C1705190;C1705190;C1705190,2350/10465
baseline % predicted fevnmbr,C0168634;C0168634;C1442488;C1442488,2351/10465
treatment characteristics,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,2352/10465
digoxin at last follow - up,C0012265;C0012265;C0012265;C0012265,2353/10465
both impaired glucose tolerance and impaired fasting glucose tolerance — no .,,2354/10465
ez / simva < % >,C0206578,2355/10465
sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0085805,2356/10465
# of prior bdmards,,2357/10465
acute reaction,C0205178,2358/10465
ulcers / gangrene,C0041582,2359/10465
fasting plasma glucose ( mmol / l ),C0015663;C0015663,2360/10465
other teaes,,2361/10465
alcohol intake,C0001948,2362/10465
change from baseline ( % ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,2363/10465
ileum only,C0020885;C0020885,2364/10465
anti - tnf - ir patients,C1448177;C1448177;C1448177,2365/10465
north america plus australia and new zealand,C0028405,2366/10465
medial - distal - diag,C0205098;C0205098,2367/10465
bw at nmbr weeks  kg +,C0005910;C0005910;C0006041;C0006041;C2986891;C2986891,2368/10465
haemoglobin ( mmol / l ),C0019046,2369/10465
severity ofcopd ( goldnmbr )  n ( % ),C0439793;C0522510,2370/10465
prior stroke — no . ( % ),,2371/10465
adalimumab ( n = nmbr ),C1122087,2372/10465
aliskiren dm = nmbr non - dm = nmbr,C1120110;C1120110,2373/10465
previous cabg ( before index acs ) *,C0205156;C1552607,2374/10465
number of patients ( % ) or mean 士 sd,,2375/10465
severity of copd  n ( % ) ( gold nmbr ) : moderate,C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,2376/10465
western friroce,C1705493,2377/10465
baseline lipids  mean ± sd ( mmol / nmbr ),,2378/10465
baseline calcium yes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,2379/10465
cardiac mediations,C0018787;C1522601,2380/10465
large vessel,C0225990,2381/10465
no . of treated vessels,,2382/10465
sinus rhythm at baseline,C0232201;C0232201,2383/10465
ipah / hpah,C0152171;C0152171;C0152171,2384/10465
ccs class §,,2385/10465
antithrombotic and anticoagulant medications,,2386/10465
ixeqnmbrw  n = nmbr,,2387/10465
warfarin group ( n = nmbr ),C0043031;C0043031;C0043031;C0043031;C0043031;C0043031,2388/10465
white - cell count — xnmbr_nmbr / liter,,2389/10465
mean % predicted fvc ( sd ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,2390/10465
only cerebrovascular disease,C0205171;C1720467,2391/10465
three or more agents,C0205449,2392/10465
msfc timed nmbr - foot walk test  median seconds,,2393/10465
mean ( sd ) baseline scores,C0444504;C2347634;C2348143,2394/10465
patients with > nmbr % ■ nmbr ml increase in fevnmbr post - bronchodilator ( % ),,2395/10465
meglitinide,C0065880,2396/10465
prior tobacco use  n ( % ),C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,2397/10465
graft occlusionsa,C0181074;C0332835;C1961139,2398/10465
ascot - lla,C0718674,2399/10465
cortical only,C0001613;C0001613;C0007776;C0007776;C0022655;C0022655,2400/10465
key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ nmbr of the indicated char least - square means  except tc an note : all treatment by subgroup,,2401/10465
prior disease - modifying drugs resulting in inadequate response — mean no . / patient,,2402/10465
extent of disease,C0449279;C4553144,2403/10465
candesartan group ( n = nmbr ),C0717550;C0717550;C0717550;C0717550;C0717550;C0717550,2404/10465
rivaroxaban alone ( n = nmbr ),C1739768,2405/10465
body mass index  mean ( sd ) [range]a,C0005893;C0578022;C1305855,2406/10465
baseline antihyperglycemic medications  n ( % ),C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,2407/10465
fasting lipid levels  mmol / l,C0015663,2408/10465
proximal gastrointestinal tract,C0205107;C0205107;C4489236;C4489236,2409/10465
diabetes mellitus ( type nmbr or nmbr ),C1320657;C1320657,2410/10465
heart failure ( hf )  ( % ),C0018801;C0018802;C4554158,2411/10465
platelet  nmbr / l,C0005821,2412/10465
hbanmbrc < nmbr % ( n - nmbr ),,2413/10465
spironolactone  n ( % ),C0037982,2414/10465
b digit symbol substitution  insulin glargine vs standard care,C0582802;C0582802;C0582802;C0582802;C3241971;C3241971;C3241971;C3241971,2415/10465
proteinurianmbr ( g / day ),,2416/10465
elevated blood pressure,C0020538;C0497247,2417/10465
ldl - c ( mg / dl ) < nmbr,,2418/10465
laser or vitrectomy,C0023089;C0458142;C1023865;C1706315,2419/10465
total study population ( n = nmbr ),C3258257;C3258257;C0439175;C0439810,2420/10465
presenting diagnosis,C0449450;C0449450;C0449450,2421/10465
duration of type nmbr diabetes ( years ),C0449238;C0449238;C2926735;C2926735,2422/10465
alt ( units / l ),C1266129;C4553172,2423/10465
severity of airflow limitation,C0439793;C0439793;C0522510;C0522510,2424/10465
patient ' s global assessment of disease,C4054229,2425/10465
daily dose nmbr - nmbr mg n = nmbr,C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070,2426/10465
in - stent restenosis of des,C3272317;C3272317,2427/10465
baseline hbanmbrc  mean ( s . e . ),C0168634;C1442488,2428/10465
predicted normal ( % ),C0681842;C0681842;C0681842;C0681842;C0681842;C1882327;C1882327;C1882327;C1882327;C1882327,2429/10465
killip class — no . ( % ) i,,2430/10465
prior ml or abnormal angiogram,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,2431/10465
placebo + mtx ( n = nmbr ),C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,2432/10465
baseline corticosteroid use ( mg ),C0168634;C1442488,2433/10465
ind / gly nmbr / nmbr mg once daily ( n = nmbr  nmbr ),C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864,2434/10465
patients who received positive results on test for antibodies to infliximabt,C0030705,2435/10465
ptca < nmbr h,C2936173,2436/10465
verapamil - sr ( « = nmbr nmbr ),,2437/10465
simvastatin ( nmbr / nmbr mg / d ),C0074554,2438/10465
insulin 一 no . ( % ),,2439/10465
duration of type nmbr diabetes mellitus ( years ),C0449238;C0449238;C2926735;C2926735,2440/10465
central america and south america,C0007674,2441/10465
hip circumference — cm,,2442/10465
rnmbr + ezio ( n = nmbr ),,2443/10465
male sex — no . of patients ( % ),,2444/10465
stents per lesion  n,C0038257;C0038257,2445/10465
infliximab ( n = nmbr ),C0666743,2446/10465
dose of rosuvastatin,C0178602;C0869039;C1114758,2447/10465
lvef < nmbr %  n = nmbr nmbr ) “,,2448/10465
n - terminal pro - brain natriuretic peptide  pg / ml,C3272900,2449/10465
bmi — mean ( sd ) ( kg / mnmbr ),,2450/10465
vorapaxar event rate ( n = nmbr )  %,C2974521;C2974521;C2974521;C2974521,2451/10465
death or nmbrmwd decrease > nmbr m,C0011065;C1306577;C4082313;C4552775,2452/10465
associated with transient or reversible risk factor,C0332281;C0332281,2453/10465
europe and australia,C0015176,2454/10465
all countries,C0454664,2455/10465
urinary protein : creatinine ratioa ( mg / mg ),C0262923;C1305628,2456/10465
serum cholesterol  median ( iqr )  mg / dl,C0587184,2457/10465
intermediate risk ( ri = nmbr ),C3640764,2458/10465
cangrelor,C1121991,2459/10465
baseline cdai score  mean ( s . d . ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,2460/10465
major bleeding events *,C0205082;C0205082;C0205164;C0205164;C4318856;C4318856;C4521762;C4521762,2461/10465
baseline  mm hg,C0168634;C1442488,2462/10465
white / caucasian,C0043157,2463/10465
body mass index  mean ± sd ( kg / mnmbr ),,2464/10465
recurrent ischemia,C1455761;C1455761;C2945760;C2945760,2465/10465
index event not confirmed,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,2466/10465
non - hdl cholesterol ( mg / dl ),C0729627;C1535899,2467/10465
comparison with placebo,C1707455;C1707455;C1707455,2468/10465
current use of an ace inhibitor,C0521116;C0521116;C1705970;C1705970,2469/10465
mean total serum ige ( sd )  iu / ml,C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143,2470/10465
af or atrial flutter 卞,,2471/10465
pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132,2472/10465
ejection fraction based on local reading,C0489482;C2700378,2473/10465
cardiac and echocardiography parameters,C0018787;C1522601,2474/10465
albuterol use ( sd )  puffs / day,C0001927;C0001927;C0001927,2475/10465
white race — number ( % ),,2476/10465
stable angina ( n - nmbr  nmbr ),C0340288,2477/10465
weight  kg  median ( nmbrth  nmbrth ),C0005910;C0043100;C1305866;C1705104,2478/10465
long - term aspirin,C0443252,2479/10465
moderately impaired,C0205081;C1881878;C4085643;C4321491,2480/10465
left side only,C3842976,2481/10465
past or never,C1444637;C4284302,2482/10465
gastroesophageal reflux disease,C0017168;C4553201,2483/10465
anticoagulant — no . ( % ),,2484/10465
region  asia / paafic,C0017446;C0205147,2485/10465
arteriosclerosis,C0003850,2486/10465
fasting plasma glucose nmbr medan,C0015663;C0015663;C0015663;C0015663,2487/10465
age mean ( yrs ± sd ),,2488/10465
chronic renal failure,C0022661;C1561643;C2316810,2489/10465
peripheral artery,C0489868,2490/10465
neither tnmbrdm nor mets,,2491/10465
time since first af diagnosis  yrs,C0040223;C3541383,2492/10465
anti - hypertensive therapy - no . ( % ),C0585941,2493/10465
pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703,2494/10465
infarct ion w ithin previous nmbr day s,C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308,2495/10465
cardiac death,C0376297,2496/10465
interval between clinical evaluation and initiation oftreatment — no . ( % ),,2497/10465
apolipoprotein b  mean ( sd )  g / l,C0003593,2498/10465
no . of participants with events ( % ),,2499/10465
mean a ± sd  mg / dl ( mmol / nmbr ),,2500/10465
homa - ir ( mu / l^mmol / l ),C0022065;C0022071;C1448132,2501/10465
> nmbr months ( n = nmbr  nmbr ),C0053917;C1334884,2502/10465
elevated troponin ( > nmbr . nmbr mg / l )  %,C0205250;C3163633,2503/10465
mean weight ( sd )  kg,C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,2504/10465
europe ( zone nmbr ),C0015176,2505/10465
cox bsl onlyc,C1565830,2506/10465
number resulting in ed visit,C0237753;C0449788,2507/10465
left ventricular systolic or diastolic dysfunction,C0225897,2508/10465
any other llts ( other than statin ),,2509/10465
other blood - pressure drug,C0003364,2510/10465
both ace inhibitor and arb,C0003015;C4541021,2511/10465
tg  median ( sdy rng / cjl,C0337445,2512/10465
statin at last follow - up,C0360714;C0360714;C0360714;C0360714,2513/10465
p - value ( lnteraction ),C1709380,2514/10465
mild dysfunction or normal,C3274775,2515/10465
recurrent infections ( > nmbr per year ),C0239998,2516/10465
estimated glomerular filtration rate < nmbr ml / min per nmbr . nmbr mnmbr,C3811844,2517/10465
median ( qnmbr : qnmbr ) duration of diabetes  years,C0549183;C0876920;C2347635;C2348144;C2939193,2518/10465
nmbrlnmbrmmhg,,2519/10465
chronic non - steroidal antiinflammatory drugs,C0205191,2520/10465
european subcategories,C0239307;C1535514,2521/10465
placebo + nmbr mg / d of simvastatin ( n = nmbr ),C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,2522/10465
median c - reactive protein — mg / dl^,,2523/10465
use of other medications — no . ( % ),,2524/10465
total - c : hdl - c,C0439175;C0439810,2525/10465
pre - bronchodilator fevnmbr / fvc ( % ),C2599602,2526/10465
reversibility ( % predicted fevnmbr ) *,C0449261,2527/10465
conversion to sinus rhythm in < nmbr days,C1321500,2528/10465
stent implanted,C0522776,2529/10465
median weight  kg ( iqr ),C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193,2530/10465
saxagliptin ( % ),C1611934,2531/10465
salmeterol - fluticasone group ( n = nmbr ),C0939232;C0939232;C0939232;C0939232;C0939232;C0939232,2532/10465
abciximab,C0288672,2533/10465
vein bypass graft stented,C0398147,2534/10465
mean age ( sd )  years,C0444504;C2347634;C2348143,2535/10465
prior treatment,C1514463,2536/10465
bivalirudin used during pci,C0168273,2537/10465
mean ( s . d . ) ldl particle number  nmol / l,C0444504;C2347634;C2348143,2538/10465
pad symptoms ( % ),C0182158;C0182158;C0332568;C0332568;C3540603;C3540603;C3669270;C3669270;C3814046;C3814046;C4319657;C4319657,2539/10465
number of treated lesions,C0449791,2540/10465
infliximab ( combined nmbr mg / kg and nmbr mg / kg )  n ( % ),C0666743,2541/10465
high dose statin ( n = nmbr  nmbr ),C0444956,2542/10465
any recurrent stroke,C2242682,2543/10465
distal one - third of radius,C0450168;C0450168;C0588207,2544/10465
mean mayo score ( sd ),C3533236;C3533236,2545/10465
diagnosis at presentation,C0011900;C1704338;C1704656,2546/10465
median disease duration — yr,,2547/10465
events / control group,C0441471;C3541888,2548/10465
lowest tg tertile,C1708760,2549/10465
other antihyperglycemic agents  not listed,C0020616,2550/10465
index stroke > nmbr days before randomization — no . ( % ),,2551/10465
renal fmclicn : creatntoe clearance,C0022646,2552/10465
prior mi ( n - nmbr  nmbr ),C0332152;C2826257,2553/10465
losartan plus placebo ( n = nmbr ),C0126174;C0126174;C0126174,2554/10465
anti - ccp positive ( > nmbr u / ml )  n ( % ),C4318437;C4318437;C4318437;C4318437;C4318437,2555/10465
total occlusion  n ( % ),C0439175;C0439175;C0439175;C0439175;C0439175;C0439175;C0439810;C0439810;C0439810;C0439810;C0439810;C0439810,2556/10465
male sex — no . ( % ) risk factors,,2557/10465
multiple tnfi and other bdmards §,,2558/10465
stiffness ( min ),C0427008,2559/10465
rosuvastatin nmbr - nmbr mg ( n = nmbr ),C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129,2560/10465
randomization to angiography,C0034656,2561/10465
thienopyridine n = nmbr,C1120149,2562/10465
treatment difference,C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,2563/10465
absolute reversibility in fevnmbr  ml *,C0205344,2564/10465
time to treatment,C3494202,2565/10465
duration of initial anticoagulation  mean ( sd )  mo,C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C0449238;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735;C2926735,2566/10465
undetermined etiology,C0478157,2567/10465
ace inhibitors through hospital discharge or day nmbr — %,,2568/10465
patient ' s global assessment ( vas ),C4054229,2569/10465
triglycerides ( mg / dl )  mean + sd  available for nmbr patients,C0041004,2570/10465
qualifying type of atherosclerosis  n ( % ),C1514624;C1514624;C1514624;C1514624,2571/10465
patient ' s preference not to take vka  only reason,C0376409,2572/10465
probable,C0033204;C0332148,2573/10465
at least two cardiovascular risk factors,C0205448,2574/10465
surgical technique post - randomisation characteristic * *,C0683469;C0683469;C0683469,2575/10465
age group  no . ( % )  y,C0027362;C2348001,2576/10465
disease location ( % ) *,C0012634;C0012634;C0012634;C0012634,2577/10465
previous oad ( % ),C0205156;C1552607,2578/10465
hdl cholesterol — mg / dl triglycerides — mg / dl,,2579/10465
< nmbr months in - nmbr kill,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,2580/10465
antialdosterone agents,C0450442;C1254351;C1521826,2581/10465
risk factors bmi ( kg / mnmbr )  mean + sd,C0035648;C1553898,2582/10465
ex - smoker / current,C0337671;C0337671;C4555205;C4555205,2583/10465
at goal,C0018017;C1571704,2584/10465
history of heart failure — no . ( % ),,2585/10465
diabetes duration subgroups,C0011847;C0011847;C0011849;C0011849,2586/10465
western europe ( including south africa ),C0043129,2587/10465
randomization stratum,C0034656,2588/10465
death  mi  idr  st or gusto severe bleeding,C0011065;C1306577;C4082313;C4552775,2589/10465
clopidogrel / total no . of patients % %,C0070166;C0070166,2590/10465
corticosteroid ( without imm ),C0001617;C3536709,2591/10465
creatinine ratio nmbr - nmbr,C0010294;C0010294;C0010294;C0010294;C1561535;C1561535;C1561535;C1561535,2592/10465
overall pad,C0282416;C1561607,2593/10465
steroids ( other ),C0038317,2594/10465
mean ± s . d . weight  kg,,2595/10465
amlodipine ( n = nmbr ),C0051696,2596/10465
previous infliximab therapy — no . of patients ( % ) * *,,2597/10465
anti - tnf - naive  n ( % ),C0432633,2598/10465
previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),,2599/10465
non - elderly ( < nmbr years ),C1518422;C1518422,2600/10465
pravastatin ( n = nmbr >,C0085542,2601/10465
week nmbr ( mean  sd ),C0332174;C0332174;C0439230;C0439230,2602/10465
factor v leiden ( % ),C0380964;C0584960;C1414509;C3542419,2603/10465
tender joint count ( nmbr - nmbr possible joints ),C0451530,2604/10465
male sex — no . / total no . ( % ),,2605/10465
insulin glargine n ( x ),C0907402,2606/10465
time since randomization,C0040223;C3541383,2607/10465
post - bronchodilator fevnmbr ( % predicted normal ) a,C2599594,2608/10465
vessel size  mean ( sd )  mm,C0005847,2609/10465
hs - crp ( median  iqr )  mg / l,C3890735;C4048285,2610/10465
insulin - requiring,C0021641;C1533581;C1579433;C3714501,2611/10465
homa . ir  median ( ql  qnmbr )  % / nmbr,C0022065;C0022071;C1448132,2612/10465
baseline short - acting anticholinergics,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,2613/10465
multivitamin use ( current ),C0301532;C0301532;C0301532,2614/10465
apob : apoal,C0003593;C3252643,2615/10465
cardiac stretch,C0018787;C1522601,2616/10465
hospitalization for heart failure within nmbr mo,C3898876,2617/10465
lv ejection fraction  mean ( sd ) [range]  %,C0023128;C0023128;C0731033;C0731033;C1881413;C1881413,2618/10465
pasi score  nmbr - nmbr *,C4528685;C4528685,2619/10465
patients with event / patients analyzed,C0030705;C0030705,2620/10465
mean ( sd ) periostin  ng / ml,C0444504;C2347634;C2348143,2621/10465
any blood transfusion,C0005841;C0281867,2622/10465
low molecular weight heparin,C0019139;C3536766,2623/10465
yes ( stopped for trial ),C1549445;C1705108;C1710701,2624/10465
previous chronic use of antiplatelet drugs,C0205156;C0205156;C1552607;C1552607,2625/10465
aspirin - erdp clopidogrel no . of patients / total no .,C0004057,2626/10465
denosumab,C1690432,2627/10465
patients randomized,C0030705,2628/10465
days with asthma symptoms / week,C0677547;C0677547;C0677547;C0677547,2629/10465
statin with fibrate,C0360714,2630/10465
delayed - start group ( n = nmbr ),C0205421;C1545665;C3272602,2631/10465
fevnmbr % predicted ( post salbutamol ),C0681842;C1882327,2632/10465
intended durat - sm of antccagubficn,C1283828;C1283828;C1551357;C1551357,2633/10465
baseline dmard use  n ( % ),C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,2634/10465
creatinine — mg / dl urinary albumin - to - creatinine ratio §,,2635/10465
companion : wake - up stroke,C0031268;C0335343;C0682323,2636/10465
placebo events / n ( % ),C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,2637/10465
cdai score < nmbr,C0683448;C0683448;C1413248;C1413248;C3273706;C3273706,2638/10465
baseline ibdq total score  mean,C0168634;C1442488,2639/10465
positive for rheumatoid factor  anti - cyclic citrullinated peptide antibodies  or both — % ff,,2640/10465
current alcohol use  n ( % ),C0521116;C1705970,2641/10465
cardiac medications at discharge  %,C0018787;C1522601,2642/10465
medical management only,C0199168;C0199168;C0199168;C0199168;C0199168;C0199168;C0199168;C0199168;C0205476;C0205476;C0205476;C0205476;C0205476;C0205476;C0205476;C0205476,2643/10465
shoulder pain,C0037011,2644/10465
hbalc  mean ( s . d . ),,2645/10465
nmbr . nmbr mg bid,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,2646/10465
pci during index hospitalization,C4049621;C4049621;C4049621;C4049621;C4049621,2647/10465
history of cv disease,C0683519;C0683519;C0683519;C0730226;C0730226;C0730226;C0850708;C0850708;C0850708;C0944983;C0944983;C0944983,2648/10465
complex lesions^,C0439855;C1704241,2649/10465
level nmbr immobility^,C0441889;C0441889;C0456079;C0456079;C1547707;C1547707;C2946261;C2946261,2650/10465
asia / pacific / other,C0003980,2651/10465
calcium  mmol nmbr nmbr,C0006675;C0006726;C2936886;C3540037;C3714611,2652/10465
race  % caucasian,C0034510;C1706779;C3853635,2653/10465
mtss cfb mean ± sd,,2654/10465
study end concentration,C0557651;C0557651;C0557651;C0557651;C0557651;C0557651;C2603343;C2603343;C2603343;C2603343;C2603343;C2603343,2655/10465
potassium  mean ( sd )  meq / l,C0032821;C0202194;C0304475;C0597277;C3714637,2656/10465
naive to antihyperglycemic agent therapy,C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616;C0020616,2657/10465
swollen joint count  of nmbr,C0451521,2658/10465
hemispheric tia n = nmbr,C0205139;C0205139;C0205139,2659/10465
c - peptide tx difference vs pbo  median change from baseline ( se ) nmbr,C0006558;C0006558,2660/10465
severity of airflow limitation ( gold nmbr )  n ( % ),C0439793;C0439793;C0522510;C0522510,2661/10465
other atherosclerotic event,C0333482;C0333482,2662/10465
retinopathy ( stage nmbr / nmbr / nmbr / nmbr ),C0035309;C1962966,2663/10465
mean — ml / min / nmbr . nmbrmnmbr,,2664/10465
fevnmbr ( % predicted normal ),,2665/10465
baseline total cholesterol,C0168634;C0168634;C1442488;C1442488,2666/10465
egfr category  n ( % ),C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,2667/10465
rhabdomyolysis,C0035410;C4552660,2668/10465
any other antihyperglycaemic drugs,,2669/10465
any risk factor for stent thrombosis,C0035648,2670/10465
copd severity : mild / moderate,C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,2671/10465
medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232,2672/10465
neither n = nmbr  nmbr,C0369718;C0441922,2673/10465
exercise at least weekly ( a ),C0015259;C1522704,2674/10465
patients with previous intolerance of infliximab,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,2675/10465
mayo clinic score §,,2676/10465
nob systolic blood pressure ( mm hg ),C0488055;C0871470;C1306620,2677/10465
geographic region - other,C0017446,2678/10465
months since first ra symptom  mean ( sd ) f,C0439231,2679/10465
continuation ( n = nmbr ),,2680/10465
timi - defined bleeding,C1704788;C3539106,2681/10465
glycosylated hemoglobin  %,C0017853,2682/10465
omeprazole,C0028978,2683/10465
in - hospital ticagrelor ( n = nmbr ),C0019994,2684/10465
mean bmi ( nmbr % ci ),C0444504;C2347634;C2348143,2685/10465
physiological measures,C0205463;C0205463,2686/10465
atrial fibrillation pattern,C0004238;C0344434;C1963067,2687/10465
corticosteroid + imm,C0001617;C3536709,2688/10465
thiazide at enrollment,C0541746;C0541746;C0541746,2689/10465
nasopharyngitis,C0027441,2690/10465
established atherosclerotic,C0443211;C1272684,2691/10465
overall effect,C0282416;C0282416;C0282416;C1561607;C1561607;C1561607,2692/10465
omega - nmbr fa,C1719844;C1719844,2693/10465
ejection fraction : < nmbr % ( n = nmbr ),C0489482;C2700378,2694/10465
< nmbr mm hg heart rate,C0053917;C1334884,2695/10465
lv ejection fraction ( % ),C0023128;C0023128;C0731033;C0731033;C1881413;C1881413,2696/10465
cangrelor clopidogrel no . of events / total no . ( % ),C1121991,2697/10465
killip at baseline,C0168634;C1442488,2698/10465
time since asthma diagnosis ( years ),C0040223;C3541383,2699/10465
nmbr placebo,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,2700/10465
carbamazepine,C0006949;C0006950;C0682993,2701/10465
postmenopausal  current hormone therapy use,C0232970;C0232970;C0232970;C0232970;C0232970;C0232970;C0232970;C0232970;C0232970;C0232970;C0232970;C0232970,2702/10465
known duration of type nmbr diabetes ( years ),C0205309;C0205309;C0205309;C0205309,2703/10465
beta - blocker at enrollment,C0001645;C0001645;C0001645,2704/10465
number of exacerbations nmbr months before randomisation,C0237753;C0237753;C0449788;C0449788,2705/10465
week nmbr hbanmbrc  mean ( s . e . ),C0332174;C0332174;C0439230;C0439230,2706/10465
tertile nmbr ( n = nmbr ),C0053917;C1334884,2707/10465
mean ( sd ) duration of copd  years,C0444504;C2347634;C2348143,2708/10465
ci - aki risk score,C0008107;C0008107;C0008107;C0008107;C0008107;C0008107;C0008107;C0008107;C3259781;C3259781;C3259781;C3259781;C3259781;C3259781;C3259781;C3259781,2709/10465
risk factors for stroke  no . ( % ),C0035648;C0035648;C1553898;C1553898,2710/10465
esr ( mm / h )  median ( min  max ),C3811131,2711/10465
units per week  mean ( sd ),C0560588,2712/10465
c - reactive protein — mg / literj,,2713/10465
non - u . s .,C1518422,2714/10465
acuity - defined bleeding,C0333276;C0333276,2715/10465
vedolizumab,C2742797,2716/10465
other / multiracial,C1881928,2717/10465
time since qualifying event,C0040223;C3541383,2718/10465
> nmbr vessels treated,C0053917;C1334884,2719/10465
statin use  n ( % ),C0360714;C0360714;C0360714,2720/10465
previous coronary - artery bypass grafting,C2144990,2721/10465
median ( min  max ),C0549183;C0876920;C2347635;C2348144;C2939193,2722/10465
intensive control ( n = nmbr ) no . of patients ( percent ),C0162425;C0162425;C0162425;C0162425;C0162425;C0162425;C0522510;C0522510;C0522510;C0522510;C0522510;C0522510;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1550453;C1550453;C1550453;C1550453;C1550453;C1550453,2723/10465
arterial hypertension  n ( % ),C0020538,2724/10465
ranolazine ( n = nmbr ) placebo ( n = nmbr ),C0073633,2725/10465
large shunt,C0549177;C0549177;C0549177,2726/10465
history of hypertension  n ( % ),C0455527,2727/10465
age y  median ( range ),C0001779,2728/10465
companion : nmbr - nmbr hours,C0031268;C0335343;C0682323,2729/10465
nt - pro bnp,C0669479;C0754710,2730/10465
lipid difference ( mg / dl ),C0023779;C0023779,2731/10465
other determined etiology,C0521095;C0521095;C0521095,2732/10465
baseline pasi score,C0168634;C0168634;C1442488;C1442488,2733/10465
mean ( sd ) total asthma symptom scores,C0444504;C2347634;C2348143,2734/10465
time since pah diagnosisc ( years ),C0040223;C3541383,2735/10465
alpha receptor antagonist,C0439095;C2003941;C2350010,2736/10465
esrd on losartan ( % ),C0022661;C0035078;C2316810,2737/10465
stroke at entry ( vs transient ischemic attack ),C0038454;C4554100,2738/10465
medical history and risk factors ( % ),C0262926;C1704706,2739/10465
placebo monthly ( n = nmbr ),C0032042;C1696465;C1706408,2740/10465
intravenous inotropes or vasopressors ( % ),C0348016,2741/10465
overall a phase population,C0282416;C1561607,2742/10465
symptom onset to first medical contact : ambulance or emergency department,C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878;C4086878,2743/10465
any glucocorticoid *,C0017710,2744/10465
mean ( sd ) post - bronchodilator fevnmbr percentage predicted,C0444504;C2347634;C2348143,2745/10465
insulin ( mu / ml ),C0021641;C1533581;C1579433;C3714501,2746/10465
creatinine clearance < nmbr ml / min,C0812399,2747/10465
nihss at randomization,C1697238,2748/10465
elevated serum potassium  > nmbr . nmbr mmol / l,C0553704,2749/10465
concordant stress test abnormalities,C4553529;C4553529;C4553529;C4553529,2750/10465
eos serum k +  meq / l,C1623465;C1861303,2751/10465
duration of diabetes,C0449238;C0449238;C2926735;C2926735,2752/10465
arterial revascularization,C0003842;C0221464,2753/10465
endpoint rate,C2349179;C2349179;C2826544;C2826544,2754/10465
highest tertile ( range  nmbr . nmbr - nmbr . nmbr mg / dl  mean ± sd  nmbr . nmbr ± nmbr . nmbr mg / dl ),,2755/10465
p interaction women vs men,C0369773;C2603361,2756/10465
malaysia,C0024552,2757/10465
populations :,C0032659;C1257890,2758/10465
serum creatinine  弘 mol 儿 | |,,2759/10465
index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546,2760/10465
retinopathy,C0035309;C1962966,2761/10465
history of nicotine use,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,2762/10465
insulin glargine n ( % ) / nmbrpy,C0907402,2763/10465
no chd simva ( n = nmbr],C0280604;C3542407,2764/10465
treated with insulin,C0332293;C0332293;C0332293;C0332293,2765/10465
previous ischemic stroke ortia,C0205156;C1552607,2766/10465
iglarlixi,,2767/10465
previous cabg surgery,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,2768/10465
statin alone,C0360714,2769/10465
study drug loading days ( actual ) : nmbr ( n = nmbr ),C0013175,2770/10465
lumbar epidural,C0581283,2771/10465
periprocedural medications,C0013227;C0802604;C2598133;C4284232,2772/10465
mean age  y  mean = sd,C0444504;C2347634;C2348143,2773/10465
group dif . ( nmbr ),C0441833;C0441833;C0687744;C0687744;C1257890;C1257890;C1519504;C1519504;C1705428;C1705428;C1705429;C1705429,2774/10465
prior cardiac resynchronization therapy  n ( % ),C0332152;C2826257,2775/10465
cardiac risk,C0018787;C0018787;C1522601;C1522601,2776/10465
albuterol use,C0001927;C0001927;C0001927,2777/10465
no . of events / total,,2778/10465
no . of participants per nmbr patient - yr,,2779/10465
estimated glomerular filtration rate < nmbr ml / min / nmbr . nmbr mnmbr — no . / total no . ( % ) §,,2780/10465
established atherosclerotic disease,C0443211;C1272684,2781/10465
ukraine,C0041580,2782/10465
negative for helicobacter pylori — no . / total no . ( % ),,2783/10465
other medical history — no . / total no . ( % ),,2784/10465
left atrial anteroposterior diameter — mm,,2785/10465
any established peripheral arterial disease,C0443211;C0443211;C1272684;C1272684,2786/10465
serum k + level and drug treatment,C0302353;C0302353;C0302353;C0302353,2787/10465
chronic inflammatory disease,C1290886,2788/10465
randomization to arrival in catheterization laboratory,C0034656;C0034656,2789/10465
rituximab,C0393022,2790/10465
hemoglobin,C0019046,2791/10465
high risk ( receiving treatment for ) :,C0332167;C3272283;C4050568;C4319571,2792/10465
c - reactive protein  median ( iqr )  mg / l,C0006560;C1413716;C4048285,2793/10465
anti - tnf - naive patients,C1448177,2794/10465
lipids  mean ( sd )  mg / dlt,C0023779,2795/10465
high - dose statin use at screening *,C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956;C0444956,2796/10465
second primary ( estimated change in total updrs score from baseline to wk nmbr ),C0205436;C0205436;C0205436;C0457385;C0457385;C0457385;C0565930;C0565930;C0565930;C1561503;C1561503;C1561503;C1705190;C1705190;C1705190,2797/10465
abciximab no . / total ( % ),C0288672,2798/10465
no . of non - tnfi,,2799/10465
current cvd / diabetes  n ( % ),C0521116;C0521116;C1705970;C1705970,2800/10465
cv mortality,C3538987;C3538987;C4048877;C4048877;C4318503;C4318503,2801/10465
duration of dementia symptoms  months,C0436359;C0436359,2802/10465
no pad baseline,C0182158;C0182158;C0332568;C0332568;C3540603;C3540603;C3669270;C3669270;C3814046;C3814046;C4319657;C4319657,2803/10465
pre ' rtous eptscde ( s } d dvt / pe,C0332152;C0740175;C2257086;C3669034,2804/10465
prior coronary artery bypass surgery,C0332152;C2826257,2805/10465
interaction p - valuenmbr,C1704675,2806/10465
ipah  hpah  hiv  drug or toxin induced,C0152171,2807/10465
< nmbr mg / dl simva ( n = nmbr],C0053917;C1334884,2808/10465
location of disease  n ( % ),C0450429;C1515974;C4284930;C4284931,2809/10465
mtx ( mean dose : nmbr . nmbr mg / wk ),C0025677;C1417487,2810/10465
labs at the index acs event,C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081;C0587081,2811/10465
black race ( n = nmbr vs nmbr ),C0005680,2812/10465
treatment with any bp lowering drugs,C3469597;C3469597;C3469597;C3469597;C3469597;C3469597;C3469597;C3469597,2813/10465
placebo nmbr / nmbr,C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,2814/10465
diagnosed  y,C0011900,2815/10465
peri - op statins : no ( n = nmbr ),C0347985,2816/10465
region  europe,C0017446;C0205147,2817/10465
copd disease severity,C0024117;C1412502;C3714496,2818/10465
baseline dyslipidemia,C0168634;C1442488,2819/10465
difference in ls means ( nmbr % ci ) nmbr,C1705241;C1705242,2820/10465
male gender  n ( % ),C0086582;C1706180,2821/10465
( nmbr - nmbr - cm vas ),C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,2822/10465
screening absolute reversibility fevnmbr  ml,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,2823/10465
k - m %,C0597277;C0597277;C1708601;C1708601,2824/10465
type of surgery,C0332307;C0332307;C0332307;C0332307;C1547052;C1547052;C1547052;C1547052,2825/10465
hosp . worsening hf,C0332271;C0332271;C0332271;C0332271;C1457868;C1457868;C1457868;C1457868;C1546960;C1546960;C1546960;C1546960,2826/10465
rest of the world,C0035253;C1622890,2827/10465
placebo no . / total no .,C0032042;C1696465;C1706408,2828/10465
azathioprine / nmbr - mercaptopurine,C0004482;C0004482,2829/10465
duration of diabetes  mean ( sd )  y,C0449238;C0449238;C2926735;C2926735,2830/10465
cox - nmbr selective nsaid,C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830,2831/10465
total ( n = nmbr  nmbr ) - -,C0439175;C0439810,2832/10465
laboratory variables,C0022877;C3244292;C4283904,2833/10465
baseline anti - hyperglycemic medications,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,2834/10465
ivabradine group ( n = nmbr ),C0257190;C0257190;C0257190;C0257190;C0257190;C0257190,2835/10465
undergoing major vascular surgery,,2836/10465
< nmbr baseline killip class,C0053917;C0053917;C1334884;C1334884,2837/10465
statin intensitynmbr * nmbr,C0360714,2838/10465
multivitamin use,C0301532;C0301532;C0301532,2839/10465
baseline body weight quartile,C1303013,2840/10465
baseline fpg  mean ( s . e . ),C0168634;C1442488,2841/10465
primary pci n = nmbr,C0205225;C0439612;C0439631,2842/10465
prior tnfi treatment,C1514463,2843/10465
multiple ( > nmbr ) chd risk factors that confer a nmbr - year risk of chd > nmbr %,C0439064,2844/10465
pctindopnl - indapamide ( n = nmbr ),C0021186,2845/10465
history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,2846/10465
stroke of any etiology,C0038454;C0038454;C0038454;C4554100;C4554100;C4554100,2847/10465
fasting insulin ( pmol / l ),C0015663;C0015663;C0015663;C0015663,2848/10465
total body ( without head ),C0229960,2849/10465
fatty acid composition,C0015684;C0015684,2850/10465
cerebral hemorrhage,C2937358,2851/10465
pasinmbr response },C0871261;C1704632;C1706817;C2911692,2852/10465
nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,,2853/10465
duration of diabetes ( months ),C0449238;C0449238;C2926735;C2926735,2854/10465
alpha - glucosidase inhibitors,C1299007;C2756986;C3539108,2855/10465
anthropometry : mean ( sd ),C0003188,2856/10465
white ethnicity,C0007457;C0007457;C0043157;C0043157;C0220938;C0220938,2857/10465
vascular history  %,C0005847;C0005847;C0005847;C0005847;C0005847;C0005847;C1558950;C1558950;C1558950;C1558950;C1558950;C1558950;C1801960;C1801960;C1801960;C1801960;C1801960;C1801960,2858/10465
time from qualifying myocardial infarction,C0040223;C0040223;C0040223;C0040223;C0040223;C3541383;C3541383;C3541383;C3541383;C3541383,2859/10465
nmbr — nmbr nlmw,,2860/10465
postoperative glucocorticoid use post - randomisation characteristic * *,C0032790;C0032790;C0032790;C0032790;C0032790;C0032790;C0032790;C0032790;C0032790,2861/10465
sinus rhythm,C0232201,2862/10465
united states or canada,C0041703,2863/10465
heparin  ‘ ondaparinux or brvalirudin use between rxjex event,,2864/10465
community hospital  n ( % ),C0020003,2865/10465
patient - reported outcome measures,C4277735,2866/10465
> nmbr . nmbr mg / liter antiplatelet agents,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,2867/10465
ara functional class — no . ( % ),,2868/10465
left ventricular ejection fraction,C0428772;C0488728,2869/10465
restenotic vessel,C0333186,2870/10465
mean nmbr - year cvd risk *,C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143,2871/10465
^median > median,C0549183;C0876920;C2347635;C2348144;C2939193,2872/10465
ace inhibitors / sartans,C0003015,2873/10465
duration of hypertension  y,C0449238;C0449238;C2926735;C2926735,2874/10465
history of pci — no . / total no . ( % ) : t,,2875/10465
current cigarette smoker or within past year,C3173209;C3173209;C3173209;C3241966;C3241966;C3241966;C0521116;C1705970,2876/10465
time to randomization from symptom onset,C0040223;C3541383,2877/10465
motor weakness,C1513492;C1705994,2878/10465
hospitalization for hf previous year  ( % ),C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993;C0019993,2879/10465
st - segment depression < nmbr . nmbr mv  %,C0520887,2880/10465
ab / ff nmbr / nmbr pg ( n = nmbr ),C4554348;C4554348;C4554348;C4554348;C4554348;C4554348,2881/10465
severity of airflow obstruction,C0439793;C0439793;C0522510;C0522510,2882/10465
tender - joint count ( of nmbr joints ),C0451530,2883/10465
tenecteplase,C0872913,2884/10465
median duration of symptoms ( range )  yr,C0549183;C0876920;C2347635;C2348144;C2939193,2885/10465
history of pci / ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,2886/10465
only dvt,C0205171;C0205171;C0205171;C1720467;C1720467;C1720467,2887/10465
glucose - lowering drug,C0017725;C0017725;C0017725;C0017725,2888/10465
age group ( years ),C0027362;C2348001,2889/10465
renal events,C0022646;C0022646,2890/10465
blood leucocyte concentration ( nmbr cells per l ),C0427728;C0699870;C1313904;C0023516;C0023516;C0023516,2891/10465
baricitinib nmbr mg,C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947,2892/10465
etd ( % ) [nmbr % ci],C1180255,2893/10465
ranolazine ( n = nmbr ),C0073633,2894/10465
below - knee popliteal,C0542339;C0542339;C0542339;C1552829;C1552829;C1552829,2895/10465
uacr ( mg / g ),,2896/10465
geographic location,C0017446,2897/10465
albuminuria,C0001925,2898/10465
angina  n ( % ),C0002962,2899/10465
acrnmbr response,C0871261;C1704632;C1706817;C2911692,2900/10465
dyslipidemianmbr,,2901/10465
past or current,C1444637;C4284302,2902/10465
interval from randomization to angiography,C1272706;C1552654;C1552713,2903/10465
enthesitis,C1282952,2904/10465
previous treatment,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,2905/10465
non - tnf inhibitors,C1518422,2906/10465
any blood - pressure - lowering drug 一 no . ( % ),,2907/10465
previous stroke — no . ( % ),,2908/10465
proximal to the splenic flexure,C0205107;C4489236,2909/10465
high eosinophil subgroup ( > nmbr / ml ) ( n = nmbr ),C0014457;C0014457,2910/10465
patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr  n,C0030705;C0030705;C0030705,2911/10465
slo days,C1416602;C3539661,2912/10465
cardiovascular mortality,C0007226;C0007226;C3887460;C3887460,2913/10465
mnmbr subgroup,C1079230;C1515021,2914/10465
valsartan ( n = nmbr ),C0216784,2915/10465
japan n = nmbr,C0022341,2916/10465
modified se - adl scale,C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737,2917/10465
corticosteroids only,C0001617;C0001617;C3539185;C3539185;C3540725;C3540725;C3540726;C3540726;C3540727;C3540727,2918/10465
p - value interaction,C1709380,2919/10465
undetermined  other  or cardioembolism,C0205258;C3536725;C4082977,2920/10465
percentage patients reaching target,C0439165;C1549488;C1561533,2921/10465
hispanic  n ( % ),C0086409,2922/10465
modified has - bled,C0392747;C3889737,2923/10465
insulin alone,C0021641;C1533581;C1579433;C3714501,2924/10465
statin only  n ( % ),C0360714;C0360714,2925/10465
body - mass index categories — no . ( % ) : c,,2926/10465
monocytes  nmbr / nl,C0026473,2927/10465
criteria for subcortical vad ( by mri )  %,C0243161,2928/10465
crp mean ( mg / dl ± sd ),,2929/10465
angiographic features,C0002978;C0002978;C0002978;C0002978,2930/10465
> nmbr years to < nmbr years ( n = nmbr ),C0053917;C1334884,2931/10465
pathologic q waves  n ( % ),C0429090,2932/10465
duration of metformin therapy ( months ),C0444917,2933/10465
baseline bmi > nmbr kg / mnmbr  n = nmbr change from baseline to nmbr weeks,C0168634;C1442488,2934/10465
lesion location,C0221198;C0221198;C0221198;C0221198;C1546698;C1546698;C1546698;C1546698,2935/10465
patients treated with statins ( n = nmbr ),C0030705,2936/10465
copd exacerbations during the previous year,C0740304;C0740304;C0740304;C0740304,2937/10465
biasp nmbr,C0053917;C1334884,2938/10465
insulin — iu,,2939/10465
subject characteristics,C0681884;C1519021;C1706465,2940/10465
primary composite outcome,C0205225;C0205225;C0439612;C0439612;C0439631;C0439631,2941/10465
category nmbr and nmbr,C0683312;C0683312;C3889287;C3889287,2942/10465
race or ethnic background — no . ( % ) f,,2943/10465
renal function subgroups,C0232804,2944/10465
percent of patients,C0439165,2945/10465
placebo / simvastatin,C0032042;C1696465;C1706408,2946/10465
% of predicted normal value *,,2947/10465
body - mass index ( kg / mnmbr )  mean ( sd ),C0005893;C0578022;C1305855,2948/10465
rolofylline dose,C0166128;C0166128;C0166128,2949/10465
canagliflozin dose,C2974540;C2974540;C2974540,2950/10465
pbo + statin nmbr,C0031962;C0031962,2951/10465
orthopaedic,C0029355,2952/10465
geographic region — number ( % ),,2953/10465
black race — no . / total no . ( % ) f,,2954/10465
versus olodaterol nmbr pg,,2955/10465
antihypertensive agents  n ( % ),C0003364,2956/10465
baseline cardiovascular medication,C0168634;C1442488,2957/10465
alpha - blocker,C0001641,2958/10465
modified total sharp score * *,C0392747;C0392747;C0392747;C3889737;C3889737;C3889737,2959/10465
beta - blocker use at baseline,C0001645;C0001645;C0001645;C0001645;C0001645;C0001645,2960/10465
all - cause,C0015127;C1524003,2961/10465
class nmbr or no symptoms,C0456387;C0456387;C1518526;C1518526;C1705943;C1705943,2962/10465
laboratory variables at baseline,C0022877;C0022877;C3244292;C3244292;C4283904;C4283904,2963/10465
pneumonia in past year,C0032285,2964/10465
apixaban  nmbr mg ( n = nmbr ),C1831808,2965/10465
chd men,C0280604;C3542407,2966/10465
calcium antagonist strategy ( cas ) ( events / n ),C0006684,2967/10465
muscle twitching,C0015644;C0231530,2968/10465
other medication usage,C0013227;C3244316;C4284232,2969/10465
qvanmbr nmbr / nmbr | ig od n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,2970/10465
female sex — number ( % ),,2971/10465
heart rate  beats / min  mean ± sd,,2972/10465
mitral insufficiency  n ( % ),C0026266,2973/10465
from baseline ( nmbr % ci ),C0168634;C1442488,2974/10465
compression stockings,C0038348,2975/10465
baseline triglycerides < nmbr mg / dl,C0168634;C1442488,2976/10465
apo b / apo a - l,C1447574;C1447574;C1447574;C4521365;C4521365;C4521365,2977/10465
beta - carotene ( n = nmbr  nmbr ),C0053396;C0696105,2978/10465
> nmbr years baseline ldl - c,C0053917;C0053917;C1334884;C1334884,2979/10465
prevalence of each metabolic syndrome criterion,C0033105;C0220900,2980/10465
sex  men / women  %,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,2981/10465
high - dose statin use  n ( % ) e,C0444956;C0444956;C0444956,2982/10465
fasting glucose ( mmol / l ),C0015663,2983/10465
fistula at baseline  n ( % ),C0016169;C0016169,2984/10465
dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830,2985/10465
coronary angiography — no . ( % ),,2986/10465
presenting signs and symptoms,C0449450;C0449450;C0449450,2987/10465
moderate copdb [n z nmbr],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,2988/10465
planned conservative therapy subgroup,C1301732;C1301732,2989/10465
sonti amenca,,2990/10465
clopidogrel  nmbr mg *,C0070166,2991/10465
methotrexate,C0025677,2992/10465
hs - crp ( mg / l  median ),C3890735;C4048285,2993/10465
previously taken dmards other than methotrexate  %,,2994/10465
non - ischaemic ( n = nmbronmbr ),C1518422,2995/10465
progestins,C0033306,2996/10465
fasting serum glucose ( mg / dl )  median ( iqr ),C0015663;C0015663,2997/10465
normalized,C1882115,2998/10465
time from hospital admission to pci  h  median ( qnmbr  qnmbr ),C0040223;C0040223;C3541383;C3541383,2999/10465
known t ' rc - iitoji cccndilon,C0205309;C0205309,3000/10465
ii or iii,,3001/10465
left ventricular ejection,C2733342,3002/10465
left ventricular ejection fraction — no . / total no . ( % ),,3003/10465
previous loss of response to and intolerance of infliximab  n ( % ) *,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,3004/10465
reported diabetes mellitus,C0684224;C0700287;C4319718,3005/10465
other / missing,C1551393;C1705492;C3272743,3006/10465
severe or moderate,C0205082;C4050465;C4050466,3007/10465
coronary bypass  n ( % ),C0010055,3008/10465
new zealand,C0027978;C0324547,3009/10465
cox - nmbr selective nsaid use,C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830;C1565830,3010/10465
heart failure cause,C0018801;C0018801;C0018802;C0018802;C4554158;C4554158,3011/10465
sbp ( mmhg ) < nmbr,C0085805,3012/10465
past smoker  n ( % ),C1444637;C4284302,3013/10465
previous stroke — no . ( % ) concomitant treatment — no . ( % ),,3014/10465
mean ( s . d . ) hdl cholesterol,C0444504;C2347634;C2348143,3015/10465
amiodarone ( n = nmbr ),C0002598,3016/10465
previous disease — no . ( % ) f,,3017/10465
esrd on placebo ( % ),C0022661;C0022661;C0022661;C0035078;C0035078;C0035078;C2316810;C2316810;C2316810,3018/10465
acute respiratory insufficiency,C0865850,3019/10465
> nmbr % predicted arr ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,3020/10465
associated with drug or toxin exposure,C0332281;C0332281,3021/10465
ls mean change ± sea,,3022/10465
reversible ( % ),C0205343,3023/10465
left atrial dimension  cm,C3275097,3024/10465
aspirin alone ( n = nmbr ) nmbr . nmbr,C0004057,3025/10465
diuretics ( % ),C0012798,3026/10465
ldl cholesterohhdl cholesterol ratio,C0023824;C0023824;C0202117;C0202117,3027/10465
renal insufficiencynmbr,C0022646,3028/10465
> nmbr : nmbr hrs : min ( n = nmbr ),C0053917;C1334884,3029/10465
sr ii b nmbr - cjl nmbr,C0753208;C0753208;C0753208;C0753208;C1709991;C1709991;C1709991;C1709991;C3813610;C3813610;C3813610;C3813610;C3890900;C3890900;C3890900;C3890900;C3891546;C3891546;C3891546;C3891546,3030/10465
csdmards + mtx ( n = nmbr ),C0025677;C1417487,3031/10465
uc duration  y  mean ( range ),C0449238;C2926735,3032/10465
ejection fraction category,C0489482;C0489482;C2700378;C2700378,3033/10465
high - probability ventilation / perfusion lung scanning,C4699572,3034/10465
mmse nmbr - nmbr,C0451306;C0451306,3035/10465
use oforal glucose - lowering agent — no . ( % ),,3036/10465
baseline sgrq total score,C0168634;C1442488,3037/10465
min - max age,C0702093;C1524029;C3813700,3038/10465
baseline gfr < nmbr ml / min per nmbr . nmbr mnmbr  n ( % ),C0168634;C0168634;C1442488;C1442488,3039/10465
ischemic stroke,C0948008,3040/10465
medications at discharge,C0806915,3041/10465
multiracial  n ( % ),C1881928,3042/10465
qnmbr : nmbr . nmbr to < nmbr . nmbr kg ( n = nmbr vs nmbr ),,3043/10465
heart rate,C0018810,3044/10465
self - reported disease severity  nmbr - nmbr scale *,C0681906;C2700446,3045/10465
concomitant aedsa,C0521115,3046/10465
immunosuppressant use  %,C0021081;C0021081;C0021081,3047/10465
moderately high risk,C0205081;C0205081;C0205081;C0205081;C1881878;C1881878;C1881878;C1881878;C4085643;C4085643;C4085643;C4085643;C4321491;C4321491;C4321491;C4321491,3048/10465
triglycerides  median ( ql  qnmbr )  mmol / l,C0041004,3049/10465
nmbr = some restrictions  no help needed,C0053917;C1334884,3050/10465
nmbr or nmbr high - risk categories,C0053917;C1334884,3051/10465
calcium antagonist strategy ( n = nmbr nmbr ),C0006684,3052/10465
time to balloon / needle  min *,C0040223;C0040223;C0040223;C0040223;C3541383;C3541383;C3541383;C3541383,3053/10465
no - diuretics group ( n = nmbr ),C0012798;C0012798;C0012798;C0012798;C0012798;C0012798,3054/10465
egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr  nmbr ),C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,3055/10465
patients with any clinical,C0030705,3056/10465
squamous cell carcinoma,C0007137;C1302853,3057/10465
( pg / mg ),C1627892,3058/10465
phosphodiesterase type nmbr inhibitors,C0031638;C0031638;C0031638;C0031638;C1656262;C1656262;C1656262;C1656262;C3539996;C3539996;C3539996;C3539996,3059/10465
history of stroke ( % ),C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,3060/10465
age ^nmbr yrs  n ( % ),C0001779;C0001779,3061/10465
cangrelor ( n = nmbr ),C1121991,3062/10465
previous cabg ( % total ),C0205156;C0205156;C1552607;C1552607,3063/10465
baseline composite mayo clinic score,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,3064/10465
ticlopidine after completion of study drug,C0040207;C0040207;C0040207;C0040207,3065/10465
admission for hf in previous year  n ( % ),C0184666;C0184666;C0184666;C0184666;C0809949;C0809949;C0809949;C0809949,3066/10465
time since diagnosis — mo,,3067/10465
left main coronary artery,C1261082,3068/10465
other llt at randomization,C2347090,3069/10465
other anti - hypertensives,C0003364,3070/10465
a ngina > nmbr day s previously *,,3071/10465
% predicted,C0681842;C1882327,3072/10465
use of antihypertensive drugs,C1524063,3073/10465
total cholesterol ( median  iqr )  mg / dl,C0201950;C0543421,3074/10465
hr ( nmbr % ci ) p   value,,3075/10465
loop or thiazide diuretic : ! :,C0445022,3076/10465
monitoring group ( n = nmbr ),C0150369;C0150369;C0150369;C0150369;C0150369;C0150369;C1283169;C1283169;C1283169;C1283169;C1283169;C1283169,3077/10465
ischemic coronary artery disease,C0852149,3078/10465
blood eosinophil count > nmbr / mmnmbr at screening — no . ( % ),,3079/10465
no known frtrontxtfufoc cond aon,C0205309,3080/10465
mssbp / msdbp,,3081/10465
devices for heart failure at screening visit,C0025078;C2024216;C2024216;C0025080;C0025080;C0025080;C0220819;C0220819;C0220819;C0699733;C0699733;C0699733,3082/10465
interleukin nmbr ( pg / ml ),C0021764;C0021764;C1527200;C1527200,3083/10465
priorvascular disease  %,C0012634,3084/10465
planned thienopyridine at enrollment,C1709561,3085/10465
background csdmard category,C1706907;C1706907,3086/10465
relative risk ( nmbr % ci ) ofprimary end point,C0242492,3087/10465
history of gi bleeding or ulcer — no . / total no . ( % ),,3088/10465
non - fibrin - specific,C0205370,3089/10465
gly nmbr . nmbr mg b . i . d . n = nmbr,C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124;C1415124,3090/10465
previous coronary angioplasty  n ( % ),C2114427,3091/10465
mean ± sd egfr  ml / min / nmbr . nmbr mnmbr,,3092/10465
octave induction nmbr and nmbr,C0205263;C0205263;C0857127;C0857127,3093/10465
single vessel coronary artery diseasenmbr,C0265903,3094/10465
greater than or equal to nmbr %,C0439093,3095/10465
baseline nih stroke scale — no . ( % ) ^,,3096/10465
history of stroke or tia — no . ( % ),,3097/10465
chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr ),C0280604;C0280604;C3542407;C3542407,3098/10465
albumin ( mg / dl ),C0001924,3099/10465
lp ( a ) ( pmol / l ),C0065058;C1439335;C4553379,3100/10465
st - segment depression,C0520887,3101/10465
statin — no . / total no . ( % ),,3102/10465
> nmbr episodes of atrial fibrillation in previous nmbr mo,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,3103/10465
ascvd as per protocol,C3665365,3104/10465
oral antidiabetes combination therapy without insulina  n ( % ),C0442027;C0442027;C4521986;C4521986,3105/10465
interquartile range — yr,,3106/10465
beta - blockers through hospital discharge or day nmbr — %,,3107/10465
korea  republic of,C0022771,3108/10465
corticosteroid ( without imm )  n,C0001617;C3536709,3109/10465
index event subtype,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,3110/10465
residual perfusion defect > nmbr % on lung scan  no . ( % ),C1609982;C1609982,3111/10465
antiplatelet agent or anticoagulant,C0085826,3112/10465
atorvastatin monotherapy ( n = nmbr * ),C0286651,3113/10465
glycoprotein ilb / iiia inhibitor before pci],C0017968,3114/10465
extensive disease other,C0849867,3115/10465
catheter access site,C0449652;C0449652;C0085590,3116/10465
number of individuals,C1549735,3117/10465
congenital heart disease,C0152021,3118/10465
ff nmbr gg ( n = nmbr  nmbr ),C4554348;C4554348;C4554348;C4554348,3119/10465
time from event to randomization — days,,3120/10465
clinical,C0205210,3121/10465
presence of mets ( % ) a,C0150312;C0150312;C0150312;C0392148;C0392148;C0392148;C3854307;C3854307;C3854307,3122/10465
parental history of mii,C0030551;C0030551;C0030551;C0030551;C0030551;C0030551,3123/10465
fasting serum glucose  mg / dl,C0015663;C0015663,3124/10465
treatment at randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,3125/10465
glomerular filtration rate ( ml / min / nmbr . nmbrma ,C0017654;C1561549,3126/10465
qrs duration > nmbr ms  n ( % ),C0429025;C0488377,3127/10465
median time to first exacerbation ( months [nmbr % ci] ),C0549183;C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193;C2939193,3128/10465
fasting c - peptide ( nmol / l ) c,C0015663,3129/10465
tender joint count ( nmbr joints ),C0451530,3130/10465
all - cause hospitalization,C0015127;C1524003,3131/10465
duration of full - dose warfarin therapy before enrollment ( mo ),C0444917,3132/10465
severe or very severe copd,C0205082;C4050465;C4050466,3133/10465
nmbrmg vs placebo,,3134/10465
nmbrmwd  m,,3135/10465
proportion ( nmbr % ci ) adjusted for baseline hbanmbrc  %,C1709707,3136/10465
waist ( cm ),C0230097,3137/10465
qualifying diagnosis,C1514624;C1514624;C1514624,3138/10465
mean disease duration  y ( sd ),C0444504;C2347634;C2348143,3139/10465
daily activities / social functioning,C0871707,3140/10465
saxa nmbr . nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,3141/10465
rosuva nmbr mg n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,3142/10465
bmi group — no . ( % ),,3143/10465
lv mass,C0455825,3144/10465
hours from clopidogrel loading  mean ( sd ),C0439227,3145/10465
non - ischaemic,C1518422,3146/10465
omega nmbr allocation,C1719844;C1719844,3147/10465
adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),C1137094,3148/10465
n - nmbr pufa,C0369718;C0369718;C0441922;C0441922,3149/10465
combined ( n = nmbr ),C0205195,3150/10465
lamotrigine,C0064636;C0524166,3151/10465
maximal diameter stenosis,C0205289;C0205289;C0205289;C0806909;C0806909;C0806909;C4049713;C4049713;C4049713,3152/10465
hispanic ethnic group  n ( % ),C0086409;C0086409,3153/10465
multivessel coronary artery disease — no . / total no . ( % ),,3154/10465
history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,3155/10465
patient ' s global assessment of disease activity ( nmbr - nmbr mm vas )  mean ( sd ),C4054228,3156/10465
prior cardiovascular event " ' ",C0332152;C2826257,3157/10465
no . with event / total no . { % ),,3158/10465
ras - aldosterone inhibitor^,C1514727;C0034678;C0525678,3159/10465
mean ( sd ) post - bronchodilator fevnmbr / fvc  %,C0444504;C2347634;C2348143,3160/10465
non - hispanic white,C1518424;C1518424;C1518424,3161/10465
ethacrynic acid,C0014963,3162/10465
aqlq ( s ) score,C4055434,3163/10465
patients who received negative results on test for antibodies to infliximabt,C0030705,3164/10465
non - hdl ( mg / dl ) < nmbr,C1518422,3165/10465
all completers,,3166/10465
mean difference = seb,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,3167/10465
> nmbr  n ( % ) gender  n ( % ),C0053917;C1334884,3168/10465
prior use of $ nmbr systemic therapies,C1514463;C1514463;C0332152;C0332152;C2826257;C2826257,3169/10465
health assessment questionnaire ( nmbr - nmbr range ),C0451208,3170/10465
low - molecular - weight heparin,C0019139;C3536766,3171/10465
non - hdl cholesterol ( mmol / l ),C0729627;C1535899,3172/10465
previous medication for respiratory disease — no . ( % ),,3173/10465
characteristics of the index ml,C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970;C1521970,3174/10465
history of heart failure,C0455531,3175/10465
prior cardiovascular history,C0332152;C2826257,3176/10465
metabolic syndromenmbr *,C0311400;C1524026;C2707259,3177/10465
consistency of effect,C0332529;C0332529;C0332529;C1547017;C1547017;C1547017,3178/10465
fondaparinux,C1098510,3179/10465
other lipid - modifying drug 一 no . ( % ),,3180/10465
initial timi flow,C0205265;C1279901;C1555582;C1705685,3181/10465
overall nmbr,C0282416;C0282416;C1561607;C1561607,3182/10465
absolute decrease > nmbr %,C0205344;C0205344,3183/10465
recurrent hf hospitalization,C1455761;C1455761;C1455761;C1455761;C2945760;C2945760;C2945760;C2945760,3184/10465
intrathoracic or intraperitoneal surgery,C0595836,3185/10465
former or never diabetes,C0205156;C0750523,3186/10465
geographic site  %,C0017446,3187/10465
history of high cholesterol ( a ) nmbr,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,3188/10465
history of heart failure  n ( % ),C0455531,3189/10465
sco . ’ ita ' rojs dvt . ' pe,,3190/10465
general health vas  nmbr - nmbr mm,C0424575;C0424575;C0424575;C4018875;C4018875;C4018875,3191/10465
placebo / open - label abatacept,C0032042;C1696465;C1706408,3192/10465
prior known stenosis > nmbr %,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,3193/10465
ras antagonist  %,C0034678;C0525678,3194/10465
cancer medications,C0006826;C0006826;C0006826;C0006826;C0998265;C0998265;C0998265;C0998265;C1306459;C1306459;C1306459;C1306459,3195/10465
current other ( predefined ) medical conditions,C0521116;C1705970,3196/10465
center location,C0205099,3197/10465
time from qualifying stroke to randomization,C0040223;C0040223;C3541383;C3541383,3198/10465
geographical region  n ( % ),C0017446,3199/10465
priorbone disease,C0012634,3200/10465
laba - inhaled glucocorticoid use at screening,C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048,3201/10465
main concomitant treatments  no . ( % ),C0205225;C1542147,3202/10465
use of rescue medication,C0240320,3203/10465
p vs placebo,C0369773;C2603361,3204/10465
cardiac troponin t level > nmbr . nmbr pg / l,C3538889;C3538889;C3538889;C3538889,3205/10465
aspirin < nmbr day,C0004057,3206/10465
native coronary,C0302891,3207/10465
arthralgia,C0003862;C4551938,3208/10465
other bdmards ( no tnfi taken ) t  n ( % ),,3209/10465
hmgcoa rl,C0047420;C0047420,3210/10465
egfrmdrd  ml - min - nmbr - nmbr . nmbr m - nmbr,,3211/10465
prior angioplasty,C0332152;C0332152;C2826257;C2826257,3212/10465
anti - ccp antibody ( u /,C0003242;C0003242;C4318437;C4318437;C4318437;C4318437,3213/10465
mean baseline ldl - c ( mmol / l ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,3214/10465
composite events,C0205199;C0205199;C1547335;C1547335,3215/10465
foot fracture,C0272774,3216/10465
non - caucasian simva ( „ = nmbr },,3217/10465
tc  mean ( sd )  rrig / dl,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,3218/10465
high risk and fewer symptoms ( group c ),C0332167;C3272283;C4050568;C4319571,3219/10465
type nmbr diabetes history  n ( % ),C1320657;C1320657;C1320657;C1320657;C1320657;C1320657;C1320657;C1320657;C1320657;C1320657;C1320657;C1320657,3220/10465
total cholesterol / hdl - c,C0201950;C0543421;C0439175;C0439810,3221/10465
hypertension absent,C0020538;C1963138,3222/10465
warfarin,C0043031,3223/10465
moderate  n ( % ) a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,3224/10465
urine acr ( mg / g ),C0042036;C0042036;C0042037;C0042037;C2963137;C2963137,3225/10465
baseline systolic blood pressure,C4274438,3226/10465
hrnmbr and nmbr % cl,,3227/10465
ventricular tachyarrhythmias,C3827656,3228/10465
sulfonylurea based,C0038766;C3536898,3229/10465
medication use — no . ( % ) ^ |,,3230/10465
bivalirudin ( n = nmbr ),C0168273,3231/10465
p - blockers  n ( % ),C0369773;C2603361,3232/10465
acarbose 一 no . ( % ),,3233/10465
unfractionated heparin,C0019134;C2825026,3234/10465
all patients n = nmbr,C0030705,3235/10465
sitagliptin no . / total no .,C1565750,3236/10465
% anti - ccp + ( > nmbr units ),C4318437,3237/10465
septal anomaly — no . ( % ),,3238/10465
intensified ( n 二 nmbr ),,3239/10465
long - acting bnmbr - agonists,C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317,3240/10465
bodily pain,C3890602,3241/10465
mmrc grade,C3826977;C3826977;C3826977,3242/10465
alcohol consumption > once weekly,C0001948,3243/10465
p - value for trend *,C1709380;C1709380,3244/10465
blood eosinophil count > nmbr / mmnmbr in nmbr months before screening — no . ( % ),,3245/10465
at entry,C1705654,3246/10465
tiotropium group ( n = nmbr ),C0213771;C0213771;C0213771;C0213771;C0213771;C0213771,3247/10465
nmbr - nmbr months ( n = nmbr ),C0053917;C1334884,3248/10465
dapagliflozin nmbr mg group ( n = nmbr ),C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951,3249/10465
p value ( aged > nmbr vs . < nmbr years ),C1709380,3250/10465
valvular disease,C3258293,3251/10465
prior angina,C0332152;C2826257,3252/10465
japan and south korea,C0022341,3253/10465
postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0032790;C0032790,3254/10465
all randomized patients,C0034656;C3815594,3255/10465
pack - years  mean ( sd ),C1277691,3256/10465
epa hr events ( % ),C0441471;C3541888,3257/10465
type of myocardial infarction — no . ( % ),,3258/10465
pciperformed for qualifying event,C1514624;C1514624,3259/10465
nonsustained ventricular tachycardia — no . ( % ) - j -,,3260/10465
ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446,3261/10465
percutaneous intervention,C0522523;C0522523;C0522523,3262/10465
hazard ratio for cardiovascular death  stroke  or myocardial infarction ( nmbr % ci ),C2985465;C2985465;C2985465;C2985465;C2985465;C2985465;C2985465;C2985465,3263/10465
hypercholesterolemia  n ( % ),C0020443;C1522133,3264/10465
diclofenac,C0012091,3265/10465
nmbr week to nmbr month,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,3266/10465
gp llb / llla inhibitors,C1705010;C3811116,3267/10465
current  n ( % ),C0521116;C1705970,3268/10465
syndesmophyte present  n ( % ),C0221690;C0221690,3269/10465
angiographic findings | |,C0002978;C0002978;C0002978,3270/10465
apixaban  nmbr mg,C1831808,3271/10465
bypass graft,C0185098,3272/10465
bmnmbr ( kg / mnmbr ),,3273/10465
nmbr = no symptoms,C0053917;C1334884,3274/10465
prior brachytherapy,C0332152;C2826257,3275/10465
time since cessation of full - dose warfarin therapy,C0040223;C3541383,3276/10465
history of or current cardiac disorders  %,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,3277/10465
impaired glucose tolerance or impaired fasting glucose,C0271650,3278/10465
severe  n ( % ) b,C0205082;C4050465;C4050466,3279/10465
hospitalization for heart failure within previous nmbr mo — no . ( % ),,3280/10465
diuretics  n ( % ),C0012798,3281/10465
mmse ( points ),C0451306,3282/10465
apixaban ( n = nmbr ),C1831808,3283/10465
corticosteroid ( with or without immunosuppressants ),C0001617;C3536709,3284/10465
congestive heart failure,C0018802,3285/10465
chf on placebo ( % ),C0018802;C0018802;C0018802,3286/10465
overall hr ( nmbr % cl ),C0282416;C1561607,3287/10465
hyperlipidemia — no . ( % ),,3288/10465
p value for trend across tertiles,C1709380;C1709380,3289/10465
nmbr - nmbr drinks / wk,C0053917;C0053917;C1334884;C1334884,3290/10465
> nmbr mg / dl — %,,3291/10465
diagnosis of allergic rhinitis,C0011900;C0011900;C0011900;C1704338;C1704338;C1704338;C1704656;C1704656;C1704656,3292/10465
refractory to such therapy — no . ( % ),,3293/10465
lymphocytes  nmbr / + il,C0024264;C4018897,3294/10465
adjusted * or ( nmbr % ci ) p value,C0456081,3295/10465
fevnmbr % pred . ( post - albuterol )  %,C0032952;C0044955,3296/10465
known thrombophilia — no . ( % ),,3297/10465
nmbr - nmbr ( mild ),C0053917;C1334884,3298/10465
simvastatin  n ( % ),C0074554,3299/10465
age  mean ( sd ) [range]  y,C0001779,3300/10465
copd exacerbation history  n ( % ),C0740304;C0740304;C0740304;C0740304;C0740304;C0740304,3301/10465
atio - pla,C0456170,3302/10465
cardiac troponin t level  median ( iqr )  pg / l,C3538889;C3538889;C3538889;C3538889,3303/10465
estimated glomerular filtration rate  ml / min per nmbr . nmbr mnmbr,C3811844,3304/10465
toast classification of qualifying stroke ( % ),C1710306;C1710306;C4521230;C4521230,3305/10465
duration of diabetes by tertiles,C0449238;C0449238;C2926735;C2926735,3306/10465
on drug treatment ( % ),C0150270;C3469597,3307/10465
triglyceride ( median  mg / dl ) - nmbr [nmbr - nmbr percentile |,C0041004,3308/10465
pre - specified hr ( nmbr % cl ),C2826245,3309/10465
cardiac medications during indexhospitalization and / or discharge,C0018787;C0018787;C0018787;C0018787;C1522601;C1522601;C1522601;C1522601,3310/10465
neither corticosteroid nor immunosuppressant,C0001617;C3536709,3311/10465
albumin / creatinine ratio  n ( % ),C0486293;C1318293,3312/10465
score on modified rankin scale — median ( iqr ),,3313/10465
placebo group,C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408,3314/10465
discontinuations due to ae,C0457454,3315/10465
creatinine clearance  n ( % ),C0812399,3316/10465
multi vessel ( or left main ),C0439064;C3266262,3317/10465
infarct location,C0021308;C0021308;C0021308;C0021308,3318/10465
elevated hscrp,C0205250;C3163633,3319/10465
laba + ics n = nmbr,C0815320;C4551720,3320/10465
renal function  severe,C0232804,3321/10465
high - density lipoprotein cholesterol  median  ( nmbrth — nmbrth percentiles )  mg / dl,,3322/10465
mean ± sd fasting insulin  uu / ml,,3323/10465
at least nmbr / mo,C0053917;C0053917;C1334884;C1334884,3324/10465
atrial fibrillation — no . / total no . ( % ),,3325/10465
ls - mean between - group difference ( nmbr % ci ),C0023668;C0023668,3326/10465
all others  n ( % ),C1955473;C3539125,3327/10465
joint swelling  effusion  or both on clinical examination — no . ( % ),,3328/10465
median age ( nmbr %  nmbr % )  y,C0549183;C0876920;C2347635;C2348144;C2939193,3329/10465
history of cerebrovascular disease,C0585890,3330/10465
laba or lama ’,,3331/10465
metformin ( n = nmbr ),C0025598,3332/10465
prior cabg ( before index acs ),C0332152;C2826257,3333/10465
anti - tnf - experienced patients,C1448177,3334/10465
digoxin / digitalis glycoside,C0012265,3335/10465
body mass index ( range ) ( kg / mnmbr ),C0005893;C0578022;C1305855,3336/10465
patients with previous loss of response to infliximab,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,3337/10465
treatment group,C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704,3338/10465
haq - di  mean ( sd ),C3826998;C4321476,3339/10465
duration of copd ( years )  mean ( sd ),C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,3340/10465
egfr < nmbr  ml / min / mnmbr,C1739039;C3811844;C3812682,3341/10465
carotid infarct,C0741968,3342/10465
negative ( < nmbr . nmbr )  n ( % ),C0205160;C1513916;C2825415;C2825491;C3853545,3343/10465
endpoint week nmbr,C2349179;C2349179;C2349179;C2349179;C2826544;C2826544;C2826544;C2826544,3344/10465
homa - ir  mean ( sd ) ( mu / l $ mmol / l ) b,C0022065;C0022071;C1448132,3345/10465
lipid and lipoprotein values ( mg / dl ),C0023779,3346/10465
placebo no . of events / no .,C0032042;C1696465;C1706408,3347/10465
for treatment of index event,C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704,3348/10465
mild ( > nmbr to < nmbr ),C2945599,3349/10465
heterogeneity p value,C0019409;C0242960,3350/10465
number of stents ( per patient ),C0237753;C0449788,3351/10465
preoperative serum creatinine > nmbr pmol / l,C0445204;C0445204,3352/10465
sacubitril / valsartan ( n = nmbr ),C4033631,3353/10465
mean ( s . d . ) apoc - ll nmbr  mg / dl,C0444504;C2347634;C2348143,3354/10465
implanted cardioverter - defibrillator,C0021102;C2828363,3355/10465
swollen joint count ( n / nmbr ),C0451521,3356/10465
postmenopausal ( % ),C0232970,3357/10465
coronary disease,C0010068;C1956346,3358/10465
prior lev treatment,C1514463,3359/10465
rsg nmbr mg / day,C0053917;C1334884,3360/10465
former or current smokers ( % ),C0205156;C0750523,3361/10465
topiramate,C0076829,3362/10465
hydrochlorothiazide,C0020261,3363/10465
toast classification of qualifying stroke  no . ( % ),C1710306;C1710306;C4521230;C4521230,3364/10465
class nmbr antiarrhythmic agents,C0456387;C0456387;C0456387;C0456387;C1518526;C1518526;C1518526;C1518526;C1705943;C1705943;C1705943;C1705943,3365/10465
age  mean nmbr sd years,C0001779,3366/10465
concomitant methotrexate  n ( % ),C0521115,3367/10465
corticosteroids . immunosuppressants . and antimalarials,C0001617;C3539185;C3540725;C3540726;C3540727,3368/10465
bl mean  mg / dl ( mmol / nmbr ),C0005918;C0005918;C0005918;C0006413;C0006413;C0006413;C1552663;C1552663;C1552663;C2827109;C2827109;C2827109,3369/10465
history of diabetes mellitus  n ( % ),C0455488,3370/10465
median ( iqr ) admission data,C0549183;C0876920;C2347635;C2348144;C2939193,3371/10465
not provided,C1518422,3372/10465
current bone disease,C0521116;C1705970,3373/10465
triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],C0041004,3374/10465
stent plus abciximab,C0038257,3375/10465
systolic blood pressure < nmbr mm hg and diastolic blood pressure < nmbr mm hg,C0488055;C0871470;C1306620,3376/10465
vasoprotectives,C0304533,3377/10465
associatedproximaldeep - veinthrombosisatdiagnosis  no . ( % ),,3378/10465
discharge medication  n ( % ),C0012621;C0012621;C0012621;C0030685;C0030685;C0030685;C2926602;C2926602;C2926602,3379/10465
other cardiac surgery  n ( % ),C0018821;C0524727,3380/10465
induction - trial group assignment — no . ( % ),,3381/10465
bw  mean ( sd )  kg,C0005910;C0006041;C2986891,3382/10465
first procedure,C0205435;C0205435;C0205435;C0205435;C1279901;C1279901;C1279901;C1279901,3383/10465
prior af ablation  n ( % ),C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,3384/10465
fevnmbr reversibilityz ( pre / post salbutamol )  %,,3385/10465
second - generation stent,C0205436;C0205436;C0457385;C0457385;C0565930;C0565930;C1561503;C1561503;C1705190;C1705190,3386/10465
msasss  mean ( sd ),,3387/10465
total cholesterohhdl cholesterol ratio,C0201950;C0201950;C0543421;C0543421,3388/10465
primary safety end point : severe / life - threatening,C2986535;C2986535,3389/10465
nt - probnp ( pg / ml ) ( qnmbr - qnmbr ),C0669479;C0754710,3390/10465
remodeling,,3391/10465
smoking past,C0037369;C0037369;C0453996;C0453996;C1881674;C1881674,3392/10465
cigarette smoking status,C0239059;C0700219;C0677453;C1704760;C3890423,3393/10465
use of concomitant lipid - lowering therapy - no . ( % ),C1524063,3394/10465
prior arrhythmias  n ( % ),C0332152;C2826257,3395/10465
thienopyridine at enrollment,C1120149;C1120149;C1120149,3396/10465
coronary risk factors — no . ( % ),,3397/10465
cardiovascular risk factors,C0850624,3398/10465
less than nmbr year,C0439092;C0439092;C0439092;C0439092,3399/10465
anti - arthritic medications,C0013227;C0802604;C2598133;C4284232,3400/10465
some physical activity,C0015259;C0026606,3401/10465
first medical contact — no . ( % ) §,,3402/10465
premature cad among family members,C0151526;C0151526;C0151526;C0151526;C0205252;C0205252;C0205252;C0205252;C4018905;C4018905;C4018905;C4018905,3403/10465
ppci in - nmbr,C0053917;C1334884,3404/10465
overall n = nmbr  nmbr,C0282416;C1561607,3405/10465
fevnmbr % predicted  post - albuterol  %,C0681842;C0681842;C0681842;C1882327;C1882327;C1882327,3406/10465
medical therapy only,C0418981;C0418981,3407/10465
aspirin and thienopyridine therapy,C0004057,3408/10465
heart rate  mean ( sd )  beats / min,C0018810,3409/10465
tg  median ( interquartile range ),C0337445,3410/10465
non - hispanic black,C1518424;C1518424;C1518424;C1518424,3411/10465
normal renal function,C0232805,3412/10465
renal parameters,C0022646,3413/10465
fasting blood glucose — mmol / liter,,3414/10465
glycoprotein iib / iiiareceptorinhibitor,C0017968,3415/10465
plaque ( n  % ),C0011389;C0241148;C0332461;C0333463;C4316797,3416/10465
coronary angiography,C0085532;C1548829,3417/10465
age  mean ( min - max ) ( yrs ),C0001779,3418/10465
evolocumab nmbr mg every nmbrweeks ( n = nmbr ),C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352,3419/10465
patients not receiving immunosuppressive agents at baseline,C0030705,3420/10465
no . ( % ) with event [incidence rate per nmbr patient - y],,3421/10465
screening hbanmbrc ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,3422/10465
modified rankin scale — no . ( % ) |,,3423/10465
previous cancer  n ( % ),C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,3424/10465
penetrating,C0205321,3425/10465
more than nmbr vessels stented,C0205172;C0205172,3426/10465
changes ( a ) in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172,3427/10465
baseline acq - nmbr score,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,3428/10465
dm medication  n ( % ) c,C0011816;C0011816;C0011816;C3250443;C3250443;C3250443,3429/10465
left main disease,C0205091;C0205091;C0443246;C0443246;C1552822;C1552822,3430/10465
> nmbr lesions per vessel,C0053917;C1334884,3431/10465
xanthinesnmbr,,3432/10465
tg ( mmol / l  median ),C0337445,3433/10465
verapamil sr strategy ( n = nmbr  nmbr ),C1527129,3434/10465
aspirin ( asa ) ( » = nmbr nmbr ),,3435/10465
weight  mean nmbr sd kg,C0005910;C0043100;C1305866;C1705104,3436/10465
hispanic black,C0086409;C0086409;C0086409;C0086409,3437/10465
atrial fibrillation or flutter — no . ( % ),,3438/10465
on - treatment,C4684449,3439/10465
killip class i — no . ( % ),,3440/10465
killip class ( interaction : p = nmbr . nmbr ),C1881332,3441/10465
adjusted hr ( enl vs lcz ) ( nmbr % cl ),C0456081,3442/10465
total basdai  mean ( sd ),C0439175;C0439810,3443/10465
placebo + statin ( n = nmbr  nmbr ),C0032042;C1696465;C1706408,3444/10465
thrombus aspiration,C0087086;C0087086;C0087086;C0087086;C0087086;C0302148;C0302148;C0302148;C0302148;C0302148;C3146237;C3146237;C3146237;C3146237;C3146237,3445/10465
marital status  married,C0024819;C1716536;C3172566,3446/10465
no . of days to randomization — median ( iqr ),,3447/10465
exacerbations in previous year,C4086268;C4086268;C4086268;C4086268,3448/10465
pain ( nmbr mm vas ),C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132,3449/10465
angiogenesis,C0302600;C1519670,3450/10465
non - fatal mi,C1518422;C1518422,3451/10465
who functional class — no . ( % ) : c,,3452/10465
diabetic patients,C0241863,3453/10465
type nmbr  n ( % ),C0332307;C0332307;C1547052;C1547052,3454/10465
abatacept nmbr / — nmbr mg / kg ( n = nmbr ),,3455/10465
black race and ss < nmbr ( n = nmbr vs nmbr ) ■ -,,3456/10465
baseline treatments  n ( % ) a,C0168634;C1442488,3457/10465
imm ( without corticosteroid ),C0205470,3458/10465
mean ( sd ) number of exacerbations *,C0444504;C2347634;C2348143,3459/10465
s . e .,C0565930;C2603362,3460/10465
spiralcomputedtomographyangiography,,3461/10465
p ( losartan versus placebo ),C0369773;C2603361,3462/10465
apo b / apo a - l ratio ( mean ),C1447574;C1447574;C1447574;C1447574;C1447574;C1447574;C4521365;C4521365;C4521365;C4521365;C4521365;C4521365;C0003593;C0003593;C0003593;C0003593;C0003593;C0003593;C3252643;C3252643;C3252643;C3252643;C3252643;C3252643,3463/10465
mean ( s . d . ) non - hdl cholesterol,C0444504;C2347634;C2348143,3464/10465
secukinumab nmbr mg,C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547,3465/10465
early - start group ( n = nmbr ),C1279919;C1279919;C1279919;C1279919;C1279919;C1279919,3466/10465
p interaction ( rx arm * sex ),C0369773;C2603361,3467/10465
left ventricular hypertrophy  n ( % ),C0149721;C3484363,3468/10465
af pattern,C0344434;C4049859,3469/10465
severity of copd,C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,3470/10465
post - bronchodilator fev   % predicted,C2599594,3471/10465
copd or asthma  ( % ),C0024117;C1412502;C3714496,3472/10465
body - mass index — no . ( % ) $,,3473/10465
waist - to - hip ratio,C0205682,3474/10465
nmbr years or older,C0053917;C1334884,3475/10465
years since myocardial infarction,C0439234,3476/10465
with alogliptin nmbr mg ( n nmbr nmbr ),C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126,3477/10465
hoehn and yahr stage,C0205390;C1300072;C1306673,3478/10465
elevated cardiac markers — no . ( % ) : t,,3479/10465
scores for global and pain assessments §,,3480/10465
documented coronary artery disease,C1301725;C1301725;C1301725;C1609436;C1609436;C1609436,3481/10465
large vessel atherosclerosis,C0225990;C0225990,3482/10465
hbalc < nmbr % ( < nmbr mmol / mol )  n ( % ),,3483/10465
copd severity,C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,3484/10465
geometric mean,C2986759,3485/10465
assoc  with connective tissue disease,,3486/10465
chronic kidney disease stage : egfr ( ml / min per nmbr . nmbr mnmbr ),C1561643;C1561643;C1561643;C4553188;C4553188;C4553188,3487/10465
haq - di ( nmbr - nmbr )  mean ( sd ),C3826998;C4321476,3488/10465
egfr crcl < nmbr ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,3489/10465
baseline weight  kg,C1303013,3490/10465
bifurcation  n ( % ),C0184906;C3146289,3491/10465
pe ( with or without dvt ),C0070939;C1880476;C4284304,3492/10465
differencenmbr,,3493/10465
dilatative  n ( % ),C0002940;C0012359;C0700124;C1322279,3494/10465
arterial access,C0003842;C0003842;C0221464;C0221464,3495/10465
serum cholesterol ( mg / l ) *,C0587184,3496/10465
cerebral thrombosis,C0079102;C0151945;C0795687,3497/10465
rosuva nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,3498/10465
dose of atorvastatin,C0178602;C0869039;C1114758,3499/10465
mean ( sd ) weight  kg,C0444504;C2347634;C2348143,3500/10465
congestive heart failure — %,,3501/10465
no prior ms therapies,C1514463;C1514463;C1514463,3502/10465
glucocorticoids only,C0017710;C0017710;C3540777;C3540777;C3540778;C3540778,3503/10465
background aha therapy at screening  n ( % ),C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907,3504/10465
established atherosclerotic cv disease §,,3505/10465
angina symptoms^,C0858277,3506/10465
pain ( vas ),C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132,3507/10465
stroke subtype  n ( % ),C0038454;C4554100,3508/10465
with placebo,C0032042;C1696465;C1706408,3509/10465
relative risk ( nmbr % confidence interval ),C0242492,3510/10465
r nmbr mg + fa ( « = nmbr ),,3511/10465
previous pci or cabg,C0205156;C1552607,3512/10465
total pack - yrs,C0439175;C0439175;C0439175;C0439810;C0439810;C0439810,3513/10465
baseline trl - c by quintiles,C0168634;C1442488,3514/10465
mtx > nmbr and £ nmbr mg / week,,3515/10465
ff / vi nmbr / nmbr | ig ( n = nmbr ),C4554348;C4554348;C4554348;C4554348;C4554348;C4554348,3516/10465
( nmbr % ell ' ll,C0053917;C0053917;C1334884;C1334884,3517/10465
corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727,3518/10465
number of vessels treated  index pci,C0237753;C0449788,3519/10465
mra ( spironolactone or eplerenone ),C0243032;C1609165;C3891069,3520/10465
peripheral artery occlusive disease,C1306889,3521/10465
baseline value,C0168634;C1442488,3522/10465
chronic cvd,C0205191,3523/10465
established ( n = nmbr ),C0443211;C1272684,3524/10465
known thrombophilia,C0205309,3525/10465
normal > nmbr - nmbr,C0205307;C0231683;C0439166;C2347086;C4553972,3526/10465
estimated gfr renal function stage,C0750572;C0750572;C0750572;C0750572;C0750572;C0750572,3527/10465
tg  mmol / l ( mg / dl ) [median],C0337445,3528/10465
clinical characteristics,C0683325,3529/10465
interval after index event,C1272706;C1272706;C1272706;C1272706;C1272706;C1272706;C1272706;C1272706;C1272706;C1272706;C1552654;C1552654;C1552654;C1552654;C1552654;C1552654;C1552654;C1552654;C1552654;C1552654;C1552713;C1552713;C1552713;C1552713;C1552713;C1552713;C1552713;C1552713;C1552713;C1552713,3530/10465
country  n ( % ),C0454664;C1511538,3531/10465
fractures ( site not specified ),C0016658,3532/10465
number of previous dmards,C0237753;C0237753;C0449788;C0449788,3533/10465
non - hispanic,C1518424,3534/10465
proportion of patients in corticosteroid - free clinical remission at week nmbr,C1709707,3535/10465
pramlintide,C0537551,3536/10465
height  inches,C0489786,3537/10465
antithrombotic agents,C1704311,3538/10465
ambulance  n ( % ),C0002422;C3846685,3539/10465
chd risk - no . ( % ),C1282512,3540/10465
infusion administered — no . / total no . ( % ),,3541/10465
non - hdl cholesterol ( week nmbr ),C0729627;C1535899,3542/10465
inhaled glucocorticoid use at screening,C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048;C0004048,3543/10465
type of vessel involved,C1282017,3544/10465
oral blood glucose - lowering drug nmbr ( nmbr . nmbr ),C0442027;C0442027;C0442027;C0442027;C0442027;C0442027;C0442027;C0442027;C0442027;C0442027;C0442027;C0442027;C4521986;C4521986;C4521986;C4521986;C4521986;C4521986;C4521986;C4521986;C4521986;C4521986;C4521986;C4521986,3545/10465
baseline pos frequency per nmbr days  median ( min  max ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,3546/10465
mean ( sd ) mtx dose  mg / week,C0444504;C2347634;C2348143,3547/10465
laboratory ae  n ( % },C0022877;C3244292;C4283904,3548/10465
use of concomitant lipid - lowering treatment,C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063;C1524063,3549/10465
age ( y )  median ( iqr ),C0001779,3550/10465
heart failure  lvef < nmbr %  or both,C0018801;C0018802;C4554158,3551/10465
omalizumab ( lsm ),C0966225,3552/10465
baseline cv medications  n ( % ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,3553/10465
nmbr or nmbr high cardiovascular risk categories,C0053917;C1334884,3554/10465
pack - years smoked,C1277691,3555/10465
exenatide lar,C0167117,3556/10465
concomitant treatment,C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115,3557/10465
score on the minnesota living with heart failure scaled,C0449820;C0449820;C0449820;C4050231;C4050231;C4050231,3558/10465
eosinophil count ( cells per pl ),C0200638;C0750879,3559/10465
disease duration ( yr )  mean ± sd,,3560/10465
baseline total pcsknmbr level by median,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,3561/10465
antiplatelet agents ( % ),C0085826,3562/10465
peripheral vascular disease  n ( % ),C0085096,3563/10465
duration of disease — yr : t,,3564/10465
infarction nmbr - nmbr days,C0021308;C0021308,3565/10465
estimated difference ( nmbr % ci ),C0750572;C0750572,3566/10465
non - st - elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010,3567/10465
aspirin i clopidogrel ( n = nmbr  nmbr ),C0004057;C0004057,3568/10465
pulmonary disease — no . ( % ),,3569/10465
etn nmbr mg + mtx n = nmbr,C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0014758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758;C0717758,3570/10465
all stroke,C0038454;C4554100,3571/10465
previous respiratory disease other than copd — no . ( % ),,3572/10465
history of stroke or transient ischemic attack,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,3573/10465
pelvic fractures,C0149531,3574/10465
standard care allocation,C1442989;C2828392,3575/10465
ra duration ( months ) *,C3538806;C3538806;C4048756;C4048756,3576/10465
other drugs — no . ( % ),,3577/10465
atherosclerotic disease *,C0333482,3578/10465
angiography and revascularization,C0002978,3579/10465
unfractionated heparin ( n = nmbr ),C0019134;C2825026,3580/10465
demographic and clinical characteristics,C0011298,3581/10465
mean lixi dose ± sd ( lg / day ),,3582/10465
number ( % ),C0237753;C0449788,3583/10465
age subgroups,C0001779,3584/10465
ind / gly nmbr / nmbr mg once daily ( n = nmbr ),C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864;C4049864,3585/10465
glycated hemoglobin  mean ( sd )  %,C0017853,3586/10465
no . of events / no . of patients,,3587/10465
carotid artery intervention *,C0007272;C0007272;C0007272;C0162859;C0162859;C0162859;C0741968,3588/10465
hope patients with coronary - artery disease ( n = nmbr ),C0392347;C0392347;C0392347,3589/10465
linagliptin / metformin,C3264599,3590/10465
ultrasound carotid arteries,C0948945,3591/10465
pci or cabg surgery for index event,C4049621,3592/10465
dasnmbr - nmbr ( esr ) nmbr,C0053917;C1334884,3593/10465
cardiac therapy §,,3594/10465
low - dose statin,C0445550;C1708745,3595/10465
oral anticoagulant  n ( % ),C0354604,3596/10465
p - value for interaction nmbr . nmbr,C1709380;C1709380,3597/10465
> nmbr des type,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,3598/10465
placebo patients with events / total,C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408,3599/10465
average age ( year ),C1510992;C2825518,3600/10465
placebo + nmbr mg / d of simvastatin,C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,3601/10465
baseline hb nmbrg i nmbr n = nmbr,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,3602/10465
type of end point,C0332307;C0332307;C1547052;C1547052,3603/10465
copd medication at study entry,C0024117;C1412502;C3714496,3604/10465
emphysema,C0013990;C0034067,3605/10465
mean ( sd ) esr  mm / h *,C0444504;C2347634;C2348143,3606/10465
vilanterol  n = nmbr,C2935023,3607/10465
latin america ( n = nmbr ),C0023122,3608/10465
third heart sound,C0232237;C0232278,3609/10465
tnfi naive,,3610/10465
continued thienopyridine ( n = nmbr ),C0549178,3611/10465
total intravenous loop diuretic ( mg ) median,C0439175;C0439175;C0439810;C0439810,3612/10465
mild to moderate,C1299392,3613/10465
median n - terminal probnp ( iqr ) — pg / ml,,3614/10465
degree of stenosis  % of diameter,C4034225,3615/10465
diagnostic angiography,C0002978,3616/10465
left ventricular hypertrophy on echo,C0149721;C0149721;C3484363;C3484363,3617/10465
fasting serum glucose  median ( sd )  mg / dl,C0015663;C0015663,3618/10465
abatacept plus mtx ( n = nmbr ),C1619966;C1619966,3619/10465
baseline measurements,C0168634;C1442488,3620/10465
non - compliance,C0376405;C0457432,3621/10465
duration of pre - randomization anticoagulant therapy,C2711563;C2711563;C2711563;C2711563,3622/10465
bmi at baseline ( kg / mnmbr ),C0578022;C0578022,3623/10465
average maximum common and bifurcation cimt ( mm ),C1510992;C1510992;C1510992;C2825518;C2825518;C2825518,3624/10465
location,C0450429;C1515974;C4284930;C4284931,3625/10465
kheeatne index dvt,C0600653;C0600653;C0600653;C0918012;C0918012;C0918012;C1552854;C1552854;C1552854;C1637833;C1637833;C1637833;C2986546;C2986546;C2986546,3626/10465
osteitis,C0029400,3627/10465
nmbr - nmbr months fn = nmbr . nmbr ),C0053917;C1334884,3628/10465
glinide 一 no . ( % ),,3629/10465
below - knee popliteal crural,C0542339;C0542339;C0542339;C0542339;C0542339;C0542339;C1552829;C1552829;C1552829;C1552829;C1552829;C1552829,3630/10465
pre - enrollment antihyperglycemic therapy,C1882440;C1882440;C1882440,3631/10465
symptom duration,C1457887;C1457887;C3854129;C3854129,3632/10465
% patients with no progression,C0030705;C0030705,3633/10465
measured at clinic visit with automated device §,,3634/10465
previous episode of heart failure,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,3635/10465
liraglutide ( n = nmbr ),C1456408,3636/10465
hbanmbrc  % ( sd ),,3637/10465
post - bronchodilator fevnmbr — liters,,3638/10465
renal insufficiency,C0035078;C1565489,3639/10465
lvef within nmbr mo  %,C0428772;C0428772;C0428772;C0428772;C0488728;C0488728;C0488728;C0488728,3640/10465
ldl cholesterol  mmol / l  mean ± sd,,3641/10465
history of hypertension for nmbr mo or more,C0455527,3642/10465
fish oil ( n = nmbr ),C0016157,3643/10465
digitalis glycoside,C0012253,3644/10465
baseline mean,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,3645/10465
no previous dmard therapy,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,3646/10465
hbanmbrc at nmbr weeks *,C0053917;C1334884,3647/10465
glycated hemoglobin,C0017853,3648/10465
elevated fasting glucose,C0205250;C3163633,3649/10465
no adk / e cancer,C1412243;C1412243;C1412243,3650/10465
indacaterol + tiotropium ( n[nmbr ),C1722260,3651/10465
ras % target dose,C0034678;C0034678;C0034678;C0034678;C0034678;C0034678;C0525678;C0525678;C0525678;C0525678;C0525678;C0525678,3652/10465
history of upper gastrointestinal event,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,3653/10465
ibdq score |,C0449820;C4050231,3654/10465
first primary ( change in updrs score / wk  wk nmbr - nmbr ),C0205435;C0205435;C0205435;C1279901;C1279901;C1279901,3655/10465
overweight ( nmbr to < nmbr kg / mnmbr ),C0497406,3656/10465
symptom onset - to -,C4086878,3657/10465
median ( iqr ) cholesterol ,C0549183;C0876920;C2347635;C2348144;C2939193,3658/10465
week nmbr mean ( se ),C0332174;C0332174;C0332174;C0332174;C0332174;C0332174;C0439230;C0439230;C0439230;C0439230;C0439230;C0439230,3659/10465
western europe  israel  australia  or south africa,C0043129,3660/10465
imm + corticosteroid  n,C0205470;C0205470,3661/10465
tnmbrdm duration  y,C0449238;C2926735,3662/10465
previous myocardial infarction  n ( % ),C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607,3663/10465
no . ( % ) of participants,,3664/10465
previous tnf antagonist exposure  n ( % ),C0205156;C0205156;C1552607;C1552607,3665/10465
pharmacotherapy,C0013216;C0013217,3666/10465
ulcerative colitis,C0009324,3667/10465
received nmbr prior anti - tnf therapy  n,C1514756;C1514756;C1514756;C1514756,3668/10465
placebo n ( rate ) *,C0032042;C1696465;C1706408,3669/10465
low - density lipoprotein,C0023823,3670/10465
family history^,C0241889,3671/10465
fvc ( % predicted ),C3714541;C3714541,3672/10465
clinical ae  n ( % },C0205210,3673/10465
dietary epa - dha intake ( mg / day ) *,C1286104;C1286104,3674/10465
other llt use,C2347090;C2347090;C2347090,3675/10465
ada nmbr / nmbr n[nmbr,C1060325;C1060325;C3811629;C3811629,3676/10465
serious adverse events,C1519255,3677/10465
change from baseline at week nmbr,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,3678/10465
medications at coronary angiography,C0013227;C0013227;C0802604;C0802604;C2598133;C2598133;C4284232;C4284232,3679/10465
nmbr nmbr years  n ( % ),C0053917;C1334884,3680/10465
no . of subjects,,3681/10465
fpg  mean ( sd )  mg / dl [mmol / l],,3682/10465
acrnmbr response  n / n ( % ),C0871261;C1704632;C1706817;C2911692,3683/10465
sfc nmbr / nmbr mg twice daily ( n = nmbr  nmbr ),C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536;C4521536,3684/10465
geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mmnmbr,,3685/10465
copd - placebo ( n = nmbr ),C0024117;C0024117;C0024117;C1412502;C1412502;C1412502;C3714496;C3714496;C3714496,3686/10465
pga subscore,C0016410;C3541266;C4050369,3687/10465
mafcaiancy at randorrtzaton,,3688/10465
nmbr . nmbr mg / dl triglycerides^,C0053917;C1334884,3689/10465
antiplatelet within nmbr mo before randomization,C0053917;C0053917;C1334884;C1334884,3690/10465
lesion characteristics,C1286326,3691/10465
handihaler and diskus  n,,3692/10465
baseline dyspnea index score,C1511069;C1511069,3693/10465
creatinine clearance — no . ( % ),,3694/10465
any oral hypoglycemic drug 一 no . ( % ),,3695/10465
sfcnmbr / nmbr pg b . i . d . n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,3696/10465
infarct related artery location,C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308;C0021308,3697/10465
pen - label empagliflozin nmbr mg ( baseline hbanmbrc > nmbr % ),C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C1424886;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C3273588;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659;C4319659,3698/10465
other vasculars,,3699/10465
patients who received indeterminate results on test for antibodies to infliximabt,C0030705,3700/10465
history of diabetes requiring drugs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0011847;C0011849,3701/10465
coronary intervention,C0018787;C0018787;C0018787,3702/10465
elevated at wk nmbr — no . ( % ) !,,3703/10465
body mass index category  no . ( % ) l,C0005893;C0005893;C0578022;C0578022;C1305855;C1305855,3704/10465
liraglutide nmbr . nmbr mg mean ( n ),C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,3705/10465
habnmbrc ( mean ± sem )  %,,3706/10465
low risk ( nmbr - nmbr ),C3272281;C3538919,3707/10465
gfr as assessed by mdrd,C0017654;C1424601,3708/10465
history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,3709/10465
nmbr - minute walk distance — m,,3710/10465
male / female  %,C0086582;C0086582;C0086582;C0086582;C1706180;C1706180;C1706180;C1706180;C1706428;C1706428;C1706428;C1706428;C1706429;C1706429;C1706429;C1706429,3711/10465
current inhaler +,C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,3712/10465
phosphate ( mmol / l ),C0031603;C0031701;C1601799,3713/10465
established cardiovascular disease,C0443211;C1272684,3714/10465
smoker ( current / former ),C0337664,3715/10465
total cholesterol - to - hdl cholesterol ratio,C0439175;C0439810,3716/10465
oral anticoagulant drugs  n ( % ),C0354604,3717/10465
definite,C0439544;C1704787,3718/10465
abciximab - facilitated pci ( n = nmbr ),C0288672,3719/10465
computed tomographic angiography,C1536105,3720/10465
distribution — no . ( % ),,3721/10465
intravenous heparin,C0354566,3722/10465
nmbr . nmbr to < nmbr . nmbr % ( nmbr to < nmbr mmol / mol ),C0053917;C1334884,3723/10465
nmbr - month follow - up median ( iq range ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,3724/10465
biventricular pacemaker,C1719274,3725/10465
warfarin group,C0043031;C0043031;C0043031;C0043031;C0043031;C0043031,3726/10465
nmbr aspirin ( n = nmbr nmbr ),C0053917;C1334884,3727/10465
short form nmbr ( sf - nmbr ),C2964478;C2964478,3728/10465
individual intended study duration — no . ( % ),,3729/10465
male nyha class,C0086582;C1706180;C1706428;C1706429,3730/10465
metoprolol group ( n = nmbr ),C0025859;C0025859;C0025859;C0025859;C0025859;C0025859,3731/10465
fenofibric acid,C0060179,3732/10465
warfarin at enrollment,C0043031;C0043031;C0043031,3733/10465
global ischemia,C0205246;C0205246;C2348867;C2348867,3734/10465
p value § ( < nmbr vs . > = nmbr years ),,3735/10465
hf or lvef < nmbr % associated with index event,C0018488;C1313497;C1538440;C3273279,3736/10465
subject completion status  n ( % ),C3891295;C3891295;C2348577;C0681850;C1550501;C1706203;C2349001;C2697811,3737/10465
egfr — ml / min / nmbr . nmbr m * *,,3738/10465
coronary angioplasty or stenting,C0002997;C0190211,3739/10465
death from cardiovascular causes,C0007465;C0007465,3740/10465
nmbr mg / dl ldl cholesterol | |,C0053917;C0053917;C1334884;C1334884,3741/10465
femur fracture,C0015802,3742/10465
erythrocyte sedimentation rate  mm / hour,C1176468;C1619634,3743/10465
insulin sensitivity — % §,,3744/10465
anti - tnf agent ( s ),C1448177;C1448177;C1448177,3745/10465
medication after enrolment,C0013227;C0013227;C0013227;C3244316;C3244316;C3244316;C4284232;C4284232;C4284232,3746/10465
number insulin glargine,C0237753;C0449788,3747/10465
asian ( nmbr . nmbr % ),C0078988,3748/10465
lifestyle modifications,C0870811;C2960841,3749/10465
change from,C0392747;C0443172;C1705241;C4319952,3750/10465
% change  nmbr % ci ),C0392747;C0443172;C1705241;C4319952,3751/10465
< nmbrnwrrtn,,3752/10465
moderate renal impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,3753/10465
major diabetic eye disease  n ( % ),C0205082;C0205164;C4318856;C4521762,3754/10465
all participants,C0679646,3755/10465
history of atrial fibrillation / flutter  ( % ),C0729790;C0729790;C1998417,3756/10465
apixaban dose ( or matching placebo ),C1831808;C1831808;C1831808,3757/10465
symptom onset,C4086878,3758/10465
prosthetic,,3759/10465
disease hare . no . ( % ) i,C0012634;C0012634,3760/10465
treatment by egfr stage,C0815181;C0815181;C0815181,3761/10465
hormonal therapy — no . ( % ),,3762/10465
angina pectoris  ( % ),C0002962,3763/10465
type of stent at index procedure,C0332307;C1547052,3764/10465
blood pressure lowering medication use,C0005823;C0005823;C1271104;C1271104;C1272641;C1272641,3765/10465
gpi used during pci,C1415351,3766/10465
lowzmedium intensity,C0522510,3767/10465
antihypertensive therapy  n ( % ),C0585941,3768/10465
any medication,C0013227;C3244316;C4284232,3769/10465
mean — mm hg level — no . ( % ),,3770/10465
chd simva nmbr = nmbr],C0280604;C0280604;C3542407;C3542407,3771/10465
diabetic history ( years ) x,C0241863;C0241863;C0241863;C0241863;C0241863;C0241863,3772/10465
urine albumin / creatinine ratio ( mg / g ),C0455271;C1318330,3773/10465
extensive colitis or pancolitis,C0205231;C0205231,3774/10465
moderate ckd at randomization,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,3775/10465
less than the median,C0439092;C0439092;C0439092;C0439092;C0439092,3776/10465
qualifying cv event  n ( % ),C1514624;C1514624;C1514624;C1514624;C1514624;C1514624,3777/10465
peripheral artery occlusive disease ( stage nmbr / nmbr / nmbr / nmbr / nmbr ),C1306889,3778/10465
or placebo treatment,,3779/10465
diabetesnmbr ( % ),,3780/10465
continued thienopyridine ( n nmbr nmbr ),C0549178,3781/10465
saxagliptin nmbr . nmbr mg,C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,3782/10465
patients with ra  as  or psa ( n = nmbr ),C0030705;C0030705,3783/10465
chronic bronchitis ( % ),C0008677,3784/10465
reduction 
 in risk 
 ( nmbr % ci ) %,C1137094,3785/10465
moderate disease activity : > nmbr . nmbr to < nmbr . nmbr  n ( % ),C1513375;C3833417;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,3786/10465
age nmbr years or more,C1510829;C1510829,3787/10465
valsartan / hctz ( n = nmbr ),C0216784,3788/10465
ics users  n ( % ),C0815320;C4551720,3789/10465
since onset,,3790/10465
diabetes at randomization,C0011847;C0011849,3791/10465
treated with pci — no . / total no . ( % ),,3792/10465
device group ( n = nmbr ),C1706365,3793/10465
left main coronary artery  n ( % ),C1261082,3794/10465
statin use at study entry  n ( % ),C0360714,3795/10465
lipid disorder,C0154251,3796/10465
history of atrial fibrillation  type 一 no . ( % ),,3797/10465
total diuretic dose ( iv + oral ) on day nmbr  mg,C2986497,3798/10465
enthesitis  n ( % ),C1282952,3799/10465
immobazaton,,3800/10465
digit symbol substitution,C0582802;C0582802;C0582802;C0582802;C3241971;C3241971;C3241971;C3241971,3801/10465
prior coronary revascularization ( pci or cabg ),C0332152;C2826257,3802/10465
hbalc  median ( ql  qnmbr )  %,,3803/10465
fasting cholesterol — mg / dl,,3804/10465
idiopathic,C0332240,3805/10465
mean ( sd ) [range],C0444504;C2347634;C2348143,3806/10465
inhaled corticosteroids,C0004048;C0004048;C0004048;C0004048;C0004048,3807/10465
fasting insulin — pmol / liter,,3808/10465
watchman ( n = nmbr ),C0335390,3809/10465
apixaban  nmbr . nmbr mg ( n = nmbr ),C1831808,3810/10465
primary renal endpoint,C2986535,3811/10465
hgb  g / dl,C0019029;C0019046;C0518015;C1424337,3812/10465
normal ( > nmbr ),C0205307;C0231683;C0439166;C2347086;C4553972,3813/10465
type of des at index procedure,C0332307;C0332307;C1547052;C1547052,3814/10465
nmbr vitamin e ( n = nmbr nmbr ),C0053917;C0053917;C1334884;C1334884,3815/10465
persistent wrf ( n = nmbr ),C0205322;C0332996,3816/10465
estonia,C0014908,3817/10465
score on modified rankin scale ( ' % / ',C0449820;C0449820;C4050231;C4050231,3818/10465
atrial fibrillation or flutter ( ecg ) §,,3819/10465
adcs - adl score *,C3641947;C3641947,3820/10465
mean sfnmbr score ( nmbr % ci ),C3533236,3821/10465
qrs > nmbr ms  n ( % )  available for nmbr patients,,3822/10465
baseline high - sensitivity crp,C0168634;C0168634;C1442488;C1442488,3823/10465
heart rates ( beats / minutes ),C0018810,3824/10465
insulin glargine allocation,C0907402,3825/10465
left side of colon,C0227388,3826/10465
left ventricular hypertrophy,C0149721;C3484363,3827/10465
non - cortical,C1518422;C1518422;C1518422,3828/10465
low - density lipoprotein cholesterol  median  ( nmbrth — nmbrth percentiles )  mg / dl,,3829/10465
unsuccessful procedure,C1272705;C1272705;C1272705;C1272705,3830/10465
previous angina  n ( % ),C0205156;C1552607,3831/10465
nmbr . nmbr to nmbr . nmbr ( % ),C0053917;C1334884,3832/10465
nt - pro - bnp — pmol / liter - j -,,3833/10465
sirukumab nmbr mg qnmbrw,C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570;C3254570,3834/10465
baseline post - bronchodilator % predicted fev  > nmbr % and concurrent tiotropium use,C0168634;C0168634;C1442488;C1442488,3835/10465
euroscore additive  median ( nmbrth  nmbrth % ) §,,3836/10465
lev - naive,C0023556,3837/10465
clinical disease activity index score ( nmbr - nmbr ),C3869583;C3869583,3838/10465
black / african - american ( nmbr . nmbr % ),C0085756,3839/10465
chronic coxnmbr inhibitors,C0205191,3840/10465
no . of coronary vessels with > nmbr % diameter stenosis,,3841/10465
history of claudication,C2315493,3842/10465
seated sbp at nmbr weeks  mmhg +,C0277814;C0277814;C1283233;C1283233,3843/10465
ended > nmbr days before trial entry,C1272693;C2746065,3844/10465
rope score * *,C1563164;C1563164,3845/10465
inter p - value,C0205103;C1548610,3846/10465
risk factor profile index event,C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C0035648,3847/10465
use of ace inhibitor  arb  or both — no . ( % ),,3848/10465
clopidogrel  nmbr mg loading dose !,C0070166,3849/10465
adverse eventy,,3850/10465
discontinued,C1444662,3851/10465
duration of osteoarthritis symptoms — yr,,3852/10465
total cholesterol - mg / dl * *,C0201950;C0543421,3853/10465
peripheral revascularization ( n = nmbr ),C0205100,3854/10465
smoking in past yr,C0037369;C0037369;C0453996;C0453996;C1881674;C1881674,3855/10465
percentage of patients using ics or ics / laba on entry,C0439165;C1549488;C1561533,3856/10465
mean change ,C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,3857/10465
neither ics nor laba,C0815320;C4551720,3858/10465
combination - facilitated pci ( n = nmbr ),C0205195;C1947911;C3811910,3859/10465
bifurcation,C0184906;C3146289,3860/10465
coronary heart disease death,C0010054;C0010054;C0010054;C0010054;C0010068;C0010068;C0010068;C0010068;C1956346;C1956346;C1956346;C1956346,3861/10465
< nmbr mg / dl eze / simva ( n = nmbr },C0053917;C1334884,3862/10465
a / v ( n = nmbr ) v ( n = nmbr ),,3863/10465
hypertrophic cardiomyopathy,C0007194;C4551472,3864/10465
median body mass index  kg / mnmbr ( iqr ),C0549183;C0549183;C0549183;C0876920;C0876920;C0876920;C2347635;C2347635;C2347635;C2348144;C2348144;C2348144;C2939193;C2939193;C2939193,3865/10465
nmbr - year framingham chd risk ( % ) nmbr mean / sd ),C0053917;C0053917;C1334884;C1334884,3866/10465
ecrcl  ml / min,,3867/10465
time from longest event to randomisation,C0040223;C0040223;C3541383;C3541383,3868/10465
no prior hf hospitalization,C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257,3869/10465
conservative,,3870/10465
serum creatinine ( pmol / l )  mean ( sd ),C0201976;C0600061,3871/10465
any cv history / risk factors  n ( % ),C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503,3872/10465
vte at day nmbr +,C0630906;C0630906;C0630906;C0630906;C0630906;C0630906,3873/10465
age of completion of highest education  years ( sd ),C0001779;C0001779;C0001779;C0001779;C0001779;C0001779;C0001779;C0001779,3874/10465
pfo + asa,C0004057;C3853627,3875/10465
nmbr mg / day - placebo,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,3876/10465
mtss cfb,C0009002;C1824728,3877/10465
mental component summary,C0229992;C0229992;C0229992;C0229992,3878/10465
low - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023824;C0023824,3879/10465
dihydropyridine calcium - channel blocker,C2945601,3880/10465
germany,C0017480,3881/10465
high sensitivity c - reactive protein ( mg / l ),C1441604;C1441604;C1441604,3882/10465
azathioprine,C0004482,3883/10465
high risk ( ri ≥ nmbr ),,3884/10465
egfr ( ml / min per nmbr - nmbr m ' ),C1739039;C3811844;C3812682,3885/10465
ez / simva nmbr mg,C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578;C0206578,3886/10465
patients receiving immunosuppressive agents at baseline,C0030705,3887/10465
demographics age  years  mean ( sd ),C0011298;C1704791,3888/10465
previous aorta - femoral or lower extremity bypass surgery  pta of iliac  or infrainguinal artery,C0205156;C1552607,3889/10465
fracture,C0016658,3890/10465
clopidogrel loading dose nmbr mg,C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166,3891/10465
renal insufficiency — no . ( % ),,3892/10465
caucasian eze / simva ( „ = nmbr },,3893/10465
tg mg / dl  median ( sd ),C0337445,3894/10465
locafon of index dvt,C0600653;C0600653;C0600653;C0918012;C0918012;C0918012;C1552854;C1552854;C1552854;C1637833;C1637833;C1637833;C2986546;C2986546;C2986546,3895/10465
baseline nihss,C0168634;C1442488,3896/10465
clinical details,C0205210,3897/10465
limited i -,C0439801;C2674459;C3542948;C4050251,3898/10465
intracranial disease of major artery 寸,,3899/10465
mean bp ( mmhg ),C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,3900/10465
no chd eze / simva nmbr = nmbr },C0280604;C0280604;C3542407;C3542407,3901/10465
heart rate  b . p . m . mean ± sd,,3902/10465
estimated glomerular filtration rate - no . ( % ) : :,C3811844,3903/10465
moderate n z nmbr,C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,3904/10465
central nervous system,C3540014;C3714787,3905/10465
drug - eluting stent implanted — no . ( % ),,3906/10465
elevated bnp ( nmbr pg / ml )  %,C0205250;C0205250;C0205250;C0205250;C3163633;C3163633;C3163633;C3163633,3907/10465
verapamil - sr strategy,C1527129,3908/10465
baseline steroids,C0168634;C1442488,3909/10465
c - reactive protein  median ( qnmbr  qnmbr ),C0006560;C1413716;C4048285,3910/10465
albumin measurements^^,C0201838,3911/10465
dactylitis,C0239161,3912/10465
no hypertension ( n = nmbr ),C0020538;C1963138,3913/10465
history of other medical conditions  n ( % ),C0262926;C0262926;C0262926;C0262926,3914/10465
placebo allocation,C0032042;C1696465;C1706408,3915/10465
cyclosporin,C0010592;C0010594,3916/10465
symptom onset to hospital arrival  hours,C4086878;C4086878;C4086878;C4086878,3917/10465
before amendment,C0680532;C2346732,3918/10465
baseline erosion,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,3919/10465
minimal important change threshold ( improvement ) a,C3845594;C3845594,3920/10465
digoxin,C0012265,3921/10465
left ventricular ejection fraction  mean ( sd )  %,C0428772;C0488728,3922/10465
new york heart association congestive heart failure class,C1882083,3923/10465
haemoglobin ( g / dl )  mean + sd  available for nmbr patients,C0019046,3924/10465
peripheral arterial revascularization,C0205100;C0205100,3925/10465
median daily dose - iu ™,,3926/10465
hla - bnmbr positive  n ( % ),C4049595;C4049595;C4049595;C4049595;C4049595,3927/10465
renal function ( egfr  ml / min / nmbr . nmbr mnmbr ),C0232804,3928/10465
ldl particle numbers ( week nmbr ),C2612459;C2612459,3929/10465
serum ldl cholesterol,C0428474,3930/10465
all grafts,,3931/10465
stroke thought due to atherothrombotic disease,C0038454;C4554100,3932/10465
first hhf,C0205435;C1279901,3933/10465
primary angioplasty ( n = nmbr ),C0205225;C0205225;C0439612;C0439612;C0439631;C0439631,3934/10465
atenolol strategy ( n = nmbr ),C0004147,3935/10465
prothrombin mutation ( % ),C1610621,3936/10465
cardiovascular risk factors and medical history,C0850624,3937/10465
valsartan  n ( % ),C0216784,3938/10465
qrs > nmbr msec nmbr - min walk test,,3939/10465
immobilization at randomization  n ( % ),C0020944;C4048292,3940/10465
difference,C1705241;C1705242,3941/10465
participants n,C0679646,3942/10465
left ventricular ejection fraction  median ( iqr )  %,C0428772;C0488728,3943/10465
associated with corrected,C0332281,3944/10465
ckd ( egfr < nmbrb ),C1561643,3945/10465
lowering drugs,C0441994;C0441994;C2003888;C2003888,3946/10465
concomitant cardiovascular therapy ( taken > nmbr days ),C1707479;C1707479;C0521115,3947/10465
post - bronchodilator fevnmbr / fvc ( % ) a,C2599594,3948/10465
no . evenls,,3949/10465
medical treatment,C0679624,3950/10465
previous angina pectoris,C0205156;C1552607,3951/10465
indeterminate ! !,C0205258,3952/10465
select lipids and lipoproteins,C1707391,3953/10465
nmbr - year framingham chd risk,C0053917;C0053917;C1334884;C1334884,3954/10465
> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr ) — number / n ( % ),,3955/10465
egfr ( ckd - epi  cystatin c )  ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,3956/10465
previous receipt of therapy against tnf - a — no . ( % ),,3957/10465
prior to index event,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,3958/10465
race  % of patients,C0034510;C1706779;C3853635,3959/10465
apo a - i  mg / dl,C0085201;C1677784,3960/10465
vessel treated  n,C0005847,3961/10465
non - smokers receiving lipid - lowering drugs  p blockers ,C0337672;C4554605,3962/10465
estrogen therapy,C0279494,3963/10465
haq - di total score  mean ( sd ),C3826998;C4321476,3964/10465
high density lipoprotein cholesterol - mg / dl * *,C0023822,3965/10465
systolic pulmonary arterial pressure  mean ( sd )  mm hg,C0871470;C0871470;C0871470;C0871470;C0039155,3966/10465
> qnmbr ( nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % ),,3967/10465
das - nmbr ( crp )  mean ( sd ),C0051767;C0051767;C0057671;C0057671,3968/10465
blood transfusion,C0005841;C0281867,3969/10465
partial evolving to secondarily generalized ( ic ),C0728938;C1550516,3970/10465
hscrp > nmbr to < nmbr mg / l,,3971/10465
ra symptom duration < nmbr months — number ( % ),,3972/10465
ldl - c < nmbr mg / dl,,3973/10465
ace / arb medication ( % ),C1452534;C1452534;C1452534;C4284014;C4284014;C4284014,3974/10465
positive family history of type nmbr diabetes ( % ),C0439178;C0439178;C0439178;C0439178;C1446409;C1446409;C1446409;C1446409;C1514241;C1514241;C1514241;C1514241;C2825490;C2825490;C2825490;C2825490;C3812269;C3812269;C3812269;C3812269,3975/10465
urinary albumimcreatinine ratio,C1273442,3976/10465
diabetes treatment,C0011847;C0011847;C0011847;C0011847;C0011847;C0011847;C0011847;C0011849;C0011849;C0011849;C0011849;C0011849;C0011849;C0011849,3977/10465
mucolytics,C0026698,3978/10465
pooled analysis,C1709595;C1709595;C1709595;C2349200;C2349200;C2349200;C4522255;C4522255;C4522255,3979/10465
infliximab,C0666743,3980/10465
iduration of symptoms > nmbr min,C0683368;C1457887,3981/10465
estrogens,C0014939;C3537250;C3541386;C3714615,3982/10465
nmbr mg twice daily n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,3983/10465
major gastro - intestinal bleeding,C0205082;C0205164;C4318856;C4521762,3984/10465
anti - ccp antibody positive  n ( % ),C4318437,3985/10465
egfrmdrd  ml / min / nmbr . nmbr mnmbr bsa,,3986/10465
weight > nmbr kg  n ( % ),C0005910;C0043100;C1305866;C1705104,3987/10465
multiple diagnoses,C0439064,3988/10465
cholecystitis chronic,C0008325;C1963083;C4553186,3989/10465
baseline % bsa involvement,C0168634;C1442488,3990/10465
> nmbr corticosteroids or immunosuppressants,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,3991/10465
history of atrial arrhythmia  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,3992/10465
chronic pulmonary disease,C0746102,3993/10465
> nmbr  obesity class nmbr,C0053917;C1334884,3994/10465
congestive heart failure ( definite ),C0018802,3995/10465
average dose ( mg / week ),C1510992;C1510992;C1510992;C2825518;C2825518;C2825518,3996/10465
urinary albumin : creatinine ratio *,C2362049,3997/10465
previous pci ( % total ),C0205156;C0205156;C1552607;C1552607,3998/10465
highest killip classiciation pre - pci,C1522410,3999/10465
edss stratification  no . ( % ),C0451246;C3887783,4000/10465
exenatide no . of events / total no . ( % ),C0167117,4001/10465
method used to diagnose the incident pulmonary embolism  no . ( % ),C0025663;C0449851;C0871511,4002/10465
blood glucose,C0005802,4003/10465
rf or acpa positive,C0035448;C0201660;C0748398;C1547111,4004/10465
congestive heart failure — no . ( % ),,4005/10465
mean ucsd - sobq score * ( sd ),C3533236,4006/10465
morphine use for index event / pci,C0242000;C0242000;C0242000;C0242000;C0242000;C0242000;C0242000;C0242000;C0242000;C0242000,4007/10465
albumin - to - creatinine ratio ,C0486293;C1318293,4008/10465
region  north america,C0017446;C0205147,4009/10465
medical therapy alone,C0418981,4010/10465
continuation,,4011/10465
nmbr ( fevi nmbr - < nmbr % pred ),C0053917;C1334884,4012/10465
anmbrs - hydroxy -,C0700307,4013/10465
qrs interval > nmbr msec — no . ( % ),,4014/10465
streptokinase,C0038418,4015/10465
haq - di improvement > nmbr . nmbr,C3826998;C4321476,4016/10465
baseline cv treatment  n ( % ) y,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,4017/10465
adalimumab croup  n / n ( % ),C1122087,4018/10465
apob ( week nmbr ),C0003593;C3252643,4019/10465
systemic arterial hypertension  n ( % ),C0020538,4020/10465
reversibility to salbutamol  %,C1271924,4021/10465
overall  male : female,C0282416;C1561607,4022/10465
nmbr p value,C0053917;C1334884,4023/10465
evolocumab ( nmbr mg ),C3529352,4024/10465
bifurcation lesion,C0184906;C0184906;C3146289;C3146289,4025/10465
time from onset of symptoms to randomization — days,,4026/10465
thiazide at last follow - up,C0541746;C0541746;C0541746;C0541746,4027/10465
% change median baseline crp > nmbrmg / l,C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952,4028/10465
blood pressure systolic  mm hg,C0005823;C1271104;C1272641,4029/10465
hf hospitalizations  median ( iqr ),C0018488;C1313497;C1538440;C3273279,4030/10465
history of carotid artery disease,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,4031/10465
history of diabetes mellitus,C0455488,4032/10465
prior treatment historynmbr,C1514463,4033/10465
patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,4034/10465
interactionnmbr,,4035/10465
no history of migraine,C0455512,4036/10465
mild ( gold nmbr ),C2945599,4037/10465
iii : fevnmbr > nmbr % - < nmbr % predicted,C0439070;C1705160,4038/10465
cat score category,C0007450;C0007450;C0007450;C0007450;C0325090;C0325090;C0325090;C0325090;C0524517;C0524517;C0524517;C0524517;C1443200;C1443200;C1443200;C1443200;C3665481;C3665481;C3665481;C3665481;C4050461;C4050461;C4050461;C4050461;C4284282;C4284282;C4284282;C4284282,4039/10465
baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr  nmbr,C0168634;C0168634;C1442488;C1442488,4040/10465
statin only,C0360714;C0360714,4041/10465
drug therapy at admission 一 no . ( % ) aspirin,,4042/10465
fatty acid profile,C0015684;C0015684,4043/10465
residual deep - vein thrombosis  no . ( % ),C1609982,4044/10465
unstable angina  n ( % ),C0002965,4045/10465
completed trial,C0205197;C3854010,4046/10465
duration of symptoms  h,C0436359,4047/10465
% predicted ” fev  at baseline  % *,,4048/10465
aspirin dose at randomization,C4696290,4049/10465
normoglycemia^,C0580545,4050/10465
race / ethnicity,C0034510;C0034510;C1706779;C1706779;C3853635;C3853635,4051/10465
oral antidiabetic drugs,C0029167;C0175795;C0304289;C0442027;C4521986,4052/10465
ef nmbr - nmbr % hfmref ( n = nmbr  nmbr % ),C0053917;C1334884,4053/10465
cerebral embolism,C0007780,4054/10465
fevnmbr / fvc prebronchodilatort,C3714541,4055/10465
previous use of antiplatelet drugs,C0205156;C0205156;C1552607;C1552607,4056/10465
laba non - users,C1518422,4057/10465
thiazolidinedione based,C0289779;C1257987;C3537039,4058/10465
chronic respiratory failure,C0264492,4059/10465
coronary artery disease history,C0010054;C0010054;C0010054;C0010054;C0010054;C0010054;C0010068;C0010068;C0010068;C0010068;C0010068;C0010068;C1956346;C1956346;C1956346;C1956346;C1956346;C1956346,4060/10465
current prescribed medications,C0521116;C0521116;C1705970;C1705970,4061/10465
current weekly alcohol use ( % ),C0521116;C1705970,4062/10465
calcium ( mmol / l ),C0006675;C0006726;C2936886;C3540037;C3714611,4063/10465
region ( pooled ),C0017446;C0205147,4064/10465
bdmard - naive,,4065/10465
general andthoracic epidural,C0205246;C0205246;C3812897;C3812897;C3891294;C3891294;C4521767;C4521767,4066/10465
first co - primary outcome,C0205435;C0205435;C0205435;C1279901;C1279901;C1279901,4067/10465
cvd  mi  stroke  or recurrent ischemia - urgent revascularization  or hospitalization for unstable angina,C0007222,4068/10465
age at enrolment  years,C0001779;C0001779;C0001779,4069/10465
not available,C0686905,4070/10465
use of antiplatelet agents^,C1524063,4071/10465
aspirin or thienopyridines ( % ),C0004057,4072/10465
baseline trig > nmbr millycerides g / dl,C0168634;C0168634;C1442488;C1442488,4073/10465
baseline anti - hypertensive usea,C0168634;C1442488,4074/10465
intent - to - treat population  n ( % ),C0162425;C0162425;C0162425;C0162425;C0162425;C0162425;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1550453;C1550453;C1550453;C1550453;C1550453;C1550453,4075/10465
dyslipidaemia and hypertension  n ( % ),C0242339,4076/10465
saxa nmbr . nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,4077/10465
estimated response rate and odds ratio,C0750572,4078/10465
first loading dose,C0205435;C1279901,4079/10465
ex - smokers nmbr,C0337671;C0337671;C4555205;C4555205,4080/10465
atrial fibrillation ldl cholesterol level,C0004238;C0004238;C0004238;C0004238;C0004238;C0004238;C0004238;C0004238;C0344434;C0344434;C0344434;C0344434;C0344434;C0344434;C0344434;C0344434;C1963067;C1963067;C1963067;C1963067;C1963067;C1963067;C1963067;C1963067,4081/10465
duration of,C0449238;C2926735,4082/10465
weight ab  %,C0005910;C0043100;C1305866;C1705104,4083/10465
race or ethnic group — no . / total no . ( % ) f,,4084/10465
loop at enrollment,C0445022;C0445022;C0445022,4085/10465
current cigarette use  n ( % ),C0521116;C1705970,4086/10465
central europe,C0682369,4087/10465
atopic ( based on phadiatop test ),C0392707,4088/10465
baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr change from baseline to nmbr weeks,C0168634;C0168634;C1442488;C1442488,4089/10465
kccq ( nmbr months ),C3476798,4090/10465
mean eq - nmbrd response ( nmbr % ci ),C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143,4091/10465
tp vs no tp,C0036183;C3541334,4092/10465
mitral insufficiency,C0026266,4093/10465
r nmbr mg + fa,C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358,4094/10465
total study population,C3258257;C3258257;C0439175;C0439810,4095/10465
subacute ( nmbr - nmbr days ),C0205365,4096/10465
assoc  with corrected congenital shunts,,4097/10465
spinal fractures,C0080179;C0518450,4098/10465
multivessel disease  n ( % ),C0012634,4099/10465
normoalbuminuria or microalbuminuria,,4100/10465
low ( no risk factor ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223,4101/10465
hospitalisation for chf within nmbr years of randomisation,C0019993,4102/10465
rec . ischemia due to ecg changes,C1424025;C1424025;C2606415;C2606415,4103/10465
event / patients ( nmbr / pt - y ),C0441471;C4019010,4104/10465
calcium - channel antagonists,C0006684;C2757014,4105/10465
angiotensin receptor,C0034787;C1622222,4106/10465
dbp  mean ( sd )  mm hg glycaemic parameters,C0536221;C3813197;C4281799,4107/10465
priorother ( predefined ) medical conditions,,4108/10465
tnmbr lesion volume  mmnmbr,C0221198;C0221198;C0221198;C0221198;C1546698;C1546698;C1546698;C1546698,4109/10465
african - american / african heritage ( n = nmbr ),C0085756,4110/10465
new anti - anginal therapy,C3242274;C3242274,4111/10465
smoking : current smoker,C0037369;C0453996;C1881674,4112/10465
total cataract,C3665439,4113/10465
no . of patients ( % ),,4114/10465
ami nmbr mg n = nmbr,C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936,4115/10465
baseline lvef,C0168634;C0168634;C1442488;C1442488,4116/10465
change from baseline stage nmbr ckd,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,4117/10465
indacaterol group ( n = nmbr ),C1722260;C1722260;C1722260;C1722260;C1722260;C1722260,4118/10465
iv : fevnmbr < nmbr % predicted,C0022326;C4265176,4119/10465
education nmbr - nmbr years,C0013621;C0013621;C0013622;C0013622;C0013658;C0013658;C0039401;C0039401,4120/10465
waist circumference,C0455829,4121/10465
hispanic — no . ( % ),,4122/10465
> nmbr . nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,4123/10465
rituximab  n = nmbr,C0393022,4124/10465
stroke  n ( % ),C0038454;C4554100,4125/10465
family history of premature,C0241889;C0241889;C0241889,4126/10465
change in bp  mm hg,C1268766,4127/10465
nonfatal ischemic stroke,C0948008,4128/10465
pci delay due to low risk,C4049621,4129/10465
prior percutaneous coronary intervention,C0332152;C2826257,4130/10465
oral anticoagulant agent,C0354604,4131/10465
alcohol intake ( a ),C0001948,4132/10465
hbanmbrc subgroups,C1079230,4133/10465
history of atherosclerotic vascular disease — no . ( % ) §,,4134/10465
renal function : creatinine clearance,C0232804,4135/10465
mercaptopurine,C0000618,4136/10465
transient monocular blindness,C0149793,4137/10465
nyha functional class  n ( % ),C1882083;C1882083;C1882083,4138/10465
entire cohort gender,C0439751;C0439751;C0439751;C0439751;C0444667;C0444667;C0444667;C0444667,4139/10465
inhaled §,,4140/10465
patient global assessment of pain ( vas nmbr - nmbr mm ),C4054229;C4054229;C4054229;C4054229;C4054229;C4054229;C4054229;C4054229;C4054229,4141/10465
rituximab ( nmbrxnmbr mg ) + mtx ( n = nmbr ),C0393022,4142/10465
peripheral artery revascularization without amputation,C0489868;C0489868;C0489868,4143/10465
other cause  n ( % ),C0015127;C1524003,4144/10465
immunosuppressants and antimalarials only,C0021081,4145/10465
* * positive stress test,,4146/10465
aspirin use at baseline,C0004057;C0004057;C0004057;C0004057;C0004057;C0004057,4147/10465
randomisation scheme,C0034656,4148/10465
ala carriers,C0523459;C3888236,4149/10465
arterial hypertension — no . ( % ),,4150/10465
bmi ( median  iqr )  kg / mnmbr,C0578022,4151/10465
alternative disability,C1523987,4152/10465
non - hdl cholesterol / apob ( ratio ),C0729627;C0729627;C1535899;C1535899,4153/10465
other risk factors,C0035648;C1553898,4154/10465
hf hospitalization or cardiovascular death,C0018488;C1313497;C1538440;C3273279,4155/10465
no revascularization for index acs event,C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603;C0581603,4156/10465
p - value for variance,C1709380;C1709380,4157/10465
apo b  mean ( sd )  mg / dl,C0003593;C3252643,4158/10465
at ldl - c ( bq ) goal * at baseline - no . ( % ),,4159/10465
missing data initial diagnosis — no .,,4160/10465
aspirin at enrollment,C0004057;C0004057;C0004057,4161/10465
prespecified analysis,C0002778;C0936012;C1524024,4162/10465
k ( rate ),C0597277;C0597277;C1708601;C1708601,4163/10465
r | r ' ' ' ( nmbr % ci ),C0053917;C0053917;C1334884;C1334884,4164/10465
glyburide dose duringthe study ( mg ),C0017628;C0017628;C0017628;C0017628;C0017628;C0017628,4165/10465
ptca / cabg,C2936173,4166/10465
score  %,C0449820;C4050231,4167/10465
seizure types reported during baseline  b n ( % ),C0036572;C1959629;C4553401,4168/10465
biologic therapeutic failure,C0005515;C0005515;C0005515;C0005515;C0205460;C0205460;C0205460;C0205460,4169/10465
simva ( „ = nmbr },,4170/10465
partial mayo score  mean ( sd ),C0728938;C0728938;C0728938;C0728938;C1550516;C1550516;C1550516;C1550516,4171/10465
selected clinical characteristics — no . / total no . ( % ),,4172/10465
. nmbr . nmbr ml / s / mnmbr ( nmbr ml / min / nmbr . nmbr mnmbr )  n ( % ),C0053917;C1334884,4173/10465
prior use of conventional dmards only ( biologic - nai ' ve )  n ( % ),C0332152;C0332152;C2826257;C2826257,4174/10465
family history  n ( % ),C0241889,4175/10465
patients with diabetes mellitus,C0030705,4176/10465
thiazolidinedione ( includes pioglitazone ),C0289779;C1257987;C3537039,4177/10465
corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727,4178/10465
total pack - years mean ( sd ),C0439175;C0439175;C0439175;C0439810;C0439810;C0439810,4179/10465
medications at study entry — no . / total no . ( % ),,4180/10465
gold iii - iv,C0018026;C0018026;C0018026;C0018026;C1304897;C1304897;C1304897;C1304897,4181/10465
reason for enrollment in active a,C0392360;C0392360;C0392360,4182/10465
asia / australia / new zealand,C0003980,4183/10465
octave induction nmbr,C0205263;C0205263;C0857127;C0857127,4184/10465
tachyarrhythmias  n ( % ),C0080203,4185/10465
europe n z nmbr,C0015176;C0015176,4186/10465
atrial fibrillation alone ) ,C0004238;C0344434;C1963067,4187/10465
supraventricular tachyarrhythmias ( incl . atrial,C1698480;C3853833,4188/10465
previous cerebrovascular event,C0205156;C0205156;C1552607;C1552607,4189/10465
stroke — no . ( % ),,4190/10465
bronchodilator response  ml,C0006280;C0006280;C0006280;C0006280,4191/10465
nmbr ( fevi ^nmbr % pred ),C0053917;C1334884,4192/10465
mental component,C0229992;C0229992,4193/10465
apo a - l ( g / l ),C1447574;C4521365,4194/10465
veflonzumao,,4195/10465
pfo with large shunt and atrial septal aneurysm,C0549177;C0549177;C0549177,4196/10465
classification of index venous thromboembolism — no . ( % ),,4197/10465
fevnmbr at baseline,C0168634;C1442488,4198/10465
incidence rate per nmbr person - years,C1708485;C1708485;C1708485;C1708485,4199/10465
time of randomization ( interaction : p = nmbr . nmbr ),C0040223;C3541383,4200/10465
chronic renal failure  n ( % ),C0022661;C1561643;C2316810,4201/10465
both deep - vein thrombosis and pulmonary embolism,C0149871,4202/10465
myocardial infarction without st - segment elevation — no . ( % ),,4203/10465
pooled eze / simva,C1709595;C2349200;C4522255,4204/10465
other sglt - nmbr inhibitor,C0053917;C1334884,4205/10465
clavicle fracture,C0159658,4206/10465
ecg abnormality ( resting )  %,C1623258,4207/10465
musculoskeletal stiffness,C0497254;C2707260,4208/10465
psoriatic arthritis  %,C0003872,4209/10465
medication prior to admission  ( % ),C0013227;C0013227;C3244316;C3244316;C4284232;C4284232,4210/10465
death / st,C0011065;C0011065;C1306577;C1306577;C4082313;C4082313;C4552775;C4552775,4211/10465
bdi focal score,C0006448;C0006448;C0451022;C0451022;C3714938;C3714938;C3889415;C3889415,4212/10465
time to randomisation [hours] ( interaction : p = nmbr . nmbr ),C0040223;C3541383,4213/10465
laboratory examination,C0260877,4214/10465
placebo patients with events,C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,4215/10465
organ system involvement  no . ( % ),C0460002,4216/10465
enalapril lcznmbr ( n = nmbr ) ( n = nmbr ),C0014025,4217/10465
high - dose statin,C0444956,4218/10465
peripheral,C0205100,4219/10465
ldl cholesicrol ( minol / l ),,4220/10465
hispanic / latino ethnicity  n ( % ),C0086409;C0086409,4221/10465
nmbr - nmbr drinks,C0053917;C1334884,4222/10465
aborted cardiac arrest,C1550015;C1609614;C4085625;C4318470,4223/10465
baseline crp < nmbrmg / l,C0168634;C0168634;C1442488;C1442488,4224/10465
relative risk reduction ( nmbr % cl ) percent,C0242492;C0242492;C0242492;C0242492;C0080103;C0205345;C1547039,4225/10465
unprotected left main stented,C0205091;C0205091;C0443246;C0443246;C1552822;C1552822,4226/10465
catheterization performed for qualifying event,C0007430,4227/10465
fraction ( % ),C1264633;C1554103,4228/10465
nmbr % ci for difference,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,4229/10465
index event to randomization  median ( iqr )  h,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,4230/10465
inclusion criteria — no . ( % ),,4231/10465
normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972,4232/10465
^nmbr - cell function — % §,,4233/10465
previous tnf - antagonist use  n ( % ),C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,4234/10465
depressed only,C0344315;C0549249,4235/10465
acute infection without septic shock,C0275518,4236/10465
mtss units,C0439148;C1519795;C3853603,4237/10465
previous statin use,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,4238/10465
mean ( s . d . ) calculated ldl cholesterol,C0444504;C2347634;C2348143,4239/10465
nmbr % confidence interval,C0053917;C1334884,4240/10465
type of concomitant statin by daily dose,C0332307;C1547052,4241/10465
statin with ezetimibe,C0360714,4242/10465
history of ml or ischemic stroke,C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062,4243/10465
within nmbr h,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,4244/10465
placebo n = nmbr n ( % ),C0032042;C1696465;C1706408,4245/10465
nyha class not reported,C1882083,4246/10465
neither uh or lmw heparin,,4247/10465
fpg tx difference vs pbo  median change from baseline ( se ) nmbr,C0041403;C0041403,4248/10465
iglarlixi ( fixed - ratio combination ),,4249/10465
previous congestive heart failure,C0205156;C1552607,4250/10465
periostin ( ng / ml ),C0219433;C1424662;C3812270,4251/10465
belimumab nmbr mg sc ( n nmbr ),C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401;C1723401,4252/10465
glycatedhemoglobin category  %,C0683312;C3889287,4253/10465
canvas - r,C3281223;C3281223;C3281223,4254/10465
waist circumference  cm mean ( sd ),C0455829,4255/10465
tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr ),C0337445,4256/10465
africa  asia  or the middle east,C0001737,4257/10465
history of gestational diabetes mellitus — no . ( % of women ),,4258/10465
non - black race ( n = nmbr vs nmbr ),C1518422,4259/10465
community hospital,C0020003,4260/10465
not - japan n = nmbr  nmbr,C1518422,4261/10465
stage > nmbr chronic kidney disease ( % ),C0205390;C1300072;C1306673,4262/10465
nmbr - hr plasma glucose — mg / dl,,4263/10465
not at goal,C1518422;C1518422,4264/10465
concomitant aminosalicylates  n [ % ] concomitant corticosteroids  n [ % ] mayo score  mean [sd],C0521115,4265/10465
baseline fecal caicrctectin,C0168634;C1442488,4266/10465
hospitalization for unstable angina,C0019993,4267/10465
patients having exacerbation,C0030705,4268/10465
regular alcohol consumption per week  no . ( % ),C0205272;C0205272,4269/10465
improving anemia bsl hb < nmbrg i - nmbr  yr nmbr > nmbrg i - nmbr,C1272745;C1272745;C1272745;C1272745;C1272745;C1272745;C1272745;C1272745;C1272745;C1272745;C1272745;C1272745,4270/10465
qualifying peripheral arterial disease,C1514624,4271/10465
previous bypass surgery  n ( % ),C0205156;C1552607,4272/10465
anthropometric characteristics,C0003188,4273/10465
baseline fevnmbr  l *,C0168634;C1442488,4274/10465
nmbr - lead ecg heart rate  beats / min,C0053917;C1334884,4275/10465
aspirin + dipyridamole ( n = nmbr ),C0732279,4276/10465
patients entering pt period n = nmbr,C0030705,4277/10465
surgical technique,C0683469,4278/10465
psoriatic arthropathy,C0003872,4279/10465
with alogliptin nmbr mg,C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126,4280/10465
revascularisation but no antiplatelets  lipid - lowering agents  or p blockers,C0581603,4281/10465
pfo with large shunt without atrial septal aneurysm,C0549177;C0549177;C0549177,4282/10465
clinical and patient - reported characteristics at baseline and randomization,C0205210,4283/10465
or ( unadjusted ),,4284/10465
unknown or missing,C0439673;C3541433;C4050014,4285/10465
reported high cholesterol ' !,C0684224;C0684224;C0700287;C0700287;C4319718;C4319718,4286/10465
syndecan - nmbr ( ng / ml ),C0075691;C0075691;C1419891;C1419891,4287/10465
long - acting,C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317,4288/10465
use of antiarrhythmic agent,C1524063;C1524063,4289/10465
egfr using cg / mdrd formulae  % of patients,C1739039;C3811844;C3812682,4290/10465
baseline body mass index,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,4291/10465
swollen - joint count ( of nmbr joints ),C0451521,4292/10465
region  n ( % ),C0017446;C0205147,4293/10465
> nmbr - nmbr mg / week,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,4294/10465
hypertensionnmbr ( % ),,4295/10465
psa - modified total shs,C3810537;C3810537;C3810537;C3810537;C3813209;C3813209;C3813209;C3813209,4296/10465
minor ischaemic stroke,C0026193;C0205165,4297/10465
annualized rate ind / gly sfc,C0871208;C0871208;C1521828;C1521828,4298/10465
sulfasalazine,C0036078,4299/10465
mean change at week nmbr,C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143,4300/10465
acpa positive ( > nmbr iu / ml )  n ( % ),C1525410;C1525410;C1525410;C1525410;C1525410;C1706063;C1706063;C1706063;C1706063;C1706063,4301/10465
history of strokenmbr,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,4302/10465
long - term warfarin ( n - nmbr ),C0443252,4303/10465
crp ( mg / l )  median ± sd,,4304/10465
obese ( > nmbr kg / mnmbr ),C0028754,4305/10465
facit - fatigue . mean nmbrsd ( range nmbr - nmbr ),C3476791;C3476791;C3476791;C3476791;C3476791;C3476791;C3476791;C3476791;C3476791;C3476791;C3476791;C3476791,4306/10465
infarct location ( interactsn $ : p = nmbr . nmbr ),C0021308;C0021308;C0021308;C0021308,4307/10465
not hospitalized for heart failure in the year prior to study enrollment,C1518422,4308/10465
calcification  n ( % ),C0006660;C0006663;C0175895;C1533591;C1879982;C2242558,4309/10465
all ischemic stroke,C0948008,4310/10465
rosuvastatin  n ( % ),C0965129,4311/10465
hormone replacement therapy use,C0282402;C0282402;C0282402,4312/10465
older than nmbr years,C0580836;C0580836,4313/10465
rolofylline,C0166128,4314/10465
apo a - nmbr  mean ( sd )  mg / dl,C0003592;C0003592;C0523508;C0523508;C4553344;C4553344;C4553379;C4553379,4315/10465
long - term antiplatelet therapy,C0443252,4316/10465
prior bypass graft surgery,C0455610,4317/10465
bone erosion ( judged by physician )  n ( % ),C0587240,4318/10465
triglyceride ( mm,C0041004,4319/10465
cigarettesmoking  %,,4320/10465
pentraxin - nmbr ( ng / ml ),C0053917;C1334884,4321/10465
tnfi exposed,,4322/10465
history of atrial fibrillation  n ( % ),C0729790,4323/10465
asa or antiplatelet agent,C0004057;C3853627,4324/10465
ischemic stroke ( vs . tia ),C0948008,4325/10465
men : women ( % ),C0025266,4326/10465
patients not treated with statins ( n = nmbr ),C0030705,4327/10465
severe renal impairment,C0205082;C4050465;C4050466,4328/10465
om nmbr mg / aml nmbr mg / hctz nmbr mg,C0028971;C0028971;C0028971;C0028971;C1705272;C1705272;C1705272;C1705272,4329/10465
history of atrial fibrillation,C0729790,4330/10465
corticosteroid use at baseline,C0239126;C0239126,4331/10465
sedentary,C0205254,4332/10465
no . of patients ( indacaterol / placebo ),,4333/10465
insulin plus oral,C0021641;C0021641;C1533581;C1533581;C1579433;C1579433;C3714501;C3714501,4334/10465
> nmbr . nmbr  n ( % ),C0053917;C1334884,4335/10465
ics use  %,C0815320;C4551720,4336/10465
age category ( years )  n ( % ),C0001779;C0001779,4337/10465
atherosclerotic disease ( % ),C0333482,4338/10465
copd duration  y,C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,4339/10465
thrombolytic therapy,C0040044,4340/10465
acpa positive  n ( % ),C1525410;C1525410;C1525410;C1525410;C1525410;C1706063;C1706063;C1706063;C1706063;C1706063,4341/10465
baseline bmi nmbr to < nmbr kg / mnmbr  n = nmbr  nmbr change from baseline to nmbr weeks,C0168634;C0168634;C1442488;C1442488,4342/10465
acei vs . non - acei,,4343/10465
risk factors for atherosclerosis,C0035648;C0035648;C1553898;C1553898,4344/10465
bifurcation lesion with side branch $ nmbr . nmbr mm stented,C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C0184906;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289;C3146289,4345/10465
fevi  % predicted *,C0849974;C1561566;C4528367,4346/10465
heart rate at rest in the supine position ( beats / min ),C0018810;C0018810,4347/10465
feno nmbr mg / eze nmbr mg ( n = nmbr ),C0053917;C1334884,4348/10465
mean ( s . d . ) total pcsknmbr  ng / ml,C0444504;C2347634;C2348143,4349/10465
baseline cdai score  mean ( sd ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,4350/10465
severity of copd  combined assessment  n ( % ),C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,4351/10465
ambulance ( % ),C0002422;C3846685,4352/10465
estimated means and difference,C0750572,4353/10465
concomitant medication ( % ),C0521115;C0521115;C0521115,4354/10465
qualifying atherosclerosis,C1514624;C1514624,4355/10465
ada impaired fasting glucose,C1060325;C3811629,4356/10465
death  q wave mi or ischemia - driven revasc,C0011065;C1306577;C4082313;C4552775,4357/10465
stented vessels,C0183521,4358/10465
diabetes duration  n ( % ),C0011847;C0011847;C0011849;C0011849,4359/10465
tender - joint count  of nmbr joints examined,C0451530,4360/10465
verapamil sr,C1527129,4361/10465
thiazolidinedione 一 no . ( % ),,4362/10465
difference  % median,C1705241;C1705242,4363/10465
edema  ( % ),C0013604;C1717255,4364/10465
medications on admission  %,C0013227;C0802604;C2598133;C4284232,4365/10465
rf positive ( > nmbr iu / ml )  n ( % ),C0035448;C0035448;C0035448;C0035448;C0035448;C0201660;C0201660;C0201660;C0201660;C0201660;C0748398;C0748398;C0748398;C0748398;C0748398;C1547111;C1547111;C1547111;C1547111;C1547111,4366/10465
worsening heart failure,C0332271;C0332271;C0332271;C1457868;C1457868;C1457868;C1546960;C1546960;C1546960,4367/10465
previous limb or foot amputation,C0205156;C1552607,4368/10465
alcohol consumption ( % ),C0001948,4369/10465
uacr  mgg nmbr ( gm ),,4370/10465
om nmbr / aml nmbr /,C0028971;C0028971;C0028971;C0028971;C1705272;C1705272;C1705272;C1705272,4371/10465
hypertension history,C0020538;C0020538;C0020538;C0020538;C0020538;C0020538;C1963138;C1963138;C1963138;C1963138;C1963138;C1963138,4372/10465
swollen - joint count  of nmbr joints examined,C0451521,4373/10465
racial group  n ( % ),C0034510,4374/10465
nmbr to < nmbr ml per nmbr - nmbr mnmbr,C0053917;C1334884,4375/10465
risk factors,C0035648;C1553898,4376/10465
deep vein thrombosis only,C0149871;C0149871,4377/10465
within last nmbr d,C1517741;C1517741,4378/10465
egfr at baseline  nmbr ml / min ( % ) b,C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,4379/10465
low - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023824,4380/10465
intermediate,C0205103;C1550465;C2827755;C3889971,4381/10465
duration of hypertension ( months ),C0449238;C0449238;C2926735;C2926735,4382/10465
wapnmbrc ( ng / ml ),,4383/10465
left circumflex artery  n ( % ),C0226037,4384/10465
fpg  median ( ql  qnmbr )  mmol / l,,4385/10465
ischaemic cause,C0475224;C0475224,4386/10465
total cholesterol > nmbr mg / dl,C0201950;C0543421,4387/10465
intention - to - treat,C0162425;C1283828,4388/10465
enoxaparin / vka n / n ( % ) nmbr / nmbr ( nmbr . nmbr ),C0206460,4389/10465
in - stent restenosis,C3272317,4390/10465
high risk without atherosclerotic vascular disease +,C0332167;C3272283;C4050568;C4319571,4391/10465
priorother ( not predefined ) medical conditions,,4392/10465
reteplase / abciximab - facilitated pci ( n = nmbr ),C0256103,4393/10465
established atherosclerotic disease  n ( % ),C0443211;C1272684,4394/10465
concomitant drugs  %,C0521115;C0521115,4395/10465
after amendment ( % ),C0680532;C2346732,4396/10465
antianginal medications,C1874267;C1874267;C1874267;C1874267;C3537168;C3537168;C3537168;C3537168,4397/10465
eular good response,C0205170;C0205170;C0205170;C0205170,4398/10465
ls means difference ( nmbr % ci ) nmbr,C0023668;C0023668,4399/10465
prior stroke ( before index event ),C0332152;C0332152;C2826257;C2826257,4400/10465
interval from onset of symptoms,C1272706;C1552654;C1552713,4401/10465
low risk ( ri = nmbr - nmbr ),C3272281;C3538919,4402/10465
patients with prior copd - related,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,4403/10465
duration of ra  mean ( min - max ) ( yrs ),C0449238;C0449238;C2926735;C2926735,4404/10465
myocardial infarction / cabg / pci < nmbr years,C0027051;C0428953;C2926063;C3810814;C4552959,4405/10465
dilatative,C0002940;C0012359;C0700124;C1322279,4406/10465
ncep atp iii risk factors,C2744579;C2744579;C2744579;C2744579;C4552600;C4552600;C4552600;C4552600,4407/10465
change from baseline  adjusted mean ( nmbr % ci ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,4408/10465
antiarrhythmic therapy,C0003195;C0003195;C0003195;C3537142;C3537142;C3537142,4409/10465
mean ( sd ) tender joint count *,C0444504;C2347634;C2348143,4410/10465
• ? sd ml / min,,4411/10465
renal function ( egfr  ml / min / nmbr . nmbr mnmbr  according to mdrd )  n ( % ),C0232804,4412/10465
serum creatinine,C0201976;C0600061,4413/10465
first - recorded event  no . ( and % ) of patients,C0205435;C0205435;C0205435;C0205435;C1279901;C1279901;C1279901;C1279901,4414/10465
fevi  l  mean ( sd ) nmbr,C0849974;C1561566;C4528367,4415/10465
male / female,C0086582;C0086582;C0086582;C0086582;C1706180;C1706180;C1706180;C1706180;C1706428;C1706428;C1706428;C1706428;C1706429;C1706429;C1706429;C1706429,4416/10465
unknown ( none of the above ),C0439673;C3541433;C4050014,4417/10465
baseline creatinine clearance,C0168634;C1442488,4418/10465
drug - eluting stent — no . ( % ),,4419/10465
mean disease duration  years,C0444504;C2347634;C2348143,4420/10465
spacer use during the study,C0221874,4421/10465
non - end - stage renal dysfunction,C1518422;C1518422,4422/10465
duration of epilepsy  years  mean ( sd ),C0449238;C2926735,4423/10465
blood pressure control,C0005823;C0005823;C0005823;C0005823;C0005823;C0005823;C1271104;C1271104;C1271104;C1271104;C1271104;C1271104;C1272641;C1272641;C1272641;C1272641;C1272641;C1272641,4424/10465
medications through day nmbr,C0013227;C0013227;C0013227;C0013227;C0013227;C0013227;C0802604;C0802604;C0802604;C0802604;C0802604;C0802604;C2598133;C2598133;C2598133;C2598133;C2598133;C2598133;C4284232;C4284232;C4284232;C4284232;C4284232;C4284232,4425/10465
nyha class ii ( n = nmbrlnmbr ),C1882085,4426/10465
nadroparin,C0206232,4427/10465
past smoking,C1444637;C1444637;C1444637;C4284302;C4284302;C4284302,4428/10465
nmbr - min walk distance ( m ),C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,4429/10465
biologics user,C0005515;C0005515;C0005522;C0005522;C4553887;C4553887,4430/10465
other medical history — no . ( % ),,4431/10465
blood pressure ( % ),C0005823;C1271104;C1272641,4432/10465
sfc nmbr mg / nmbr mg,C4521536;C4521536,4433/10465
cardioversion in previous nmbr wk,C0013778;C0013778;C0013778;C0013778;C0013778;C0013778;C0013778;C0013778,4434/10465
nmbr - nmbr ( low risk ),C0053917;C1334884,4435/10465
hypercholesterolemia ( > nmbr mg / dl ),C0020443;C1522133,4436/10465
use of medication at baseline — no . ( % ),,4437/10465
revascularization during index hospitalization  %,C0581603;C0581603;C0581603;C0581603;C0581603,4438/10465
gender  %,C0079399;C1522384,4439/10465
brv dosage  mg / d,C0155502;C0155502,4440/10465
not rando . in na *,C1518422,4441/10465
age  median ( iqr )  years,C0001779,4442/10465
oral antidiabetic drugs / insulin ( % / % ),C0029167;C0029167;C0029167;C0029167;C0175795;C0175795;C0175795;C0175795;C0304289;C0304289;C0304289;C0304289;C0442027;C0442027;C0442027;C0442027;C4521986;C4521986;C4521986;C4521986,4443/10465
risk factors specified as inclusion criteria — no . ( % ) f,,4444/10465
asian or pacific islander,C0078988,4445/10465
reversibility : > nmbr - < nmbr %,C0449261,4446/10465
average daily dose ( % of target ) *,C1510992;C2825518,4447/10465
target - vessel revascularization,C0449618,4448/10465
severity of copd — no . ( % ) f,,4449/10465
lvef  %  median ( iqr ),C0428772;C0488728,4450/10465
fevnmbr / fvc  post - albuterol  %,C3714541,4451/10465
esrd saxa nmbr . nmbr mg ( n = nmbr ),C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0022661;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C0035078;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810;C2316810,4452/10465
time since diagnosis of pah — yrf,,4453/10465
right coronary artery  n ( % ),C1261316,4454/10465
younger patients ( agednmbr years ),C0332239,4455/10465
fvc ( l ) proportion taking pulmonary medications ( % ) b,C3714541,4456/10465
vein graft stented,C0042449;C0042449;C0042449,4457/10465
qualifying stroke,C1514624;C1514624,4458/10465
difference vs . pbof mean ( s . e . ) t,C1705241;C1705242,4459/10465
oral hypoglycaemics only,C0359086;C0359086,4460/10465
baseline history of vascular disease ( % ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,4461/10465
prednisone - equivalent dose — mg,,4462/10465
aspirin alone group no of events / total n ( % ),C0004057,4463/10465
known thrombophilic condition — no . ( % ),,4464/10465
blood eosinophil proportion ( % ),C0014467,4465/10465
( a ) demographics,,4466/10465
cox bsl + yr nmbr hbd,C1565830;C1565830,4467/10465
direct thrombin inhibitors,C0003440;C3541936,4468/10465
body - mass index - kg / mnmbr  median ( iqr ),C0005893;C0005893;C0005893;C0578022;C0578022;C0578022;C1305855;C1305855;C1305855,4469/10465
acute coronary syndrome,C0948089,4470/10465
waist circumference  cm ( sd ),C0455829,4471/10465
moderate impairment ( egfr nmbr - nmbr ),C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,4472/10465
use of supplemental oxygen  n ( % ),C4067893;C4554557,4473/10465
unadjusted or ( nmbr % ci ) p value,C1439367,4474/10465
rarely / never,C4035880,4475/10465
st - elevation myocardial infarction,C1536220;C3538872,4476/10465
woscops,,4477/10465
age ( yrs )  mean *,C0001779,4478/10465
non - ischaemic cardiomyopathy,C1518422,4479/10465
history of myocardial infarction  n ( % ),C1275835,4480/10465
cardiac catheterization,C0018795,4481/10465
estimated glomerular filtration rate  n ( % ),C3811844,4482/10465
no aspirin or ppi,C0004057,4483/10465
inadequate response,C0205412;C0205412;C0205412;C0205412;C0439856;C0439856;C0439856;C0439856,4484/10465
drinking  n ( % ),C0001948;C0684271,4485/10465
non - ics +,C1518422;C1518422,4486/10465
endovascular,C0524425,4487/10465
sbp ( mmhg )  mean ± sd,,4488/10465
hormone - refractory prostate carcinoma,C1328504,4489/10465
drug - eluting stent implanted ( at least one ),C1322815,4490/10465
pah origin / cause,C1418251;C1418251,4491/10465
experience,C0237607;C0596545,4492/10465
chinese subgroup,C0008120;C0008120;C0152035;C0152035,4493/10465
history of cardiovascular events,C1880008;C1880008;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,4494/10465
disease duration : < baseline mean,C0872146,4495/10465
physician ' s global assessment . mean nmbr sd,C4050369;C4050369;C4050369;C4050369;C4050369;C4050369,4496/10465
glycated hemoglobin < median,C0017853,4497/10465
% stenosis  as assessed by core laboratory,C0678234;C1261287;C2632116,4498/10465
upper respiratory tract infection,C0041912,4499/10465
antibiotics * *,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710,4500/10465
normoalbuminuria — no . / total no . ( % ),,4501/10465
aggressive ( nmbr ),C0001807;C0580822,4502/10465
patients with specific disease characteristics,C0030705;C0030705,4503/10465
work and school,C0043227,4504/10465
activity ( nmbr - nmbr vas ),C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939,4505/10465
age ( yrs ) nmbr - nmbr,C0001779,4506/10465
afcaps /,,4507/10465
clinical presentation of vte at initial diagnosis — no . ( % ),,4508/10465
aspirin < nmbr hours,C0004057,4509/10465
glucosamine ( n = nmbr ),C0017718,4510/10465
neither ace inhibitor nor arb,C0003015;C4541021,4511/10465
previous coronary intervention,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,4512/10465
time since diagnosis of diabetes — no . ( % ),,4513/10465
egfr ( ckd - epi  cystatinc )  ml / min / nmbr . nmbr mnmbr  n ( % ),C1739039;C3811844;C3812682,4514/10465
dyslipidaemia and hypertensiont,C0242339,4515/10465
presence of erosions  n ( % ),C0150312;C0150312;C0392148;C0392148;C3854307;C3854307,4516/10465
sitting pulse  bpma,C0277814;C0277814;C0277814;C2584297;C2584297;C2584297;C4050224;C4050224;C4050224,4517/10465
post - cabg,C0687676;C1704687;C3469826,4518/10465
cigarette smoking  mean pack - years ( sd ),C0239059;C0700219,4519/10465
> nmbr - nmbr ( moderate risk ),C0053917;C1334884,4520/10465
triglycerides tx difference vs pbo  ls mean % change from baseline ( se ),C0041004;C0041004,4521/10465
nmbr - nmbr / nmbr - nmbr mm hg,C0053917;C1334884,4522/10465
body mass indexa < median,C0518010,4523/10465
dmard user,C0242708;C0242708,4524/10465
admission for hf in previous year,C0184666;C0184666;C0184666;C0184666;C0809949;C0809949;C0809949;C0809949,4525/10465
duplex ultrasonography,C3825392,4526/10465
all of the colon,C0009368;C3888384,4527/10465
nmbr - nmbr - nmbr  obesity class nmbr,C0053917;C1334884,4528/10465
coronary artery disease — no . / total no . ( % ),,4529/10465
body mass index  mean + sd ( kg / m ),C0005893;C0578022;C1305855,4530/10465
> nmbr previous venous thromboembolisms ( % ),C0053917;C0053917;C1334884;C1334884,4531/10465
remission at maintenance - trial entry — no . ( % ),,4532/10465
improved,C0184511;C0332272;C1561611;C4084203,4533/10465
treatment stratum^ :,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,4534/10465
red blood cell counting  nmbr / l,C0014772;C1287262,4535/10465
nmbr - wk kaplan - meier rate  %,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,4536/10465
continuous variables  mean ( sd ),C0549178,4537/10465
intensified nmbr months ( n - nmbr ),C0053917;C1334884,4538/10465
elevated troponin,C0205250;C3163633,4539/10465
smoking history : current smoker,C1519384,4540/10465
jbs - nmbr primary prevention onlynmbr,C0175692;C0175692;C0795841;C0795841;C1416527;C1416527,4541/10465
( se]tf hdl - c,C0036919,4542/10465
baseline hs - crp tertiles ( mg / i],C0168634;C0168634;C1442488;C1442488,4543/10465
not reported,C1518422,4544/10465
diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849,4545/10465
standard care n ( % ) / nmbrpy,C1442989;C2828392,4546/10465
apremilast,C1678805,4547/10465
anterior myocardial infarction — no . ( % ),,4548/10465
oxcarbazepine,C0069751,4549/10465
mildly impaired,C0750532;C2945599,4550/10465
incidence [n / n ( rate per nmbr person - years ) ],C0021149;C0220856,4551/10465
blood pressure at target level ( % ) §,,4552/10465
egfrmdrd ， ml - min - nmbr - nmbr . nmbr m_nmbr,,4553/10465
benign prostatic hyperplasia,C1704272,4554/10465
> nmbr erosion  n ( % ),C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,4555/10465
body - mass index > nmbr,C0005893;C0578022;C1305855,4556/10465
alcohol consumption  n ( % ),C0001948,4557/10465
rhabdomyolysis or myopathy,C0035410;C4552660,4558/10465
treatment arm,C1522541,4559/10465
concomitant therapies at hospital discharge,C1707479,4560/10465
hbanmbrc in patients with baseline hbanmbrc > nmbr % ( > nmbr mmol / mol )  % [mmol / mol]  la  n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se ),C0030705,4561/10465
specific risk of bleeding^,C0205369;C1552740,4562/10465
number resulting in emergency department visit,C0237753;C0449788,4563/10465
elevated troponin ( > nmbr . nmbr pg / l ),C0205250;C3163633,4564/10465
hi ) ah ( % ),C0018619;C0239849;C1412082;C1412316;C1431594;C4552857,4565/10465
number of exacerbations,C0237753;C0449788,4566/10465
cpk > nmbr times uln,,4567/10465
glucosamine + chondroitin sulfate ( n = nmbr ),C0017720;C0876712;C0876712;C0876712;C0876712;C0017718,4568/10465
serum trap - nmbrb ( u / liter ),C0229671;C0229671;C0229671;C0229671;C0229671;C0229671;C1546774;C1546774;C1546774;C1546774;C1546774;C1546774;C1550100;C1550100;C1550100;C1550100;C1550100;C1550100,4569/10465
sex ( male ) ethnic origin,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,4570/10465
no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727,4571/10465
lvef within nmbr months  %,C0428772;C0428772;C0488728;C0488728,4572/10465
ls mean change from baselinenmbr,C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668,4573/10465
uric acid ( mg / dl ) creatinine clearance ( ml / min per nmbr . nmbr mnmbr ),C0041980,4574/10465
weight — kg ( median ),,4575/10465
non - black,C1518422;C1518422;C1518422;C1518422,4576/10465
myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959,4577/10465
duration of assigned regimen before surgery,C0449238;C0449238;C0449238;C0449238;C2926735;C2926735;C2926735;C2926735,4578/10465
asian / black / white / hispanic / other ( % ) clinical parameters,C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988;C0078988,4579/10465
> nmbr mg / dl eze / simva nmbr = nmbr },C0053917;C1334884,4580/10465
risk factors for pad,C0035648;C0035648;C0035648;C0035648;C0035648;C0035648;C1553898;C1553898;C1553898;C1553898;C1553898;C1553898,4581/10465
baseline hemoglobin  median ( iqr  g / dl ),C0168634;C1442488,4582/10465
insulin  iu / ml  median ( qnmbr  qnmbr ),C0021641;C1533581;C1579433;C3714501,4583/10465
prior percutaneous coronary intervention — no . ( % ),,4584/10465
other bdmard §,,4585/10465
icd therapy ( n =,C0021122;C0021122;C0021122,4586/10465
apo a - l ( mg / dl ) - mean ± sd,,4587/10465
with alogliptin nmbr . nmbr mg ( n nmbr nmbr ),C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126,4588/10465
symptomatic pad of lower extremities *,C0231220;C0231220;C0231220;C0231220;C0231220;C0231220,4589/10465
pfor heterogeneity,C1151635;C1151635,4590/10465
severe impairment ( egfr < nmbr ),C0205082;C0205082;C4050465;C4050465;C4050466;C4050466,4591/10465
previous use of amiodarone,C0205156;C1552607,4592/10465
levetiracetam,C0377265;C3693636,4593/10465
peri - op beta - blockers : no ( n = nmbr ),C0347985,4594/10465
patient global assessment ( nmbr - nmbr mm vas ),C4054229,4595/10465
background treatment  n ( % ),C1706907;C1706907;C1706907;C1706907;C1706907;C1706907;C1706907,4596/10465
high titre ( > nmbr times of uln )  n ( % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,4597/10465
no corticosteroid  no imm,C0001617;C3536709,4598/10465
greater than or equal to nmbr mm hg,C0439093,4599/10465
antiarrhythmic agent,C0003195;C0301380,4600/10465
white not of hispanic origin,C0007457;C0043157;C0220938,4601/10465
cause of dvt or pe — no . ( % ),,4602/10465
sulfonylurea — no . ( % ),,4603/10465
mean preoperative abpi of the index,C0444504;C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143;C2348143,4604/10465
met criterion at finalt,C0428210;C1550543;C4317104,4605/10465
orthopnea  ( % ),C0085619,4606/10465
total mortality,C0439175;C0439175;C0439810;C0439810,4607/10465
pace  no . ( nmbr ),C0287990;C1552930;C4048252,4608/10465
non - caucasian simva,C1518422;C1518422,4609/10465
high periostin subgroup ( > nmbr ng / ml ) ( n = nmbr ),C0205250;C0205250;C0205250;C0205250;C0205250;C0205250;C1299351;C1299351;C1299351;C1299351;C1299351;C1299351;C2700149;C2700149;C2700149;C2700149;C2700149;C2700149;C3887512;C3887512;C3887512;C3887512;C3887512;C3887512;C3889660;C3889660;C3889660;C3889660;C3889660;C3889660;C4321237;C4321237;C4321237;C4321237;C4321237;C4321237;C4522209;C4522209;C4522209;C4522209;C4522209;C4522209,4610/10465
overall population,C0282416;C0282416;C1561607;C1561607,4611/10465
all randomized women,C0034656;C3815594,4612/10465
respiratory - related^,C0521346;C0521346;C1546767;C1546767,4613/10465
treated vessel - native coronary,C1522326,4614/10465
< nmbr . nmbr mmol / liter estimated gfr,C0053917;C1334884,4615/10465
prior ms treatment with ifn - beta or,C1514463;C1514463;C1514463,4616/10465
no hemoconcentration hemoconcentration,C0549409;C0854379,4617/10465
clopidogrel  nmbr - mg loading dose,C0070166,4618/10465
body weight ( kg )  mean ( s . d . ),C0005910;C1305866,4619/10465
dasnmbr ( c - reactive protein ),,4620/10465
blood pressure  pbo y patients with diabe teristics ( ncep atp i,C0005823;C1271104;C1272641,4621/10465
patients with normoalbuminuria at baseline,C0030705,4622/10465
stenting plus medical therapy ( n = nmbr ),C0038257;C2348535,4623/10465
mean - sd change in pre - bronchodilator fevnmbr  l,C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,4624/10465
change from baseline in % predicted fevnmbr,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,4625/10465
patients with uncomplicated events ( p = o - nmbr 十 ),,4626/10465
post - bronchodilator percent of predicted fevnmbr  % ( sd ),C2599594,4627/10465
comparison with baseline,C1707455;C1707455,4628/10465
previous ml ( interaction : p = nmbr . nmbr ),C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,4629/10465
cardiac glycosides,C0007158,4630/10465
previously taken any other dmards  n ( % ),,4631/10465
crp ( normal range : nmbr - nmbr . nmbr )  mg / dl  mean ( sd ),C3890735;C4048285,4632/10465
modified rankin score,C0392747;C0392747;C3889737;C3889737,4633/10465
a a ( nmbr ( % ),,4634/10465
mean involved bsa  % ( nmbr % ci ),C0444504;C2347634;C2348143,4635/10465
other defined,C1704788;C3539106,4636/10465
without ( n = nmbr nmbr ),,4637/10465
treatment with drugeluting stent,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,4638/10465
nmbr - nmbr ( moderate ),C0053917;C1334884,4639/10465
angiography,C0002978,4640/10465
sbp / dbp $ nmbr / $ nmbr mmhg,C0085805;C0085805;C0085805;C0085805;C0085805;C0085805,4641/10465
non - extensive,C1518422,4642/10465
electrocardiographic findings — no . ( % ),,4643/10465
beta receptor antagonist,C0330390;C0439096;C2004068,4644/10465
baseline triglycerides by quintiles,C0168634;C1442488,4645/10465
median albumin - to - creatinine ratio ( interquartile range ),C0549183;C0549183;C0876920;C0876920;C2347635;C2347635;C2348144;C2348144;C2939193;C2939193,4646/10465
< nmbr regardless of historical count,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,4647/10465
stent type,C0038257;C0038257,4648/10465
nmbr vessel pci,C0053917;C1334884,4649/10465
body mass index subgroups,C0005893;C0578022;C1305855,4650/10465
pioglitazone,C0071097,4651/10465
b - agonists ( long - acting ) a,C0243192;C2987634,4652/10465
tg ( mg / dl )  median ± sd,,4653/10465
risk factors for recurrent vte — no . ( % ) f,,4654/10465
caucasian eze / simva,C0007457;C0043157,4655/10465
nmbr - < nmbr mvmin,C0053917;C1334884,4656/10465
pioglitazone ( n = nmbr  nmbr ),C0071097,4657/10465
time from onset to medication  h  mean ± sd,,4658/10465
baseline insulin daily dose / kg,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,4659/10465
mean — ml / min / nmbr . nmbr mnmbr of body - surface area,,4660/10465
telmisartan group ( n = nmbr ),C0248719;C0248719;C0248719;C0248719;C0248719;C0248719,4661/10465
total cholesterol ( mmo nmbr / nmbr ),C0201950;C0543421,4662/10465
african - latin american,C0085756,4663/10465
more than nmbr lesions per vessel,C0205172;C0205172,4664/10465
fpg  mg / dl ( mmol / l ),,4665/10465
> = nmbr % and < nmbr % ( > = nmbrand < nmbr mmol / mol ),,4666/10465
no . of events / total no . ( % ),,4667/10465
ind nmbr mg q . d . n = nmbr,C4049864;C4049864,4668/10465
smoking history : ex - smoker,C1519384,4669/10465
troponin level,C0041199;C0041199;C0041199;C0041199,4670/10465
duration of copd — days^,,4671/10465
other antiplatelet agents  n ( % ),C0085826,4672/10465
thienopyridine at randomization,C1120149,4673/10465
bmi ( kg / mnmbr ) cardiovascular history,C0578022,4674/10465
controllednmbr — no . ( % ),,4675/10465
sulfonylurea derivatives,C0038766,4676/10465
score nmbr - nmbr,C0449820;C0449820;C4050231;C4050231,4677/10465
radial access site,C0442038;C0920847,4678/10465
use of parenteral antithrombotic agents — no . ( % ),,4679/10465
immunosuppressant ( with or without corticosteroid ),C0021081,4680/10465
ml with st - segment elevation,C0439526;C1705224;C3887665,4681/10465
remission in overall population,C0544452;C0544452;C0544452;C0544452;C0687702;C0687702;C0687702;C0687702,4682/10465
v / hctz,C0020261,4683/10465
pulse ( beats / min ) cholesterol ( mmol / l ),C0232117;C0391850;C1947910,4684/10465
number of participants,C0237753;C0449788,4685/10465
beta - carotene,C0053396;C0696105,4686/10465
hemispheric stroke n = nmbr,C0205139;C0205139,4687/10465
pci for index mi ( % ),C4049621;C4049621;C4049621;C4049621;C4049621,4688/10465
absolute fvc decrease > nmbr %,C0205344;C0205344,4689/10465
hemoglobin ( gl ' ),C0019046,4690/10465
low ( nmbr - nmbr ) ( n = nmbr  nmbr  nmbr % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223,4691/10465
> nmbr % and < nmbr % predicted arr ( n = nmbr  nmbr ),C0053917;C1334884,4692/10465
duration from hospital admission to pci  h ( median  iqr ),C0449238;C0449238;C2926735;C2926735,4693/10465
prednisone,C0032952,4694/10465
enalapril dm = nmbr non - dm = nmbr,C0014025;C0014025,4695/10465
entire cohort,C0439751;C0439751;C0444667;C0444667,4696/10465
intravenous loop diuretics !,C0348016,4697/10465
peripheral revascularization,C0205100,4698/10465
no ischemia ( n = nmbr  nmbr ),C0022116;C4321499,4699/10465
fp / sal nmbr / nmbr pg ( n = nmbr ),C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412,4700/10465
antithrombotic use,C0042153;C0457083;C1947944,4701/10465
p lace of randomization ( interaction : p = nmbr . nmbr ),C0369773;C0369773;C2603361;C2603361,4702/10465
km event rate ( % ),C3887676;C3887676;C3887676;C3887676,4703/10465
revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0581603,4704/10465
betanmbr selective,,4705/10465
iii and iv ejection fraction,C0439070;C1705160,4706/10465
antiarrhythmic drug,C0003195;C0301380,4707/10465
median time since diagnosis * ( range )  yr,C0549183;C0549183;C0876920;C0876920;C2347635;C2347635;C2348144;C2348144;C2939193;C2939193,4708/10465
bmi  kg / mnmbr uac  no . ( % ),C0578022,4709/10465
high - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023822,4710/10465
serum potassium ( mmol / l ),C0302353;C0543465,4711/10465
gissi prevention nmbr / nmbr - nmbr / nmbr,C0199176;C0199176;C1706420;C1706420;C2700409;C2700409,4712/10465
nyha class nmbr or higher,C1882083;C1882083,4713/10465
concomitant medication — no . ( % ),,4714/10465
history of major cardiovascular disease  n ( % ),C0455539;C0455539;C0455539;C0455539,4715/10465
versus tiotropium nmbr pg,,4716/10465
nyha functional class at screening,C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083;C1882083,4717/10465
time from most recent qualifying,C0040223;C3541383,4718/10465
use of loop diuretics  n ( % ),C1524063,4719/10465
glycemia  mg / dl,C0005802,4720/10465
duration of asthma  years,C0449238;C0449238;C2926735;C2926735,4721/10465
bisphosphonates,C0012544;C3541401,4722/10465
cardiovascular disease history,C1880008;C0007222;C0007222;C0007222;C0007222;C0007222;C0007222;C0007226;C3887460,4723/10465
no pci or cabg — no . ( % ),,4724/10465
any statin ( with / without llt ),C0360714,4725/10465
associated with drug / toxin,C0332281,4726/10465
non - diabetic patients,C1829939,4727/10465
baseline hbanmbrc in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,4728/10465
coronary artery disease — no . ( % ) : ! :,,4729/10465
patients with egfr nmbr > nmbr to < nmbr ml / min / nmbr . nmbrmnmbr  n,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,4730/10465
baseline corticosteroidst ( mean dose : nmbr . nmbr mg / day )  n ( % ),C0168634;C1442488,4731/10465
vka  only reason,,4732/10465
reported in ecrf,C0684224;C0700287;C4319718,4733/10465
evidence or thombus  n ( % ),C3887511,4734/10465
prior aortocoronary bypass surgery 一 no . ( % ),,4735/10465
regional anaesthesia,C0002911,4736/10465
events / n,C0441471;C3541888,4737/10465
anti - coagulants - no . ( % ),C0848112,4738/10465
other antihypertensive,C0003364,4739/10465
thrombus - containing lesion,C0087086;C0087086;C0087086;C0087086;C0302148;C0302148;C0302148;C0302148;C3146237;C3146237;C3146237;C3146237,4740/10465
sgrq total score ( week,C2964552,4741/10465
americas ( n = nmbr ),C0002454;C0596070,4742/10465
placebo - adjusted mean difference in % hbanmbrc ( nmbr % ci  [ p value] ),C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408,4743/10465
serum total cholesterol ( mmol / l )  mean ( sd ),C0587184;C1287371,4744/10465
creatinine level,C0428279,4745/10465
heart rate  mean ( sd ) [range]  beats / min,C0018810,4746/10465
cv death / mi / stroke / ucr,C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503;C4318503,4747/10465
irbesartan,C0288171,4748/10465
time from acs to randomization,C0040223;C0040223;C3541383;C3541383,4749/10465
time intervals  h,C0872291,4750/10465
history of stroke or tia,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,4751/10465
medications at timing of randomization  n ( % ),C2359859,4752/10465
cv death or hf hospitalization n,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,4753/10465
cvd events,C0007222;C0007222,4754/10465
nmbr - point mace,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,4755/10465
low - dose aspirin use,C2608320;C2608320;C2608320,4756/10465
moderate / severe exacerbations  itt population  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,4757/10465
lp ( a ) §,,4758/10465
hbanmbrc levels,C0441889,4759/10465
weekly,C0332174,4760/10465
> nmbr ( high risk ),C0053917;C1334884,4761/10465
percentage of time in therapeutic inr range  mean ( sd ),C0439165;C0439165;C1549488;C1549488;C1561533;C1561533,4762/10465
> nmbr prior myocardial infarction — no . ( % ),,4763/10465
threatened abrupt vessel closure,C1276802;C1276802,4764/10465
prior therapy  %,C1514463,4765/10465
duration of pci ( min )  median n ( iqr ),C0449238;C2926735,4766/10465
age > nmbr y  n ( % ),C0001779,4767/10465
van der heijde mtss  mean ( sd ),C0557775,4768/10465
form / bud,C0348078;C0348078;C0376315;C0376315;C1522492;C1522492;C4255237;C4255237,4769/10465
no . of patients ind / gly sfc,,4770/10465
missing hb at yr nmbr,C1551393;C1551393;C1705492;C1705492;C3272743;C3272743,4771/10465
within nmbr h after,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,4772/10465
left ventricular ejection fraction < nmbr %,C0428772;C0488728,4773/10465
mestizos,C0682082,4774/10465
ankle - brachial index < nmbr . nmbr,C1328319;C3888326,4775/10465
p - value ( anova ),C1709380,4776/10465
patients with > nmbr exacerbations resulting in emergency department visit,C0030705,4777/10465
difference in change,C1705241;C1705241;C1705241;C1705241;C1705242;C1705242;C1705242;C1705242,4778/10465
established atherosclerotic cardiovascular disease,C0443211;C1272684,4779/10465
other vascular disease,C0042373,4780/10465
black race and ss > nmbr ( n = nmbr vs nmbr ),C0005680,4781/10465
qualifying mi : stemi,C1514624,4782/10465
coenzyme qnmbr,C0009235,4783/10465
history of a transient ischaemic attack,C0455536,4784/10465
known tiromtcch * c ccndifeon,C0205309,4785/10465
total patients,C0439175;C0439810,4786/10465
periprocedural medications  n ( % ) clopidogrel  nmbr mg *,C0013227;C0802604;C2598133;C4284232,4787/10465
swollen joint count ( nmbr - nmbr possible joints ),C0451521,4788/10465
prior amputation,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,4789/10465
weight  kg  median ( range ),C0005910;C0043100;C1305866;C1705104,4790/10465
arterial area ( mmnmbr ),C0003842;C0003842;C0221464;C0221464,4791/10465
statin + fibrate or,C0360714,4792/10465
presence of enthesitis  n ( % ),C0150312;C0392148;C3854307,4793/10465
nyha class ( when patient was last in stable condition before admission )  %,C1882083,4794/10465
history of second prior mi  n ( % ),C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062,4795/10465
ischaemic ( n = nmbrlnmbr ),C0475224,4796/10465
sbp > nmbr mmhg and / or dbp > nmbr mmhg,C0085805,4797/10465
caucasian  n ( % ),C0007457;C0043157,4798/10465
use of cardiac medication *,C1524063;C1524063;C1524063;C1524063;C1524063;C1524063,4799/10465
pioglitazone ( n = nmbr ),C0071097,4800/10465
hdl cholesterol < nmbr ( men ) or < nmbr mg / dl ( women ),C0023822;C0392885,4801/10465
cardiac valvular disease,C0018824,4802/10465
randomized to receive vitamin e,C0034656;C3815594,4803/10465
indication for index procedure,C2315323;C2315323;C2315323;C2315323;C2315323,4804/10465
total c ( mmol / l  mean ),C0439175;C0439810,4805/10465
left ventricular ejection fraction — %,,4806/10465
non - reversible ( % ),C1518422,4807/10465
peripheral neuropathy,C0031117,4808/10465
acuity major,C0750509,4809/10465
standard therapyy ( n = nmbr ),C1442989;C2828392,4810/10465
acqnmbr score,C0449820;C4050231,4811/10465
baseline cardiovascular disease,C0168634;C1442488,4812/10465
myalgia,C0231528;C4552646,4813/10465
time since as diagnosis  mean ( sd ) years,C0040223;C3541383,4814/10465
albumin / creatinine ratio - mg / mmol  median ( iqr ),C0486293;C0486293;C1318293;C1318293,4815/10465
change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr,C0392747;C0443172;C1705241;C4319952,4816/10465
venous insufficiency,C0042485,4817/10465
pdqol scale,C0175659;C0349674;C1947916,4818/10465
baseline nmbr - asa,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,4819/10465
current medication  n ( % ),C0746467,4820/10465
baseline pulmonary medication,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,4821/10465
median ( range ),C0549183;C0876920;C2347635;C2348144;C2939193,4822/10465
mean ( sd ) aqlq,C0444504;C2347634;C2348143,4823/10465
humerus fracture,C0020162,4824/10465
high - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023822;C0023822,4825/10465
clopidogrel pretreatment duration,C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166;C0070166,4826/10465
lower than normal range — % ^,,4827/10465
months ( log - transformed ),C0439231,4828/10465
saba reversibility,C0449261,4829/10465
previous stroke or tia,C0205156;C0205156;C1552607;C1552607,4830/10465
high disease activity : > nmbr . nmbr  n ( % ),C4699623;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,4831/10465
alcohol use ( % ),C0001948,4832/10465
americas  excluding us,C0002454;C0596070,4833/10465
acitretin,C0050559,4834/10465
stratification variables,C1514983,4835/10465
factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419,4836/10465
simplified disease activity index score,C3869582;C3869582,4837/10465
diabetic kidney disease,C0011881,4838/10465
prior coronary artery disease yes,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,4839/10465
intravenous nitrates,C0348016,4840/10465
toast classification,C1710306;C4521230,4841/10465
£ nmbr . nmbr % * *,,4842/10465
yes previous revascularization,C1549445;C1549445;C1705108;C1705108;C1710701;C1710701,4843/10465
no . / nmbr person - yr,,4844/10465
p - blocker intake at randomisation ( n = nmbro ),C0369773;C2603361,4845/10465
> l : nmbrhrs : min ( n = nmbr ),C0439394;C1706495;C3642217,4846/10465
oral glucocorticoid use at baseline — no . ( % ) : t,,4847/10465
adjusted mean change,C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081;C0456081,4848/10465
age at completion of highest level of,C0001779;C0001779,4849/10465
age group 一 ％,,4850/10465
combined macro + micro,C0205195;C0205195;C0205195;C0205195,4851/10465
race / ethnicity chinese,C0034510;C0034510;C0034510;C0034510;C1706779;C1706779;C1706779;C1706779;C3853635;C3853635;C3853635;C3853635,4852/10465
history of more than nmbr prior mi ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,4853/10465
physical activity §,,4854/10465
systolic blood pressure  mm hg < nmbr,C0488055;C0871470;C1306620,4855/10465
diagnoses / risk factors  n ( % ),C0011900;C0011900,4856/10465
medication effects,C1319171,4857/10465
insulin glargine,C0907402,4858/10465
mean age  years ( sd ),C0444504;C2347634;C2348143,4859/10465
diuretic thiazide,C0012802,4860/10465
paclitaxel,C0144576,4861/10465
total back pain  mean ( sd ),C0439175;C0439175;C0439175;C0439810;C0439810;C0439810,4862/10465
previous intolerance of infliximab  n ( % ) *,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,4863/10465
uae ( p  g / min ),C1519789,4864/10465
any statin versus no statin at randomization,C0360714,4865/10465
adalimumab group ( n = nmbr ) t,C1122087;C1122087;C1122087;C1122087;C1122087;C1122087,4866/10465
hgb  g / dl < nmbr men  < nmbr women,C0019029;C0019046;C0518015;C1424337,4867/10465
fracture during follow - up,C0016658;C0016658;C0016658;C0016658,4868/10465
biguanides,C0005382;C0360396;C3540012,4869/10465
> nmbr . nmbr kg / mnmbr hypertension :,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,4870/10465
values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .,C0042295,4871/10465
aminosalicylates,C0368663,4872/10465
prediabetes — no . ( % ) nmbr,,4873/10465
history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,4874/10465
brain volume  cmnmbr,C1113695,4875/10465
swollen joint count ( nmbr - nmbr ),C0451521,4876/10465
no . of strokes ( % ),,4877/10465
demographic and medical variables,C0011298,4878/10465
australia / nz,C0004340,4879/10465
no . of events / patients,,4880/10465
chd history  n ( % ),C0280604;C0280604;C0280604;C0280604;C0280604;C0280604;C3542407;C3542407;C3542407;C3542407;C3542407;C3542407,4881/10465
jsn score ( nmbr - nmbr ),C0449820;C4050231,4882/10465
ascvdor > nmbr cv risk factors,,4883/10465
previous transient ischemic attack,C0205156;C0205156;C1552607;C1552607,4884/10465
number of stent = l or nmbr or nmbr,C0237753;C0449788,4885/10465
ischemic stroke with hemnrrhnaic cnnversinn,C0948008,4886/10465
chronic stable angina,C0340288,4887/10465
fenofibric acid + low - dose statin,C0060179;C0060179,4888/10465
daily iglar dose at week nmbr ( u ),C2348070;C2348070;C2348070;C2348070,4889/10465
anticholinergic,C0242896;C3537004,4890/10465
contrast volume,C0009924;C0009924;C0009924;C0009924;C1979874;C1979874;C1979874;C1979874,4891/10465
rituximab ( nmbrxnmbr mg ) + mtx,C0393022,4892/10465
> nmbr mg / dl simva nmbr = nmbr],C0053917;C1334884,4893/10465
glucagon - like peptide - nmbr agonist,C0014361;C0014361,4894/10465
acrnmbr response at week nmbr  n ( % ),C0871261;C0871261;C0871261;C0871261;C1704632;C1704632;C1704632;C1704632;C1706817;C1706817;C1706817;C1706817;C2911692;C2911692;C2911692;C2911692,4895/10465
alcohol intake ( + ) ( % ),C0001948,4896/10465
# of prior tnfi among non - tnfi naive,,4897/10465
remission,C0544452;C0687702,4898/10465
triglycerides ( median  iqr )  mg / dl,C0041004,4899/10465
total antihypertensive use,C0439175;C0439175;C0439175;C0439810;C0439810;C0439810,4900/10465
anmbrc distribution ( % ),C0520511;C1704711,4901/10465
middle third,C0442050,4902/10465
symptom score ( sd ),C3476546,4903/10465
atorvastatin factorial study,C0286651,4904/10465
former / non - drinker,C0205156;C0750523,4905/10465
electrocardiographic findings at randomization,C0438154,4906/10465
lumbar spine bmd t - score,C0024091;C0024091;C3887615;C3887615,4907/10465
multiple ( nmbr + ) chd risk,C0439064,4908/10465
hyperlipidemia  n ( % ),C0020473;C0428465;C4555212,4909/10465
place of randomization,C0442504;C1533810;C1704765;C1882509,4910/10465
beta - blocker % target dose,C0001645;C0001645;C0001645;C0001645;C0001645;C0001645,4911/10465
left circumflex  n ( % ),C0205091;C0443246;C1552822,4912/10465
ranolazine vs . placebo km failure rate,C0073633,4913/10465
biomarker high ( periostin > nmbrng / ml or blood eosinophils > nmbrcells per pl )  na,C0005516,4914/10465
at or above the median,,4915/10465
indacaterol - glycopyrronium group ( n = nmbr ),C1722260;C1722260;C1722260;C1722260;C1722260;C1722260,4916/10465
infarct on brain imaging 丰,,4917/10465
baseline laboratory values  median ( iqr ) d,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,4918/10465
timi major or minor bleeding,,4919/10465
olodaterol nmbr mg ( n = nmbr ),C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193,4920/10465
race / ethnicity white,C0034510;C0034510;C0034510;C0034510;C0034510;C0034510;C1706779;C1706779;C1706779;C1706779;C1706779;C1706779;C3853635;C3853635;C3853635;C3853635;C3853635;C3853635,4921/10465
tnfi ( no other bdmard taken ) t  n ( % ),,4922/10465
patients treated,C0030705,4923/10465
distribution time,C0520511;C0520511;C1704711;C1704711,4924/10465
previous treatment failure — no . ( % ) § * *,,4925/10465
median body weight — kg,,4926/10465
raas inhibitor use,C1999216;C1999216;C1999216,4927/10465
previous cardiovascular event at randomization,C0205156;C1552607,4928/10465
aspirin alone ( n = nmbr ),C0004057,4929/10465
wml load at baseline mri,C1550025;C1550025;C1550025;C1550025;C1550025;C1550025;C1704782;C1704782;C1704782;C1704782;C1704782;C1704782;C1708715;C1708715;C1708715;C1708715;C1708715;C1708715,4930/10465
clopidogrel plus aspirin,C0070166,4931/10465
alanine aminotransferase or aspartate aminotransferase > nmbrx upper limit of normal ( n = nmbr ),C0001899;C0057041;C1415274;C3887708,4932/10465
non - endstage renal dysfunction *,C1518422;C1518422,4933/10465
active inflammatory bowel disease,C0205177;C3853793;C3888249,4934/10465
current alcohol use — no . / total no . ( % ),,4935/10465
complex partial ( ib ),C0439855;C0439855;C1704241;C1704241,4936/10465
saxagliptin ( n = nmbr  nmbr ),C1611934,4937/10465
low subgroup,C0205251;C0205251;C1550472;C1550472;C3890211;C3890211;C4048187;C4048187;C4321351;C4321351;C4522223;C4522223,4938/10465
high - dose statin pretreatment ( n = nmbr ),C0444956;C0444956;C0444956;C0444956,4939/10465
common study baseline,C0205214;C0205214;C0205214;C0205214;C1522138;C1522138;C1522138;C1522138;C3245511;C3245511;C3245511;C3245511,4940/10465
lm bifurcation treated,C1261082;C1261082;C1551056;C1551056,4941/10465
renal impairment  n ( % ),C1565489,4942/10465
> nmbr failure,C0053917;C0053917;C1334884;C1334884,4943/10465
coronary revascularization procedure,C0877341,4944/10465
intensified baseline ( n - nmbr ),C0168634;C1442488,4945/10465
time from onset of qualifying stroke to randomization,C0449244;C0449244,4946/10465
statin non - users ( n = nmbr ),C0360714,4947/10465
barc nmbr - nmbr,C0053917;C1334884,4948/10465
laba use  % patients,C0042153;C0457083;C1947944,4949/10465
enoxaparin ( n = nmbr ),C0206460,4950/10465
who / idf impaired fasting glucose,C1272092,4951/10465
dip involvement  ! n ( % ),C3539618,4952/10465
copd severity ( gold nmbr ),C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,4953/10465
erosion score ( nmbr - nmbr ),C0333307;C0333307;C1880549;C1880549;C1959609;C1959609;C3887524;C3887524,4954/10465
st - segment depression > nmbr . nmbr mv,C0520887,4955/10465
fasting tgs §,,4956/10465
total cataract extraction,C3665439;C3665439;C0439175;C0439810,4957/10465
nmbr mg / day early - start,C0053917;C1334884,4958/10465
nmbr - nmbr with cv risk but not disease ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,4959/10465
oral treprostinil ( n = nmbr ),C0442027;C4521986,4960/10465
acute ( < nmbr hr ),C0205178,4961/10465
total ldl - c *,C0439175;C0439810,4962/10465
obese patients  ! n ( % ),C0028754,4963/10465
baseline aspirin dose < nmbr mg,C0168634;C1442488,4964/10465
immunologic,C0152036;C0205470,4965/10465
high - dose aspirin,C0444956,4966/10465
a - glucosidase inhibitor,C1512211,4967/10465
history of stroke  n ( % ),C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,4968/10465
crusade bleeding score,C0019080;C0019080,4969/10465
% with haq - di decrease > nmbr . nmbr,,4970/10465
= nmbr ’ ),,4971/10465
simple partial ( ia ),C0205352;C0205352,4972/10465
monitoring ( n = nmbr ),C0150369;C1283169,4973/10465
crp median ( se )  rng / l,C3890735;C3890735;C3890735;C3890735;C3890735;C4048285;C4048285;C4048285;C4048285;C4048285,4974/10465
no . of previous venous thromboembolic events,,4975/10465
d / mi / idr / st,,4976/10465
smoking ( % ) laboratory parameters,C0037369;C0453996;C1881674,4977/10465
female sex  n ( % ) race  n ( % ),C0086287,4978/10465
hypertension  treated,C0020538;C1963138,4979/10465
no . in the nmbr mo before screening,,4980/10465
severity of copd  n ( % ) *,C0439793;C0439793;C0439793;C0522510;C0522510;C0522510,4981/10465
reduced ef,C0392756,4982/10465
disease duration  years : median ( range ),C0872146,4983/10465
absent ( < nmbr mg / dl ),C0332197;C4285062,4984/10465
sgrq total score * *,C2964552,4985/10465
black race  n ( % ),C0005680,4986/10465
indication for index pci,C0392360;C0392360;C0392360;C0392360;C0392360;C3146298;C3146298;C3146298;C3146298;C3146298,4987/10465
forearm fracture,C1305215,4988/10465
clinical copd phenotype^,C0205210;C0205210;C0205210;C0205210;C0205210;C0205210,4989/10465
symptoms and feelings,C0683368;C1457887,4990/10465
extent of index event,C0439792;C0439792;C0439792;C0439792;C0439792;C0439792;C0439792;C0439792;C0439792;C0439792,4991/10465
gold stage — no . ( % ) * *,,4992/10465
drugs used in diabetes,C0013227;C3687832,4993/10465
baseline short - acting anticholinergics  n ( % ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,4994/10465
stent plus medical therapy,C0038257,4995/10465
significant worsening in kccq clinical score ( > nmbr ) at nmbr monthsnmbr,C0332271;C0332271;C1457868;C1457868;C1546960;C1546960,4996/10465
diet + pravastatin,C0012155;C0012159;C1519433;C2983588;C3668949,4997/10465
doubling of serum creatinine,C0205173;C0205173;C1705764;C1705764,4998/10465
before index acs event,C0600653;C0600653;C0600653;C0600653;C0918012;C0918012;C0918012;C0918012;C1552854;C1552854;C1552854;C1552854;C1637833;C1637833;C1637833;C1637833;C2986546;C2986546;C2986546;C2986546,4999/10465
global ischemia ( % ) * *,C0205246;C0205246;C2348867;C2348867,5000/10465
il - nmbr  ng / l,C0020898;C0020898;C0021764;C0021764;C0022271;C0022271,5001/10465
> nmbr . nmbr to < nmbr . nmbr mu / l $ mmol / l,C0053917;C1334884,5002/10465
glycoprotein llb / llla inhibitors,C0017968,5003/10465
statin intolerancenmbr  n ( % ),C0360714,5004/10465
ccsc at nmbr month before enrollment,C1516705;C1516705;C1516705;C1516705,5005/10465
fevi aucnmbr - nmbrl,C0429706;C0849974;C1561566;C4528367,5006/10465
total  adjusted weight of nmbr . nmbr for gastrointestinal bleeding,C0439175;C0439810,5007/10465
indacaterol n = nmbr,C1722260,5008/10465
cv risk factors  % of patients,C3538987;C3538987;C4048877;C4048877;C4318503;C4318503,5009/10465
egfr  median ( sd )  ml / min,C1739039;C3811844;C3812682,5010/10465
% rf +,C0035448;C0201660;C0748398;C1547111,5011/10465
moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,5012/10465
beta - blocker use at randomization,C0001645;C0001645;C0001645,5013/10465
hscrp > nmbr mg / l,,5014/10465
exacerbation rate in the previous year ( range ),C4086268;C4086268;C4086268;C4086268;C4086268;C4086268;C4086268;C4086268,5015/10465
bdp / ff / g ( n = nmbr ),C0004906;C1422585;C1538710,5016/10465
high density lipoprotein ( mg / dl ),C0023821,5017/10465
dose ( n ),C0178602;C0869039;C1114758,5018/10465
hormone replacement therapy,C0282402,5019/10465
europe ( eu ),C0015176,5020/10465
events / statin group,C0441471;C0441471;C0441471;C0441471;C0441471;C0441471;C3541888;C3541888;C3541888;C3541888;C3541888;C3541888,5021/10465
site of disease — no . ( % ),,5022/10465
proximal - mainleft,C0205107;C4489236,5023/10465
pharmaco - invasive n = nmbr,C0205281;C1334278,5024/10465
nmbr % c . i .,C0053917;C0053917;C1334884;C1334884,5025/10465
metformin : no / yes  %,C0025598,5026/10465
laba or lamab n = nmbr,,5027/10465
physical role,C0031809;C0031809;C0031809;C0205485;C0205485;C0205485;C1509143;C1509143;C1509143,5028/10465
colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412,5029/10465
estimated odds ratio,C0750572,5030/10465
secukinumab intravenous nmbr mg ( n = nmbr ),C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547,5031/10465
clopidogrel dose,C0070166;C0070166;C0070166,5032/10465
ex - smoker / smoker  %,C0337671;C4555205,5033/10465
moderate ( > nmbr to < nmbr ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,5034/10465
stroke of undetermined cause,C0038454;C0038454,5035/10465
screening visit,C0220908;C0220908;C0220908;C0220909;C0220909;C0220909;C1698960;C1698960;C1698960;C1710031;C1710031;C1710031;C1710032;C1710032;C1710032;C1710477;C1710477;C1710477;C2348164;C2348164;C2348164,5036/10465
medications before admission,C0013227;C0013227;C0802604;C0802604;C2598133;C2598133;C4284232;C4284232,5037/10465
antiplatelet therapy dual,C1096021,5038/10465
fenofibric acid nmbr = nmbr,C0060179;C0060179,5039/10465
asia / pacific ( % ),C0003980,5040/10465
number of patients with fractures,C2360800,5041/10465
before amendment ( % ),C0680532;C2346732,5042/10465
( haq - di  nmbr - nmbr ),C3826998;C4321476,5043/10465
race or ethnic group — no . f,,5044/10465
loss of response : ! : : ! :,C1517945;C1517945;C1517945;C1517945,5045/10465
post - bronchodilator fevnmbr — % of predicted value,,5046/10465
medical history duration of heart failure ( years ) primary cause of heart failure,C0199168;C0199168;C0205476;C0205476,5047/10465
major cardiovascular,C0205082;C0205082;C0205164;C0205164;C4318856;C4318856;C4521762;C4521762,5048/10465
bmi > nmbr ( % ),C0578022,5049/10465
high risk ( nmbr - nmbr ),C0332167;C3272283;C4050568;C4319571,5050/10465
seronegative ( rf - ve and acpa - ve ) subgroup,C0521144,5051/10465
functional outcome ( mrs nmbr - nmbr ),C0205245;C0542341;C2700217,5052/10465
previous balloon angioplasty,C0205156;C0205156;C1552607;C1552607,5053/10465
mean number of exacerbations in previous nmbr months ( sd ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,5054/10465
duration from clopidogrel / placebo to pci  min ( median  iqr ),C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,5055/10465
( ci ) b,C0008107;C3259781,5056/10465
hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,,5057/10465
age  y . o .,C0001779,5058/10465
serum triglycerides  mg / dle,C0542495,5059/10465
post - acute ischemic stroke,C0687676;C0687676;C1704687;C1704687;C3469826;C3469826,5060/10465
death / mi / idr / st / gusto - defined moderate or severe bleeding,C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C0011065;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C1306577;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4082313;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775;C4552775,5061/10465
use of rescue albuterol  puffs / day *,C1524063,5062/10465
intent of conservative strategy  %,C0162425;C1283828;C1550453,5063/10465
> < nmbr . nmbr  < nmbr . nmbr  r < mmse = mini - mental ,,5064/10465
estimated gfr,C0750572;C0750572,5065/10465
stenosis > nmbr %,C0678234;C1261287;C2632116,5066/10465
nmbr - year rates in placebo groups,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,5067/10465
previously on acei + arb,C3888198,5068/10465
peripheral artery disease details,C1704436;C4025272,5069/10465
egfr ( median  iqr )  ml / min / nmbr  nmbrmnmbr,C1739039;C3811844;C3812682,5070/10465
dipeptidyl peptidase - nmbr inhibitor,C0003015;C0003015;C2757044;C2757044;C3536837;C3536837,5071/10465
body mass indexnmbr,C0518010,5072/10465
traditional nsaid,C0443324;C0443324;C1548559;C1548559,5073/10465
menopausal status and use of ht,C1513126,5074/10465
standard care,C1442989;C2828392,5075/10465
non - european trial,C1518422;C1518422,5076/10465
patient ' s assessment of pain ( nmbr - nmbr vas ),C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0030705,5077/10465
tdi total score ( week nmbr,C0205976;C2674784;C3714807,5078/10465
p  treatment - by - region interaction,C0369773;C2603361,5079/10465
insulin only,C0021641;C0021641;C1533581;C1533581;C1579433;C1579433;C3714501;C3714501,5080/10465
catscorecategory  n ( % ),,5081/10465
anacetrapib ( n = nmbr  nmbr ),C2604745,5082/10465
control nmbr months ( n - nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389,5083/10465
no immomtedion,,5084/10465
delayed reaction,C0205421;C1545665;C3272602,5085/10465
disease site — no . of patients ( % ) |,,5086/10465
nmbr . nmbr - < nmbr,C0053917;C1334884,5087/10465
sgrq total score ( units ) : ! :,C2964552,5088/10465
qualifying myocardial infarction,C1514624,5089/10465
psoriasis,C0033860,5090/10465
no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778,5091/10465
mean ± s . d . hbanmbrc,,5092/10465
time from last dose of pnmbrynmbr inhibitor  days,C0946444,5093/10465
snmbr gallop  n ( % ),,5094/10465
any condition,C0012634;C0348080;C1705253;C3864998,5095/10465
sitagliptin n = nmbr,C1565750,5096/10465
mean weight  kg  mean = sd,C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,5097/10465
abciximab ( n = nmbr ),C0288672,5098/10465
antiplatelet — no . ( % ),,5099/10465
ischemic heart disease indicator no ( n = nmbrl ),C0010054;C0010054;C0010054;C0151744;C0151744;C0151744,5100/10465
ifg / prediabetes^,C1334085;C1708411,5101/10465
no . of target vessels,,5102/10465
adjusted mean ± se ( nmbr % ci ),,5103/10465
albuminuria < nmbr gram / gram cr,C0001925,5104/10465
nyha lll - iv,C1275491;C1275491,5105/10465
chronic kidney disease  n ( % ),C1561643;C4553188,5106/10465
patients with fistulas at baseline,C0030705,5107/10465
standard control,C1442989;C1442989;C1442989;C1442989;C1442989;C1442989;C2828392;C2828392;C2828392;C2828392;C2828392;C2828392,5108/10465
cvd  mi  stroke  or recurrent ischemia - urgent revascularization,C0007222,5109/10465
white race  %,C0007457;C0043157,5110/10465
> nmbr / tmol / liter — no . ( % ),,5111/10465
renin inhibitors,C2917241;C3653375,5112/10465
not localized,C1518422,5113/10465
ischemic stroke without hemorrhagic conversior,C0948008;C0475224,5114/10465
constitutional,C1511487,5115/10465
smoking status  n ( % ) former,C1519386,5116/10465
crp ( mg / dl ) * *,C3890735;C4048285,5117/10465
ularitide ( n = nmbr ),C0077910,5118/10465
vorapaxar placebo nmbr - yr . km %,C2974521;C2974521;C2974521;C2974521;C2974521;C2974521,5119/10465
cv death  ml  ischemic stroke  hosp . for hf  cor . revasc .  ua,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,5120/10465
prior anti - tnf therapy,C0332152;C2826257,5121/10465
reinfarction,,5122/10465
sgrq total score,C2964552,5123/10465
first primary composite outcome,C0205435;C0205435;C0205435;C0205435;C0205435;C0205435;C1279901;C1279901;C1279901;C1279901;C1279901;C1279901,5124/10465
score on modified mini - mental state examination — median ( iqr ),,5125/10465
hormone replacement,C0282402,5126/10465
composite endpoint of doubling of serum creatinine  esrd ,C0205199;C0205199;C0205199;C0205199;C0205199;C0205199;C0205199;C0205199;C1547335;C1547335;C1547335;C1547335;C1547335;C1547335;C1547335;C1547335,5127/10465
exercise ( % ),C0015259;C1522704,5128/10465
history of ischemic heart disease — no . ( % ),,5129/10465
statin therapy,C1278454,5130/10465
stratified analyses,C0205363;C0205363;C0205363,5131/10465
seated sbp at nmbr weeks  mmhg + * *,C0277814;C0277814;C1283233;C1283233,5132/10465
former / current smoker  n ( % ),C0337671;C0337671;C0205156;C0205156;C0750523;C0750523,5133/10465
( sd )  mg / dl,C2699239,5134/10465
primary trial end point,C2986535,5135/10465
fasting blood glucose,C0428568;C1261430,5136/10465
number ( % ) reporting migraine on nmbr - month questionnaire,C0237753;C0449788,5137/10465
concomitant corticosteroid use,C0521115,5138/10465
elevated bun ( > nmbr . nmbr meq / l ),C0151539,5139/10465
slowest third,C0439834,5140/10465
clinical features of hf,C0683325;C0683325;C0683325;C0683325,5141/10465
tertile nmbr index pci performed,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,5142/10465
risk factor ( predefined ) for falling at screening  n ( % ),C0035648,5143/10465
left ventricular dysfunction,C0242698,5144/10465
serum cholesterol  mg / dld,C0587184,5145/10465
acs treatment,C0742343;C0742343;C0742343;C0742343;C0742343;C0742343;C0742343;C4318612;C4318612;C4318612;C4318612;C4318612;C4318612;C4318612,5146/10465
< nmbr ml / min / nmbr . nmbr mnmbr nt - pro - bnp,C0053917;C0053917;C1334884;C1334884,5147/10465
prednisone use  %,C0032952;C0032952;C0032952,5148/10465
actual treatment strategy,C0237400;C0237400;C0237400;C0237400;C0237400;C0237400;C0237400,5149/10465
other antiplatelet agent 一 no . ( % ),,5150/10465
% change from baseline ls means ( se ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,5151/10465
use of blood pressure lowering medication *,C1524063;C1524063;C1524063,5152/10465
multivessel disease 一 no . ( % ),,5153/10465
patients using concurrent tiotropium,C0030705,5154/10465
time since copd diagnosis ( yrs ),C0040223;C3541383,5155/10465
use of medications for pah — no . ( % ),,5156/10465
ace - i or arb use at baseline,C1452534;C1452534;C4284014;C4284014,5157/10465
medical history of diabetic retinopathy §,,5158/10465
anmbr + ez n = nmbr anmbr n = nmbr,C0206578,5159/10465
anti - tnf - naive patientsnmbr,C1448177,5160/10465
total patients  n,C0439175;C0439810,5161/10465
heterogeneity test,C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0019409;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960;C0242960,5162/10465
infarction  date not reported,C0021308,5163/10465
rates per nmbr patient - years,C0871208;C0871208;C1521828;C1521828,5164/10465
% difference  nmbr % ci ),C1705241;C1705242,5165/10465
tofacitinib nmbr mg bid,C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696;C2930696,5166/10465
smoking index — pack - yr §,,5167/10465
body weight ( kg )  n ( % ),C0005910;C1305866,5168/10465
spironolactone,C0037982,5169/10465
non - frail,C1518422,5170/10465
nmbr vitamin e,C0053917;C0053917;C1334884;C1334884,5171/10465
low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223,5172/10465
osteopontin ( ng / ml ),C0069676;C1420369;C1505427;C4084879,5173/10465
pvaluefor any mi versus no mi,,5174/10465
prerandomization statin therapy,C1278454,5175/10465
multivessel cad  n ( % ),C1504769;C2239547;C3813548;C4284121,5176/10465
glomerular filtration rate §,,5177/10465
nmbr mg sirukumab every nmbr weeks ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,5178/10465
baseline lvef  %,C0168634;C0168634;C1442488;C1442488,5179/10465
hypertension ( % ) : t,C0020538;C1963138,5180/10465
previous loss of response to infliximab  n ( % ) *,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,5181/10465
number of treated vessels,C0237753;C0449788,5182/10465
extracranial carotid stenosis  n ( % ),C0580586,5183/10465
coronary artery disease  n ( % ),C0010054;C0010068;C1956346,5184/10465
telmisartan,C0248719,5185/10465
physician,C0031831;C0804815,5186/10465
black and other,C0005680;C0027567;C0085756;C0439541,5187/10465
diclofenac nmbr mg ( n nmbr nmbr )  . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .,C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091,5188/10465
smokers ( at baseline ),C0337664,5189/10465
baseline use of hormone therapy ( % ),C0168634;C1442488,5190/10465
high hdl - c ( for men ≥ nmbr   mg / dl / for women ≥ nmbr   mg / dl ),,5191/10465
myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959,5192/10465
exposed ( n = nmbr ),C0332157,5193/10465
primary composite end point,C2986535;C2986535,5194/10465
fasting insulin ( giu / ml ),C0015663;C0015663;C0015663;C0015663,5195/10465
met criterion at final ( n [ % ] ),C0428210;C0428210;C0428210;C1550543;C1550543;C1550543;C4317104;C4317104;C4317104,5196/10465
mean ( sd ) bmi ( kg / mnmbr ),C0444504;C2347634;C2348143,5197/10465
mean body weight ( sd )  kg,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,5198/10465
lean ( < nmbr kg / mnmbr ),,5199/10465
previous treatment with a laba and / or lama  n ( % ) c,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,5200/10465
new des ( n = nmbr ),C0205314;C0205314,5201/10465
homa - ir index — median ( iqr ),,5202/10465
timi risk score ( interaction : p = nmbr . nmbr ),C0035647;C0035647;C4552904;C4552904,5203/10465
prior use of systemic,C0332152;C2826257,5204/10465
all randomized,,5205/10465
obesity ( % ) §,,5206/10465
diabetes therapy,C3274787;C3539002,5207/10465
balloon angioplasty,C0002996;C0002997,5208/10465
ibdq domain scores  mean [sd],C1880389;C1883221;C3541951,5209/10465
rosiglitazone ( n = nmbr ),C0289313,5210/10465
smoking ( ever ),C0037369;C0453996;C1881674,5211/10465
patella fracture,C0159849,5212/10465
screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164,5213/10465
medical history and risk factors,C0262926;C1704706,5214/10465
ineffective therapy,C3242229;C3242229;C3242229,5215/10465
risk group,C0242444,5216/10465
hdl - c ( mg / dl ) - mean ± sd,,5217/10465
very severe ( gold nmbr ),C3641272;C4050419,5218/10465
glycated hemoglobin  n ( % ),C0017853,5219/10465
antihypertensive therapy — no . ( % ),,5220/10465
non - ischaemic cause,C1518422;C1518422,5221/10465
low periostin subgroup (  nmbr ng / ml ) ( n = nmbr ),C0205251;C0205251;C0205251;C0205251;C0205251;C0205251;C1550472;C1550472;C1550472;C1550472;C1550472;C1550472;C3890211;C3890211;C3890211;C3890211;C3890211;C3890211;C4048187;C4048187;C4048187;C4048187;C4048187;C4048187;C4321351;C4321351;C4321351;C4321351;C4321351;C4321351;C4522223;C4522223;C4522223;C4522223;C4522223;C4522223,5222/10465
infarct location — no . / total no . ( % ),,5223/10465
enrollment by region  no . ( % ),C1516879;C1516879;C1696073;C1696073;C3888021;C3888021,5224/10465
fixed triple ( n = nmbr ),C0443218;C2827483;C3714578,5225/10465
multivessel stenting,C0038257;C2348535,5226/10465
estimated creatinine clearance < nmbr rmb ' mint,C0750572,5227/10465
event rate,C0441471;C0441471;C4019010;C4019010,5228/10465
fevnmbr  litres ( pre salbutamol )  mean ( sd ),,5229/10465
gpifeellla inhibitor use before angography,C1999216;C1999216;C1999216,5230/10465
gender  female  n ( % ),C0079399;C1522384,5231/10465
latin america or south africa,C0023122,5232/10465
patients with complicated events ( p = nmbr - nmbr 十 ),,5233/10465
triglycerides $ nmbr mg / dl ( nmbr . nmbr mmol / l ),C0041004;C0041004,5234/10465
patients with > nmbr exacerbations resulting in ed visit,C0030705,5235/10465
use of statins,C1524063,5236/10465
time between cessation of full - dose warfarin therapy and enrollment ( mo ),C1880019;C1880019;C1880019;C1880019;C1880019;C1880019,5237/10465
egfr nmbr - nmbr,C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,5238/10465
egfr > = nmbrml / min / nmbr . nmbrmnmbr n = nmbr  nmbr ( nmbr . nmbr % ),C1739039;C3811844;C3812682,5239/10465
peri - op ace - inhibitors / arbs : no ( n = nmbr ),C0347985,5240/10465
cangrelor ( n = nmbr ) n / n ( % ),C1121991,5241/10465
baseline fevnmbr % predicted,C0168634;C0168634;C1442488;C1442488,5242/10465
age ( range ) ( years ),C0001779,5243/10465
mean — yr age group — no . ( % ),,5244/10465
history of atrial fibrillation or flutter treatment at randomisation,C0729790,5245/10465
previous stenting ( % previous pci ),C0205156;C0205156;C1552607;C1552607,5246/10465
bivalirudin only,C0168273;C0168273,5247/10465
medical history ( % ),C0262926;C1704706,5248/10465
clopidogrel given before procedure,C0070166,5249/10465
ezetimibe + simvastatin ( n = nmbr  nmbr * ),C1532737,5250/10465
aliskiren / valsartan ( n = nmbr ),C2733073,5251/10465
urinary protein - to - creatinine ratio | |,C1096054,5252/10465
cerebrovascular accident,C0038454,5253/10465
male sex — no . ( % ) weight — no . ( % ),,5254/10465
weight — no . ( % ),,5255/10465
nmbr non - mtx,C0053917;C0053917;C1334884;C1334884,5256/10465
fasting triglycerides — mg / dl,,5257/10465
concomitant csdmards other than methotrexate  n ( % ),C0521115,5258/10465
( b ) concomitant respiratory medications [n ( % ) ],C0521115,5259/10465
copd population ( n = nmbr ),C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,5260/10465
ibdq score  mean ( sd ),C0449820;C4050231,5261/10465
lifestyle,C0023676,5262/10465
disease location  %,C0012634;C0012634;C0012634;C0012634,5263/10465
haq - di  number ( % ),C3826998;C4321476,5264/10465
cardiac pacemaker — no . ( % ),,5265/10465
patient ' s preference not to take,C0376409,5266/10465
tofacitinib  nmbr mg twice daily,C2930696,5267/10465
diet + pravastatin group,C0012155;C0012155;C0012155;C0012155;C0012155;C0012155;C0012159;C0012159;C0012159;C0012159;C0012159;C0012159;C1519433;C1519433;C1519433;C1519433;C1519433;C1519433;C2983588;C2983588;C2983588;C2983588;C2983588;C2983588;C3668949;C3668949;C3668949;C3668949;C3668949;C3668949,5268/10465
glycated hemoglobin level,C0202054,5269/10465
asthma population ( n = nmbr ),C0004096;C0004096;C2984299;C2984299,5270/10465
albumin creatinine ratio,C0486293;C1318293,5271/10465
apolipoproiein b ( mij / nmbr ),C0053917;C1334884,5272/10465
aliskiren ( dm - vs . dm + ),C1120110,5273/10465
regadenoson,C1698215,5274/10465
change in erosion score ( mean ),C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C0443172;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C1705241;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952;C4319952,5275/10465
fecal calprotectin — pg / g * *,,5276/10465
infarction before age nmbr ( a ),C0021308;C0021308,5277/10465
patients  no . / total no . ( % ),C0030705,5278/10465
prior biologic use,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,5279/10465
time since diagnosis of type nmbr diabetes - no . ( % ),C0040223;C3541383,5280/10465
metabolic syndrome visit nmbr low - density lipoprotein cholesterol strata,C0524620;C0524620;C0524620;C0524620;C0524620;C0524620,5281/10465
nonbiologic disease - modifying drug other than methotrexate : :,C0392747,5282/10465
moderate risk ( nmbr - nmbr ),C0205081;C0205081;C1881878;C1881878;C4049705;C4049705;C4049706;C4049706;C4085643;C4085643;C4321335;C4321335,5283/10465
csf a ( nmbr ( pm ),C3540512;C3889436,5284/10465
combination - facilitated pci ( % ),C0205195;C1947911;C3811910,5285/10465
time since psa diagnosis ( years )  mean ( sd ),C0040223;C3541383,5286/10465
deep - vein thrombosis,C0149871,5287/10465
> nmbr to < nmbr - nmbr mg / week,C0053917;C1334884,5288/10465
aspirin alone ( n / n ),C0004057,5289/10465
prior treatment — %,,5290/10465
homa - ir ( % ) b,C0022065;C0022071;C1448132,5291/10465
duration of diabetes  median ( iqr ),C0449238;C0449238;C2926735;C2926735,5292/10465
interquartile range height — cm,,5293/10465
mild thrombocytopenia ( < nmbrx nmbr / l ),C1856453,5294/10465
reversibility ( anticholinergic )  %  mean ( sd ) $,C0449261,5295/10465
number of exacerbation in the previous nmbr months  n ( % ),C0237753;C0449788,5296/10465
established cvd ( age > nmbr ),C0443211;C1272684,5297/10465
crci > nmbr - < nmbr,,5298/10465
who functional class ii / iii,C0205245;C0205245;C0205245;C0205245;C0205245;C0205245;C0205245;C0205245;C0542341;C0542341;C0542341;C0542341;C0542341;C0542341;C0542341;C0542341;C2700217;C2700217;C2700217;C2700217;C2700217;C2700217;C2700217;C2700217,5299/10465
( n nmbr nmbr ),C0369718;C0369718;C0441922;C0441922,5300/10465
cigarette smoking in the past year,C0239059;C0700219,5301/10465
candesartan,C0717550,5302/10465
previous pci / cabg  n ( % ),C0205156;C1552607,5303/10465
coronary angiography during the index hospitalization,C0085532;C0085532;C0085532;C0085532;C0085532;C1548829;C1548829;C1548829;C1548829;C1548829;C0428776,5304/10465
baseline free pcsknmbr level by median,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,5305/10465
( se]tf total - c,C0036919,5306/10465
continued thienopyridine %,C0549178,5307/10465
before pci,C4049621,5308/10465
glomerular filtration rate  nmbr ml / min / nmbr . nmbr mnmbr,C0017654;C1561549,5309/10465
elevated troponin t ( > nmbr . nmbr / xg / l ),C0205250;C0205250;C3163633;C3163633,5310/10465
rivaroxaban,C1739768,5311/10465
prior history ml or stroke,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,5312/10465
atorvastatin nmbr mg ( n = nmbr  nmbr ),C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651,5313/10465
alcohol  % with > nmbr drink / d,C0001962;C0001975,5314/10465
western europe and lebanon,C0043129,5315/10465
body mass index  kg / mnmbr ( sd ),C0005893;C0578022;C1305855,5316/10465
current smoker ( > nmbr cigarettes / day ) — no . ( % ),,5317/10465
atorvastatin nmbr mg ( n = nmbr ),C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651,5318/10465
unstable angina > nmbr mo ago,C0002965,5319/10465
amlodipine / valsartan nmbr / nmbr vs nmbr / nmbr mg,C1962523;C1962523,5320/10465
mean ( s . d . ) apob  mg / dl,C0444504;C2347634;C2348143,5321/10465
tobacco use — no . ( % ),,5322/10465
previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis,C0042487,5323/10465
dapagliflozin nmbr mg / day ( n = nmbr ),C2353951;C2353951,5324/10465
edema  peripheral,C0013604;C1717255,5325/10465
peripheral vascular disease,C0085096,5326/10465
angina ( past nmbr weeks ),C0002962,5327/10465
drug - eluting stent implanted,C1322815,5328/10465
rhabdomyolysis ( n = nmbr ),C0035410;C4552660,5329/10465
hospitalizations  n,C0019993,5330/10465
baseline heart failure severity amongthose with priorheartfailure  %,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,5331/10465
patients with end point,C0030705;C0030705,5332/10465
us resident,C1320928;C1549439;C2347958;C3835651,5333/10465
less than nmbr mm hg,C0439092;C0439092,5334/10465
p value for mra vs no mra,C1709380;C1709380;C1709380,5335/10465
insulin - treated diabetes,C0021641;C0021641;C1533581;C1533581;C1579433;C1579433;C3714501;C3714501,5336/10465
nmbrrrmnl ),,5337/10465
metastatic disease,C0027627;C2939419;C2939420,5338/10465
no stroke n = nmbr nmbr,C0038454;C4554100,5339/10465
physical component score ( pcs ),C4483112;C4483112,5340/10465
bmi > nmbr — no . ( % ) f,,5341/10465
oral contraceptive pills — no . / total no . ( % ),,5342/10465
renal function  moderate,C0232804,5343/10465
nmbr - yr risk of coronary heart disease ( % ) ^ |,C0053917;C1334884,5344/10465
llt other than statin at randomization,C2347090,5345/10465
other antihypertensive agents,C0003364,5346/10465
ace inhibitor at enrollment,C0003015;C0003015;C0003015;C4541021;C4541021;C4541021,5347/10465
b - agonists ( short - acting ) a,C0243192;C2987634,5348/10465
egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr  nmbr ( nmbr . nmbr % ),C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,5349/10465
hemoglobin anmbrc  mean ( sd )  % b,C0019046,5350/10465
duration of ulcerative colitis,C0449238;C2926735,5351/10465
positive for rheumatoid factor — no . ( % ) : t,,5352/10465
euroscore logistic  median ( nmbrth  nmbrth % ) £,,5353/10465
simvastatin nmbr mg plus fenofibrate nmbr mg ( n = nmbr /,C0074554;C0074554,5354/10465
age — mean ( sd ) ( years ),,5355/10465
cerebrovascular or peripheral arterial disease  n ( % ),C1880018,5356/10465
low feno subgroup (  nmbr . nmbr ppb ) ( n = nmbr ),C0205251;C0205251;C1550472;C1550472;C3890211;C3890211;C4048187;C4048187;C4321351;C4321351;C4522223;C4522223,5357/10465
blood - pressure medications at randomization — no . / total no . ( % ),,5358/10465
index event  n ( % ),C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,5359/10465
other or missing data,,5360/10465
number of copd exacerbations in the previous year  n ( % ),C0237753;C0449788,5361/10465
rivaroxaban plus aspirin ( n = nmbr ),C1739768,5362/10465
diuretics * *,C0012798,5363/10465
one vessel,C0205447,5364/10465
intended duration of anticoagulation,C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1283828;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357;C1551357,5365/10465
non - stenotic vessels  n ( % ),C1518422,5366/10465
gusto severe,,5367/10465
> nmbr . nmbr bpm current smoker,C0053917;C0053917;C1334884;C1334884,5368/10465
patients with any clinical event,C0030705;C0030705,5369/10465
previous diabetes,C0205156;C0205156;C1552607;C1552607,5370/10465
mmrc dyspnea scale  n ( % ),C3826977;C3826977;C3826977;C3826977;C3826977;C3826977,5371/10465
brv nmbr mg / day ( n = nmbr ),C0155502;C0155502,5372/10465
urinary tract infection,C0042029;C0262655;C4554638,5373/10465
baseline bmi > nmbr kg / mnmbr  n = nmbr  nmbr,C0168634;C1442488,5374/10465
hospitalization for heart failure,C3898876,5375/10465
any history of congestive heart failure,C0455531,5376/10465
time from study drug administration to coronary revascularization  median ( iqr )  h,C0040227;C0040227;C0206209;C2349982;C2349982,5377/10465
heart failure ( class i — iii ),,5378/10465
c - reactive protein — mg / liter * *,,5379/10465
liraglutide nmbr . nmbr mg  n = nmbr  nmbr,C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,5380/10465
placebo nmbr yr km %,C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,5381/10465
prebronchodilator fevnmbr ( % predicted normal ) t,C2599602,5382/10465
rest of world,C0035253;C1622890,5383/10465
mean age ( sd )  y,C0444504;C2347634;C2348143,5384/10465
low - molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766,5385/10465
nmbr early intervention ( n = nmbr ),C0053917;C0053917;C1334884;C1334884,5386/10465
no statin ( + / - llt ),C0360714,5387/10465
treatment satisfaction,C3476649,5388/10465
pathologic q waves — no . ( % ),,5389/10465
total periventricular wml score  mean ( sd ),C2964552,5390/10465
laboratory values at admission ( median and iqr ),C0022877;C0022877;C3244292;C3244292;C4283904;C4283904,5391/10465
corticosteroid use  nmbr n ( % ),C0239126,5392/10465
use of inhaled glucocorticoids at screening — no . ( % ),,5393/10465
comorbidity score  mean ( sd ) t,C0009488;C0009488,5394/10465
non - smokers ( at baseline ),C0337672;C4554605,5395/10465
tender joint count ( n / nmbr ),C0451530,5396/10465
total intravenous loop diuretics  mg,C0439175;C0439810,5397/10465
atorvastatin nmbr mg + ezetimibe nmbr mg ( n = nmbr ),C0286651;C0286651,5398/10465
angiotensin ll - receptor antagonist — no . ( % ),,5399/10465
mean serum glucose  mg / dl  mean = sd,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,5400/10465
gold stage ( % ) f,C0018026;C0018026;C0018026;C1304897;C1304897;C1304897,5401/10465
non - hdl - c / hdl - c,C1518422,5402/10465
multivessel ( two vessel  three vessel  or left main ),,5403/10465
body weight index ( kg / mnmbr ),C0005910;C0005910;C0005910;C0005910;C0005910;C1305866;C1305866;C1305866;C1305866;C1305866,5404/10465
triglycerides  mmoltnmbr ( gm * ),C0041004,5405/10465
procalcitonin ( ng / ml ),C0072027,5406/10465
fasting blood glucose > nmbr mg / dl,C0428568;C1261430,5407/10465
category nmbr,C0683312;C0683312;C3889287;C3889287,5408/10465
type of event,C1561488,5409/10465
quality of life,C0034380;C0518214,5410/10465
diagnosis ( y )  mean ( sd ),C0011900;C1704338;C1704656,5411/10465
persistent or permanent immobilization,C0205322;C0332996,5412/10465
modified rankin scale at screening  nmbr - nmbr,C2984908;C2984908;C2984908;C2984908;C2984908;C2984908;C2984908;C3854213;C3854213;C3854213;C3854213;C3854213;C3854213;C3854213,5413/10465
placebo nmbr . nmbr pt yrs,C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408,5414/10465
diet controlled or no,C0743195,5415/10465
body weight,C0005910;C1305866,5416/10465
cvd  mi  or stroke,C0007222,5417/10465
no . of patients / no . of events,,5418/10465
intravenous study drug administered — no . ( % ),,5419/10465
number of females n ( % ),C0237753;C0449788,5420/10465
> nmbr . nmbr % and ≤ nmbr . nmbr %,,5421/10465
treatment with statins,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,5422/10465
prior heart failure  n ( % ),C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,5423/10465
systemic symptoms,C0205373;C0205373,5424/10465
persistent or paroxysmal,C0205322;C0332996,5425/10465
metabolic syndrome w / o tnmbrdm,C0524620,5426/10465
stroke — no . / total no . ( % ),,5427/10465
nice primary prevention onlyb,C4087029,5428/10465
cv death  mi  ischemic stroke  hospitalization for hf  coronary revascularization  ua,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,5429/10465
change from pre - to,C0392747;C0392747;C0392747;C0392747;C0443172;C0443172;C0443172;C0443172;C1705241;C1705241;C1705241;C1705241;C4319952;C4319952;C4319952;C4319952,5430/10465
any lipid - lowering agent,C0086440,5431/10465
abatacept,C1619966,5432/10465
indacaterol - glycopyrronium group,C1722260;C1722260;C1722260;C1722260;C1722260;C1722260,5433/10465
warfarin naive,C0043031,5434/10465
prior or new diabetes,C0332152;C2826257,5435/10465
tender and swollen joints — mean no . : :,,5436/10465
systolic blood pressure > nmbr mm hg or diastolic blood pressure > nmbr mm hg,C0488055;C0871470;C1306620,5437/10465
rolofylline ( n = nmbr  nmbr ),C0166128,5438/10465
total stent length ( mm )  mean ± sd,,5439/10465
swollen joint count ( nmbr joints ),C0451521,5440/10465
mean nmbr sd,C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,5441/10465
previously taken methotrexate  %,,5442/10465
gusto moderate,,5443/10465
procedure * *,C0184661;C2700391;C3274430;C3539779,5444/10465
hormone replacement ! !,C0282402,5445/10465
other cardiovascular risk factors,C0850624,5446/10465
severe copdc [n z nmbr],C0205082;C4050465;C4050466,5447/10465
cardiac biomarker status !,C1999091;C2735302;C1271630;C0018787;C1522601,5448/10465
nmbr - mercaptopurine,C0053917;C1334884,5449/10465
patient presentation,C0030705,5450/10465
baseline serum k +  meq / l,C0168634;C1442488,5451/10465
other sulfonylurea 一 no . ( % ),,5452/10465
hctz * ( n = nmbr ),C0020261,5453/10465
cardiometabolic syndrome  ^n ( % ),C0039082,5454/10465
carotid artery — no . ( % ),,5455/10465
cardiac valve surgery : no ( n = nmbr ),C0018821;C0018821;C0018821;C0018821;C0524727;C0524727;C0524727;C0524727;C0018826;C0018826;C0018826;C0018826,5456/10465
other cause,C0015127;C1524003,5457/10465
beyond popliteal pedal,C0442037;C0442037,5458/10465
> nmbr cv risk factors 咐 or established atherosclerotic cv disease,,5459/10465
oral anticoagulant drugs,C0354604,5460/10465
fracture history ( predefined )  n ( % ),C0016658;C0016658;C0016658;C0016658;C0016658;C0016658,5461/10465
any coronary revascularization,C0877341,5462/10465
ex - / current smoker,C0337671;C0337671;C4555205;C4555205;C1704625;C1704625,5463/10465
vorapaxar nmbr - y,C2974521;C2974521,5464/10465
fluindione  no . ( % ),C0117899,5465/10465
current n z nmbr,C0521116;C0521116;C1705970;C1705970,5466/10465
concomitant oral corticosteroids  n ( % ) * *,C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115;C0521115,5467/10465
anaesthesia / analgesia,C0002905,5468/10465
local eosinophil count ( cells per pl ) t,C0205276;C0205276,5469/10465
age ( years )  mean ( s . d . ),C0001779,5470/10465
ethnic group ( % ),C0015031;C1879937,5471/10465
physician ' s global assessment ( vas ),C4050369,5472/10465
antihypertensive drugs,C0003364,5473/10465
median age — yr §,,5474/10465
cad and / or crvd ( % ),C1504769;C2239547;C3813548;C4284121,5475/10465
chronic obstructive lung disease,C0024117,5476/10465
exercise category ( % ),C3669314,5477/10465
prior congestive heart failure yes,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,5478/10465
secondary prevention subgroup,C0679699;C0679699,5479/10465
aspirin nmbr mg ( n = nmbr ),C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057,5480/10465
night - time awakenings / week,C0860510;C0860510,5481/10465
non - hdl - c  mean ( sd )  rng / dl,C1518422,5482/10465
laa closure ( n - nmbr ),C0185003;C1521802,5483/10465
p - value * ' ',C1709380,5484/10465
known prothrombotic genotype,C0205309,5485/10465
> nmbr concomitant medication,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,5486/10465
function subscale,C0031843;C0542341;C0700205;C1705273,5487/10465
high risk and more symptoms ( group d ),C0332167;C3272283;C4050568;C4319571,5488/10465
white ( nmbr . nmbr % ),C0007457;C0043157;C0220938,5489/10465
osteoarthritis,C0029408,5490/10465
age ( y )  median ( nmbrth to nmbrth percentiles ),C0001779,5491/10465
history of microalbuminuria — no . ( % ),,5492/10465
tender joint count ( nmbr joints )  mean ( sd ),C0451530,5493/10465
nmbr mg / day delayed - start,C0053917;C1334884,5494/10465
documented symptomatic chdb,C1301725;C1609436,5495/10465
c - reactive protein,C0006560;C1413716;C4048285,5496/10465
ejection fraction  percent ( sd ),C0489482;C2700378,5497/10465
previous pneumonia,C0205156;C1552607,5498/10465
dasnmbr - esr remission  %,C3811131;C3811131,5499/10465
budesonide — no . ( % ),,5500/10465
linagliptin  patients with events / total patients,C2746078,5501/10465
middle tg tertile,C0444598;C0549183;C1552826,5502/10465
density lipoprotein  csf =,C0178587,5503/10465
hscrp  median ( min  max )  mg / l,,5504/10465
concomitant medication after randomisation,C0521115;C0521115;C0521115,5505/10465
non - black ( n = nmbr ),C1518422;C1518422;C1518422;C1518422,5506/10465
dmard or corticosteroid,C0242708,5507/10465
non - epa number of <,C1518422;C1518422,5508/10465
hbalc tx difference vs pbo  median change from baseline ( se ) nmbr,C0041403;C0041403,5509/10465
trough fevi l,C0444506;C0444506;C0444506;C0444506,5510/10465
eq - nmbrd ( visual analog score ),C0205163;C0439185,5511/10465
antihypertensive medication  open - label  no . ( % ),C0003364,5512/10465
mer ’ s disease assessment,,5513/10465
baseline ldl - c strata  n ( ° / o ),,5514/10465
with alogliptin nmbr . nmbr mg,C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126;C1958126,5515/10465
anacetrapib ( n = nmbr ),C2604745,5516/10465
secondary dvt . ' fe,C0027627;C0027627;C0027627;C0175668;C0175668;C0175668;C0205436;C0205436;C0205436,5517/10465
with laba  n ( % ) pretreatment,,5518/10465
basal insulin analogue dose * ( coefficient,C0650607;C0650607;C0650607;C0205112;C0205112;C0205112;C0205112,5519/10465
theophyllines,C0039771,5520/10465
angina class iii or iv — no . ( % ),,5521/10465
n ( nmbryr km event rate  % ),C0369718;C0441922,5522/10465
age — year ( median ),,5523/10465
tnt and ideal ( pooled ),,5524/10465
cabg or ptca / pci,C0010055,5525/10465
ex - smoker ( n z nmbr ),C0337671;C4555205,5526/10465
event rate ( % ) of primary endpoints,C0441471;C0441471;C4019010;C4019010,5527/10465
insulin - dependent diabetes,C0011854,5528/10465
malignancy at randomization,C0006826;C1306459;C4282132,5529/10465
short - acting,C1282927;C1282927;C1282927;C1282927;C1282927;C1806781;C1806781;C1806781;C1806781;C1806781;C2350002;C2350002;C2350002;C2350002;C2350002,5530/10465
serum potassium  meq / l,C0302353;C0543465,5531/10465
rest of world n z nmbr,C0035253;C0035253;C1622890;C1622890,5532/10465
never smoked  n ( % ),C2003901,5533/10465
seizure worry,C0036572;C1959629;C4553401,5534/10465
placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408,5535/10465
rest - of - world ( n = nmbr ),C0035253;C1622890,5536/10465
no use ofdiabetes drugs — no . ( % ),,5537/10465
no estimate,C0750572,5538/10465
baseline ( n ),C0168634;C1442488,5539/10465
pci > nmbr month ago,C4049621,5540/10465
swollen joint count ( nmbr joints )  mean ( sd ),C0451521,5541/10465
> nmbr years nmbr / nmbr ( nmbr . nmbr ),C0053917;C1334884,5542/10465
time in therapeutic range before inclusion,C1554109;C1554109;C0040223;C3541383,5543/10465
initial diagnosis — no . ( % ),,5544/10465
angiotension converting enzyme - inhibitor,C0014432;C0919438;C4521603,5545/10465
xanthines,C0043318;C3541955,5546/10465
management distribution medical treatment,C0030677;C0030677;C0030677;C0030677;C0001554;C0001554;C0376636;C0376636;C1273870;C1273870;C3273539;C3273539,5547/10465
pharmaco - invasive ( n = nmbr ),C0205281;C1334278,5548/10465
estrogen - containing hormones,C0014939;C0014939;C2936882;C2936882;C4542544;C4542544,5549/10465
uac nmbr - nmbr mg / g,C0053917;C1334884,5550/10465
nmbr % < hbanmbrc < = nmbr % ( n nmbr nmbr ),C0053917;C1334884,5551/10465
mean ( s . d . ) measured ldl cholesterol,C0444504;C2347634;C2348143,5552/10465
history of hypertension — no . ( % ),,5553/10465
prior cv history  n ( % ),C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,5554/10465
time to end - of - study ivus  median ( iqr )  days,C0040227;C0040227,5555/10465
steroids ( inhaled ) a,C0038317,5556/10465
> qnmbr ( nmbr . nmbr ) - qnmbr ( nmbr . nmbr ) — number / n ( % ),,5557/10465
previous angioplasty  n ( % ),C0205156;C0205156;C1552607;C1552607,5558/10465
time since diagnosis of diabetes,C0040223;C3541383,5559/10465
uric acid tertile nmbr ( nmbr . nmbr to < nmbr . nmbr mg / dl ),C0041980;C0041980,5560/10465
major hypoglycemia,C0205082;C0205082;C0205164;C0205164;C4318856;C4318856;C4521762;C4521762,5561/10465
prosper,,5562/10465
dyspnea at rest ( nyha iv )  ( % ),C0743330,5563/10465
czech republic,C0206578,5564/10465
gusto moderate or severe bleeding,,5565/10465
baseline cdai ,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,5566/10465
% change from baseline  mean ( s . e . ),C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,5567/10465
enalapril + aliskiren ( n = nmbr ),C0014025,5568/10465
non - calcium antagonist strategy ( n = nmbr nmbr ),C1518422,5569/10465
ankle fracture,C0159877;C4552974,5570/10465
number standard care,C0237753;C0237753;C0449788;C0449788,5571/10465
digitalis  n ( % ),C0012252;C0304520,5572/10465
warfarin at last follow - up,C0043031;C0043031;C0043031;C0043031,5573/10465
pci data,C4049621;C4049621;C4049621,5574/10465
end of follow - up,C0444930;C0444930;C0444930;C0444930;C2746065;C2746065;C2746065;C2746065,5575/10465
handihaler only  n,C0205171;C1720467,5576/10465
certolizumab pegol ( n = nmbr ),C1872109,5577/10465
mean — ml / min / nmbr . nmbr mnmbr level — no . ( % ),,5578/10465
egfr via mdrd ( ml / min / nmbr . nmbrmnmbr ),C1739039;C3811844;C3812682,5579/10465
core laboratory percent stenosis,C0444669;C0444669;C0444669;C0444669;C0444669;C0444669;C0444669;C0444669;C0444669;C1167518;C1167518;C1167518;C1167518;C1167518;C1167518;C1167518;C1167518;C1167518;C1706352;C1706352;C1706352;C1706352;C1706352;C1706352;C1706352;C1706352;C1706352;C1882467;C1882467;C1882467;C1882467;C1882467;C1882467;C1882467;C1882467;C1882467;C3274653;C3274653;C3274653;C3274653;C3274653;C3274653;C3274653;C3274653;C3274653,5580/10465
native american / alaskan,C0682125;C0282204;C1515945,5581/10465
mean cdai score ( sd ),C3533236;C3533236;C3533236,5582/10465
insulin glargine vs standard care least - squares mean ( nmbr % cl ),C0907402,5583/10465
difference in ls meannmbr ( nmbr % cl ),C1705241;C1705242,5584/10465
prior diagnosis - no . ( % ),C0332132,5585/10465
moderate - dose statin,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,5586/10465
tnf - alpha ( pg / ml ),C1448177;C1456820;C1522669,5587/10465
antithrombotic drug use at time of event,C0013227;C0013227;C0013227;C0013227;C1254351;C1254351;C1254351;C1254351,5588/10465
jbs - nmbr secondary prevention onlynmbr,C0175692;C0175692;C0795841;C0795841;C1416527;C1416527,5589/10465
full cohort,C0443225;C0443225,5590/10465
c - peptide,C0006558,5591/10465
immobilization,C0020944;C4048292,5592/10465
death  mi  idr  st  or gusto moderate / severe bleeding,C0011065;C1306577;C4082313;C4552775,5593/10465
thienopyridine ( n = nmbr ),C1120149,5594/10465
nmbr - year framingham chd risk  %,C0053917;C0053917;C1334884;C1334884,5595/10465
etoricoxib,C0972314,5596/10465
previous coronary artery disease  n ( % ),C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,5597/10465
elevated cardiac markers,C0205250;C3163633,5598/10465
ifx + aza ( n = nmbr ),C0020823,5599/10465
open - label clopidogrel after completion of study drug,C1709323;C1709323;C1709323;C1709323,5600/10465
baseline low - density lipoprotein cholesterol ( mg / dl ),C0168634;C1442488,5601/10465
symptom onset to randomization,C4086878,5602/10465
stricturing,C1261287,5603/10465
insulin tx difference vs pbo  median change from baseline ( se ) nmbr,C0021641;C0021641;C1533581;C1533581;C1579433;C1579433;C3714501;C3714501,5604/10465
duration of rheumatoid arthritis ( years ),C0449238;C2926735,5605/10465
beta - blocker — no . / total no . ( % ),,5606/10465
second loading dose,C0205436;C0457385;C0565930;C1561503;C1705190,5607/10465
trochanter,C0162370,5608/10465
low perceived social support only,C0205251;C0205251;C0205251;C0205251;C0205251;C0205251;C0205251;C0205251;C1550472;C1550472;C1550472;C1550472;C1550472;C1550472;C1550472;C1550472;C3890211;C3890211;C3890211;C3890211;C3890211;C3890211;C3890211;C3890211;C4048187;C4048187;C4048187;C4048187;C4048187;C4048187;C4048187;C4048187;C4321351;C4321351;C4321351;C4321351;C4321351;C4321351;C4321351;C4321351;C4522223;C4522223;C4522223;C4522223;C4522223;C4522223;C4522223;C4522223,5609/10465
white / other,C0007457;C0043157;C0220938,5610/10465
treatment groups [n / nb ( % ) ],C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704,5611/10465
cardiovascular medication usage,C0007220,5612/10465
non - calcium antagonist strategy ( ncas ) ( events / n ),C1518422,5613/10465
simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr ),C0074554,5614/10465
baseline bmi > nmbr kg / mnmbr  n = nmbr,C0168634;C1442488,5615/10465
n / n nmbr / nmbr,C0369718;C0369718;C0441922;C0441922,5616/10465
not - japan,C1518422,5617/10465
previous cardiovascular events,C0205156;C1552607,5618/10465
trigl yeerides * ( m mol / l ),,5619/10465
total cholesterol : hdl - c ratio,C0201950;C0543421,5620/10465
proadm ( ng / ml ),,5621/10465
interact !,,5622/10465
older des ( n = nmbr ),C0580836;C0580836,5623/10465
second co - primary outcome,C0205436;C0205436;C0205436;C0457385;C0457385;C0457385;C0565930;C0565930;C0565930;C1561503;C1561503;C1561503;C1705190;C1705190;C1705190,5624/10465
pe ± dvt,,5625/10465
previous warfarin use  no . ( % ),C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,5626/10465
nice secondary prevention onlyb,C4087029,5627/10465
ankle / brachial index,C1328319;C3888326,5628/10465
non - caucasian eze / simva,C1518422;C1518422,5629/10465
use of compression stockings  no . ( % ),C1524063,5630/10465
prior angiography showing stenosis > nmbr %  n = nmbr °,,5631/10465
previous use of antiarrhythmic drugs,C0205156;C1552607,5632/10465
location  n ( % ),C0450429;C1515974;C4284930;C4284931,5633/10465
associated with ctd,C0332281;C0332281,5634/10465
clopidogrel ( n = nmbr ) n / n ( % ),C0070166,5635/10465
physical exam oedema,C0031809;C0031809,5636/10465
triglyceride ( mmol / l ) * blood pressure,C0041004,5637/10465
valproate,C0080356,5638/10465
ls - mean change from baseline ( nmbr % ci ),C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668;C0023668,5639/10465
median age ( iqr  years ),C0549183;C0876920;C2347635;C2348144;C2939193,5640/10465
cardiac medications during index hospital stay and / or discharge,C0428776;C0428776;C0428776;C0428776,5641/10465
cardiac medications during index hospitalization  %,C0428776;C0428776;C0428776;C0428776,5642/10465
no ipst ( n = nmbr  nmbr ),,5643/10465
non high dose statin ( n = nmbr  nmbr ),C1518422,5644/10465
gall bladder adverse event ( n = nmbr ),C0016976,5645/10465
elevated crp ( > ulnt )  n ( % ),C0742906,5646/10465
liraglutide,C1456408,5647/10465
type of drug - eluting stent  n ( % ),C0457591;C0332307;C1547052,5648/10465
ratio of fevnmbr to fvc,C0456603;C1547037,5649/10465
infarct localization  n ( % ),C0021308;C0021308,5650/10465
racial category *,C0034510;C0034510;C1706779;C1706779;C3669213;C3669213;C3853635;C3853635,5651/10465
inhaled jnmbr - agonist §,,5652/10465
nonwhite race — no . ( % ) ejection fraction,,5653/10465
theophylline use at screening,C0241361;C0241361;C0241361;C0241361;C0241361;C0241361;C0241361,5654/10465
history of omalizumab treatment,C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062,5655/10465
symptom onset to arrival in catheterization laboratory,C4086878;C4086878,5656/10465
omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),C1719844;C1719844,5657/10465
tnfi and other bdmardst  n ( % ),,5658/10465
atenolol strategy ( n = nmbr  nmbr ),C0004147,5659/10465
left atrial diameter : < nmbr mm ( n = nmbr ),C0225860;C0225861,5660/10465
ethnic group,C0015031;C1879937,5661/10465
baseline bmi > nmbr kg / mnmbr  n = nmbr  nmbr change from baseline to nmbr weeks,C0168634;C1442488,5662/10465
rf ( iu / ml ),C0035448;C0201660;C0748398;C1547111,5663/10465
coronary heart disease risk equivalents  n ( % ) c,C1277690;C1277690,5664/10465
medical history of hypertension,C0262926;C0262926;C0199168;C0205476,5665/10465
mepolizumab group,C0969324;C0969324;C0969324;C0969324;C0969324;C0969324,5666/10465
microalbuminuria or macroalbuminuria,C0730345,5667/10465
baseline ldl - c > nmbr mg / dl,C0168634;C1442488,5668/10465
combination therapy * *,C0009429;C0556895,5669/10465
uac > nmbr mg / g,,5670/10465
health assessment questionnaire score,C2960025,5671/10465
age at onset  y,C0206132;C3870509,5672/10465
antidiabetes drug usage [ % ( n ) ],C0242510,5673/10465
ibdq total score  mean [sd],C2964552,5674/10465
fenofibric,,5675/10465
era and pdenmbr inhibitors,C1521863;C3495919,5676/10465
allogliptin,,5677/10465
current smoker ( n = nmbr  nmbr ),C3173209;C3241966,5678/10465
weight ( kg )  mean ( s . d . ),C0005910;C0043100;C1305866;C1705104,5679/10465
previous stroke or tia ( % ),C0205156;C0205156;C1552607;C1552607,5680/10465
average of maximum common carotid cimt ( mm ),C1510992;C1510992;C1510992;C1510992;C1510992;C1510992;C1510992;C1510992;C1510992;C2825518;C2825518;C2825518;C2825518;C2825518;C2825518;C2825518;C2825518;C2825518,5681/10465
new or suspected thrombus,C0205314,5682/10465
lacosamide,C0893761,5683/10465
natalizumab ( n = nmbr ) f,C1172734,5684/10465
family history of coronary disease,C0850707,5685/10465
multivessel cad ( % ),C1504769;C2239547;C3813548;C4284121,5686/10465
long - acting bronchodilator use at screening,C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317,5687/10465
fevnmbr / fvc ratio  % ( sd ),C3714541;C3714541,5688/10465
mild impairment ( egfr nmbr - nmbr ),C2945599;C2945599,5689/10465
all randomly assigned,,5690/10465
diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949,5691/10465
diabetesduration  mean ( sd )  y,,5692/10465
median feno  ppba,C0549183;C0876920;C2347635;C2348144;C2939193,5693/10465
non - detectable / unknown,C1518422;C1518422;C1518422,5694/10465
primary enrollment diagnoses  n ( % ),C0332137;C0332137;C0332137;C0801658;C0801658;C0801658,5695/10465
low hdl - c ( for men < nmbr   mg / dl / for women < nmbr   mg / dl ),,5696/10465
mean body mass index ( sd )  kg / mnmbr,C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,5697/10465
ace inhibitor or angiotensin ii receptor,C0003015;C4541021,5698/10465
diet diet + pravastatin,C0012155;C0012159;C1519433;C2983588;C3668949,5699/10465
unspecified,C0205370;C1549663;C2983689;C4048188,5700/10465
atherosclerotic cardiovascular disease,C0004153,5701/10465
dilated cardiomyopathy,C0007193;C2984282,5702/10465
participation in phase a,C0679823;C0679823,5703/10465
region of enrollment,C0017446;C0017446;C0017446;C0205147;C0205147;C0205147,5704/10465
white race  n ( % ),C0007457;C0043157,5705/10465
after amendment,C0680532;C2346732,5706/10465
laba + ics versus indzgly lsm difference ( nmbr % cl ),C0815320;C4551720,5707/10465
number of patients > nmbr years ( % ),C2360800,5708/10465
hypoglycemia,C0020615;C4553659,5709/10465
gold stage [n ( % ) ],C0018026;C0018026;C0018026;C1304897;C1304897;C1304897,5710/10465
not treated,C1518422,5711/10465
motor subscale ( range  nmbr - nmbr ),C1513492;C1705994,5712/10465
feno + eze,,5713/10465
total group,C0439175;C0439175;C0439175;C0439175;C0439175;C0439175;C0439810;C0439810;C0439810;C0439810;C0439810;C0439810,5714/10465
asthma control test score at baseline,C2733224;C2733224,5715/10465
lipid values  mmol / l,C0023779,5716/10465
esr  nmbr - nmbr mm / hour,C3811131,5717/10465
europe and canada,C0015176,5718/10465
total mayo score $ | |,C2964552;C2964552,5719/10465
egfr  nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ),C1739039;C3811844;C3812682,5720/10465
as - needed inhalations / day,C1879745;C1879745;C1879745;C1879745;C1879745;C1879745;C1883728;C1883728;C1883728;C1883728;C1883728;C1883728,5721/10465
warfarin  no . ( % ),C0043031,5722/10465
habitual fish intake : < nmbr servings / wk ( n = nmbr ),C0205353,5723/10465
number resulting in hospital admission,C0237753;C0449788,5724/10465
infarction > nmbr days previously,C0021308,5725/10465
pasi score ( nmbr - nmbr ) t  mean ( sd ),C4528685;C4528685,5726/10465
index mi ( n - nmbr  nmbr ),C0600653;C0918012;C1552854;C1637833;C2986546,5727/10465
> nmbr % coronary stenosis,C0053917;C1334884,5728/10465
mean ( s . d . ) egfr  ml / min / nmbr . nmbr mnmbr,C0444504;C2347634;C2348143,5729/10465
triglycerides  mmol / l  mean ± sd,,5730/10465
losartan + lisinopril,C0126174,5731/10465
male  n / n ( % ),C0086582;C1706180;C1706428;C1706429,5732/10465
isolated deep - vein thrombosis,C0205409;C1548221,5733/10465
esrd or death,C0022661;C0035078;C2316810,5734/10465
tiotropium nmbr . nmbr mg,C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771,5735/10465
other major risk factors,C0205082;C0205082;C0205164;C0205164;C4318856;C4318856;C4521762;C4521762,5736/10465
csf lathosterol ( | jlg / cll ),C3540512;C3889436,5737/10465
diagnosis at presentation — no . ( % ),,5738/10465
number of concomitant csdmards  n ( % ),C0237753;C0449788,5739/10465
radiographic characteristics at baseline and randomization,C0444708,5740/10465
probability " of event %,C0033204,5741/10465
d - dimer ( ng / ml ),C0060323,5742/10465
insulin  median ( ql  qnmbr )  pmol / l,C0021641;C1533581;C1579433;C3714501,5743/10465
cerebrovascular,C1880018,5744/10465
methotrexate use at randomisation,C0025677;C0025677;C0025677,5745/10465
method of identification ofstenosis ( % ),C1301921,5746/10465
treatment of the index ml,C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0039798;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C0087111;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1522326;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1533734;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C1705169;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3538994;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704;C3887704,5747/10465
saba puffs per day at baseline,C1533107;C1533107;C1533107,5748/10465
joint space narrowing score,C1859695;C1859695,5749/10465
evolocumab nmbr mg monthly ( n = nmbr ),C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352;C3529352,5750/10465
intent - to - treatb,C0162425;C1283828;C1550453,5751/10465
ace - i or angiotensin receptor blocker,C1452534;C1452534;C4284014;C4284014,5752/10465
body mass index > nmbr — no . ( % ) f,,5753/10465
mean change  % ( se ),C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,5754/10465
prebronchodilator fevnmbr / fvc,C2599602,5755/10465
less than nmbr ml / min / nmbr . nmbrmnmbr,C0439092;C0439092,5756/10465
previous tia or stroke,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,5757/10465
non - ischaemic aetiology,C1518422;C1518422;C1518422,5758/10465
stroke n = nmbr,C0038454;C4554100,5759/10465
crp concentration > nmbr mg / l  n ( % ) \,C3890735;C3890735;C3890735;C4048285;C4048285;C4048285,5760/10465
european quality of life - nmbr dimensions - nmbr level ( eq - nmbrd ),C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C0239307;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514;C1535514,5761/10465
major clinical response,C0205082;C0205164;C4318856;C4521762,5762/10465
mean ham - d score ( nmbr % ci ),C3533236;C3533236,5763/10465
bowel function,C0011135,5764/10465
laa ostium,C0444567,5765/10465
bnp o nmbr pg / ml or nt pro - bnp o nmbr pg / ml  n ( % ),C0054015;C0054015;C1095989;C1095989;C1417808;C1417808;C2982014;C2982014,5766/10465
laa length,C1444754;C1706316,5767/10465
patient ' s preference not to take vka  only reason * *,C0376409,5768/10465
risk factors and immobility level  n ( % ),C0035648;C1553898,5769/10465
pasi score > nmbr *,C4528685;C4528685,5770/10465
cardiac history,C0018787;C0018787;C0018787;C0018787;C0018787;C0018787;C1522601;C1522601;C1522601;C1522601;C1522601;C1522601,5771/10465
drug - eluting stent  n ( % ),C1322815,5772/10465
copd — no . ( % ) medication use,,5773/10465
interquartile range,C1711350,5774/10465
acute stroke of other determined cause,C0751956;C0751956,5775/10465
severe exacerbations  itt population  n ( % ),C0205082;C4050465;C4050466,5776/10465
europe nmbr,C0015176;C0015176,5777/10465
male gender ( % ),C0086582;C1706180,5778/10465
no . of vessels,,5779/10465
n - nmbr fatty acids - placebo lsm ( nmbr % cl ),C0369718;C0369718;C0369718;C0369718;C0369718;C0369718;C0441922;C0441922;C0441922;C0441922;C0441922;C0441922,5780/10465
rheumatoid arthritis,C0003873,5781/10465
> nmbr % focal seizure frequency responders,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,5782/10465
medication within nmbr days before enrolment,C0013227;C0013227;C3244316;C3244316;C4284232;C4284232,5783/10465
sex ( male ) - no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,5784/10465
worsened,C1457868;C4084902,5785/10465
digoxin at enrollment,C0012265;C0012265;C0012265,5786/10465
prostate cancer,C0376358;C0600139;C2984325;C3541264,5787/10465
pre - bronchodilator fvc ( l ),C2599602,5788/10465
creatinine clearance,C0812399,5789/10465
no . of treated lesions,,5790/10465
cholecystectomy ( n = nmbr ),C0008320,5791/10465
# of prior non - tnfi bdmards *,,5792/10465
immunosuppressive agents only,C0021081;C0021081,5793/10465
enalapril ( n = nmbr ),C0014025,5794/10465
deep - vein thrombosis or pulmonary embolism — no . ( % ),,5795/10465
age - years  median ( iqr ),C1510829,5796/10465
total no . of patients,C0439175;C0439810,5797/10465
n - nmbr fatty acids ( n = nmbr ),C0369718;C0369718;C0441922;C0441922,5798/10465
baseline cv treatment,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,5799/10465
selena - sledai ( range u - nmbrunmbr ) t,C0451528,5800/10465
bnp > nmbr pg / ml  n = nmbr,C0054015;C1095989;C1417808;C2982014,5801/10465
ms & ng,C2349943;C3539704;C3713294,5802/10465
global assessment of disease status score,C0281858;C0281858,5803/10465
all patients ( n = nmbr ),C0030705,5804/10465
isolated impaired glucose tolerance — no .,,5805/10465
angiographic extent of disease,C0002978;C0002978,5806/10465
type of concomitant statin by daily dose - no . ( % ),C0332307;C1547052,5807/10465
postoperative nsaid or glucocorticoid use,C0032790;C0032790,5808/10465
airflow reversibility — no . ( % ) |,,5809/10465
devices,C0025080;C0220819;C0699733,5810/10465
age at enrollment ( years ),C0001779;C0001779;C0001779,5811/10465
mean ( sd ) disease duration  years,C0444504;C2347634;C2348143,5812/10465
race - white ( n = nmbr  nmbr ),C0034510;C0034510;C0034510;C1706779;C1706779;C1706779;C3853635;C3853635;C3853635,5813/10465
fluticasone furoate  n = nmbr,C1948374,5814/10465
baseline hbanmbrc  n ( % ),C0168634;C1442488,5815/10465
aldosterone antagonists ( e . g . spironolactone ),C0002007;C2757004,5816/10465
pci duration in min ( median  iqr ),C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621;C4049621,5817/10465
age > nmbr years  n ( % ),C0001779,5818/10465
active cancer — no . ( % ),,5819/10465
insulina  n ( % ),,5820/10465
skull  and facial bone fractures,C0037303;C2951888,5821/10465
nmbr - aminosalicylates {,C0053917;C1334884,5822/10465
hemorrhagic stroke,C0553692,5823/10465
immy ( without corticosteroid )  n,,5824/10465
renal function  normal - mild,C0232804,5825/10465
log rank p - value,C1708728;C1708728;C2986775;C2986775,5826/10465
prior myocardial infarction  n ( % ),C0155668,5827/10465
high - density lipoprotein,C0023821,5828/10465
antibodies to infliximab  n ( % ) * *,C3533054,5829/10465
safety : non - cabg - related bleeding,C0036043;C1705187,5830/10465
diabetes mellitus — no . ( % ),,5831/10465
mmrc grade  n ( % ),C3826977;C3826977;C3826977,5832/10465
inspiratory capacity ( l ),C0021610;C0802663,5833/10465
hf  lvd  or both,C0018488;C1313497;C1538440;C3273279,5834/10465
percent of predicted fevnmbr,C1882327,5835/10465
ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),,5836/10465
diuretics group ( n = nmbr ),C0012798;C0012798;C0012798;C0012798;C0012798;C0012798,5837/10465
prior aortocoronary bypass surgery,C0455610,5838/10465
neutrophils  nmbr / nl,C0027950,5839/10465
antiplatelet or anti - inflammatory drugs,,5840/10465
presentation of index event,C0449450;C0449450;C0449450;C0449450;C0449450;C0449450;C0449450;C0449450;C0449450;C0449450,5841/10465
statin at enrollment,C0360714;C0360714;C0360714,5842/10465
ethnicitya hispanic or latino,C0086409,5843/10465
waist circumference snmbr ( men ) or > nmbr cm ( women ),C0455829,5844/10465
baseline mssbp / msdbp  mm hg,C0168634;C1442488,5845/10465
hispanic american,C0019576,5846/10465
hba]c ( mmol / mol ),C0019016;C1825777;C3538758,5847/10465
men / women,C0025266,5848/10465
pbo ( nnmbr nmbr ),C0031962,5849/10465
creatinine clearance < nmbr ml / min ( % ),C0812399,5850/10465
total comparators ( n = nmbr ),C0439175;C0439175;C0439175;C0439810;C0439810;C0439810,5851/10465
heart rate ( b . p . m . ),C0018810,5852/10465
smoking history  n ( % ),C1519384,5853/10465
disease duration  mean yr ( sd ),C0872146,5854/10465
high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr ),C0205250;C0205250;C1299351;C1299351;C2700149;C2700149;C3887512;C3887512;C3889660;C3889660;C4321237;C4321237;C4522209;C4522209,5855/10465
hbanmbrc in patients with baseline hbanmbrc < nmbr % ( < nmbr mmol / l )  % [mmol / mol]  la  n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se ),C0030705,5856/10465
overall event rate,C0282416;C0282416;C0282416;C0282416;C1561607;C1561607;C1561607;C1561607,5857/10465
prior biologic therapeutic failures  n ( % ),C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,5858/10465
losartan plus lisinopril ( n = nmbr ),C0126174,5859/10465
us site of enrollment,C2945843;C2945843;C2945843,5860/10465
killip class lll - iv,C2697847,5861/10465
coronary artery osteochondrosis,C0205042;C0205042;C0205042,5862/10465
time from onset of pain to randomization  median ( nmbrth — nmbrth percentiles )  n,,5863/10465
subset of patients not on metformin,C1515021,5864/10465
no persistent wrf ( n = nmbr  nmbr ),C0205322;C0332996,5865/10465
clopidogrel plus aspirin % / yr,C0070166,5866/10465
percutaneous coronary revascularization,C1532338,5867/10465
plus metformin,C0332287,5868/10465
calcium - channel inhibitor,C0006685,5869/10465
uacra  mg / g  gmean = gcv,,5870/10465
cure trial,C1880198,5871/10465
ratio ( nmbr % ci ) *,C0456603;C1547037,5872/10465
baseline pre - bronchodilator fevnmbr  l,C0168634;C1442488,5873/10465
physical component summary,C0031809;C0031809;C0031809;C0031809;C0205485;C0205485;C0205485;C0205485;C1509143;C1509143;C1509143;C1509143,5874/10465
placebo croup  n / n ( % ),C0032042;C1696465;C1706408,5875/10465
smoking status at screening,C1519386;C1519386;C1519386;C1519386;C1519386;C1519386;C1519386;C0037369;C0453996;C1881674,5876/10465
copd medication taken for at least nmbr months before st,C0024117;C0024117;C0024117;C1412502;C1412502;C1412502;C3714496;C3714496;C3714496,5877/10465
st - segment - elevation myocardial infarction — no . ( % ),,5878/10465
ada nmbr / nmbr ( n[nmbr ),C1060325;C1060325;C3811629;C3811629,5879/10465
previous segmental resection — no . ( % ),,5880/10465
older patients ( aged > nmbr years ),C0580836,5881/10465
pre - operative cardiac medications *,C2347660;C2347660,5882/10465
other forms of,C0348078;C0376315,5883/10465
mean ( s . d . ) hbalc  mmol / mol,C0444504;C2347634;C2348143,5884/10465
number of ( % ) patients > nmbr years,C0237753;C0449788,5885/10465
ck - mb  ng / ml,C0010290,5886/10465
prior cardiovascular disease,C0332152;C2826257,5887/10465
current / past smoker,C3173209;C3173209;C3241966;C3241966,5888/10465
on - pump time : < l : nmbrhrs : min ( n = nmbr ),C3842462;C3842462,5889/10465
diuretic — no . ( % ) surgery,,5890/10465
< nmbr ml / min / nmbr . nmbr mnmbr  n ( % ),C0053917;C1334884,5891/10465
types of fibrinolytic agent,C0332307,5892/10465
u » c » ( mg / g ),,5893/10465
anticoagulant group ( n = nmbr ),C0003280;C0003280;C0003280;C0003280;C0003280;C0003280;C0848112;C0848112;C0848112;C0848112;C0848112;C0848112;C3536711;C3536711;C3536711;C3536711;C3536711;C3536711,5894/10465
< nmbr yr of education — no . ( % ),,5895/10465
non - colorectal cancer,C1518422;C1518422;C1518422;C1518422;C1518422,5896/10465
all bleeding,,5897/10465
hbalc ( % )  mean ( sd ) ^,,5898/10465
simvastatin nmbr mg ( n = nmbr  nmbr ),C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554,5899/10465
losmapimod ( n = nmbr ),C3272847,5900/10465
number of e,C0237753;C0449788,5901/10465
region  europe union,C0017446;C0205147,5902/10465
hydochlorothiazide ( n = nmbr ),,5903/10465
continued treatment study,C0549178,5904/10465
death / q - wave mi / idr,C0011065;C1306577;C4082313;C4552775,5905/10465
p value for trend,C1709380;C1709380,5906/10465
time since diagnosis of heart failure,C0040223;C3541383,5907/10465
mean ( s . d . ) ldl particle size  nm,C0444504;C2347634;C2348143,5908/10465
single vessel pci,C0037179;C0087136;C0205171,5909/10465
pfo with mild - to - moderate shunt and atrial septal aneurysm,C1299392;C1299392;C1299392,5910/10465
obesity ( bmi > nmbr kg / mnmbr )  %,C0028754;C1963185,5911/10465
colon only,C0009368;C0009368;C3888384;C3888384,5912/10465
lp ( a ) ( week nmbr ),C0065058;C1439335;C4553379,5913/10465
n - nmbr pufa events / patients ( % ),C0369718;C0369718;C0369718;C0369718;C0441922;C0441922;C0441922;C0441922,5914/10465
arthritis type *,C0003864;C0003864;C4552845;C4552845,5915/10465
aml / val  nmbr / nmbr mg rr = nmbr *,C0023465;C0023465;C0023467;C0023467,5916/10465
in emergency department before ambulance transfer,C0562508;C0562508;C0562508;C0562508;C0562508;C0562508,5917/10465
gold d,C0018026;C1304897,5918/10465
saaca,,5919/10465
ecg,C1623258,5920/10465
之 nmbr,,5921/10465
total ( n = nmbr ),C0439175;C0439810,5922/10465
race  %,C0034510;C1706779;C3853635,5923/10465
race — no . ( % ) |,,5924/10465
% nmbr - nmbr,C0053917;C1334884,5925/10465
severe,C0205082;C4050465;C4050466,5926/10465
pbo  n = nmbr,C0031962,5927/10465
bnp,C0054015;C1095989;C1417808;C2982014,5928/10465
male sex  ( % ),C0086582,5929/10465
females  %,C0086287,5930/10465
< nmbr mm,C0053917;C0053917;C1334884;C1334884,5931/10465
snmbr %,,5932/10465
age ' ^nmbr yrs,C0001779;C0001779,5933/10465
atvnmbr mg ( n = nmbr ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761,5934/10465
female  no . ( % ),C0043210;C0086287;C1705497;C1705498,5935/10465
> nmbr mo,C0053917;C0053917;C1334884;C1334884,5936/10465
male sex — %,,5937/10465
lvh,C0149721,5938/10465
stent,C0038257,5939/10465
acrnmbr,,5940/10465
diet,C0012155;C0012159;C1519433;C2983588;C3668949,5941/10465
cg / ld,C0043444;C1567075;C3540479,5942/10465
age ( years ) *,C0001779,5943/10465
nonsmoker,C0337672;C0425293;C4554605,5944/10465
ics use,C0815320;C4551720,5945/10465
no ( % ),C0028128;C1298908;C1518422;C1549444;C3810607,5946/10465
lips,C0023759,5947/10465
≤ nmbr,,5948/10465
ocs,,5949/10465
tg < = nmbr . nmbr,C0337445,5950/10465
vka,,5951/10465
rate * ( n ),C0871208;C1521828,5952/10465
statin ( n - nmbr ),C0360714,5953/10465
« snmbr - nmbr,,5954/10465
nmbr to < nmbrmmhg,C0053917;C1334884,5955/10465
males ( % ),C0086582,5956/10465
三 nmbr to < nmbr,,5957/10465
cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727,5958/10465
> median,C0549183;C0876920;C2347635;C2348144;C2939193,5959/10465
smoking *,C0037369;C0453996;C1881674,5960/10465
etd ( nmbr % ci ),C1180255,5961/10465
% ( se ),,5962/10465
pm  n ( % ),C0030266;C4049155,5963/10465
placebo  n ( % ),C0032042;C1696465;C1706408,5964/10465
n ( % ),C0369718;C0441922,5965/10465
> nmbr beds,C0053917;C1334884,5966/10465
number,C0237753;C0449788,5967/10465
male  no ( % ),C0086582;C1706180;C1706428;C1706429,5968/10465
> nmbr years ( n = nmbr ),C0053917;C1334884,5969/10465
femaleb,,5970/10465
< nmbr hr,C0053917;C1334884,5971/10465
> nmbr to < nmbr mm hg,C0053917;C1334884,5972/10465
deaths,C0011065;C1306577,5973/10465
uvb,C0454530;C0564461,5974/10465
asian ( n — nmbr ),,5975/10465
bms,,5976/10465
p - int,C0369773;C2603361,5977/10465
l ’ - value ’,,5978/10465
abnormal,C0205161;C2347472;C2699333,5979/10465
placebo,C0032042;C1696465;C1706408,5980/10465
crt,,5981/10465
sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,5982/10465
icd,C0021122,5983/10465
cabg,C0010055,5984/10465
≤ median,,5985/10465
nmbr - nmbr ft,C0053917;C0053917;C1334884;C1334884,5986/10465
lad,,5987/10465
nmbr yrs,C0053917;C1334884,5988/10465
hs - crp,C3890735;C4048285,5989/10465
no prior llt,C0332152;C2826257,5990/10465
range,C1514721;C2348147;C3542016,5991/10465
phi ( n = nmbr ),C1333690;C1704947;C1706536;C2975867;C4084801,5992/10465
> nmbr h,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,5993/10465
women ( n = nmbr ),C0043210,5994/10465
> nmbr - < nmbr years,C0053917;C1334884,5995/10465
men ( % ),C0025266,5996/10465
> nmbr ug / g,C0053917;C1334884,5997/10465
cdai,C0683448;C1413248;C3273706,5998/10465
age nmbr,C0001779;C0001779,5999/10465
age > = nmbr years,C0001779,6000/10465
hbalc < median,,6001/10465
arr ( nmbr % ci ),C2170357;C4084934,6002/10465
msdbp,,6003/10465
ato nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6004/10465
redon,,6005/10465
daily,C0332173,6006/10465
placebo n / n ( % ),C0032042;C1696465;C1706408,6007/10465
statin ( n = nmbr ),C0360714,6008/10465
white,C0007457;C0043157;C0220938,6009/10465
blockers,,6010/10465
idr,,6011/10465
p - valuec,C0369773;C2603361,6012/10465
nmbr ( > nmbr % ),C0053917;C1334884,6013/10465
≥ nmbr . nmbr years,,6014/10465
men  %,C0025266,6015/10465
anmbr n = nmbr,,6016/10465
p valued,C0369773;C2603361,6017/10465
study,C0557651;C2603343,6018/10465
> nmbr % nmbr,C0053917;C1334884,6019/10465
no pci,C4049621,6020/10465
igm,,6021/10465
ex - smoker,C0337671;C4555205,6022/10465
etn  no,C0014758;C0717758,6023/10465
rales  n ( % ),C0034642;C0240859,6024/10465
pooled,C1709595;C2349200;C4522255,6025/10465
total,C0439175;C0439810,6026/10465
female sex ( % ),C0086287,6027/10465
acs,C0742343;C4318612,6028/10465
nmbr . nmbr min,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6029/10465
motor,C1513492;C1705994,6030/10465
apo bt,,6031/10465
age  years,C0001779,6032/10465
asian  n ( % ),C0078988,6033/10465
age < nmbr yr,C0001779,6034/10465
hr nmbr % cl,C0053917;C1334884,6035/10465
sal nmbr mg,C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136,6036/10465
frail,C0871754,6037/10465
> lnmbr years,C0439234,6038/10465
iv ( n z nmbr ),C0022326;C4265176,6039/10465
( nmbr % cl ),C0053917;C1334884,6040/10465
* p value,C1709380,6041/10465
arb,C3888198,6042/10465
oad,,6043/10465
fema le,C0023190;C0439090;C1423767;C2697858,6044/10465
nmbr enmbr years,C0053917;C1334884,6045/10465
black ( n = nmbr ),C0005680;C0027567;C0085756;C0439541,6046/10465
missing,C1551393;C1705492;C3272743,6047/10465
single,C0037179;C0087136;C0205171,6048/10465
events ( % ),C0441471;C3541888,6049/10465
> nmbr kg,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6050/10465
s,C0565930;C2603362,6051/10465
< nmbr ng / ml,C0053917;C1334884,6052/10465
rr ( nmbr % ci ),,6053/10465
result,C1274040;C1546471;C2825142,6054/10465
age > nmbr years  %,C0001779,6055/10465
patients n,C0030705,6056/10465
placebo [n = nmbr |,C0032042;C1696465;C1706408,6057/10465
nmbr % cl,C0053917;C1334884,6058/10465
nmbr nmbr,C0053917;C1334884,6059/10465
> nmbr %,C0053917;C1334884,6060/10465
hbak < median,,6061/10465
yes,C1549445;C1705108;C1710701,6062/10465
> nmbr yr sex,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6063/10465
< nmbr,C0053917;C1334884,6064/10465
> = nmbr years,,6065/10465
nmbr mg / g,C0053917;C1334884,6066/10465
ascvd  n ( % ),C3665365,6067/10465
lgm ( n = nmbr ),,6068/10465
mace,C0349381;C0949745;C1445339,6069/10465
neither,,6070/10465
> = nmbrkg,,6071/10465
( se ) t *,C0036919,6072/10465
esrd,C0022661;C0035078;C2316810,6073/10465
placebo n[nmbr,C0032042;C1696465;C1706408,6074/10465
death,C0011065;C1306577;C4082313;C4552775,6075/10465
mtx,C0025677;C1417487,6076/10465
loop,C0445022,6077/10465
japanese,C0376247;C1556094,6078/10465
chda,,6079/10465
> nmbr lb,C0053917;C1334884,6080/10465
age ( years ) +,C0001779,6081/10465
l ( % ),C0439394;C1706495;C3642217,6082/10465
chadsnmbr,,6083/10465
( n = nmbr ),C0369718;C0441922,6084/10465
new om,C0205314;C0205314,6085/10465
nmbr % nmbr,C0053917;C1334884,6086/10465
former  n ( % ),C0205156;C0750523,6087/10465
b lack,C0332268,6088/10465
median,C0549183;C0876920;C2347635;C2348144;C2939193,6089/10465
nmbr — < nmbr years,,6090/10465
hdl - cd,C3715113;C3715113;C3715113,6091/10465
low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223,6092/10465
> nmbr ( n — nmbr ),,6093/10465
rr *,,6094/10465
iii / iv,C0439070;C0439070;C1705160;C1705160,6095/10465
pla,C0456170,6096/10465
hr,,6097/10465
placebo ,C0032042;C1696465;C1706408,6098/10465
bmi < nmbr,C0578022,6099/10465
nmbr . nmbr yrs,C0053917;C1334884,6100/10465
plac,C0048838,6101/10465
women  n ( % ),C0043210,6102/10465
other  n ( % ),,6103/10465
lmwh,C0019139;C3536766,6104/10465
mexico,C0025885,6105/10465
lcznmbr ( n = nmbr ),,6106/10465
nmbr % cit,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,6107/10465
black ( n — nmbr ),,6108/10465
< nmbr yr,C0053917;C1334884,6109/10465
< nmbr » < nmbry,,6110/10465
hba „ ( % ),,6111/10465
htn,C0020538,6112/10465
p for i,C0369773;C0369773;C2603361;C2603361,6113/10465
af,C0344434;C4049859,6114/10465
# nmbr year,C0053917;C0053917;C1334884;C1334884,6115/10465
beta - blocker use,C0001645;C0001645;C0001645,6116/10465
naive ( n = nmbr ),,6117/10465
changenmbr,,6118/10465
< lnmbr years,C0439234,6119/10465
treated,C1522326,6120/10465
tnmbrd,,6121/10465
mtx n = nmbr,C0025677;C1417487,6122/10465
white ( n — nmbr ),,6123/10465
pasi *,C4528685,6124/10465
aged ^nmbr years,C0001779;C0001779;C0001792;C0001792;C1999167;C1999167,6125/10465
> nmbr - < nmbr mmhg,C0053917;C1334884,6126/10465
copd ( n = nmbr ),C0024117;C1412502;C3714496,6127/10465
nmbrto < nmbrmmhg,,6128/10465
nmbr +,C0053917;C1334884,6129/10465
< nmbrkg,,6130/10465
< nmbr ( n — nmbr ),,6131/10465
bmi > nmbr,C0578022,6132/10465
lsm ( nmbr % ci ),,6133/10465
dd,C3538867;C3814791,6134/10465
x / n,,6135/10465
age yrs,C0001779,6136/10465
diet alone,C0012155;C0012159;C1519433;C2983588;C3668949,6137/10465
sfc ( n [nmbr ),C4521536,6138/10465
> nmbr / > nmbr mm hg,C0053917;C1334884,6139/10465
former,C0205156;C0750523,6140/10465
< nmbr ft,C0053917;C0053917;C1334884;C1334884,6141/10465
■ nmbr years,,6142/10465
nmbr - nmbr years,C0053917;C1334884,6143/10465
p value *,C1709380,6144/10465
beta blocker,C0001645,6145/10465
< nmbr years ( n = nmbr ),C0053917;C1334884,6146/10465
beta - blocker  %,C0001645,6147/10465
race ( % ) $,C0034510;C1706779;C3853635,6148/10465
fibrate,,6149/10465
primary pci,C0205225;C0439612;C0439631,6150/10465
egfr,C1739039;C3811844;C3812682,6151/10465
colon,C0009368;C3888384,6152/10465
n,C0369718;C0441922,6153/10465
arb  n ( % ),C3888198,6154/10465
aphasia,C0003537,6155/10465
heparin,C0019134;C0770546,6156/10465
white  %,C0007457;C0043157;C0220938,6157/10465
low ’,,6158/10465
f emale,C0016327,6159/10465
igm ( n = nmbr ),,6160/10465
> nmbr nmbr,C0053917;C1334884,6161/10465
< nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6162/10465
ics : yes,C0815320;C4551720,6163/10465
< nmbr ml,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6164/10465
placebo ( n = nmbr,C0032042;C1696465;C1706408,6165/10465
unprovoked,,6166/10465
strategy,C0679199,6167/10465
asia ( n = nmbr ),C0003980,6168/10465
region  %,C0017446;C0205147,6169/10465
cse] +,,6170/10465
age > nmbr y * *,C0001779,6171/10465
i % nmbr,C0021966;C0021966;C0221138;C0221138,6172/10465
mca,C0149566,6173/10465
taci ( n = nmbr ),C0666480;C1425349;C4284230,6174/10465
hdl - c,C3715113,6175/10465
medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283,6176/10465
placebo ( n = nmbr ),C0032042;C1696465;C1706408,6177/10465
women men,C0043210,6178/10465
both,,6179/10465
rca  n ( % ),,6180/10465
events,C0441471;C3541888,6181/10465
patients  n,C0030705,6182/10465
italy,C0022277,6183/10465
 nmbr,C0053917;C1334884,6184/10465
> nmbr - nmbr years,C0053917;C1334884,6185/10465
snmbr,,6186/10465
chf,C0018802,6187/10465
^ - blockers,,6188/10465
nmbr ( n = nmbr ),C0053917;C1334884,6189/10465
ale,C0678386;C2632076,6190/10465
p valuea,C0369773;C2603361,6191/10465
age ( yrs ),C0001779,6192/10465
≤ nmbr %,,6193/10465
nmbrmg,,6194/10465
placebo n = nmbr,C0032042;C1696465;C1706408,6195/10465
anemia,C0002871;C1000483;C4554633,6196/10465
eze,,6197/10465
mean *,C0444504;C2347634;C2348143,6198/10465
atv nmbr mg,C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0210243;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C0674679;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1145759;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862;C1334862,6199/10465
ef nmbr - nmbr %,C0053917;C1334884,6200/10465
open — no . ( % ),,6201/10465
oriental,C0078988;C0699027,6202/10465
\nmbr %,C1823521;C4049614,6203/10465
anakinra,C0245109,6204/10465
of patients,C0030705,6205/10465
arb  %,C3888198,6206/10465
sex  men ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,6207/10465
sedbp,,6208/10465
£ nmbr kg,,6209/10465
japan,C0022341,6210/10465
> nmbr hrs,C0053917;C1334884,6211/10465
female ( % ),C0043210;C0086287;C1705497;C1705498,6212/10465
hbak > median,,6213/10465
aspirin  n ( % ),C0004057,6214/10465
other — no . ( % ),,6215/10465
male ( n z nmbr ),C0086582;C1706180;C1706428;C1706429,6216/10465
dm absent,C0011816;C3250443,6217/10465
vora,,6218/10465
* nmbr to < nmbry,C0053917;C1334884,6219/10465
male,C0086582;C1706180;C1706428;C1706429,6220/10465
never smoking,C2003901,6221/10465
female sex — no . ( % ),,6222/10465
( gm ),C0017480;C3854019,6223/10465
st +,C0036056;C3272372,6224/10465
≥ nmbr to < nmbr %,,6225/10465
aqe inmbr,,6226/10465
n / pyr,C0369718;C0441922,6227/10465
< nmbr kg,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6228/10465
apobe,,6229/10465
age : > nmbr years,C0001779,6230/10465
crci > nmbr,,6231/10465
nmbr mg bid,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6232/10465
psa ( n = nmbr ),C3810537;C3813209,6233/10465
ldl *,,6234/10465
pin /,C0175718;C1168556;C1704584,6235/10465
overall,C0282416;C1561607,6236/10465
( se]tf,C0036919,6237/10465
oa,C0029408;C3887876,6238/10465
grade nmbr,C0441800;C0441800;C0919553;C0919553;C3244287;C3244287,6239/10465
off omt,,6240/10465
gold a,C0018026;C1304897,6241/10465
no ascvd,C3665365,6242/10465
mean bmi,C0444504;C2347634;C2348143,6243/10465
female sex,C0086287,6244/10465
serum,C0229671;C1546774;C1550100,6245/10465
othersc,,6246/10465
eze nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6247/10465
crt - p,,6248/10465
itherchdt,,6249/10465
dm present,C0011816;C0011816;C3250443;C3250443,6250/10465
non - smoker,C0337672;C0425293;C4554605,6251/10465
> = nmbr - < nmbr mmhg,,6252/10465
nmbr or nmbr days,C0053917;C1334884,6253/10465
group d,C0441838,6254/10465
age  nmbr years,C0001779,6255/10465
placebo pts / n ( % ),C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,6256/10465
= snmbr,,6257/10465
nmbr - nmbr min,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6258/10465
ii ( n = nmbr ),,6259/10465
rectum,C0034896,6260/10465
age  yrs *,C0001779,6261/10465
total *,C0439175;C0439810,6262/10465
 nmbr ( n = nmbr ),C0053917;C1334884,6263/10465
< nmbr . nmbr %,C0053917;C1334884,6264/10465
cana nmbrmg ( n = nmbr ),C1418845,6265/10465
mae,C0286540;C4085238,6266/10465
nmbr % - nmbr %,C0053917;C1334884,6267/10465
^nmbr - nmbr,C0053917;C1334884,6268/10465
on omt,,6269/10465
race — no . ( % ),,6270/10465
age : < nmbr years,C0001779,6271/10465
hdl - cy,C3715113;C3715113;C3715113,6272/10465
≥ nmbr %,,6273/10465
africa,C0001737,6274/10465
cardiac,C0018787;C1522601,6275/10465
feno nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6276/10465
lvef < nmbr %,C0428772;C0488728,6277/10465
pa,C0030428;C3541314,6278/10465
hr ( nmbr % ci ),,6279/10465
nsaid,C0003211;C3536840,6280/10465
pe,C0070939;C1880476;C4284304,6281/10465
white ( n = nmbr ),C0007457;C0043157;C0220938,6282/10465
placebo n ( % ),C0032042;C1696465;C1706408,6283/10465
egfr > nmbr,C1739039;C3811844;C3812682,6284/10465
other *,,6285/10465
> nmbr . nmbr yrs,C0053917;C1334884,6286/10465
past,C1444637;C4284302,6287/10465
< nmbr mm hg,C0053917;C1334884,6288/10465
> nmbr % to < nmbr %,C0053917;C1334884,6289/10465
known chd,C0205309;C0205309,6290/10465
sex  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,6291/10465
nnt,C1417750,6292/10465
all ( n = nmbrf ),,6293/10465
tia,C0007787;C0917805;C1054154,6294/10465
nmbr / nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6295/10465
mmse < nmbr,C0451306,6296/10465
> nmbr - nmbr kg,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6297/10465
< nmbr . nmbr bpm,C0053917;C1334884,6298/10465
placebo ( n z nmbr ),C0032042;C1696465;C1706408,6299/10465
locf ),C2825507,6300/10465
< nmbr days,C0053917;C1334884,6301/10465
erosion,C0333307;C1880549;C1959609;C3887524,6302/10465
smokers  %,C0337664,6303/10465
weight,C0005910;C0043100;C1305866;C1705104,6304/10465
iiiv,,6305/10465
( i - blocker,C0021966;C0221138,6306/10465
dasnmbr,,6307/10465
all ( n = nmbr ),,6308/10465
placebo  n = nmbr,C0032042;C1696465;C1706408,6309/10465
no htn,C0020538,6310/10465
sex  no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,6311/10465
race ( % ),C0034510;C1706779;C3853635,6312/10465
vitality,C0424589,6313/10465
us,,6314/10465
pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132,6315/10465
age — y £,,6316/10465
< nmbr week,C0053917;C0053917;C1334884;C1334884,6317/10465
hbalc  %,,6318/10465
open,C0175566,6319/10465
> nmbr y,C0053917;C1334884,6320/10465
avm ( n = nmbr ),C0003857;C0279476,6321/10465
mild,C2945599,6322/10465
ami nmbr mg,C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936;C4319936,6323/10465
nmbr mg / day,C0053917;C1334884,6324/10465
ever - smoker,C3887636,6325/10465
no . ( % ),,6326/10465
lateral,C0205093,6327/10465
placebo  n / n ( % ),C0032042;C1696465;C1706408,6328/10465
region — no . ( % ),,6329/10465
age ^nmbr,C0001779;C0001779,6330/10465
pvd,C0085096;C4521226,6331/10465
> nmbr mm hg,C0053917;C1334884,6332/10465
romania,C0035826,6333/10465
nmbr < - nmbr,C0053917;C1334884,6334/10465
< nmbr mg / dl,C0053917;C1334884,6335/10465
patients,C0030705,6336/10465
n / n ( % ),C0369718;C0441922,6337/10465
> = median,,6338/10465
> nmbr ( n = nmbr ),C0053917;C1334884,6339/10465
nmbr — nmbr years,,6340/10465
> nmbr % and < nmbr %,C0053917;C1334884,6341/10465
cancer,C0006826;C0998265;C1306459,6342/10465
macce,,6343/10465
£ nmbr to < nmbr years,,6344/10465
or nmbr % ci,,6345/10465
> i,C0021966;C0221138,6346/10465
any use,C0042153;C0457083;C1947944,6347/10465
never,C2003901,6348/10465
p - blocker,C0369773;C2603361,6349/10465
age > nmbr,C0001779,6350/10465
period i,C0439531;C0439531;C1948053;C1948053,6351/10465
nmbr to < nmbr hr,C0053917;C1334884,6352/10465
swollen,C0038999,6353/10465
rrr ( nmbr % cl ),,6354/10465
≤ nmbr . nmbr %,,6355/10465
hscrp,,6356/10465
nmbr % ci,C0053917;C0053917;C1334884;C1334884,6357/10465
second ( n = nmbr ),C0205436;C0457385;C0565930;C1561503;C1705190,6358/10465
chd death,C0280604;C0280604;C0280604;C0280604;C3542407;C3542407;C3542407;C3542407,6359/10465
pbo ( n = nmbr ),C0031962,6360/10465
mean — kg,,6361/10465
ab nmbr pg ( n = nmbr ),C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6362/10465
p +,C0369773;C2603361,6363/10465
yes *,C1549445;C1705108;C1710701,6364/10465
age,C0001779,6365/10465
ageadj,,6366/10465
aqc < nmbr,,6367/10465
rr^ ( nmbr % ci ),C4554402,6368/10465
nmbr mmhg,C0053917;C1334884,6369/10465
nmbr - nmbr mo,C0053917;C0053917;C1334884;C1334884,6370/10465
> nmbr mg / dl,C0053917;C1334884,6371/10465
age - years,C1510829,6372/10465
statin usage,C0360714,6373/10465
age nmbr y,C0001779;C0001779,6374/10465
race — no . ( % ) 卞,,6375/10465
> nmbr / day,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6376/10465
des,C0011702;C4551552,6377/10465
< median,C0549183;C0876920;C2347635;C2348144;C2939193,6378/10465
nmbr - < nmbr yrs,C0053917;C1334884,6379/10465
taiwan,C0039260,6380/10465
nmbr - nmbr yrs,C0053917;C1334884,6381/10465
some,,6382/10465
≥ nmbr years,,6383/10465
> nmbr to < nmbr years,C0053917;C1334884,6384/10465
female  no ( % ),C0043210;C0086287;C1705497;C1705498,6385/10465
cabg — no . ( % ),,6386/10465
women - no . ( % ),C0043210,6387/10465
paci,C1165245,6388/10465
anmbrc,,6389/10465
age :,C0001779,6390/10465
vldl,C0523560,6391/10465
lvef ( % ),C0428772;C0488728,6392/10465
nmbr - nmbr hr,C0053917;C1334884,6393/10465
mi,C3810814,6394/10465
ls mean,C0023668;C0023668;C0023668,6395/10465
n *,C0369718;C0441922,6396/10465
ldl,,6397/10465
risk *,C0035647;C4552904,6398/10465
present,C0150312;C0449450,6399/10465
age > nmbr y  %,C0001779,6400/10465
sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,6401/10465
bid,,6402/10465
pci,C4049621,6403/10465
statin use,C0360714;C0360714;C0360714,6404/10465
monthnmbr,,6405/10465
primary,C0205225;C0439612;C0439631,6406/10465
placebo ( n = nmbro ),C0032042;C1696465;C1706408,6407/10465
< nmbr years,C0053917;C1334884,6408/10465
niacini,,6409/10465
dm,C0011816;C3250443,6410/10465
nmbr to < nmbr yr,C0053917;C1334884,6411/10465
edge,C0205154;C2697523,6412/10465
spoke,,6413/10465
bmi < = nmbr,C0578022,6414/10465
epa ( n = nmbr ),,6415/10465
mean ( sd ),C0444504;C2347634;C2348143,6416/10465
cdmard,,6417/10465
sd,C2699239,6418/10465
nmbr mo to nmbr yr,C0053917;C0053917;C1334884;C1334884,6419/10465
pfor,C1151635,6420/10465
nmbr - < nmbr %,C0053917;C1334884,6421/10465
alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014,6422/10465
lvef,C0428772;C0488728,6423/10465
$ nmbr,C0053917;C1334884,6424/10465
apo - b,C0003593;C3252643,6425/10465
cohort,C0009247;C0599755,6426/10465
ali,,6427/10465
ace,C1452534;C4284014,6428/10465
woman,C0043210;C4281745,6429/10465
apob,C0003593;C3252643,6430/10465
nmbr to < nmbr mm hg,C0053917;C1334884,6431/10465
£ median,,6432/10465
ckd,C1561643,6433/10465
or ( nmbr % cl ),,6434/10465
af alone,C0344434;C4049859,6435/10465
region ,C0017446;C0205147,6436/10465
nsclc,C0007131,6437/10465
other ( n  % ),,6438/10465
monthly,C0332177,6439/10465
beta - blockers,C0001645,6440/10465
race  n ( % ),C0034510;C1706779;C3853635,6441/10465
australasia,C0282279;C1257882,6442/10465
fp nmbr mg,C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C0016704;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419068;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C1419906;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541238;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412;C3541412,6443/10465
mean ( se ),C0444504;C2347634;C2348143,6444/10465
iii - iv,C0439070;C0439070;C1705160;C1705160,6445/10465
nmbr or nmbr,C0053917;C1334884,6446/10465
or [nmbr % ci],,6447/10465
asian,C0078988,6448/10465
itt,,6449/10465
id ( n = nmbr ),C0009450;C0600091;C1441613,6450/10465
state,C1301808;C1442792;C3148680,6451/10465
anmbr,,6452/10465
hub,C0063034;C1414372;C1708389,6453/10465
> nmbr hr,C0053917;C1334884,6454/10465
lsm ( nmbr % cl ),,6455/10465
pci  n ( % ),C4049621,6456/10465
no . ( % ) *,,6457/10465
≥ nmbr to < nmbr years,,6458/10465
wssng,,6459/10465
f,C0016327,6460/10465
fp ( n [nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412,6461/10465
» nmbr yr,,6462/10465
mean — yr,,6463/10465
prior dm,C0332152;C0332152;C2826257;C2826257,6464/10465
pre - h,C0332152;C0332152;C0332152;C0332152;C0332152;C0740175;C0740175;C0740175;C0740175;C0740175;C2257086;C2257086;C2257086;C2257086;C2257086;C3669034;C3669034;C3669034;C3669034;C3669034,6465/10465
acid,C0001128;C0202406,6466/10465
hctz,C0020261,6467/10465
rnmbr,,6468/10465
korean,C1556095,6469/10465
placebo %,C0032042;C1696465;C1706408,6470/10465
. nmbr,C0053917;C1334884,6471/10465
age < median,C0001779,6472/10465
nste - acs,C0742343;C4318612,6473/10465
age £ nmbr,,6474/10465
w,,6475/10465
p - value *,C1709380,6476/10465
stent ( n = nmbr ),C0038257,6477/10465
> nmbrh,,6478/10465
value *,C1522609,6479/10465
sso - nmbr,C0053917;C1334884,6480/10465
id,C0009450;C0600091;C1441613,6481/10465
iorii ( n z nmbr ),,6482/10465
belgium,C0004950,6483/10465
hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193,6484/10465
use,C0042153;C0457083;C1947944,6485/10465
male sex ( % ),C0086582,6486/10465
> nmbr yrs sex :,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6487/10465
female ( n z nmbr ),C0043210;C0086287;C1705497;C1705498,6488/10465
pci ( % ),C4049621,6489/10465
or ( nmbr % ci ),,6490/10465
( e - blocker,,6491/10465
nsteacs,,6492/10465
other ',,6493/10465
bmi^,C0578022,6494/10465
smoking,C0037369;C0453996;C1881674,6495/10465
race n ( % ),C0034510;C1706779;C3853635,6496/10465
risk,C0035647;C4552904,6497/10465
homa,,6498/10465
africa *,C0001737,6499/10465
sex ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,6500/10465
jvp  ( % ),,6501/10465
rnmbr ( n = nmbr ),,6502/10465
py = nmbr ),C0030428;C3538810,6503/10465
a - blocker,,6504/10465
p blocker,C0369773;C2603361,6505/10465
hba  c ( % ),C0019016;C1825777;C3538758,6506/10465
r nmbr mg,C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358,6507/10465
female sex  n ( % ),C0086287,6508/10465
> nmbr,C0053917;C1334884,6509/10465
> nmbr to < nmbr,C0053917;C1334884,6510/10465
rales  ( % ),C0034642;C0240859,6511/10465
tion — no . ( % ),,6512/10465
p trend,C0369773;C0369773;C2603361;C2603361,6513/10465
ada  no,C1060325;C3811629,6514/10465
macce ( % ),,6515/10465
nonwhite,,6516/10465
pt,C0032743;C0699718,6517/10465
apo b *,C0003593;C3252643,6518/10465
% ( nmbr % ci ),,6519/10465
^ - blocker,,6520/10465
no betablocker use,C0001645;C0001645;C0001645,6521/10465
age  ( years ),C0001779,6522/10465
> nmbr type,C0053917;C0053917;C1334884;C1334884,6523/10465
female,C0043210;C0086287;C1705497;C1705498,6524/10465
us ( n = nmbr ),,6525/10465
tzd,,6526/10465
nmbr - < nmbr,C0053917;C1334884,6527/10465
peace ( n = nmbr ),C0680443,6528/10465
< nmbr lb,C0053917;C1334884,6529/10465
< nmbr mg / g,C0053917;C1334884,6530/10465
non - mtx,C1518422;C1518422,6531/10465
age  year,C0001779,6532/10465
py *,C0030428;C3538810,6533/10465
feno,,6534/10465
mental,C0229992,6535/10465
smokers,C0337664,6536/10465
> nmbr ft,C0053917;C0053917;C1334884;C1334884,6537/10465
women  %,C0043210,6538/10465
mssbp,,6539/10465
uac =,,6540/10465
acei,,6541/10465
usa,C0041703,6542/10465
class > nmbr,C0456387;C1518526;C1705943,6543/10465
europe ii,C0015176;C0015176,6544/10465
/ ’ - value ",,6545/10465
sabaa,,6546/10465
prior mi,C0332152;C2826257,6547/10465
no statin,C0360714,6548/10465
cv death,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,6549/10465
age > = nmbr,C0001779,6550/10465
nmbr §,,6551/10465
alone,C0205171;C0439044;C0679994,6552/10465
r,C0205090;C0684010;C2603358,6553/10465
ultra,C0728475,6554/10465
paci ( n = nmbr ),C1165245,6555/10465
age < nmbr,C0001779,6556/10465
stage nmbr,C0205390;C0205390;C1300072;C1300072;C1306673;C1306673,6557/10465
laba alone,,6558/10465
eze nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6559/10465
no prior ml,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,6560/10465
nmbr ( < nmbr % ),C0053917;C1334884,6561/10465
statin,C0360714,6562/10465
nnmbr yrs,,6563/10465
male ( n = nmbr ),C0086582;C1706180;C1706428;C1706429,6564/10465
psa,C3810537;C3813209,6565/10465
nmbr / nmbr,C0053917;C1334884,6566/10465
region - no . ( % ),C0017446;C0205147,6567/10465
placebo ( n = nmbrl ),C0032042;C1696465;C1706408,6568/10465
otherz,,6569/10465
nmbr years,C0053917;C1334884,6570/10465
nmbr yr,C0053917;C1334884,6571/10465
asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371,6572/10465
aqe < nmbr,,6573/10465
n = nmbr,C0369718;C0441922,6574/10465
fh ii,C1854107,6575/10465
overallb,,6576/10465
nitrate,C0028125;C0699857;C3848573,6577/10465
age > nmbr y,C0001779,6578/10465
black,C0005680;C0027567;C0085756;C0439541,6579/10465
new dm,C0205314;C0205314,6580/10465
< nmbr mon ( n = nmbr ),C0053917;C1334884,6581/10465
lower,C0441994;C1548802;C2003888,6582/10465
age  mean,C0001779,6583/10465
dvt,C0149871;C2926618;C3899446,6584/10465
m,C0369637;C0441923,6585/10465
black  n ( % ),C0005680;C0027567;C0085756;C0439541,6586/10465
obesity,C0028754;C1963185,6587/10465
women,C0043210,6588/10465
nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6589/10465
il - nmbr,C0020898;C0020898;C0021764;C0021764;C0022271;C0022271,6590/10465
< nmbr y ( n = nmbr ),C0053917;C1334884,6591/10465
placebo r %,C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408,6592/10465
mg / dl,C0439269,6593/10465
ml c,C0439526;C1705224;C3887665,6594/10465
tg +,C0337445,6595/10465
sotalol,C0037707,6596/10465
cdai < nmbrt,C0683448;C1413248;C3273706,6597/10465
nmbr ( nmbr % ),C0053917;C1334884,6598/10465
mmse > nmbr,C0451306,6599/10465
tg §,,6600/10465
v ( n = nmbr ),,6601/10465
= nmbr,C0053917;C1334884,6602/10465
p,C0369773;C2603361,6603/10465
race  no . ( % ),C0034510;C1706779;C3853635,6604/10465
fa nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6605/10465
none,,6606/10465
no smoking,C0037369;C0453996;C1881674,6607/10465
usa ( n = nmbr ),C0041703,6608/10465
rate *,C0871208;C1521828,6609/10465
gender,C0079399;C1522384,6610/10465
male ( n - nmbr ),C0086582;C1706180;C1706428;C1706429,6611/10465
austria,C0004348,6612/10465
$ nmbr years,C0053917;C1334884,6613/10465
fh nmbr,C0053917;C1334884,6614/10465
no ?,,6615/10465
dd ( n = nmbr ),C3538867;C3814791,6616/10465
lu / kg,C0024171;C0024171;C0024171;C0024176;C0024176;C0024176;C2697939;C2697939;C2697939,6617/10465
no ststm,,6618/10465
st -,C0036056;C3272372,6619/10465
p - valuea,C0369773;C2603361,6620/10465
yes ( n = nmbr ),C1549445;C1705108;C1710701,6621/10465
abi < nmbr . nmbr,C1328319;C3888326,6622/10465
iv,C0022326;C4265176,6623/10465
sama,C1075468,6624/10465
latvia,C0023128,6625/10465
mra,C0243032;C1609165;C3891069,6626/10465
asian *,C0078988,6627/10465
bm i < nmbr,C0006416;C0006416;C0006416;C0006416,6628/10465
age > nmbr yrs,C0001779,6629/10465
chf ( % ),C0018802,6630/10465
ef  %,,6631/10465
vi nmbr mg ( n = nmbr ),C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999;C0205999,6632/10465
< nmbr % ( n = nmbr ),C0053917;C1334884,6633/10465
hbaic ( % ),,6634/10465
tjc,,6635/10465
cvd,C0007222,6636/10465
> nmbr ml,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6637/10465
nmbr to < nmbr,C0053917;C1334884,6638/10465
obese,C0028754,6639/10465
gold  n ( % ),C0018026;C1304897,6640/10465
age $ nmbr yrs,C0001779;C0001779,6641/10465
placebo ( % ),C0032042;C1696465;C1706408,6642/10465
rr ( nmbr % cl ),,6643/10465
« nmbr - nmbr,,6644/10465
whitea,C1021495,6645/10465
age > : nmbr,C0001779,6646/10465
stroke,C0038454;C4554100,6647/10465
median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193,6648/10465
sjc,,6649/10465
< nmbr h,C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,6650/10465
pbo,C0031962,6651/10465
nmbr - nmbr yr,C0053917;C1334884,6652/10465
< nmbr %,C0053917;C1334884,6653/10465
chadsnmbr^,,6654/10465
p blockers,C0369773;C2603361,6655/10465
£ nmbr years,,6656/10465
> nmbr / week,C0053917;C0053917;C1334884;C1334884,6657/10465
nmbr - < nmbr y,C0053917;C1334884,6658/10465
non - c,C1518422,6659/10465
group a,C0441835;C4522145,6660/10465
< nmbr - nmbr,C0053917;C1334884,6661/10465
ldu - c,,6662/10465
$ nmbr ( n = nmbr ),C0053917;C1334884,6663/10465
≥ nmbr mg / dl,,6664/10465
> nmbr % ( n = nmbr ),C0053917;C1334884,6665/10465
rca,,6666/10465
age  n ( % ),C0001779,6667/10465
nyha ii,C1275491;C1275491,6668/10465
nmbr . nmbr,C0053917;C1334884,6669/10465
£ nmbr yo ( n = nmbr ),,6670/10465
ni,C0028075;C2348274;C3869926;C3869927,6671/10465
noneh,,6672/10465
» nmbry,,6673/10465
saba §,,6674/10465
cabg  n ( % ),C0010055,6675/10465
nitrates,C0028125;C0699857;C3848573,6676/10465
sita nmbr,C0053917;C1334884,6677/10465
anmbr + eznmbr,,6678/10465
male sex  %,C0086582,6679/10465
laaca,,6680/10465
> nmbr mmhg,C0053917;C1334884,6681/10465
age > nmbr yr,C0001779,6682/10465
bmi,C0578022,6683/10465
stemi ( % ),C1536220;C3538872,6684/10465
cabg ( % ),C0010055,6685/10465
european,C0239307;C1535514,6686/10465
pvalue,,6687/10465
lll - iv,C1261077;C1261077,6688/10465
bmi > = nmbr,C0578022,6689/10465
onmbr,,6690/10465
fp ( n = nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412,6691/10465
crt - d,,6692/10465
severity,C0439793;C0522510,6693/10465
normal,C0205307;C0231683;C0439166;C2347086;C4553972,6694/10465
age > nmbr yrs  %,C0001779,6695/10465
patients ( n ),C0030705,6696/10465
hr  nmbr % cl,,6697/10465
sdai < nmbr t,C3871128,6698/10465
no *,,6699/10465
age years,C1510829,6700/10465
row,C1552840;C1552846,6701/10465
beta blockers,C0001645,6702/10465
lvmi ( nmbr,,6703/10465
care,C1947933,6704/10465
egfr -,C1739039;C3811844;C3812682,6705/10465
prior om,C0332152;C0332152;C2826257;C2826257,6706/10465
n %,C0369718;C0441922,6707/10465
early ( n = nmbr ),C1279919,6708/10465
nmbr to < nmbr cells,C0053917;C1334884,6709/10465
mm hg,C0439475,6710/10465
any death,C0011065;C1306577;C4082313;C4552775,6711/10465
> nmbr < nmbr,C0053917;C1334884,6712/10465
cl nmbr %,C0596019;C0596019,6713/10465
poci ( n = nmbr ),,6714/10465
pbo n ( % ),C0031962,6715/10465
$ nmbr years ( n = nmbr ),C0053917;C1334884,6716/10465
all patients,C0030705,6717/10465
laba ',,6718/10465
< nmbr ( n = nmbr ),C0053917;C1334884,6719/10465
smoking  %,C0037369;C0453996;C1881674,6720/10465
male  %,C0086582;C1706180;C1706428;C1706429,6721/10465
level nmbr,C0441889;C0441889;C0456079;C0456079;C1547707;C1547707;C2946261;C2946261,6722/10465
placebo  n = inmbr,C0032042;C1696465;C1706408,6723/10465
< nmbr mmhg,C0053917;C1334884,6724/10465
no psa,C3810537;C3813209,6725/10465
nmbrenmbr,,6726/10465
placebo [n z nmbr],C0032042;C1696465;C1706408,6727/10465
ls mean ( se ),C0023668;C0023668;C0023668,6728/10465
prior stemi,C0332152;C0332152;C2826257;C2826257,6729/10465
betablocker use,C0001645;C0001645;C0001645,6730/10465
aml nmbr /,C0023465;C0023465;C0023467;C0023467,6731/10465
acr,C1412134;C1515941,6732/10465
\nmbr,C1823521;C4049614,6733/10465
homa > median,,6734/10465
p - blocker yes,C0369773;C0369773;C0369773;C2603361;C2603361;C2603361,6735/10465
> = nmbr mmhg,,6736/10465
no dm ( n = nmbr ),C0011816;C3250443,6737/10465
otherx,,6738/10465
age — yrf,,6739/10465
fragile,C0302113,6740/10465
no beta - blocker use,C0001645;C0001645;C0001645,6741/10465
n o,C0369718;C0441922,6742/10465
asa > nmbr mg,C0004057;C3853627,6743/10465
mra  ( % ),C0243032;C1609165;C3891069,6744/10465
india,C0021201;C2700456,6745/10465
gold nmbr,C0018026;C0018026;C1304897;C1304897,6746/10465
csf,C3540512;C3889436,6747/10465
nmbr mo,C0053917;C0053917;C1334884;C1334884,6748/10465
sites,C0205145,6749/10465
aspirin ( n = nmbr ),C0004057,6750/10465
< nmbr days ( n = nmbr ),C0053917;C1334884,6751/10465
first ( n = nmbr ),C0205435;C1279901,6752/10465
age > nmbr  y,C0001779,6753/10465
sesbp,,6754/10465
( se]t *,C0036919,6755/10465
value,C1522609,6756/10465
ics usage,C0815320;C4551720,6757/10465
> nmbr to < nmbr yr,C0053917;C1334884,6758/10465
< nmbr beds,C0053917;C1334884,6759/10465
ptca,C2936173,6760/10465
≥ nmbr bpm ( n = nmbr ),,6761/10465
no beta - blocker,C0001645,6762/10465
age < nmbr y,C0001779,6763/10465
fa nmbr mg ( « = nmbr ),,6764/10465
p value 十,,6765/10465
spinal,C0521329,6766/10465
arr,C2170357;C4084934,6767/10465
acm,C0001143;C1549040,6768/10465
age > nmbr yrs *,C0001779,6769/10465
orc ( nmbr % cl ),C1167125,6770/10465
saba,,6771/10465
in - h,C0033727;C0369286;C0441932;C0564385;C4528284,6772/10465
males,C0086582,6773/10465
female  n ( % ),C0043210;C0086287;C1705497;C1705498,6774/10465
brachial,C0445456,6775/10465
month nmbr,C0332177;C0332177;C0439231;C0439231,6776/10465
nmbryr,,6777/10465
age ( yr ),C0001779,6778/10465
italy ( n = nmbr ),C0022277,6779/10465
nmbr - nmbr,C0053917;C1334884,6780/10465
hiv,C0019682;C0019699,6781/10465
ale < nmbr,C0678386;C2632076,6782/10465
chd *  n ( % ),C0280604;C3542407,6783/10465
region,C0017446;C0205147,6784/10465
iglar,,6785/10465
arbs,C3888198,6786/10465
age in years,C1510829,6787/10465
l / ll,C0439394;C1706495;C3642217,6788/10465
> nmbr yrs,C0053917;C1334884,6789/10465
tg ’,,6790/10465
age < nmbryrs,C0001779,6791/10465
ff nmbr pg ( n = nmbr ),C4554348;C4554348;C4554348;C4554348;C4554348;C4554348,6792/10465
pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657,6793/10465
arr ( nmbr % cl ),C2170357;C4084934,6794/10465
americas,C0002454;C0596070,6795/10465
st,C0036056;C3272372,6796/10465
hctz *,C0020261,6797/10465
> nmbr . nmbr mm hg,C0053917;C1334884,6798/10465
placebo ( n - nmbr ),C0032042;C1696465;C1706408,6799/10465
gold ii,C0018026;C0018026;C1304897;C1304897,6800/10465
lama,C0999593;C1416775,6801/10465
chd,C0280604;C3542407,6802/10465
median  iqr,C0549183;C0876920;C2347635;C2348144;C2939193,6803/10465
cv death n,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,6804/10465
ldl  - c,,6805/10465
p - value,C1709380,6806/10465
edge ii,C0205154;C0205154;C2697523;C2697523,6807/10465
nmbr kg,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6808/10465
both ( % ),,6809/10465
ml,C0439526;C1705224;C3887665,6810/10465
cana nmbr mg ( n = nmbr ),C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845,6811/10465
cad,C1504769;C2239547;C3813548;C4284121,6812/10465
all,,6813/10465
age > nmbr years,C0001779,6814/10465
sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691,6815/10465
racea,,6816/10465
male sex  n ( % ),C0086582,6817/10465
others,C1955473;C3539125,6818/10465
reqion,,6819/10465
m / f,C1306057,6820/10465
cat > nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282,6821/10465
atv n ( % ),C0210243;C0674679;C1145759;C1334862,6822/10465
< nmbry,,6823/10465
> nmbr days,C0053917;C1334884,6824/10465
ebria,C1917247,6825/10465
other,,6826/10465
no pa,C0030428;C3541314,6827/10465
poland,C0032356,6828/10465
prior pci,C0332152;C2826257,6829/10465
b - blocker,,6830/10465
( n = nmbr ,C0369718;C0441922,6831/10465
abi # nmbr . nmbr,C1328319;C1328319;C3888326;C3888326,6832/10465
oradj ( nmbr % cl ),,6833/10465
labaa,,6834/10465
hr nmbr % ci,C0053917;C0053917;C1334884;C1334884,6835/10465
minor,C0026193;C0205165,6836/10465
ufh,,6837/10465
dm ( n = nmbr ),C0011816;C3250443,6838/10465
never smoked,C2003901,6839/10465
copd,C0024117;C1412502;C3714496,6840/10465
v total ( n = nmbr ),C0439175;C0439810,6841/10465
egfr < nmbr,C1739039;C3811844;C3812682,6842/10465
other !,,6843/10465
hba < median,C0019016;C1825777;C3538758,6844/10465
event ( % ),C0441471;C4019010,6845/10465
general,C0205246;C3812897;C3891294;C4521767,6846/10465
≤ nmbr ug / g,,6847/10465
rr ( nmbr % ci ) *,,6848/10465
yes ( % ),C1549445;C1705108;C1710701,6849/10465
post - mi,C0856742,6850/10465
laba,,6851/10465
 nmbr years ( n = nmbr ),C0053917;C1334884,6852/10465
sdai,C3871128,6853/10465
> nmbr mg,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6854/10465
p value,C1709380,6855/10465
stemi,C1536220;C3538872,6856/10465
< nmbr ( n z nmbr ),C0053917;C1334884,6857/10465
age > nmbr  %,C0001779,6858/10465
area,C0017446;C0205146,6859/10465
male sex — no . ( % ),,6860/10465
teaes,,6861/10465
sex — no . ( % ),,6862/10465
age  y,C0001779,6863/10465
male ( % ),C0086582;C1706180;C1706428;C1706429,6864/10465
cvd death,C0007222;C0007222;C0007222;C0007222,6865/10465
chinese,C0008120;C0152035,6866/10465
nstemi,C3537184;C4255010,6867/10465
qmi,,6868/10465
nmbr - nmbrh,C0053917;C1334884,6869/10465
apo b,C0003593;C3252643,6870/10465
> nmbr mm ( n = nmbr ),C0053917;C0053917;C1334884;C1334884,6871/10465
female sex  %,C0086287,6872/10465
all n = nmbr,C0369718;C0441922,6873/10465
abi,C1328319;C3888326,6874/10465
any statin,C0360714,6875/10465
tg > nmbr . nmbr,C0337445,6876/10465
nmbry,,6877/10465
race — no . ( % ) : c,,6878/10465
e,,6879/10465
angina,C0002962,6880/10465
ns,C0038944;C1112705;C1705982,6881/10465
age  yr,C0001779,6882/10465
oretal,,6883/10465
no smo king,C1311076;C1364142;C1423784,6884/10465
women  n ( % ) *,C0043210,6885/10465
p value c,C1709380,6886/10465
mets,C0812270;C1705694;C2939420,6887/10465
pbo ( n = nmbr ) vs,C0031962,6888/10465
race — no . ( % ) f,,6889/10465
lipid,C0023779,6890/10465
females,C0086287,6891/10465
nmbrmg ( n = nmbr ),,6892/10465
ada  yes,C1060325;C3811629,6893/10465
placebo [n = nmbr],C0032042;C1696465;C1706408,6894/10465
< nmbr mo,C0053917;C0053917;C1334884;C1334884,6895/10465
$ nmbr %,C0053917;C1334884,6896/10465
> = nmbr . nmbr,,6897/10465
< nmbr min,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6898/10465
no .,,6899/10465
hbaic — %,,6900/10465
n .,C0369718;C0441922,6901/10465
russia,C0035970,6902/10465
race *,C0034510;C1706779;C3853635,6903/10465
< nmbr hrs,C0053917;C1334884,6904/10465
hps,C0242994,6905/10465
patients ( ft ),C0030705,6906/10465
prior stent,C0332152;C2826257,6907/10465
nmbr — < nmbr,,6908/10465
all ( n = nmbr * ),,6909/10465
asa < nmbr mg,C0004057;C3853627,6910/10465
< nmbr year,C0053917;C0053917;C1334884;C1334884,6911/10465
stage nmbrb,C0205390;C1300072;C1306673,6912/10465
iv nitrates,C0022326;C4265176,6913/10465
pio nmbr,C0030800;C0030800;C2347712;C2347712,6914/10465
beta - blocker !,C0001645,6915/10465
femoral,C0015811,6916/10465
australia,C0004340,6917/10465
placeboa,,6918/10465
pint,C0560012;C3811619;C3890014;C3890556,6919/10465
hdl,C3715113,6920/10465
 nmbr / week,C0053917;C0053917;C1334884;C1334884,6921/10465
> nmbr y ( n = nmbr ),C0053917;C1334884,6922/10465
phi ( n - nmbr ),C1333690;C1704947;C1706536;C2975867;C4084801,6923/10465
iii & iv,C0439070;C1705160,6924/10465
aqe ^nmbr,C0053917;C1334884,6925/10465
region ( % ),C0017446;C0205147,6926/10465
nmbr to < nmbr kg,C0053917;C1334884,6927/10465
< nmbr y,C0053917;C1334884,6928/10465
age # nmbr yrs,C0001779;C0001779,6929/10465
placebo ( n nmbr ),C0032042;C1696465;C1706408,6930/10465
anemia ( % ),C0002871;C1000483;C4554633,6931/10465
pbo ( nnmbr ),C0031962,6932/10465
ckdc  n ( % ),,6933/10465
provoked,C1444748,6934/10465
race,C0034510;C1706779;C3853635,6935/10465
mtx ( n = nmbr ),C0025677;C1417487,6936/10465
> nmbr years,C0053917;C1334884,6937/10465
upper,C1282910,6938/10465
mean a ± sdt,,6939/10465
no prior mi,C0332152;C2826257,6940/10465
mean ± sd,,6941/10465
female ( n — nmbr ),,6942/10465
tics — no . ( % ),,6943/10465
apo a - i,C0085201;C1677784,6944/10465
ascvd,C3665365,6945/10465
glipizide,C0017642,6946/10465
years,C0439234,6947/10465
stage nmbra,C0205390;C1300072;C1306673,6948/10465
asian ( n = nmbr ),C0078988,6949/10465
ics alone,C0815320;C4551720,6950/10465
i / ii,C0021966;C0021966;C0221138;C0221138,6951/10465
%,,6952/10465
lesions,C0221198,6953/10465
total c,C0439175;C0439810,6954/10465
> nmbr mon ( n = nmbr ),C0053917;C1334884,6955/10465
nstemi ( % ),C3537184;C4255010,6956/10465
ppci ( n = nmbr ),,6957/10465
women  no . ( % ),C0043210,6958/10465
no ipst,,6959/10465
( n = ms ),C0369718;C0441922,6960/10465
uti,C0042029;C0077906;C1412376,6961/10465
obesityj,,6962/10465
asia,C0003980,6963/10465
p [int],C0369773;C2603361,6964/10465
rarely,C0522498,6965/10465
tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,6966/10465
qd,C0332173,6967/10465
age  yrs,C0001779,6968/10465
age ( year ),C0001779,6969/10465
age  years *,C0001779,6970/10465
> nmbr mm,C0053917;C0053917;C1334884;C1334884,6971/10465
europe,C0015176,6972/10465
≥ nmbr,,6973/10465
nmbr min,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,6974/10465
statins,C0360714,6975/10465
canvas,C3281223,6976/10465
niacin,C0027996;C1142562,6977/10465
study nmbr,C0557651;C0557651;C2603343;C2603343,6978/10465
graft  n ( % ),C0181074;C0332835;C1961139,6979/10465
c,,6980/10465
ipst ( n = nmbr ),,6981/10465
f * >,C0016327,6982/10465
high  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,6983/10465
ml ),C0439526;C1705224;C3887665,6984/10465
male sex 一 no . ( % ),,6985/10465
£ nmbr %,,6986/10465
no po,C0032729;C0442027,6987/10465
y es,C0013754;C0205944,6988/10465
ff - blocker,C4554348,6989/10465
no prior stemi,C0332152;C0332152;C2826257;C2826257,6990/10465
< nmbr . nmbr years,C0053917;C1334884,6991/10465
african,C0027567,6992/10465
fibrates,C1449704;C3540783,6993/10465
canada,C0006823,6994/10465
nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,6995/10465
venous,C0042449;C0348013,6996/10465
nmbr - < nmbr ( % ),C0053917;C1334884,6997/10465
total n = nmbr,C0439175;C0439810,6998/10465
mate,C0682323;C1260875,6999/10465
i,C0021966;C0221138,7000/10465
met ( n = nmbr ),C0428210;C1550543;C4317104,7001/10465
nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767,7002/10465
other chd,C0280604;C3542407,7003/10465
lda  %,C4553195,7004/10465
ics : no,C0815320;C4551720,7005/10465
aspirin,C0004057,7006/10465
age ( years ),C0001779,7007/10465
rrr,,7008/10465
nmbr - nmbr days,C0053917;C1334884,7009/10465
hr ( nmbr % cl ),,7010/10465
etn  yes,C0014758;C0717758,7011/10465
> nmbr and < nmbr %,C0053917;C1334884,7012/10465
male sex — no . ( % ) f,,7013/10465
n nmbr,C0369718;C0369718;C0441922;C0441922,7014/10465
ipst,,7015/10465
age > = nmbr yrs,C0001779,7016/10465
m being,C0369637;C0441923,7017/10465
oral,C0442027;C4521986,7018/10465
race  zz ( % ),C0034510;C1706779;C3853635,7019/10465
> nmbr - < nmbr,C0053917;C1334884,7020/10465
tgt,C1421391;C1428265;C4321338,7021/10465
sfc ( n = nmbr ),C4521536,7022/10465
prior llt,C0332152;C2826257,7023/10465
> = nmbr y,,7024/10465
p - value ",C1709380,7025/10465
non - white,C1518422;C1518422;C1518422,7026/10465
ldl - c,,7027/10465
( nmbr % ci]h,C0053917;C0053917;C1334884;C1334884,7028/10465
gold b,C0018026;C1304897,7029/10465
men  n ( % ),C0025266,7030/10465
hbalc ( % ),,7031/10465
never smoker,C0425293,7032/10465
men,C0025266,7033/10465
≥ nmbr mg / g,,7034/10465
≥ nmbr ng / ml,,7035/10465
no psa ( n = nmbr ),C3810537;C3813209,7036/10465
nmbr - i,C0053917;C0053917;C1334884;C1334884,7037/10465
low  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223,7038/10465
haq,C0102923;C0451208,7039/10465
beta - blocker,C0001645,7040/10465
urti,,7041/10465
renal,C0022646,7042/10465
lama +,C0999593;C1416775,7043/10465
( sem ),,7044/10465
primary *,C0205225;C0439612;C0439631,7045/10465
no mi,C3810814,7046/10465
age < nmbr yrs,C0001779,7047/10465
statini,,7048/10465
n_,C0369718;C0441922,7049/10465
metsyn,,7050/10465
< nmbr / < nmbr mm hg,C0053917;C1334884,7051/10465
no use,C0042153;C0457083;C1947944,7052/10465
> nmbr . nmbr %,C0053917;C1334884,7053/10465
tvr,,7054/10465
laa,,7055/10465
om nmbr /,C0028971;C0028971;C1705272;C1705272,7056/10465
arm,C0446516;C3715044;C4553528,7057/10465
r nmbr mg ( « = nmbr ),,7058/10465
female  %,C0043210;C0086287;C1705497;C1705498,7059/10465
cancer §,,7060/10465
hbalc > median,,7061/10465
men ( n = nmbr ),C0025266,7062/10465
crcl < nmbr,C1846718,7063/10465
chd  n ( % ),C0280604;C3542407,7064/10465
age — yr,,7065/10465
gold c,C0018026;C1304897,7066/10465
mean = sd,C0444504;C2347634;C2348143,7067/10465
avr,C0449217,7068/10465
epa,,7069/10465
lnmbr,,7070/10465
treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,7071/10465
< nmbr yo ( n = nmbr ),C0053917;C1334884,7072/10465
wegu,,7073/10465
hbanmbrc,,7074/10465
( se] +,C0036919,7075/10465
cards,C2930619;C3275277,7076/10465
nmbr mg / dl,C0053917;C1334884,7077/10465
hdl *,C3715113,7078/10465
year nmbr,C0439234;C0439234;C0439508;C0439508,7079/10465
p - blockers,C0369773;C2603361,7080/10465
< nmbr yrs,C0053917;C1334884,7081/10465
( se]t,C0036919,7082/10465
no prior pci,C0332152;C2826257,7083/10465
nmbr . nmbr %,C0053917;C1334884,7084/10465
diet ( n 二 nmbr ),,7085/10465
pnorpci,,7086/10465
hr ( nmbr % cl ) *,,7087/10465
iu,C0049272;C0439453;C0694756,7088/10465
^median,C0549183;C0876920;C2347635;C2348144;C2939193,7089/10465
> nmbr min,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,7090/10465
nmbr to < nmbr mo,C0053917;C1334884,7091/10465
> = nmbr yea ' s,,7092/10465
median — yr,,7093/10465
nnmbr,,7094/10465
nmbr to < nmbr years,C0053917;C1334884,7095/10465
no des,C0011702;C4551552,7096/10465
> nmbr mg / g,C0053917;C1334884,7097/10465
> nmbr . nmbr,C0053917;C1334884,7098/10465
hrqol,C4279947;C4300252,7099/10465
p values,C1709380,7100/10465
no acs,C0742343;C4318612,7101/10465
othernmbr,,7102/10465
> nmbr to nmbr years,C0053917;C1334884,7103/10465
cat < nmbr,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282,7104/10465
age > nmbr yr 十,,7105/10465
smoker,C0337664,7106/10465
oads  n ( % ),,7107/10465
paod,,7108/10465
nmbr or more,C0053917;C1334884,7109/10465
site,C0205145;C1515974;C2825164,7110/10465
> = nmbr years ( n = nmbr ),,7111/10465
ifg,C1334085;C1708411,7112/10465
cancer * *,C0006826;C0998265;C1306459,7113/10465
race — no . ( % ) ' (,,7114/10465
aged < nmbr years,C0001779;C0001792;C1999167,7115/10465
( ri = nmbr ),C0035487;C1826843,7116/10465
x / n *,,7117/10465
s £ nmbr,,7118/10465
aml,C0023465;C0023467,7119/10465
age ( years ) :,C0001779,7120/10465
htn hx,C0020538;C0020538,7121/10465
lvef > nmbr %,C0428772;C0488728,7122/10465
non - dm,C1518422;C1518422,7123/10465
group b,C4522078,7124/10465
total hip,C0439175;C0439175;C0439175;C0439175;C0439175;C0439810;C0439810;C0439810;C0439810;C0439810,7125/10465
obesity t,C0028754;C1963185,7126/10465
b,,7127/10465
no,,7128/10465
total  n = nmbr,C0439175;C0439810,7129/10465
race - no . ( % ),C0034510;C1706779;C3853635,7130/10465
< nmbrh,,7131/10465
< nmbr . nmbr,C0053917;C1334884,7132/10465
r nmbr mg ( n = nmbr ),C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0205090;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C0684010;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358;C2603358,7133/10465
ics # #,C0815320;C4551720,7134/10465
off pump,C1518543,7135/10465
china,C0008115,7136/10465
abi > nmbr . nmbr,C1328319;C3888326,7137/10465
male  n ( % ),C0086582;C1706180;C1706428;C1706429,7138/10465
female ( n = nmbr ),C0043210;C0086287;C1705497;C1705498,7139/10465
age  ya,C0001779,7140/10465
adl,C0001288;C1420005,7141/10465
ii - iv,C1710602;C1710602;C4082587;C4082587,7142/10465
any,,7143/10465
ff nmbr | ig ( n = nmbr ),C4554348;C4554348;C4554348;C4554348;C4554348;C4554348,7144/10465
crp,C3890735;C4048285,7145/10465
nste - mi,C3537184;C4255010,7146/10465
n =,C0369718;C0441922,7147/10465
korea,C0022771,7148/10465
ckd  n ( % ) t,C1561643,7149/10465
icd  n ( % ),C0021122,7150/10465
poba  n ( % ),,7151/10465
no aspirin,C0004057,7152/10465
yes  n ( % ),C1549445;C1705108;C1710701,7153/10465
placebo nmbr,C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,7154/10465
no chd,C0280604;C3542407,7155/10465
sfc,C4521536,7156/10465
asthma,C0004096;C2984299,7157/10465
[nmbr % cl],C0053917;C1334884,7158/10465
nmbr to < nmbr ( % ),C0053917;C1334884,7159/10465
lvef  %,C0428772;C0488728,7160/10465
> = nmbr,,7161/10465
ynmbr,,7162/10465
age < nmbr years,C0001779,7163/10465
n / n,C0369718;C0441922,7164/10465
racenmbr,,7165/10465
placebo ( n[nmbr ),C0032042;C1696465;C1706408,7166/10465
vdhmtss,,7167/10465
poci,,7168/10465
> nmbr . nmbr min,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,7169/10465
placebo ( n = nmbr * ),C0032042;C1696465;C1706408,7170/10465
aicd  ( % ),C0972395;C2611803;C3537205;C3546309,7171/10465
hscrp §,,7172/10465
nmbr,C0053917;C1334884,7173/10465
major,C0205082;C0205164;C4318856;C4521762,7174/10465
prior,C0332152;C2826257,7175/10465
ccb,C0006684,7176/10465
male - no . ( % ),C0086582;C1706180;C1706428;C1706429,7177/10465
b - blockers,,7178/10465
placebo ( lsm ),C0032042;C1696465;C1706408,7179/10465
median — vr,,7180/10465
ileum,C0020885,7181/10465
no ( n = nmbr ),,7182/10465
> nmbr - nmbr,C0053917;C1334884,7183/10465
no statin use,C0360714;C0360714;C0360714,7184/10465
absent,C0332197;C4285062,7185/10465
age $ nmbr years § *,,7186/10465
ics,C0815320;C4551720,7187/10465
laci,C1420705;C3273314;C4281721,7188/10465
< nmbr bpm ( n = nmbr ),C0053917;C1334884,7189/10465
% pred,C0032952;C0044955,7190/10465
prior ml,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,7191/10465
> nmbr yr,C0053917;C1334884,7192/10465
on nmbr,C0053917;C1334884,7193/10465
tg,C0337445,7194/10465
> = nmbr kg,,7195/10465
on pump,C3842462,7196/10465
tnmbrdm,,7197/10465
others  n ( % ),C1955473;C3539125,7198/10465
mean,C0444504;C2347634;C2348143,7199/10465
high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,7200/10465
hazard,C0598697,7201/10465
p valuey,C0369773;C2603361,7202/10465
cana nmbr mg,C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845;C1418845,7203/10465
age ( y ),C0001779,7204/10465
( nmbr % ci ),C0053917;C0053917;C1334884;C1334884,7205/10465
age ( yij,C0001779,7206/10465
ssi - nmbr,C0053917;C1334884,7207/10465
« = nmbr,,7208/10465
ucr,,7209/10465
tender,C0234234,7210/10465
p *,C0369773;C2603361,7211/10465
iii ( n z nmbr ),C0439070;C1705160,7212/10465
cyclo,C1172566,7213/10465
hbalc < medan,,7214/10465
non - hdl,C1518422,7215/10465
sodium,C0037473;C0597484;C3541959;C3714642,7216/10465
£ nmbr,,7217/10465
simva,,7218/10465
laci ( n = nmbr ),C1420705;C3273314;C4281721,7219/10465
puva,C0853073;C1704892,7220/10465
icsa,,7221/10465
ua,C0041580;C0042014,7222/10465
hr ( nmbr % ci ) “,,7223/10465
asa,C0004057;C3853627,7224/10465
ng,C0017887;C0028074,7225/10465
patient,C0030705,7226/10465
rr,,7227/10465
race ( % ) ) ',C0034510;C1706779;C3853635,7228/10465
> nmbr to nmbr,C0053917;C1334884,7229/10465
ii,,7230/10465
otherb,,7231/10465
ldl - cz,C0206578,7232/10465
( a blocker,,7233/10465
event,C0441471;C4019010,7234/10465
iii,C0439070;C1705160,7235/10465
^nmbr,C0053917;C1334884,7236/10465
ef < nmbr %,,7237/10465
israel,C0022271,7238/10465
glinide,C2266929,7239/10465
brazil,C0006137,7240/10465
nmbr to < nmbrkg,C0053917;C1334884,7241/10465
pasi^i,C4528685;C4528685,7242/10465
indian,C1524069,7243/10465
europe i,C0015176;C0015176,7244/10465
male sex,C0086582,7245/10465
 nmbr years,C0053917;C1334884,7246/10465
ifx ( n = nmbr ),C0020823,7247/10465
week nmbr,C0332174;C0332174;C0439230;C0439230,7248/10465
right,C0205090;C0444532,7249/10465
tg *,C0337445,7250/10465
samanmbr,,7251/10465
high *,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,7252/10465
hope ( n = nmbr ),C0392347,7253/10465
active ( n = nmbr ),C0205177;C3853793;C3888249,7254/10465
> nmbr  < nmbr,C0053917;C1334884,7255/10465
group c,C0441837,7256/10465
ex - smokers,C0337671;C4555205,7257/10465
male sex  no . ( % ),C0086582,7258/10465
with ( n = nmbr ),,7259/10465
poor,C0032854;C0542537;C2700379,7260/10465
radial,C0442038;C0920847,7261/10465
nnmbr / nnmbr,,7262/10465
ef > nmbr %,,7263/10465
stalin,,7264/10465
> = nmbr yr,,7265/10465
sfc ( n[nmbr ),C4521536,7266/10465
race  n ( % ) b,C0034510;C1706779;C3853635,7267/10465
ra,C3538806;C4048756,7268/10465
sal nmbr pg ( n = nmbr ),C0036140;C0036140;C0036140;C0036140;C0036140;C0036140;C0037494;C0037494;C0037494;C0037494;C0037494;C0037494;C0206136;C0206136;C0206136;C0206136;C0206136;C0206136,7269/10465
pci — no . ( % ),,7270/10465
hrt,C0282402,7271/10465
fp ( n[nmbr ),C0016704;C1419068;C1419906;C3541238;C3541412,7272/10465
mtss,,7273/10465
nmbre < nmbr %,,7274/10465
yes ',C1549445;C1705108;C1710701,7275/10465
ratio,C0456603;C1547037,7276/10465
sal ( n = nmbr ),C0036140;C0037494;C0206136,7277/10465
nyhaii,,7278/10465
women — no . ( % ),,7279/10465
smoking status  no . ( % ),C1519386,7280/10465
smoking status  n ( % ),C1519386,7281/10465
smoking status — no . ( % ),,7282/10465
systolic bp  mm hg,C0871470,7283/10465
systolic bp ( mm hg ),C0871470,7284/10465
diastolic ( mmhg ),C0012000,7285/10465
systolic — mm hg,,7286/10465
diastolic ( mm hg ),C0012000,7287/10465
systolic bp ( mmhg ),C0871470,7288/10465
systolic ( mm hg ),C0039155,7289/10465
diastolic bp  mm hg,C0428883,7290/10465
systolic ( mmhg ),C0039155,7291/10465
diastolic bp ( mmhg ),C0428883,7292/10465
diastolic — mm hg,,7293/10465
diastolic bp ( mm hg ),C0428883,7294/10465
dasnmbr ( esr ),,7295/10465
dasnmbr - crp §,,7296/10465
dasnmbr - hscrp,,7297/10465
dasnmbr ( crp ),,7298/10465
dasnmbr - crp,C3890735;C4048285,7299/10465
dasnmbr - esr,C3811131,7300/10465
unadjusted,C1439367,7301/10465
unadjusted hr,C1439367,7302/10465
unadjusted irr,C1439367,7303/10465
adjusted,C0456081,7304/10465
unadjusted hr .,C1439367,7305/10465
ejection fraction,C0489482;C2700378,7306/10465
lv ejection fraction,C0023128;C0023128;C0731033;C0731033;C1881413;C1881413,7307/10465
apolipoprotein anmbr ( g / l ),C0003591,7308/10465
apolipoprotein anmbr ( mg / dl ),C0003591,7309/10465
fpg  mmol / l,,7310/10465
fpg ( mmol / l ),,7311/10465
tg ( mmol / l ) c,C0337445,7312/10465
na ( mmol / l ),C0597484;C1272460;C1546968;C1879645;C4049872;C4552882,7313/10465
k ( mmol / l ),C0597277;C1708601,7314/10465
ldl ( mmol / l ),,7315/10465
bun  mmol / l,,7316/10465
tc ( mmol / l ),C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,7317/10465
tg ( mmol / l ),C0337445,7318/10465
ffa ( mmol / l ),C0015688,7319/10465
fpg  mmol / lt,,7320/10465
mdg ( mmol / l ),C0024443;C1417239;C2986643,7321/10465
ppg  mmol / l,C1418888,7322/10465
hdl ( mmol / l ),C3715113,7323/10465
mssbp  mm hg,,7324/10465
dbp ( mmhg ),C0536221;C3813197;C4281799,7325/10465
sbp ( mm hg ),C0085805,7326/10465
sbp  mmhg,C0085805,7327/10465
dbp  mm hg,C0536221;C3813197;C4281799,7328/10465
sbp ( mmhg ),C0085805,7329/10465
dbp  mmhg,C0536221;C3813197;C4281799,7330/10465
msdbp  mm hg,,7331/10465
msdbp  mm hga,,7332/10465
mssbp  mm hga,,7333/10465
sbp  mm hg,C0085805,7334/10465
dbp ( mm hg ),C0536221;C3813197;C4281799,7335/10465
map ( mmhg ),C0024779;C1706473;C4050322,7336/10465
cvd subjects,C0007222,7337/10465
all subjects,,7338/10465
mrf subjects,C0312443;C1412879,7339/10465
c - reactive protein ( mg / l ),C0006560;C1413716;C4048285,7340/10465
c - reactive protein ( mg / dl ),C0006560;C1413716;C4048285,7341/10465
c - reactive protein  mg / l,C0006560;C1413716;C4048285,7342/10465
c - reactive protein  * mg / l,C0006560;C1413716;C4048285,7343/10465
c - reactive protein ( mg / dl_ ),C0006560;C1413716;C4048285,7344/10465
body - mass index ( kg / mnmbr ) t,C0005893;C0578022;C1305855,7345/10465
body mass index - kg / mnmbrt,C0005893;C0005893;C0005893;C0578022;C0578022;C0578022;C1305855;C1305855;C1305855,7346/10465
body mass index ( kg / mnmbr ) ,C0005893;C0578022;C1305855,7347/10465
body mass index  kg / mnmbr,C0005893;C0578022;C1305855,7348/10465
body mass index ( kg / nr ),C0005893;C0578022;C1305855,7349/10465
body mass index ( kg / mnmbr ),C0005893;C0578022;C1305855,7350/10465
body - mass index ( kg / mnmbr ),C0005893;C0578022;C1305855,7351/10465
bodymass index ( kg / mnmbr ),C0005893;C0578022;C1305855,7352/10465
body mass index ( kg / mnmbr ) * ',C0005893;C0578022;C1305855,7353/10465
body mass index  * kg / mnmbr,C0005893;C0578022;C1305855,7354/10465
comorbidities  n ( % ) a,C0009488,7355/10465
comorbidites  n ( % ),,7356/10465
controls ( n = nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389,7357/10465
control ( n z nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389,7358/10465
control ( nznmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389,7359/10465
control ( n = nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389,7360/10465
control ( n - nmbr ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389,7361/10465
african - american,C0085756,7362/10465
african american,C0085756,7363/10465
african americans,C0085756,7364/10465
african america,C0085756,7365/10465
history of hypertension ( n = nmbr ),C0455527,7366/10465
no history of hypertension ( n = nmbr ),C0455527,7367/10465
egfr ( ml / min ),C1739039;C3811844;C3812682,7368/10465
egfr  ml / min,C1739039;C3811844;C3812682,7369/10465
- ics / + laba n z nmbr,C0815320;C0815320;C4551720;C4551720,7370/10465
+ ics / + laba nz nmbr,C0815320;C0815320;C4551720;C4551720,7371/10465
baseline mean ( se ),C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,7372/10465
baseline ( mean  sd ),C0168634;C1442488,7373/10465
baseline  mean ( sd ),C0168634;C1442488,7374/10465
no current smoking,C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,7375/10465
current smoker  %,C3173209;C3241966,7376/10465
current smokers,C3173209;C3241966,7377/10465
current smokers ( % ),C3173209;C3241966,7378/10465
current smoker ( % ),C3173209;C3241966,7379/10465
current smoker,C3173209;C3241966,7380/10465
current non - smoker,C0425311,7381/10465
current smoking,C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,7382/10465
current smokers  %,C3173209;C3241966,7383/10465
current smokers *,C3173209;C3241966,7384/10465
current smoking *,C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,7385/10465
current nonsmoker,C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,7386/10465
current smoker ,C3173209;C3241966,7387/10465
current smoker yes,C3173209;C3173209;C3173209;C3241966;C3241966;C3241966,7388/10465
current nonsmokers,C0521116;C0521116;C1705970;C1705970,7389/10465
prior ptca or pci,C0332152;C2826257,7390/10465
prior ptca / pci,C0332152;C2826257,7391/10465
interactior p - value,C1709380,7392/10465
interaction p - value,C1704675,7393/10465
interaction p value 中,,7394/10465
interaction p value §,,7395/10465
interaction p value,C1704675,7396/10465
duration of copd ( yr ),C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,7397/10465
duration of copd  y,C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,7398/10465
duration of copd — yr,,7399/10465
duration of copd  yr,C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,7400/10465
duration of copd  years,C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,7401/10465
duration of pd  y,C0449238;C0449238;C2926735;C2926735,7402/10465
duration of copd ,C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,7403/10465
duration of copd ( years ),C0449238;C0449238;C0449238;C2926735;C2926735;C2926735,7404/10465
multivariate p - value,C1709380,7405/10465
univariate p - value,C1709380,7406/10465
group b ( n = nmbr ),C4522078,7407/10465
group c ( n = nmbr ),C0441837,7408/10465
group a ( n = nmbr ),C0441835;C4522145,7409/10465
rage ( ng / ml ),C0034634;C3539760;C3815186,7410/10465
ltbr ( ng / ml ),C1416931,7411/10465
pigr ( ng / ml ),C1418569,7412/10465
vegfr ( ng / ml ),C1568520,7413/10465
imt ( nmbr ),C0334121;C1704614;C4318736,7414/10465
imt ( mm ),C0334121;C1704614;C4318736,7415/10465
haq - di *,C3826998;C4321476,7416/10465
haq - di,C3826998;C4321476,7417/10465
haq - di * *,C3826998;C4321476,7418/10465
non - fatal stroke,C1518422;C1518422;C1518422;C1518422,7419/10465
nonfatal stroke,C0038454;C4554100,7420/10465
antiplatelet or anticoagulant,,7421/10465
antiplatelets or anticoagulants,,7422/10465
hypercholesterolemia — no . ( % ) *,,7423/10465
hypercholesterolemia — no . ( % ),,7424/10465
hypercholesterolemia 一 no . ( % ),,7425/10465
pre - menopausal without hormone replacement,C0206158,7426/10465
post - menopausal with hormone replacement,C0019930,7427/10465
pre - menopausal with hormone replacement,C0206158,7428/10465
post - menopausal without hormone replacement,C0019930,7429/10465
bumetanide,C0006376,7430/10465
budesonide,C0054201,7431/10465
nmbr - hour madbp  mm hg,C0053917;C0053917;C1334884;C1334884,7432/10465
nmbr - hour masbp  mm hg,C0053917;C0053917;C1334884;C1334884,7433/10465
no prior heart failure,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,7434/10465
prior heart failure,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,7435/10465
prior cancer,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,7436/10465
no prior cancer,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,7437/10465
nmbr to < nmbr ( n = nmbr ),C0053917;C1334884,7438/10465
$ nmbr to  nmbr ( n = nmbr ),C0053917;C1334884,7439/10465
nmbr to < nmbr ( n z nmbr ),C0053917;C1334884,7440/10465
ace - i or arb,C1452534;C1452534;C4284014;C4284014,7441/10465
no ace - i / arb,C1452534;C1452534;C4284014;C4284014,7442/10465
ace - lorarb,C1452534;C4284014,7443/10465
ace - i / arb,C1452534;C1452534;C4284014;C4284014,7444/10465
acei or arb,,7445/10465
ace - l / arbs,C1452534;C4284014,7446/10465
aceis / arbs,C3888198,7447/10465
acei / arb,C3888198,7448/10465
triglycerides,C0041004,7449/10465
triglyceride a,C0041004,7450/10465
triglycerides *,C0041004,7451/10465
triglycerides * *,C0041004,7452/10465
triglyceride,C0041004,7453/10465
fluvastatin ( n = nmbr ),C0082608,7454/10465
simvastatin ( n = nmbr ),C0074554,7455/10465
rosuvastatin ( n = nmbr ),C0965129,7456/10465
diabetic yes,C0241863;C0241863;C0241863,7457/10465
diabetes,C0011847;C0011849,7458/10465
antidiabetic,C0935929,7459/10465
diabetesnmbr,,7460/10465
nondiabetic,,7461/10465
prediabetes  %,C0362046,7462/10465
diabetic no,C0241863,7463/10465
non - diabetic,C1518422,7464/10465
diabetes ( % ),C0011847;C0011849,7465/10465
diuretics,C0012798,7466/10465
diuretic use,C0012798;C0012798;C0012798,7467/10465
diabeticnmbr,,7468/10465
diabetesf,,7469/10465
diabetes  %,C0011847;C0011849,7470/10465
prediabeticb,,7471/10465
diureticff,,7472/10465
n o diabetes,C0369718;C0369718;C0441922;C0441922,7473/10465
diabetes *,C0011847;C0011849,7474/10465
dabetes,,7475/10465
non - diabetes,C1518422;C1518422,7476/10465
non - diabetics,C1518422,7477/10465
diabetics,C0241863,7478/10465
diuretic,C0012798,7479/10465
no diabetes,C0011847;C0011849,7480/10465
diurciic,,7481/10465
diabetic,C0241863,7482/10465
diabeticb,,7483/10465
stage nmbra : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr,C0205390;C1300072;C1306673,7484/10465
stage nmbrb : egfr > = nmbr and < nmbr ml / min per nmbr . nmbr mnmbr,C0205390;C1300072;C1306673,7485/10465
pm pef ( sd )  l / min,C0030266;C0030266;C0030266;C4049155;C4049155;C4049155,7486/10465
am pef ( sd )  l / min,,7487/10465
fevnmbr : fvc ratio,,7488/10465
fevnmbr : fvc ratio ,,7489/10465
fevnmbr / fvc ratio *,C3714541;C3714541,7490/10465
egfr  * ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,7491/10465
egfr  ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,7492/10465
egfr ( ml / min / nmbr . nmbrmnmbr ),C1739039;C3811844;C3812682,7493/10465
egfr ( ml / min / nmbr . nmbr mnmbr ),C1739039;C3811844;C3812682,7494/10465
egfr ( ml / min / nmbr . nmbr mnmbr ) §,,7495/10465
dyslipidaemiat,,7496/10465
dyslipidaemia,C0242339,7497/10465
dyslipidaemia 本,,7498/10465
dyslipidemia,C0242339,7499/10465
nmbr st < nmbr . nmbr,C0053917;C0053917;C1334884;C1334884,7500/10465
nmbr / nmbr ( nmbr ),C0053917;C1334884,7501/10465
nmbr ( nmbr  nmbr ),C0053917;C1334884,7502/10465
nmbr ( nmbr . nmbr % ),C0053917;C1334884,7503/10465
nmbr ( nmbre < nmbr % ),C0053917;C1334884,7504/10465
> nmbr - nmbr - nmbr,C0053917;C1334884,7505/10465
nmbrrd > nmbr . nmbr,,7506/10465
nmbr - nmbr . nmbr,C0053917;C1334884,7507/10465
nmbr ( nmbr . nmbr ),C0053917;C1334884,7508/10465
nmbr . nmbr % ( nmbr ),C0053917;C1334884,7509/10465
nmbr - < nmbr . nmbr,C0053917;C1334884,7510/10465
oral hypoglycemic,C0359086,7511/10465
oral hypoglycemics,C0359086,7512/10465
north america ( % ),C0028405,7513/10465
south america ( % ),C0037713,7514/10465
sitagliptin nmbr mg n = nmbr,C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750;C1565750,7515/10465
sitagliptin nmbrmg n = nmbr,C1565750,7516/10465
disease activity],C1292728,7517/10465
disease activity,C1292728,7518/10465
ease activity],C1331418;C1331418;C1331418;C1331418;C1331418;C1331418;C1331418,7519/10465
class i,C0441885;C1319793;C2698967,7520/10465
class ia,C0456387;C0456387;C0456387;C1518526;C1518526;C1518526;C1705943;C1705943;C1705943,7521/10465
class iii,C0441887;C2698969,7522/10465
class ii,C0441886;C2698968,7523/10465
class ib,C0456387;C0456387;C0456387;C1518526;C1518526;C1518526;C1705943;C1705943;C1705943,7524/10465
class ic,C0456387;C0456387;C1518526;C1518526;C1705943;C1705943,7525/10465
class iv,C0441888;C2698970,7526/10465
nt - probnp  pg / mlt,C0669479;C0754710,7527/10465
nt - probnp ( pg / ml ) h,C0669479;C0754710,7528/10465
nt - probnp ( pg / ml ),C0669479;C0754710,7529/10465
nt - probnp — pg / ml * *,,7530/10465
nt - probnp  pg / ml,C0669479;C0754710,7531/10465
drug - eluting stent,C1322815,7532/10465
drug eluting stent,C1322815,7533/10465
race : non - white,C0034510;C1706779;C3853635,7534/10465
race  nonwhite,C0034510;C1706779;C3853635,7535/10465
race - non - white,C0034510;C0034510;C0034510;C1706779;C1706779;C1706779;C3853635;C3853635;C3853635,7536/10465
race nonwhitet,C0034510;C1706779;C3853635,7537/10465
race  % nonwhite,C0034510;C1706779;C3853635,7538/10465
race  non - white,C0034510;C1706779;C3853635,7539/10465
smoking status *,C1519386,7540/10465
smokinq status,C0449438,7541/10465
smoking status,C1519386,7542/10465
nyha iii or iv,C1275491;C1275491,7543/10465
nyhaiiioriv,,7544/10465
csf cholesterol,C3540512;C3889436,7545/10465
hdl - cholesterol,C0023822;C0392885,7546/10465
vldl cholesterol,C0023826;C0523560,7547/10465
ldl cholesterolt,,7548/10465
ldl - cholesterol (,C0023824;C0202117,7549/10465
hdl cholesterol §,,7550/10465
ldl cholesterol,C0023824;C0202117,7551/10465
tolal choleslerol,,7552/10465
total cholesterol *,C0201950;C0543421,7553/10465
hdl cholesterol *,C0023822;C0392885,7554/10465
total cholesterol  %,C0201950;C0543421,7555/10465
total cholesterol,C0201950;C0543421,7556/10465
hdl choleslerol,C3715113,7557/10465
ldl choleslerol,,7558/10465
aldl cholesterol,C0008377,7559/10465
hdl cholesterol,C0023822;C0392885,7560/10465
ldl - cholesterol,C0023824;C0202117,7561/10465
medical therapy,C0418981,7562/10465
medical therapies,C0418981,7563/10465
topical therapy,C0332237;C0332237;C0332237,7564/10465
hbanmbrc ( n ),,7565/10465
> nmbr  no . ( % ),C0053917;C1334884,7566/10465
> nmbr h  n ( % ),C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,7567/10465
> nmbr days ( % ),C0053917;C1334884,7568/10465
< nmbr h  n ( % ),C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884,7569/10465
< nmbr %  n ( % ),C0053917;C1334884,7570/10465
> nmbr ( % ),C0053917;C1334884,7571/10465
anmbrc ( % ),,7572/10465
> nmbry  no . ( % ),,7573/10465
hbanmbrc  %,,7574/10465
hbanmbrc  % §,,7575/10465
> nmbr %  n ( % ),C0053917;C1334884,7576/10465
hbanmbrc ( % ),,7577/10465
> nmbr yr — no . ( % ),,7578/10465
< nmbr vr — no . ( % ),,7579/10465
$ nmbr %  n ( % ),C0053917;C1334884,7580/10465
> nmbr  n ( % ),C0053917;C1334884,7581/10465
< nmbr { % ),C0053917;C1334884,7582/10465
< nmbr y  n ( % ),C0053917;C1334884,7583/10465
^nmbr y  n ( % ),C0053917;C1334884,7584/10465
aabnmbr ( % ),,7585/10465
< nmbr yr — no . ( % ),,7586/10465
< nmbr ( % ),C0053917;C1334884,7587/10465
> = nmbr * ( % ),,7588/10465
> nmbr yr ( % ),C0053917;C1334884,7589/10465
> = nmbr ( % ),,7590/10465
> nmbr y  n ( % ),C0053917;C1334884,7591/10465
> nmbr y  no . ( % ),C0053917;C1334884,7592/10465
< nmbr days ( % ),C0053917;C1334884,7593/10465
> nmbr y . n ( % ),C0053917;C1334884,7594/10465
< nmbr  n ( % ),C0053917;C1334884,7595/10465
£ median ( nmbr ),,7596/10465
> median ( nmbr % ),C0549183;C0876920;C2347635;C2348144;C2939193,7597/10465
> median ( nmbr kg ),C0549183;C0876920;C2347635;C2348144;C2939193,7598/10465
> median ( nmbr mm ),C0549183;C0876920;C2347635;C2348144;C2939193,7599/10465
> median ( nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193,7600/10465
< median ( nmbr kg ),C0549183;C0876920;C2347635;C2348144;C2939193,7601/10465
women < nmbr years,C0043210,7602/10465
women > nmbr years,C0043210,7603/10465
diclofenac ( n = nmbr  nmbr ),C0012091,7604/10465
diclofenac ( n = nmbr nmbr ),C0012091,7605/10465
previous mi — no . ( % ),,7606/10465
previous vte — no . ( % ),,7607/10465
previous chf — no . ( % ),,7608/10465
bl h / y : bilateral,C0005918;C0005918;C0005918;C0005918;C0005918;C0006413;C0006413;C0006413;C0006413;C0006413;C1552663;C1552663;C1552663;C1552663;C1552663;C2827109;C2827109;C2827109;C2827109;C2827109,7609/10465
bl h / y : unilateral,C0005918;C0005918;C0005918;C0005918;C0005918;C0006413;C0006413;C0006413;C0006413;C0006413;C1552663;C1552663;C1552663;C1552663;C1552663;C2827109;C2827109;C2827109;C2827109;C2827109,7610/10465
diabetes status,C1317301,7611/10465
diabetic status,C0241863,7612/10465
mean ( sd ) age in years,C0444504;C2347634;C2348143,7613/10465
mean ( sd ) age  yr,C0444504;C2347634;C2348143,7614/10465
mean ( sd ) age  years,C0444504;C2347634;C2348143,7615/10465
mean ( sd ) age ( years ),C0444504;C2347634;C2348143,7616/10465
no symptoms,C0683368;C1457887,7617/10465
symptoms,C0683368;C1457887,7618/10465
age at randomization,C0001779,7619/10465
age at randomisation,C0001779,7620/10465
vadas score *,C0449820;C4050231,7621/10465
mmse score *,C0451306;C0451306,7622/10465
mean acrn,C0444504;C2347634;C2348143,7623/10465
rope score,C1563164;C1563164,7624/10465
cat score,C0007450;C0007450;C0325090;C0325090;C0524517;C0524517;C1443200;C1443200;C3665481;C3665481;C4050461;C4050461;C4284282;C4284282,7625/10465
sss score,C0037052;C0723181,7626/10465
gds score *,C0451184;C1149049;C1418244,7627/10465
mmse score,C0451306;C0451306,7628/10465
edss score,C0451246;C3887783,7629/10465
chads score,C0007928;C1413373,7630/10465
mean score,C3533236,7631/10465
mhis score,C0449820;C4050231,7632/10465
cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282,7633/10465
kccq score,C3476798,7634/10465
aqlq score,C4055434,7635/10465
accp score,C0449820;C4050231,7636/10465
baseline sbp ( mm hg ),C0168634;C1442488,7637/10465
baseline dbp ( mm hg ),C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,7638/10465
itt population,C0032659;C1257890,7639/10465
mitt population,C0032659;C1257890,7640/10465
tiotropium + placebo ( n[nmbr ),C0213771;C0213771;C0213771,7641/10465
tiotropium + placeb ( n[nmbr ),C0213771,7642/10465
myocardial infarction  n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959,7643/10465
myocardial infarction  ( % ),C0027051;C0428953;C2926063;C3810814;C4552959,7644/10465
sinusitis,C0037199;C4553555,7645/10465
synovitis,C0039103,7646/10465
no history of tia / stroke,C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062,7647/10465
history of tia or stroke,C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062,7648/10465
history of tia / stroke,C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062,7649/10465
heart rate ( beats per min ),C0018810,7650/10465
heart rate  beats / min,C0018810,7651/10465
heart rate  beats per min,C0018810,7652/10465
heart rate — beats / min,,7653/10465
heart rate ( beats / min ),C0018810,7654/10465
heart rate ( beats per minute ),C0018810,7655/10465
pga  nmbr - nmbr,C0016410;C3541266;C4050369,7656/10465
tjc  nmbr - nmbr,,7657/10465
sjc  nmbr - nmbr,,7658/10465
ptga  nmbr - nmbr,,7659/10465
region latin american,C0017446;C0205147,7660/10465
region  latin america,C0017446;C0205147,7661/10465
calcium - channel blockers,C0006684;C2757014,7662/10465
calcium channel blockers,C0006684;C2757014,7663/10465
calcium - channel blocker,C0006684;C3536851;C4521885,7664/10465
calcium channel blocker,C0006684;C3536851;C4521885,7665/10465
calcium - channel blockerf,C0006685,7666/10465
baseline median [mg / l],C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,7667/10465
baseline median  mg / dl,C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,7668/10465
baseline mean  mg / dl,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,7669/10465
baseline mean ( mg / dl],C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,7670/10465
baseline median  mg / l,C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488,7671/10465
baseline mean mtss,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,7672/10465
baseline mean 士 sd,,7673/10465
glucocorticoids,C0017710;C3540777;C3540778,7674/10465
glucocorticoid,C0017710,7675/10465
glucocorticoids *,C0017710;C3540777;C3540778,7676/10465
esr ( mm / h ),C3811131,7677/10465
esr  mm / hour,C3811131,7678/10465
esr — mm / hr,,7679/10465
esr ( mm / hour )git config --global user.name "Your Name",C3811131,7680/10465
ns cardiac cisease,C0038944;C0038944;C1112705;C1112705;C1705982;C1705982,7681/10465
cardiac disease,C0018799,7682/10465
no cardiac disease,C0018799,7683/10465
education < nmbr years,C0013621;C0013622;C0013658;C0039401,7684/10465
education > nmbr years,C0013621;C0013622;C0013658;C0039401,7685/10465
triglyceride ( mmol / l ),C0041004,7686/10465
triglyceride ( mmol / l ) t,C0041004,7687/10465
triglyceride  mmol / l,C0041004,7688/10465
triglycerides ( mmol / l ) :,C0041004,7689/10465
triglycerides ( mmol / l ),C0041004,7690/10465
triglycerides  mg / l,C0041004,7691/10465
triglycerides  mmol / l §,,7692/10465
triglycerides * ( mg / dl ),C0041004,7693/10465
triglycerides  mg / dl,C0041004,7694/10465
triglyceride ( mg / dl ) d,C0041004,7695/10465
triglycerides — mg / dl,,7696/10465
triglycerides ( mg / dl ),C0041004,7697/10465
triglycerides  mg / dl^,C0041004,7698/10465
triglycerides  mmol / l,C0041004,7699/10465
triglyceride ( mg / dl ),C0041004,7700/10465
triglycerides  mmol / lf,C0041004,7701/10465
patients without diabetesb,C0030705,7702/10465
patients with diabetesb,C0030705,7703/10465
no prior heart failure ( n = nmbr  nmbr ),C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,7704/10465
prior heart failure ( n = nmbr  nmbr ),C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,7705/10465
prior lev use,C0332152;C2826257,7706/10465
prior asa use,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,7707/10465
postmenopausal ,C0232970,7708/10465
postmenopausal,C0232970,7709/10465
premenopausal,C0279752,7710/10465
hs - crp ( mg / l ),C3890735;C4048285,7711/10465
apob  mg / dl,C0003593;C3252643,7712/10465
fpg  mg / dl,,7713/10465
bnp ( pg / ml ),C0054015;C1095989;C1417808;C2982014,7714/10465
fpg ( mg / dl ),,7715/10465
hs - crp  mg / l,C3890735;C4048285,7716/10465
bun  mg / dl,,7717/10465
crp — mg / l,,7718/10465
crp ( ng / ml ),C3890735;C4048285,7719/10465
hscrp  mg / l,,7720/10465
apob  g / l,C0003593;C3252643,7721/10465
bun ( mg / dl ),,7722/10465
tgs ( mg / dl ),C1156212;C1537574,7723/10465
hdl ( mg / dl ),C3715113,7724/10465
ppg  mg / dl,C1418888,7725/10465
bnp  pg / ml,C0054015;C1095989;C1417808;C2982014,7726/10465
apo b ( g / l ),C0003593;C3252643,7727/10465
crp ( mg / dl ),C3890735;C4048285,7728/10465
apoal  mg / dl,,7729/10465
mpo ( ng / ml ),,7730/10465
hscrp ( mg / l ),,7731/10465
hscrp  mg / dl,,7732/10465
hscrp ( mg / l ) c,,7733/10465
apo b  mg / dl,C0003593;C3252643,7734/10465
hscrp ( nmol / l ),,7735/10465
troy ( ng / ml ),C1420811;C1883402,7736/10465
apob ( mg / dl ),C0003593;C3252643,7737/10465
bnp ( pg / ml ) h,C0054015;C1095989;C1417808;C2982014,7738/10465
crp  mg / l,C3890735;C4048285,7739/10465
bnp  pg / mlt,C0054015;C1095989;C1417808;C2982014,7740/10465
triglycerides nmbr  d third,C0041004;C0041004,7741/10465
triglycerides nmbrst third,C0041004,7742/10465
triglycerides nmbrnd third,C0041004,7743/10465
no multivessel disease,C0012634,7744/10465
multivessel disease,C0012634,7745/10465
fastng plasma glucose < median,C0202042;C0455280,7746/10465
fascng plasma glucose a medan,C0202042;C0455280,7747/10465
fasting plasma glucose < median,C0015663;C0015663,7748/10465
caucasian  %,C0007457;C0043157,7749/10465
caucasian ( % ),C0007457;C0043157,7750/10465
caucasiana ( % ),,7751/10465
concomitant cardiovascular therapies — no . ( % ),,7752/10465
concomitant cardiovascular therapy — no . ( % ),,7753/10465
dissatisfied with / stopped $ nmbr prior systemic therapies because of side effects,C0870433;C0870433;C0870433;C0870433;C0870433;C0870433;C4085546;C4085546;C4085546;C4085546;C4085546;C4085546,7754/10465
dissatisfied with / stopped $ nmbr prior systemic therapy because of side effects,C0870433;C0870433;C0870433;C0870433;C0870433;C0870433;C4085546;C4085546;C4085546;C4085546;C4085546;C4085546,7755/10465
linagliptin ( n z nmbr ),C2746078,7756/10465
vildagliptin ( n = nmbr ),C1570906,7757/10465
linagliptin ( n = nmbr ),C2746078,7758/10465
sitagliptin ( n = nmbr ),C1565750,7759/10465
smoking — current,,7760/10465
smoking  % current,C0037369;C0453996;C1881674,7761/10465
current smoking — no . ( % ),,7762/10465
current smoking  n ( % ),C0521116;C0521116;C0521116;C1705970;C1705970;C1705970,7763/10465
current smoker 一 no . ( % ),,7764/10465
current smokers  n ( % ),C3173209;C3241966,7765/10465
current smoker — no . ( % ),,7766/10465
current smoker  n ( % ),C3173209;C3241966,7767/10465
current smoker  no ( % ),C3173209;C3241966,7768/10465
without tnmbrdm n = nmbr,,7769/10465
with tnmbrdm n = nmbr,,7770/10465
val / hctz ( n = nmbr ),C0042285;C0523975,7771/10465
v / hctz ( n = nmbr ),C0020261,7772/10465
aml / hctz ( n = nmbr ),C0023465;C0023467,7773/10465
ind / gly,C4049864;C4049864,7774/10465
indzgly,,7775/10465
gdf - nmbr ( ng / ml ),C1418244;C1418244,7776/10465
mmp - nmbr ( ng / ml ),C0623362;C0623362;C0919336;C0919336,7777/10465
st - nmbr ( ng / ml ),C0036056;C0036056;C3272372;C3272372,7778/10465
mmp - nmbr ( ng / ml ) *,C0623362;C0623362;C0919336;C0919336,7779/10465
il - nmbr ( pg / ml ),C0020898;C0020898;C0021764;C0021764;C0022271;C0022271,7780/10465
diabetes  n ( % ),C0011847;C0011849,7781/10465
diabetes — no . ( % ),,7782/10465
diabetes  no . ( % ),C0011847;C0011849,7783/10465
diabetes  * n ( % ),C0011847;C0011849,7784/10465
prediabetes  n ( % ),C0362046,7785/10465
unstable angina — no . ( % ),,7786/10465
stable angina — no . ( % ),,7787/10465
anmbrc < nmbr . nmbr % ( median ),,7788/10465
anmbr = nmbr . nmbr % ( median ),,7789/10465
hazard ratio ( nmbr % cl ),C2985465,7790/10465
hazard ratio ( nmbr % ci ) *,C2985465,7791/10465
hazard ratio ( nmbr % ci ),C2985465,7792/10465
hazard ratio * ( nmbr % ci ),C2985465,7793/10465
hazard ratiof ( nmbr % ci ),C0598697,7794/10465
lipid - lowering agent §,,7795/10465
lipid - lowering agents,C0086440,7796/10465
lipid - lowering agent,C0086440,7797/10465
zotarolimus,C1700035,7798/10465
zotarolimust,,7799/10465
pci orcabg,C4049621,7800/10465
prior cabg,C0332152;C2826257,7801/10465
no prior cabg,C0332152;C2826257,7802/10465
pnorcabg,,7803/10465
diastolic blood pressure  mm hg  median ( range ),C0428883;C1305849,7804/10465
systolic blood pressure  mm hg  median ( range ),C0488055;C0871470;C1306620,7805/10465
very severe,C3641272;C4050419,7806/10465
more severe^,C0205172;C0205172;C0205172,7807/10465
less severe,C0439092;C0439092;C0439092;C0547044;C0547044;C0547044,7808/10465
more severe,C0205172;C0205172;C0205172,7809/10465
cholesterol ( mg / dl ),C0008377,7810/10465
cholesterol — mg / dl,,7811/10465
treatment difference ( nmbr % cl ),C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,7812/10465
treatment difference ( nmbr % ci ),C0039798;C0039798;C0087111;C0087111;C1522326;C1522326;C1533734;C1533734;C1705169;C1705169;C3538994;C3538994;C3887704;C3887704,7813/10465
insulin,C0021641;C1533581;C1579433;C3714501,7814/10465
insulina,,7815/10465
> median ( nmbr ) — number / n ( % ),,7816/10465
< median ( nmbr ) — number / n ( % ),,7817/10465
baseline mssbp ( mmhg )  mean ± sd,,7818/10465
baseline msdbp ( mmhg )  mean ± sd,,7819/10465
age range ( years ),C0001779;C0001779;C0001779,7820/10465
age range  years,C0001779;C0001779;C0001779,7821/10465
inflammation,C0021368,7822/10465
inflammatory,C0333348,7823/10465
hispanic or latino,C0086409,7824/10465
hispanic / latino,C0086409,7825/10465
< nmbr cells / pl,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,7826/10465
> nmbr cells / pl,C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884,7827/10465
american indian,C0002460,7828/10465
american indian /,C0002460,7829/10465
with an sfua,,7830/10465
without an sfua,,7831/10465
men  > nmbr cm,C0025266,7832/10465
men  < nmbr cm,C0025266,7833/10465
women  < nmbr cm,C0043210,7834/10465
women  > nmbr cm,C0043210,7835/10465
sulphonylureas,C0038766,7836/10465
sulphonylurea,C0038766;C3536898,7837/10465
on sulfonylurea,C0038766;C3536898,7838/10465
sulfonylureaa,,7839/10465
sulfonylurea,C0038766;C3536898,7840/10465
pbo + mtx,C0031962;C0031962,7841/10465
czp + mtx,C0054841;C0054841;C1861828;C1861828;C1872109;C1872109,7842/10465
caucasians,C0007457;C0043157,7843/10465
caucasian,C0007457;C0043157,7844/10465
noncaucasian,,7845/10465
non - caucasian,C1518422;C1518422,7846/10465
ldl cholesterol ( mg / dl )  mean + sd  available for nmbr patients,C0023824;C0202117,7847/10465
hdl cholesterol ( mg / dl )  mean + sd  available for nmbr patients,C0023822;C0392885,7848/10465
previous or current use of im or cs : no,C0205156;C1552607,7849/10465
previous or current use of im and cs : no,C0205156;C1552607,7850/10465
nmbr to < nmbr ml / min / nmbr . nmbrmnmbr,C0053917;C1334884,7851/10465
nmbr to o nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,7852/10465
nmbr to onmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,7853/10465
≥ nmbr to < nmbr ml / min / nmbr . nmbr mnmbr,,7854/10465
nmbr to < nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,7855/10465
without psoriasis ( zi = nmbr ),C0033860,7856/10465
with psoriasis ( n = nmbr ),C0033860,7857/10465
with psoriasis ( zi = nmbr ),C0033860,7858/10465
placebo events / patients ( % ),C0032042;C0032042;C1696465;C1696465;C1706408;C1706408,7859/10465
placebo  events / patients ( % ),C0032042;C1696465;C1706408,7860/10465
ldl - cholesterol ( mg / dl ),C0023824;C0202117,7861/10465
ldl cholesterol  mg / dl,C0023824;C0202117,7862/10465
hdl cholesterol ( mg / dl ),C0023822;C0392885,7863/10465
ldl cholesterol — mg / dl,,7864/10465
i idl cholesterol ( mg / dl ),C0619865;C0021966;C0021966;C0221138;C0221138,7865/10465
hdl cholesterol — mg / dl,,7866/10465
hdl cholesterol  mg / dl,C0023822;C0392885,7867/10465
ldl cholesterol ( mg / dl ),C0023824;C0202117,7868/10465
hdl - cholesterol ( mg / dl ),C0023822;C0392885,7869/10465
baseline ldl - c,C0168634;C1442488,7870/10465
baseline ldl - c :,C0168634;C1442488,7871/10465
who fc ii symptoms at baseline,C2983605;C2983605;C2983605;C2983605;C2983605;C2983605;C2983605;C2983605,7872/10465
who fc iii symptoms at baseline,C2983605;C2983605;C2983605;C2983605;C2983605;C2983605;C2983605;C2983605,7873/10465
nmbr . nmbr - < nmbr . nmbr,C0053917;C1334884,7874/10465
> nmbr - nmbr - nmbr - nmbr,C0053917;C1334884,7875/10465
nmbr - nmbr - nmbr - nmbr,C0053917;C1334884,7876/10465
nmbr . nmbr to nmbr . nmbr %,C0053917;C1334884,7877/10465
> nmbr . nmbr - < nmbr . nmbr,C0053917;C1334884,7878/10465
nmbr . nmbr - nmbr . nmbr,C0053917;C1334884,7879/10465
nmbr . nmbr + nmbr . nmbr,C0053917;C1334884,7880/10465
nmbr nmbr ( nmbr . nmbr ),C0053917;C1334884,7881/10465
nmbr . nmbr - < nmbr . nmbr %,C0053917;C1334884,7882/10465
nmbr  nmbr ( nmbr . nmbr ),C0053917;C1334884,7883/10465
nmbr  nmbr - < nmbr . nmbr,C0053917;C1334884,7884/10465
nmbr / nmbr ( nmbr . nmbr ),C0053917;C1334884,7885/10465
nmbr . nmbr to nmbr . nmbr,C0053917;C1334884,7886/10465
> nmbr . nmbr to < nmbr . nmbr,C0053917;C1334884,7887/10465
nmbr . nmbr ( nmbr . nmbr ),C0053917;C1334884,7888/10465
> nmbr . nmbrto < nmbr . nmbr %,C0053917;C1334884,7889/10465
nmbr . nmbr % - nmbr . nmbr %,C0053917;C1334884,7890/10465
no mra at baseline,C0243032;C0243032;C1609165;C1609165;C3891069;C3891069,7891/10465
mra at baseline,C0243032;C0243032;C1609165;C1609165;C3891069;C3891069,7892/10465
ss at baseline,C2699257;C2699257;C3891295;C3891295;C4551874;C4551874,7893/10465
mmrc at baseline,C3826977;C3826977,7894/10465
pad at baseline,C0182158;C0182158;C0332568;C0332568;C3540603;C3540603;C3669270;C3669270;C3814046;C3814046;C4319657;C4319657,7895/10465
nihss at baseline,C1697238;C1697238,7896/10465
aspirin dose,C4696290,7897/10465
aspirin alone,C0004057,7898/10465
aspirin use,C0004057;C0004057;C0004057,7899/10465
arrhythmia,C0003811,7900/10465
arrhythmia !,C0003811,7901/10465
arrhythmias,C0003811,7902/10465
hypertensive,C0857121,7903/10465
hypertensiont,,7904/10465
hypertension  n ( % ),C0020538;C1963138,7905/10465
hypertension 本,,7906/10465
hypotension,C0020649;C3163620,7907/10465
hypertension  * n ( % ),C0020538;C1963138,7908/10465
hyper - tension,C0020538;C1963138,7909/10465
hypertension,C0020538;C1963138,7910/10465
hypertension  %,C0020538;C1963138,7911/10465
hypertension ( % ),C0020538;C1963138,7912/10465
hypertension  ( % ),C0020538;C1963138,7913/10465
no hypertension,C0020538;C1963138,7914/10465
hyperlension,,7915/10465
hypertension *,C0020538;C1963138,7916/10465
hypertensive  n ( % ),C0857121,7917/10465
hypertension §,,7918/10465
hypertension !,C0020538;C1963138,7919/10465
unstable angina *,C0002965,7920/10465
unstable angina age,C0002965,7921/10465
unstable angina §,,7922/10465
unstable anginad,C0443343;C1883468,7923/10465
unstableangina,,7924/10465
stable angina,C0340288,7925/10465
unstable anginat,C0443343;C1883468,7926/10465
unstable angina,C0002965,7927/10465
arb monotherapy,C3888198,7928/10465
era monotherapy,C1521863;C3495919,7929/10465
cardioembolism,,7930/10465
cardioembolic,,7931/10465
age category >,C0001779;C0001779,7932/10465
bmi category,C0578022;C0578022,7933/10465
age category,C0001779;C0001779,7934/10465
aspirin or other antiplatelet agents,C0004057,7935/10465
aspirin or other antiplatelet agent,C0004057,7936/10465
mean ( sd ) pga vas *,C0444504;C2347634;C2348143,7937/10465
mean ( sd ) ptga vas *,C0444504;C2347634;C2348143,7938/10465
mean ( sd ) pain vas *,C0444504;C2347634;C2348143,7939/10465
previous ml ( before index acs ),C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,7940/10465
previous pci ( before index acs ),C0205156;C1552607,7941/10465
fibula fracture,C0149699,7942/10465
tibia fracture,C0040185,7943/10465
weight in kg  mean ( sd ),C0005910;C0005910;C0005910;C0043100;C0043100;C0043100;C1305866;C1305866;C1305866;C1705104;C1705104;C1705104,7944/10465
weight  kg  mean ( sd ),C0005910;C0043100;C1305866;C1705104,7945/10465
weight  kg : mean ( sd ),C0005910;C0043100;C1305866;C1705104,7946/10465
weight ( kg )  mean ( sd ),C0005910;C0043100;C1305866;C1705104,7947/10465
weight ( kg )  mean ± sd,,7948/10465
serum creatinine  umol / lf,C0201976;C0600061,7949/10465
serum creatinine  gmol / l |,C0201976;C0600061,7950/10465
serum creatinine ( gmol / ),C0201976;C0600061,7951/10465
serum creatinine ( mmol / l ),C0201976;C0600061,7952/10465
serum creatinine  ^mol / l,C0201976;C0600061,7953/10465
> nmbr years eze / simva ( „ = nmbr },,7954/10465
< nmbr years eze / simva ( n = nmbr },C0053917;C1334884,7955/10465
im use : no,C1556154,7956/10465
cs use : no,C0010182;C0010182;C0010182;C0271160;C0271160;C0271160;C3540510;C3540510;C3540510;C4085345;C4085345;C4085345,7957/10465
stent diameter < nmbr mm,C0038257,7958/10465
stent diameter $ nmbr mm,C0038257;C0038257;C0038257;C0038257,7959/10465
overall ( n = nmbr  nmbr ),C0282416;C1561607,7960/10465
overall ( n = nmbr vs nmbr ),C0282416;C1561607,7961/10465
leukotriene receptor antagonists,C0595726;C2757015;C3542962,7962/10465
leukotriene - receptor antagonist,C0595726;C3537183;C4521995,7963/10465
high - sensitivity c - reactive protein  mg / ltt,C1441604;C1441604;C1441604,7964/10465
high - sensitivityc - reactive protein  mg / l,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,7965/10465
etn + mtx ( n = nmbr ),C0014758;C0014758;C0717758;C0717758,7966/10465
hcq + mtx ( n = nmbr ),C0020336;C0020336,7967/10465
ssz + mtx ( n = nmbr ),C0025677;C1417487,7968/10465
lef + mtx ( n = nmbr ),C0025677;C1417487,7969/10465
> nmbr drinks,C0053917;C1334884,7970/10465
nmbr drinks,C0053917;C1334884,7971/10465
glucose ( mg / dl ),C0017725,7972/10465
glucose — mg / dl,,7973/10465
thienopyridine,C1120149,7974/10465
+ thienopyridine,C1120149,7975/10465
no thienopyridine,C1120149,7976/10465
- thienopyridine,C1120149,7977/10465
acholesterol ( % ),,7978/10465
cholesterol ( % ),C0008377,7979/10465
< nmbr . nmbr mg / dl,C0053917;C1334884,7980/10465
> nmbr . nmbr mg / mmol,C0053917;C0053917;C1334884;C1334884,7981/10465
> nmbr . nmbr - g / l,C0053917;C0053917;C1334884;C1334884,7982/10465
nmbr - nmbr mg / g,C0053917;C1334884,7983/10465
nmbr nmbr mg / dl,C0053917;C1334884,7984/10465
≥ nmbr to < nmbr mg / g,,7985/10465
> nmbr . nmbr mg / l,C0053917;C1334884,7986/10465
> nmbr . nmbr mmol / l,C0053917;C1334884,7987/10465
≥ nmbr to < nmbr mg / dl,,7988/10465
< nmbr . nmbr mmol / l,C0053917;C1334884,7989/10465
< nmbr . nmbr mg / mmol,C0053917;C0053917;C1334884;C1334884,7990/10465
> nmbr & < nmbr mg / dl,C0053917;C1334884,7991/10465
> nmbr and < nmbr mg / dl,C0053917;C1334884,7992/10465
> nmbr to nmbr mg / g,C0053917;C1334884,7993/10465
> nmbr but < nmbr mg / dl,C0053917;C1334884,7994/10465
< nmbr . nmbr ng / ml,C0053917;C1334884,7995/10465
> nmbr + nmbr mmol / l,C0053917;C1334884,7996/10465
nmbr - nmbr mg / dl,C0053917;C1334884,7997/10465
. nmbr . nmbr mg / mmol,C0053917;C0053917;C1334884;C1334884,7998/10465
< nmbr - nmbr mmol / l,C0053917;C1334884,7999/10465
 nmbr . nmbr mg / mmol,C0053917;C0053917;C1334884;C1334884,8000/10465
nmbr to nmbr mg / g,C0053917;C1334884,8001/10465
nmbr to < nmbr mg / dl,C0053917;C1334884,8002/10465
> nmbr . nmbr mg / dl,C0053917;C1334884,8003/10465
> nmbr  < nmbr mg / dl,C0053917;C1334884,8004/10465
< nmbr . nmbr l - g / l,C0053917;C1334884,8005/10465
> nmbr . nmbr ng / ml,C0053917;C1334884,8006/10465
> nmbr ' nmbr mmol / l,C0053917;C1334884,8007/10465
> nmbr - nmbr mmol / l,C0053917;C1334884,8008/10465
< nmbr . nmbrmg / l,C0053917;C1334884,8009/10465
cerebral vascular disease,C0007820,8010/10465
cerebrovascular disease,C0007820,8011/10465
linagliptin,C2746078,8012/10465
vildagliptin,C1570906,8013/10465
sitagliptin,C1565750,8014/10465
saxagliptin,C1611934,8015/10465
mean ( s . e . ),C0444504;C2347634;C2348143,8016/10465
mean ( s . e . ) t,C0444504;C2347634;C2348143,8017/10465
mean ( s . d . ),C0444504;C2347634;C2348143,8018/10465
mean bmi  kg / mnmbr ( sd ),C0444504;C2347634;C2348143,8019/10465
mean bmi ( kg / mnmbr ) ( sd ),C0444504;C2347634;C2348143,8020/10465
tiotropium ( nznmbr ),C0213771,8021/10465
tiotropium ( n z nmbr ),C0213771,8022/10465
tiotropium ( n = nmbr ),C0213771,8023/10465
gastroduodenum,C0391900,8024/10465
gastroduodenal,C0450199,8025/10465
primary endpoint,C2986535,8026/10465
primary end point ",C2986535,8027/10465
primary end point,C2986535,8028/10465
dyslipidemia — no . ( % ),,8029/10465
dyslipidemia — no . ( % ) |,,8030/10465
tjc ( nmbr - nmbr )  mean ( sd ),,8031/10465
sjc ( nmbr - nmbr )  mean ( sd ),,8032/10465
non cv mortality,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,8033/10465
non - cv mortality,C1518422;C1518422;C1518422;C1518422;C1518422;C1518422,8034/10465
patients with prevalent kidney disease at baseline,C0030705;C0030705,8035/10465
patients without prevalent kidney disease at baseline,C0030705;C0030705,8036/10465
mean ( s . d . ) age  years,C0444504;C2347634;C2348143,8037/10465
mean ± s . d . age  years,,8038/10465
nmbr mg / day early - start - delayed - start,C0053917;C1334884,8039/10465
nmbr mg / day early - start - delayed start,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8040/10465
£ nmbr kg / mnmbr,,8041/10465
anmbr kg / mnmbr,C0022718;C0439209;C4054209,8042/10465
< nmbr kg / m nmbr,C0053917;C1334884,8043/10465
> nmbrkg / mnmbr,,8044/10465
< nmbrkg / mnmbr,,8045/10465
snmbr kg / mnmbr,C0022718;C0439209;C4054209,8046/10465
< nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8047/10465
≥ nmbr kg / mnmbr,,8048/10465
> nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8049/10465
hypokalemia ‡   ( potassium < nmbr . nmbr mmol / l ),,8050/10465
hyperkalemia ‡   ( potassium ≥ nmbr . nmbr mmol / l ),,8051/10465
heparin only,C0019134;C0019134;C0770546;C0770546,8052/10465
aspirin only,C0004057;C0004057,8053/10465
mitral regurgitation  n ( % ),C0026266,8054/10465
mitral regurgitation  ( % ),C0026266,8055/10465
< nmbr years n z nmbr,C0053917;C1334884,8056/10465
> nmbr years n z nmbr,C0053917;C1334884,8057/10465
age < nmbr y ( n = nmbr ),C0001779,8058/10465
age ' nmbr y ( n nmbr ),C0001779;C0001779,8059/10465
age > nmbr y ( n = nmbr ),C0001779,8060/10465
ace inhibitor  %,C0003015;C4541021,8061/10465
ace inhibitor,C0003015;C4541021,8062/10465
ace inhibitors,C0003015,8063/10465
tnf inhibitors,C1448177,8064/10465
tnf inhibitor,C1448177,8065/10465
ace inhibitor yes,C0003015;C0003015;C0003015;C4541021;C4541021;C4541021,8066/10465
body - mass index : ! :,C0005893;C0578022;C1305855,8067/10465
body - mass index  ! ,C0005893;C0578022;C1305855,8068/10465
change from baseline to eos  uu / ml,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,8069/10465
change from baseline to eos  mg / dl,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,8070/10465
right coronary artery,C1261316,8071/10465
r ight coronar y artery,C0205090;C0205090;C0684010;C0684010;C2603358;C2603358,8072/10465
duration of tnmbrdm > nmbr years,C0449238;C2926735,8073/10465
duration of tnmbrdm < nmbr years,C0449238;C2926735,8074/10465
time to randomization,C0040223;C3541383,8075/10465
time of randomization,C0040223;C3541383,8076/10465
p value ( cangrelor versus clopidogrel in men ),C1709380,8077/10465
p value ( cangrelor versus clopidogrel in women ),C1709380,8078/10465
weight ( kg ),C0005910;C0043100;C1305866;C1705104,8079/10465
weight  kg *,C0005910;C0043100;C1305866;C1705104,8080/10465
height — cm,,8081/10465
w eight ( k g ),C0205454,8082/10465
weight  lbs,C0005910;C0043100;C1305866;C1705104,8083/10465
weight  kg,C0005910;C0043100;C1305866;C1705104,8084/10465
height  cm,C0489786,8085/10465
weight 一 kg,,8086/10465
height ( cm ),C0489786,8087/10465
weight — kg,,8088/10465
weight - kg,C0005910;C0005910;C0005910;C0043100;C0043100;C0043100;C1305866;C1305866;C1305866;C1705104;C1705104;C1705104,8089/10465
height  cm *,C0489786,8090/10465
ldl - c  mmol / l ( mg / dl ),,8091/10465
hdl - c  mmol / l ( mg / dl ),C3715113,8092/10465
body - mass index ) -,C0005893;C0578022;C1305855,8093/10465
body mass index  %,C0005893;C0578022;C1305855,8094/10465
body - mass indexj,C0518010,8095/10465
body - mass indexf,C0518010,8096/10465
body - mass index ) ",C0005893;C0578022;C1305855,8097/10465
body - mass index ),C0005893;C0578022;C1305855,8098/10465
body - mass index *,C0005893;C0578022;C1305855,8099/10465
body - mass index §,,8100/10465
body mass index *,C0005893;C0578022;C1305855,8101/10465
body - mass index $,C0005893;C0578022;C1305855,8102/10465
body mass indexc,C0518010,8103/10465
body mass index +,C0005893;C0578022;C1305855,8104/10465
body mass index,C0005893;C0578022;C1305855,8105/10465
body mass index :,C0005893;C0578022;C1305855,8106/10465
body - mass index,C0005893;C0578022;C1305855,8107/10465
family history of premature chd,C0241889;C0241889;C0241889;C0241889;C0241889;C0241889,8108/10465
family history of premature chdj,C0241889;C0241889;C0241889,8109/10465
abatacept nmbr mg / kg ( n = nmbr ),C1619966;C1619966,8110/10465
abatacept ~ nmbr mg / kg ( n = nmbr ),C1619966;C1619966,8111/10465
prior tnf antagonist failure - no,C0332152;C0332152;C2826257;C2826257,8112/10465
prior tnf antagonist failure - yes,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,8113/10465
previous cabg,C0205156;C1552607,8114/10465
previous mi,C0205156;C1552607,8115/10465
previous ptca,C0205156;C1552607,8116/10465
previous pci,C0205156;C1552607,8117/10465
previous hf,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,8118/10465
previous tia,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,8119/10465
previous ml,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,8120/10465
previous chf,C0205156;C1552607,8121/10465
previous cad,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,8122/10465
previous ami,C0205156;C1552607,8123/10465
previously,,8124/10465
previous,C0205156;C1552607,8125/10465
w event ( rate ),C0441471;C4019010,8126/10465
n event ( rate ),C0369718;C0369718;C0441922;C0441922,8127/10465
type nmbr diabetes ( n = nmbr  nmbr ),C1320657;C1320657,8128/10465
no type nmbr diabetes ( n = nmbr  nmbr ),C1320657;C1320657,8129/10465
family history of vte,C0241889,8130/10465
family history of cad,C0241889;C0241889;C0241889;C0241889,8131/10465
with p blockers,C0369773;C2603361,8132/10465
without p blockers,C0369773;C2603361,8133/10465
triglycerides < nmbr - nmbr mmol / l,C0041004,8134/10465
triglycerides > nmbr - nmbr mmol / l,C0041004,8135/10465
non - hdl - c  mg / dl,C1518422,8136/10465
non - hdl - c ( mg / dl ),C1518422,8137/10465
lipid - lowering medications^,C0023779;C0023779;C0023779;C0023779;C0023779;C0023779;C0023779;C0023779,8138/10465
lipid - lowering medications,C0023779;C0023779;C0023779;C0023779;C0023779;C0023779;C0023779;C0023779,8139/10465
lipid - lowering medication,C0023779;C0023779;C0023779;C0023779;C0023779;C0023779,8140/10465
history of cad,C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062,8141/10465
no history of af,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,8142/10465
history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8143/10465
history of copd,C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062,8144/10465
history pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8145/10465
history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8146/10465
history of vte,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8147/10465
history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8148/10465
history of chd,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,8149/10465
history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8150/10465
no history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8151/10465
history of pad,C0019664;C0019664;C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062;C2004062;C2004062,8152/10465
history of ml,C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062,8153/10465
history of hf,C0019664;C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062;C2004062,8154/10465
history of af,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,8155/10465
lesion length $ nmbr mm,C0221198;C0221198;C0221198;C0221198;C0221198;C0221198;C0221198;C0221198;C1546698;C1546698;C1546698;C1546698;C1546698;C1546698;C1546698;C1546698,8156/10465
lesion length > nmbr mm,C0221198;C0221198;C1546698;C1546698,8157/10465
male gender,C0086582;C1706180,8158/10465
female gender,C0086287,8159/10465
ratio of hrs ( nmbr % cl )  p for sex interaction,C0456603;C1547037,8160/10465
ratio of hrs ( nmbr % ci )  p for sex interaction,C0456603;C1547037,8161/10465
statins / ezetimibe,C0360714,8162/10465
statin or ezetimibe,C0360714,8163/10465
> median ( nmbr . nmbr ) — number / n ( % ),,8164/10465
< median ( nmbr . nmbr ) — number / n ( % ),,8165/10465
renal impairment,C1565489,8166/10465
renal impairmentt,C0022646,8167/10465
antiplatelet drugs,C0085826;C2963157,8168/10465
antiplatelet drug,C0085826,8169/10465
chanmbrdsnmbr - vasc $ nmbr,C0053917;C1334884,8170/10465
chanmbrdsnmbr - vasc # nmbr,C0053917;C1334884,8171/10465
chanmbrdsnmbr - vasc > nmbr,,8172/10465
reversibility to,C0449261,8173/10465
reversibility ( % ) t,C0449261,8174/10465
reversibility *,C0449261,8175/10465
reversibility,C0449261,8176/10465
reversibility  %,C0449261,8177/10465
reversibility ( % ),C0449261,8178/10465
reversibility %,C0449261,8179/10465
present ( £ nmbr mg / dl ),,8180/10465
present ( > nmbr mg / dl ),C0150312;C0449450,8181/10465
hbanmbrc < = nmbr %,,8182/10465
hbanmbrc < nmbr %,,8183/10465
hbanmbrc > nmbr %,,8184/10465
hbanmbrc > = nmbr %,,8185/10465
metformin 一 no . ( % ),,8186/10465
metformin — no . ( % ),,8187/10465
women / men [ % ],C0043210,8188/10465
women / men  %,C0043210,8189/10465
nmbr . nmbr to # nmbr . nmbr mg / mmol,C0053917;C0053917;C1334884;C1334884,8190/10465
nmbr . nmbr - < nmbr . nmbr mg / mmol,C0053917;C1334884,8191/10465
baseline tav - > = median ( n = nmbr  nmbr ),C0168634;C1442488,8192/10465
baseline pav - > = median ( n = nmbr  nmbr ),C0168634;C1442488,8193/10465
baseline tav - < median ( n = nmbr  nmbr ),C0168634;C1442488,8194/10465
baseline pav - < median ( n = nmbr  nmbr ),C0168634;C1442488,8195/10465
ifg / igt,C1334085;C1708411,8196/10465
ifg and igt,C1334085;C1708411,8197/10465
< nmbr % ( < nmbr mmol / mol ),C0053917;C1334884,8198/10465
> nmbr % ( > nmbr mmol / mol ),C0053917;C1334884,8199/10465
> = nmbr % ( nmbr mmol / mol ),,8200/10465
< nmbr % ( nmbr mmol / mol ),C0053917;C1334884,8201/10465
no mi ( n - nmbr  nmbr ),C3810814,8202/10465
pad ( n - nmbr  nmbr ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657,8203/10465
no mvd ( n - nmbr  nmbr ),C1417507;C3272839,8204/10465
acs ( n - nmbr  nmbr ),C0742343;C4318612,8205/10465
mvd ( n - nmbr  nmbr ),C1417507;C3272839,8206/10465
any mi ( n - nmbr  nmbr ),C3810814,8207/10465
no pad ( n - nmbr  nmbr ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657,8208/10465
total cholesterol > nmbr - nmbr mmol / lt,C0201950;C0543421,8209/10465
total cholesterol < nmbr nmbr mmol / lt,C0201950;C0543421,8210/10465
total cholesterol < nmbr - nmbr mmol / lt,C0201950;C0543421,8211/10465
total cholesterol > nmbr ' nmbr mmol / lt,C0201950;C0543421,8212/10465
body mass index  mean ( sd ),C0005893;C0578022;C1305855,8213/10465
body mass index  mean ( sd ) t,C0005893;C0578022;C1305855,8214/10465
body massindex  mean ( sd ) a,C0242821;C0460148;C1268086;C4082212,8215/10465
body - mass index  mean ( sd ),C0005893;C0578022;C1305855,8216/10465
body mass index  mean ( sd ) d,C0005893;C0578022;C1305855,8217/10465
change from baseline *,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,8218/10465
change from baseline,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,8219/10465
% change from baseline,C0392747;C0392747;C0443172;C0443172;C1705241;C1705241;C4319952;C4319952,8220/10465
rectal bleeding subscore {,C0018932;C0267596,8221/10465
rectal bleeding subscore,C0018932;C0267596,8222/10465
ldl - c ( mmol / l ),,8223/10465
ldl - c  mmol / l,,8224/10465
hdl - c  mmol / l,C3715113,8225/10465
hdl - c ( mmol / l ),C3715113,8226/10465
ldl - c * ( mmol / l ),,8227/10465
insulin - dependent,C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501,8228/10465
insulin dependentc,C0021641;C1533581;C1579433;C3714501,8229/10465
antihypertensive therapy,C0585941,8230/10465
anti - hypertensive therapy,C0585941,8231/10465
ace inhibitors or angiotensin - receptor blockers^,C0003015,8232/10465
ace inhibitor or angiotensin receptor blocker,C0003015;C4541021,8233/10465
ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021,8234/10465
ace inhibitors or angiotensin receptor blockers,C0003015,8235/10465
diabetes duration  years,C0011847;C0011847;C0011849;C0011849,8236/10465
diabetes duration ( years ),C0011847;C0011847;C0011849;C0011849,8237/10465
age ( years ) mean ± sd,,8238/10465
age  y  mean ( sd ),C0001779,8239/10465
cdai  mean ( sd ),C0683448;C1413248;C3273706,8240/10465
age  years ( sd ),C0001779,8241/10465
age  years  mean + sd,C0001779,8242/10465
age  yr mean ( sd ),C0001779,8243/10465
age  mean ( sd ),C0001779,8244/10465
bmi  mean ( sd ),C0578022,8245/10465
age ( years ) mean ( sd ),C0001779,8246/10465
age ( years ) ( mean  sd ),C0001779,8247/10465
tc  mean ( sd ),C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,8248/10465
bmi  mean ( sd ) b,C0578022,8249/10465
ibdq  mean ± sd,,8250/10465
age ( years )  mean ± sd,,8251/10465
age  y  mean ± sd,,8252/10465
age  years  mean ( sd ),C0001779,8253/10465
bmi  mean ± sd,,8254/10465
age  yr  mean ( sd ),C0001779,8255/10465
sdai  mean ( sd ),C3871128,8256/10465
age  mean ± sd,,8257/10465
age ( yrs )  mean ± sd,,8258/10465
age ( years )  mean ( sd ),C0001779,8259/10465
age  years  mean ± sd,,8260/10465
age  mean yr ( sd ),C0001779,8261/10465
basfi  mean ( sd ),,8262/10465
age in years  mean ( sd ),C1510829,8263/10465
age ( years ) - mean ± sd,,8264/10465
age  yrs  mean ( sd ),C0001779,8265/10465
one of the above,C0205447,8266/10465
two of the above,C0205448,8267/10465
all of the above,C1282910;C1552828,8268/10465
none of the above,C1282910;C1552828,8269/10465
any of the above,C1282910;C1552828,8270/10465
asian or oriental,C0078988,8271/10465
asian / oriental,C0078988;C0078988,8272/10465
no . of stents,,8273/10465
no . of events,,8274/10465
no . of patients,,8275/10465
serum creatinine — mg / dl §,,8276/10465
serum creatinine ( mg / dl ),C0201976;C0600061,8277/10465
serum creatinine — mg / dl,,8278/10465
serum creatinine  mg / dlb,C0201976;C0600061,8279/10465
serum creatinine  mg / dl,C0201976;C0600061,8280/10465
no diabetes ( n - nmbr  nmbr ),C0011847;C0011849,8281/10465
diabetes ( n - nmbr  nmbr ),C0011847;C0011849,8282/10465
final median  mg / l,C0205088;C0205088;C0205088;C0205088;C0205088;C1546485;C1546485;C1546485;C1546485;C1546485;C3853528;C3853528;C3853528;C3853528;C3853528,8283/10465
final mean  mg / dl,C0205088;C0205088;C0205088;C1546485;C1546485;C1546485;C3853528;C3853528;C3853528,8284/10465
nonwhite race !,C0034510;C1706779;C3853635,8285/10465
nonwhite race,C0034510;C1706779;C3853635,8286/10465
white race,C0007457;C0043157,8287/10465
non - white race,C1518422;C1518422,8288/10465
non - white raceb,C1518422;C1518422;C1518422,8289/10465
> nmbr egfr  ml / min / nmbr . nmbr mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8290/10465
> nmbr egfr  ml / min / nmbr . nmbr mnmbr a,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8291/10465
current cigarette smoker,C3173209;C3173209;C3173209;C3241966;C3241966;C3241966;C0521116;C1705970,8292/10465
current cigarette smoking,C0521116;C0521116;C1705970;C1705970,8293/10465
at home systolic pressure > nmbr mm hg,C4534363,8294/10465
at home diastolic pressure < nmbr mm hg,C4534363,8295/10465
at home diastolic pressure > nmbr mm hg,C4534363,8296/10465
at home systolic pressure < nmbr mm hg,C4534363,8297/10465
hx stroke / tia,C0262926;C0262926;C0262926;C0262926;C0262926;C0262926;C3814444;C3814444;C3814444;C3814444;C3814444;C3814444,8298/10465
stroke or tia,C0038454;C4554100,8299/10465
stroke ortiab,C0038454;C4554100,8300/10465
stroke / tia,C0038454;C0038454;C0038454;C4554100;C4554100;C4554100,8301/10465
no stroke / tia,C0038454;C0038454;C0038454;C4554100;C4554100;C4554100,8302/10465
clinical history — no . ( % ),,8303/10465
clinical history  no . ( % ),C0205210;C0205210;C0205210;C0205210;C0205210;C0205210,8304/10465
clinical history  n ( % ),C0205210;C0205210;C0205210;C0205210;C0205210;C0205210,8305/10465
combination therapy ( n = nmbr ),C0009429;C0556895,8306/10465
combination therapy  n = nmbr,C0009429;C0556895,8307/10465
anmbrc at baseline < nmbr . nmbr %,C0168634;C1442488,8308/10465
anmbrc at baseline ≥ nmbr . nmbr %,,8309/10465
native american,C0282204;C1515945,8310/10465
latin american,C1553378,8311/10465
latin america,C0023122,8312/10465
liraglutide nmbr . nmbr mg ,C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,8313/10465
liraglutide nmbr . nmbr mg,C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,8314/10465
medical history  no . ( % ),C0262926;C1704706,8315/10465
medical history — no . ( % ),,8316/10465
medical history  n ( % ),C0262926;C1704706,8317/10465
diabetes mellitus :,C0011849,8318/10465
diabetes mellitus,C0011849,8319/10465
no diabetes mellitus,C0011849,8320/10465
diabetes mellitus  n ( % ),C0011849,8321/10465
diabetes mellitus !,C0011849,8322/10465
diabetes mellitus  § n ( % ),,8323/10465
diabetes mellitus  %,C0011849,8324/10465
diabetes mellitus ( % ),C0011849,8325/10465
diabetes mellitus  ( % ),C0011849,8326/10465
since diagnosis,,8327/10465
index diagnosis,C0600653;C0600653;C0600653;C0918012;C0918012;C0918012;C1552854;C1552854;C1552854;C1637833;C1637833;C1637833;C2986546;C2986546;C2986546,8328/10465
> nmbr months  mean ( sd ),C0053917;C1334884,8329/10465
< nmbr months  mean ( sd ),C0053917;C1334884,8330/10465
placebo ( n = nmbr nmbr ),C0032042;C1696465;C1706408,8331/10465
placebo ( n = nmbr  nmbr ),C0032042;C1696465;C1706408,8332/10465
placebo ( n - nmbr . nmbr ),C0032042;C1696465;C1706408,8333/10465
placebo ( n nmbr nmbr ),C0032042;C1696465;C1706408,8334/10465
second mi,C0205436;C0457385;C0565930;C1561503;C1705190,8335/10465
no second mi,C0205436;C0457385;C0565930;C1561503;C1705190,8336/10465
controlled,C2587213;C2911690,8337/10465
coronary,C0018787,8338/10465
country,C0454664;C1511538,8339/10465
controlld,,8340/10465
uncontrolled,C0205318,8341/10465
control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389,8342/10465
diabetes status  n ( % ),C1317301,8343/10465
diabetes status  no . ( % ),C1317301,8344/10465
ezetimibe nmbr mg ( n = nmbr * ),C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985,8345/10465
ezetimibe nmbr mg ( n = nmbr ),C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985;C1142985,8346/10465
chadsnmbr score,C0449820;C4050231,8347/10465
chadsnmbr score *,C0449820;C4050231,8348/10465
chadsnmbr scoreb,,8349/10465
age  mean = sd  years,C0001779,8350/10465
age  mean ± sd ( year ),,8351/10465
age  mean ± sd years,,8352/10465
age  mean ( sd ) years,C0001779,8353/10465
age  mean ( sd )  years,C0001779,8354/10465
age  mean ( sd )  y,C0001779,8355/10465
age  mean ( sd )  yrs,C0001779,8356/10465
age  mean ± sd  years,,8357/10465
aiirocumab ( n = nmbr ),,8358/10465
alirocumab ( n = nmbr ),C3491162,8359/10465
< nmbr enroll,C0053917;C1334884,8360/10465
> nmbr enroll,C0053917;C1334884,8361/10465
dasnmbr - crp  ls mean change from baseline ( se ) ¥,,8362/10465
dasnmbr - crp  ls mean change from baseline ( se ) §,,8363/10465
anacetrapib nmbr mg ( n = nmbr ),C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745,8364/10465
anacetrapib nmbrmg ( n = nmbr ),C2604745,8365/10465
anacetrapib nmbr mg ( n - nmbr ),C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745;C2604745,8366/10465
current,C0521116;C1705970,8367/10465
currently,C0521116,8368/10465
total stent length - mm,C0439175;C0439175;C0439175;C0439175;C0439810;C0439810;C0439810;C0439810,8369/10465
total stent length  mm,C0439175;C0439175;C0439810;C0439810,8370/10465
body mass index > nmbr kg / mnmbr *,C0005893;C0578022;C1305855,8371/10465
body mass index < nmbr kg / mnmbr,C0005893;C0578022;C1305855,8372/10465
p inleraclion,C0369773;C2603361,8373/10465
p nmbr interaction,C0369773;C0369773;C2603361;C2603361,8374/10465
p for interaction,C0369773;C2603361,8375/10465
pfor interaction,C1151635,8376/10465
p interaction,C0369773;C2603361,8377/10465
pinteraction,,8378/10465
p  interaction !,C0369773;C2603361,8379/10465
p for interaction *,C0369773;C2603361,8380/10465
interaction p,C1704675,8381/10465
age - interaction,C0001779,8382/10465
interaction - p,C1704675,8383/10465
p - interaction,C0369773;C2603361,8384/10465
p . interaction,C0369773;C2603361,8385/10465
p : interaction,C0369773;C2603361,8386/10465
p - interactio n,C0369773;C2603361,8387/10465
angiotensin receptor blockers,C0521942;C0815017,8388/10465
angiotensin receptor blocker yes,C0034787;C0034787;C0034787;C1622222;C1622222;C1622222,8389/10465
angiotensin ii receptor blocker,C0521942;C3536793,8390/10465
angiotensin - receptor blocker,C0034787;C1622222,8391/10465
angiotensin receptor blocker,C0034787;C1622222,8392/10465
angiotensin ll - receptor blocker,C0003018;C4521302,8393/10465
creatinine — mg / dl,,8394/10465
creatinine  mg / dl_,C0010294;C1561535,8395/10465
creatinine ( mg / dl ),C0010294;C1561535,8396/10465
creatinine  mg / dl,C0010294;C1561535,8397/10465
baseline post - bronchodilator % predicted fev  > nmbr % and no prior ics use,C0168634;C0168634;C1442488;C1442488,8398/10465
baseline post - bronchodilator % predicted fev  > nmbr % and prior ics use,C0168634;C0168634;C1442488;C1442488,8399/10465
fevnmbr ( % predicted ),,8400/10465
fevnmbr  % predicted,,8401/10465
fevnmbr  % predicteda,,8402/10465
fevnmbr % predicted,C0681842;C1882327,8403/10465
fevnmbr  l *,,8404/10465
fevnmbr  l,,8405/10465
fevnmbr  la,,8406/10465
fevnmbr ( l ),,8407/10465
mean sitting sbp ( mmhg ),C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,8408/10465
mean sitting dbp ( mmhg ),C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143,8409/10465
potassium ( mmol / l ),C0032821;C0202194;C0304475;C0597277;C3714637,8410/10465
potassium ( meq / l ),C0032821;C0202194;C0304475;C0597277;C3714637,8411/10465
potassium  mmol / l,C0032821;C0202194;C0304475;C0597277;C3714637,8412/10465
£ nmbr ( men ) / £ nmbr ( women ),,8413/10465
< nmbr ( men ) / < nmbr ( women ),C0053917;C1334884,8414/10465
creat clearance < nmbr ml / min,C0201975;C0201975;C0201975;C0201975,8415/10465
creat clearance > nmbr ml / min,C0201975;C0201975;C0201975;C0201975,8416/10465
pre - bronchodilator,C2599602,8417/10465
prebronchodilator,C2599602,8418/10465
post - bronchodilator,C2599594,8419/10465
postbronchodilator,C2599594,8420/10465
heritable,C0439660,8421/10465
variable,C0439828;C4553760,8422/10465
apolipoprotein b ( mg / dl ),C0003593,8423/10465
apolipoprotein b ( g / l ),C0003593,8424/10465
tiotropiumc,,8425/10465
tiotropium,C0213771,8426/10465
no prior statin use,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,8427/10465
prior statin use,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,8428/10465
nyha iv  n ( % ),C1275491;C1275491,8429/10465
nyha ii  n ( % ),C1275491;C1275491,8430/10465
nyha iii  n ( % ),C1275491;C1275491,8431/10465
metabolic syndrome,C0524620,8432/10465
metabolic syndrome ,C0524620,8433/10465
metabolic syndrome *,C0524620,8434/10465
tiotropium nmbr mg,C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771,8435/10465
tiotropium nmbrmg,C0213771,8436/10465
tiotropium nmbr m g,C0213771;C0213771,8437/10465
pitavastatin nmbr mg,C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838;C1101838,8438/10465
pravastatin nmbr mg,C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542;C0085542,8439/10465
rosuvastatin nmbr mg,C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129;C0965129,8440/10465
simvastatin nmbr mg,C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554,8441/10465
atorvastatin nmbr mg,C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651;C0286651,8442/10465
fluvastatin nmbr mg,C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608;C0082608,8443/10465
lovastatin nmbr mg,C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027;C0024027,8444/10465
stage nmbrb : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0205390;C1300072;C1306673,8445/10465
stage nmbra : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0205390;C1300072;C1306673,8446/10465
stage nmbr : nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C0205390;C0205390;C1300072;C1300072;C1306673;C1306673,8447/10465
readmission ( n = nmbr ),C1548168;C4489276,8448/10465
no readmission ( n = nmbr ),C1548168;C4489276,8449/10465
nyha class iii,C1882086,8450/10465
nyha class iv,C1882087,8451/10465
nyha class,C1882083,8452/10465
nyha class ii,C1882085,8453/10465
nyha class > ii,C1882085,8454/10465
nyha class i,C1882084,8455/10465
no prior cv event,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,8456/10465
prior lgi event,C0332152;C0332152;C2826257;C2826257,8457/10465
prior ugi event,C0332152;C0332152;C2826257;C2826257,8458/10465
no prior ugi event,C0332152;C0332152;C2826257;C2826257,8459/10465
prior cv event,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,8460/10465
major cv event,C0205082;C0205082;C0205082;C0205082;C0205082;C0205082;C0205164;C0205164;C0205164;C0205164;C0205164;C0205164;C4318856;C4318856;C4318856;C4318856;C4318856;C4318856;C4521762;C4521762;C4521762;C4521762;C4521762;C4521762,8461/10465
no prior lgi event,C0332152;C0332152;C2826257;C2826257,8462/10465
prior peripheralarterialdisease,C0332152;C2826257,8463/10465
prior peripheral arterial disease,C0332152;C0332152;C2826257;C2826257,8464/10465
pre - bronchodilator fevnmbr ( l ),C2599602,8465/10465
post - bronchodilator fevnmbr  l,C2599594,8466/10465
post - bronchodilator fevnmbr  l *,C2599594,8467/10465
postbronchodilator fevnmbr  l,C2599594,8468/10465
prebronchodilator fevnmbr ( l ) t,C2599602,8469/10465
post - bronchodilator fevnmbr ( l ) a,C2599594,8470/10465
post - bronchodilator fevnmbr ( l ) *,C2599594,8471/10465
prebronchodilator fevnmbr ( l ),C2599602,8472/10465
prebronchodilator fevnmbr  l,C2599602,8473/10465
post - bronchodilator fevnmbr ( l ),C2599594,8474/10465
pre - bronchodilator fevnmbr  l *,C2599602,8475/10465
amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523,8476/10465
amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523,8477/10465
noncardiovascular,,8478/10465
cardiovascular,C0007226;C3887460,8479/10465
etoricoxib ( n = nmbr  nmbr ),C0972314,8480/10465
etoricoxib ( n = nmbr nmbr ),C0972314,8481/10465
no previous cv event,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,8482/10465
previous cv event,C0205156;C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607;C1552607,8483/10465
asa use at baseline  n ( % ),C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C3853627;C3853627;C3853627;C3853627;C3853627;C3853627,8484/10465
ics use at baseline  n ( % ),C0815320;C4551720,8485/10465
ics users at baseline  n ( % ),C0815320;C0815320;C4551720;C4551720,8486/10465
icsusers atbaseline  n ( % ),,8487/10465
mean fvc ± sd,,8488/10465
mean dlco ± sd,,8489/10465
saphenous vein graft,C0729538,8490/10465
saphenous - vein graft,C0729538,8491/10465
hypercholesterolemia,C0020443;C1522133,8492/10465
hypercholesterolemia *,C0020443;C1522133,8493/10465
hypercholesterolemiat,,8494/10465
hypercholesterolaemia,C0020443;C1522133,8495/10465
one tnfi and,C0205447,8496/10465
one tnfi *,C0205447,8497/10465
with stent^l,C0038257,8498/10465
with stent,C0038257,8499/10465
without stent,C0038257,8500/10465
postmenopausal and current hrt,C0232970,8501/10465
postmenopausal and current ht,C0232970,8502/10465
postmenopausal  current hrt,C0232970;C0232970,8503/10465
end point,C2349179;C2826544,8504/10465
endpoint,C2349179;C2826544,8505/10465
end points,C2349179,8506/10465
endpointc,,8507/10465
telmisartan ( n = nmbr ),C0248719,8508/10465
irbesartan ( n = nmbr ),C0288171,8509/10465
olmesartan ( n = nmbr ),C1098320,8510/10465
duration of rheumatoid arthritis  year,C0449238;C2926735,8511/10465
duration of rheumatoid arthritis — yr,,8512/10465
dyslipidaemia  n ( % ),C0242339,8513/10465
dyslipidemia  n ( % ),C0242339,8514/10465
heart failure nmbr mo before admission,C0018801;C0018801;C0018801;C0018801;C0018801;C0018801;C0018801;C0018801;C0018802;C0018802;C0018802;C0018802;C0018802;C0018802;C0018802;C0018802;C4554158;C4554158;C4554158;C4554158;C4554158;C4554158;C4554158;C4554158,8515/10465
heart failure nmbr month before admission,C0018801;C0018801;C0018801;C0018801;C0018801;C0018801;C0018801;C0018801;C0018802;C0018802;C0018802;C0018802;C0018802;C0018802;C0018802;C0018802;C4554158;C4554158;C4554158;C4554158;C4554158;C4554158;C4554158;C4554158,8516/10465
no anemia bsl hb > nmbrg i - nmbr  yr nmbr > nmbrg i - nmbr,C0002871;C0002871;C0002871;C0002871;C1000483;C1000483;C1000483;C1000483;C4554633;C4554633;C4554633;C4554633,8517/10465
new anemia bsl hb > nmbrg i - nmbr  yr nmbr < nmbrg i - nmbr,C0205314;C0205314;C0205314;C0205314;C0205314;C0205314;C0205314;C0205314;C0205314;C0205314;C0205314;C0205314,8518/10465
no previous myocardial infarction,C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607,8519/10465
previous myocardial infarction,C0205156;C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607;C1552607,8520/10465
peripheral artery disease,C1704436;C4025272,8521/10465
peripheral arterial disease,C0085096;C1704436,8522/10465
peripheral - artery disease,C1704436;C4025272,8523/10465
peripheral artery disease *,C1704436;C4025272,8524/10465
peripheral artery diseasef,C0489868,8525/10465
history of pvd  n ( % ),C4534349,8526/10465
history of chd  n ( % ),C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,8527/10465
history of mi  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8528/10465
history of chf  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8529/10465
history of tia  n ( % ),C0019664;C0019664;C0019664;C0019665;C0019665;C0019665;C0262512;C0262512;C0262512;C0262926;C0262926;C0262926;C1705255;C1705255;C1705255;C2004062;C2004062;C2004062,8530/10465
history of pci  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8531/10465
history of cabg  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,8532/10465
white race — no . / total no . ( % ) $,,8533/10465
white race — no . / total no . ( % ) f,,8534/10465
aspirin nmbr,C0004057;C0004057,8535/10465
aspirin nmbr mg,C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C0004057,8536/10465
total cholesterol  mmol / l,C0201950;C0543421,8537/10465
total cholesterol ( mmol / l ),C0201950;C0543421,8538/10465
total cholesterol  mmol / l 本,,8539/10465
total cholesterol ( mmol / l ) :,C0201950;C0543421,8540/10465
no myocardial infarction at presentation ( n = nmbr ),C0027051;C0428953;C2926063;C3810814;C4552959,8541/10465
myocardial infarction at presentation ( n = nmbr ),C0027051;C0428953;C2926063;C3810814;C4552959,8542/10465
< nmbr mmol / l,C0053917;C1334884,8543/10465
> nmbr mmol / l,C0053917;C1334884,8544/10465
black / african american,C0085756,8545/10465
black or african - american,C0005680;C0027567;C0085756;C0439541,8546/10465
black / african - american,C0085756,8547/10465
black or african american,C0005680;C0027567;C0085756;C0439541,8548/10465
black or african america,C0005680;C0027567;C0085756;C0439541,8549/10465
black / african american *,C0085756,8550/10465
saxagliptin nmbr . nmbr mg ( n = nmbr ),C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,8551/10465
saxagliptin nmbr . nmbr mg ( n z nmbr ),C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,8552/10465
bmi ( kg / mnmbr )  mean ± sd,,8553/10465
bmi ( kg / mnmbr ) mean ± sd,,8554/10465
bmi ( kg / mnmbr )  mean ( sd ),C0578022,8555/10465
bmi  kg / mnmbr  mean + sd,C0578022,8556/10465
bmi  kg / mnmbr  mean ( sd ),C0578022,8557/10465
bmi  kg / mnmbr  mean ± sd,,8558/10465
bmi in kg / mnmbr  mean ( sd ),C0578022;C0578022;C0578022,8559/10465
bmi ( kg / mnmbr ) mean ( sd ),C0578022,8560/10465
> nmbr years  n ( % ),C0053917;C1334884,8561/10465
< nmbr years  n ( % ),C0053917;C1334884,8562/10465
hazard ratio or differencenmbr * ( nmbr % cl ) p - value,C2985465,8563/10465
hazard ratio or differencenmbr ( nmbr % cl ) p - value,C2985465,8564/10465
history of hypertension ( a ) c,C0455527,8565/10465
history of hypertension ( % ),C0455527,8566/10465
women ( n = nmbr )  n / n ( % ),C0043210,8567/10465
men ( n = nmbr )  n / n ( % ),C0025266,8568/10465
aldosterone antagonists,C0002007;C2757004,8569/10465
aldosterone antagonist,C0002007;C2757004;C3536833,8570/10465
diastolic blood pressure  mm hg  mean ± sd,,8571/10465
diastolic blood pressure ( mm hg )  mean ( sd ),C0428883;C1305849,8572/10465
systolic blood pressure  mm hg  mean ± sd,,8573/10465
systolic blood pressure ( mm hg )  mean ( sd ),C0488055;C0871470;C1306620,8574/10465
systolic blood pressure  mm hg  mean ( sd ),C0488055;C0871470;C1306620,8575/10465
diastolic blood pressure  mm hg  mean ( sd ),C0428883;C1305849,8576/10465
length of stent > median,C0449462,8577/10465
length of stent < median,C0449462,8578/10465
£ median ( nmbr . nmbr ),,8579/10465
< median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193,8580/10465
> median ( nmbr . nmbr ),C0549183;C0876920;C2347635;C2348144;C2939193,8581/10465
with previous surgery,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,8582/10465
without previous surgery,C0205156;C0205156;C0205156;C0205156;C1552607;C1552607;C1552607;C1552607,8583/10465
corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727,8584/10465
corticosteroid use,C0239126,8585/10465
no corticosteroid,C0001617;C3536709,8586/10465
corticosteroidsa,,8587/10465
corticosteroid,C0001617;C3536709,8588/10465
full population,C0443225;C0443225,8589/10465
full po pulatio n,C0443225,8590/10465
no epa group n = nmbr,C0441848,8591/10465
epa group n = nmbr,C0441848,8592/10465
coronary artery disease — %,,8593/10465
coronary artery disease ( % ),C0010054;C0010068;C1956346,8594/10465
olodaterol nmbr m g,C2934193;C2934193,8595/10465
olodaterol nmbr mg,C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193;C2934193,8596/10465
baseline : > nmbr . nmbr meq / l eos : < nmbr . nmbr meq / l,C0168634;C1442488,8597/10465
baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l,C0168634;C1442488,8598/10465
digoxin  ( % ),C0012265,8599/10465
digoxin  n ( % ),C0012265,8600/10465
vitamin k antagonists,C3653316,8601/10465
vitamin k antagonist,C1096489;C2267235,8602/10465
off omt ( n = nmbr ),,8603/10465
on omt ( n = nmbr ),,8604/10465
ticlopidine,C0040207,8605/10465
ticlopidin,,8606/10465
type nmbr diabetes  n ( % ),C1320657;C1320657,8607/10465
type nmbr diabetes  n ( % ) d,C1320657;C1320657,8608/10465
laba use at screening  n ( % ),C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944,8609/10465
lama use at screening  n ( % ),C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775,8610/10465
dasnmbr - nmbr ( esr ) < nmbr . nmbr *,C0053917;C1334884,8611/10465
dasnmbr - nmbr ( esr ) < nmbr . nmbrt,C0053917;C1334884,8612/10465
modified acc / aha lesion class bnmbr / c,C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737,8613/10465
modified acc - aha lesion class bnmbr or c,C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737,8614/10465
modified acc / aha lesion class bnmbr or cj,C0392747;C0392747;C0392747;C0392747;C0392747;C0392747;C3889737;C3889737;C3889737;C3889737;C3889737;C3889737,8615/10465
modified acc or aha lesion class bnmbr or c,C0392747;C0392747;C0392747;C3889737;C3889737;C3889737,8616/10465
mtss ( nmbr - nmbr ),,8617/10465
vas ( nmbr - nmbr ),C0042815;C3536884;C3827561,8618/10465
oad only,C0205171;C1720467,8619/10465
diet only,C0012155;C0012155;C0012159;C0012159;C1519433;C1519433;C2983588;C2983588;C3668949;C3668949,8620/10465
past only,C1444637;C1444637;C4284302;C4284302,8621/10465
cabg only,C0010055;C0010055,8622/10465
dvt only,C0149871;C0149871;C2926618;C2926618;C3899446;C3899446,8623/10465
ptca only,C2936173;C2936173,8624/10465
ics only,C0815320;C0815320;C4551720;C4551720,8625/10465
< nmbr ml / min per nmbr - nmbr mnmbr,C0053917;C1334884,8626/10465
> nmbr ml / min per nmbr - nmbr mnmbr,C0053917;C1334884,8627/10465
gold stage,C0018026;C0018026;C0018026;C1304897;C1304897;C1304897,8628/10465
gold stage  %,C0018026;C0018026;C0018026;C1304897;C1304897;C1304897,8629/10465
gold stage ii,C0018026;C1304897,8630/10465
gold stage iv,C0018026;C0018026;C0018026;C0018026;C0018026;C0018026;C1304897;C1304897;C1304897;C1304897;C1304897;C1304897,8631/10465
gold stage iii,C0018026;C1304897,8632/10465
gold stage #,C0018026;C0018026;C0018026;C1304897;C1304897;C1304897,8633/10465
austrafca and new zealand,,8634/10465
australia / new zealand,C4289954,8635/10465
australia and new zealand,C0004340,8636/10465
simvastatin,C0074554,8637/10465
pravastatin,C0085542,8638/10465
subjects $ nmbr years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811,8639/10465
subjects  nmbr years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811,8640/10465
previous mi  n ( % ),C0205156;C1552607,8641/10465
previous ami  n ( % ),C0205156;C1552607,8642/10465
previous cabg  n ( % ),C0205156;C1552607,8643/10465
previous pci  n ( % ),C0205156;C1552607,8644/10465
nmbr - nmbr vr — no . ( % ),,8645/10465
nmbr - nmbr yr — no . ( % ),,8646/10465
nmbr = nmbr yr — no . ( % ),,8647/10465
ldl cholesterol  mmol / l 丰,,8648/10465
hdl cholesterol  mmol / 冲,,8649/10465
hdl cholesterol ( mmol / l ),C0023822;C0392885,8650/10465
ldl - cholesterol ( mmol / ),C0023824;C0202117,8651/10465
hdl cholesterol ( mmol / l ) :,C0023822;C0392885,8652/10465
hdl cholesterol  mmol / l,C0023822;C0392885,8653/10465
kdl cholesterol ( mmol / ),C0008377,8654/10465
ldl - cholesterol ( mmol / l ),C0023824;C0202117,8655/10465
hdl cholesterol  ( mmol / l ),C0023822;C0392885,8656/10465
ldl cholesterol ( mmol / l ) :,C0023824;C0202117,8657/10465
hdl cholesterol  mmol / l *,C0023822;C0392885,8658/10465
ldl cholesterol ( mmol / l ),C0023824;C0202117,8659/10465
ldl cholesterol  mmol / l,C0023824;C0202117,8660/10465
ldl cholesterol  mmol / l *,C0023824;C0202117,8661/10465
hdl - cholesterol ( mmol / l ),C0023822;C0392885,8662/10465
no renal dysfunction,C1565489;C3279454,8663/10465
renal dysfunction,C1565489;C3279454,8664/10465
renal function,C0232804,8665/10465
prebronchodilator fevnmbr  % predicted,C2599602,8666/10465
postbronchodilator fevnmbr  % predicted,C2599594,8667/10465
post - bronchodilator fevnmbr  % predicted,C2599594,8668/10465
< qnmbr ( nmbr . nmbr ) — number / n ( % ),,8669/10465
> qnmbr ( nmbr . nmbr ) — number / n ( % ),,8670/10465
p valuenmbr,C0369773;C2603361,8671/10465
p value * nmbr,C1709380,8672/10465
eze / simva - nmbryr km rale ( % ),C3887676,8673/10465
pbo / simva - nmbryr km rale ( % ),C0031962,8674/10465
age  median ( iqr ),C0001779,8675/10465
bmi  median ( iqr ),C0578022,8676/10465
inter .,C0205103;C1548610,8677/10465
intense,C0522510,8678/10465
< nmbr . nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8679/10465
nmbr - nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8680/10465
> nmbr . nmbr kg / mnmbr,C0053917;C0053917;C0053917;C1334884;C1334884;C1334884,8681/10465
thiazide,C0541746,8682/10465
thiazides,C0541746,8683/10465
antiplatelet agents,C0085826,8684/10465
antiplatelet agent,C0085826,8685/10465
hemoglobin  g / dl,C0019046,8686/10465
haemoglobin ( g / dl ),C0019046,8687/10465
haemoglobin ( g / l ),C0019046,8688/10465
hemoglobin ( g / dl ),C0019046,8689/10465
hemoglobin ( gm / dl ),C0019046,8690/10465
hemoglobin  mg / dl,C0019046,8691/10465
hemoglobin  g / l,C0019046,8692/10465
haemoglobin  mg / dl,C0019046,8693/10465
hemoglobin — g / dl,,8694/10465
hemoglobin  g / dlf,C0019046,8695/10465
usual care ( n = nmbrla ),C3538928,8696/10465
usual care ( n = nmbra ),C3538928,8697/10465
usual care ( n = nmbr ),C3538928,8698/10465
ace - inhibitors  n ( % ),C0003015,8699/10465
ace inhibitor  n ( % ),C0003015;C4541021,8700/10465
total ho population ( n = nmbr ),C3258257;C3258257;C3258257,8701/10465
total population ( n = nmbr ),C3258257,8702/10465
mean age  years,C0444504;C2347634;C2348143,8703/10465
mean age ( years ),C0444504;C2347634;C2348143,8704/10465
mean age  yrs,C0444504;C2347634;C2348143,8705/10465
mean age ( yrs ),C0444504;C2347634;C2348143,8706/10465
mean age — yr,,8707/10465
waist - to - hip  female,C0230097;C0230097;C0230097;C0230097;C0230097,8708/10465
waist - to - hip  male,C0230097;C0230097;C0230097;C0230097;C0230097,8709/10465
at index acs event,C0600653;C0600653;C0600653;C0600653;C0918012;C0918012;C0918012;C0918012;C1552854;C1552854;C1552854;C1552854;C1637833;C1637833;C1637833;C1637833;C2986546;C2986546;C2986546;C2986546,8710/10465
index acs event,C0600653;C0600653;C0600653;C0600653;C0918012;C0918012;C0918012;C0918012;C1552854;C1552854;C1552854;C1552854;C1637833;C1637833;C1637833;C1637833;C2986546;C2986546;C2986546;C2986546,8711/10465
chronic bronchitis !,C0008677,8712/10465
chronic bronchitis,C0008677,8713/10465
post - bronchodilation fevnmbr,C0439576,8714/10465
pre - bronchodilation fevnmbr,C0439566,8715/10465
pre - bronchodilator fevnmbr,C2599602,8716/10465
lama use at screening,C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C0999593;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775;C1416775,8717/10465
laba use at screening,C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0042153;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C0457083;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944;C1947944,8718/10465
exetimibe / simvastatin,C0074554,8719/10465
ezetimibe / simvastatin,C1532737,8720/10465
cv death  ml  ischemic stroke,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,8721/10465
cv death  mi  ischemic stroke,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,8722/10465
cv death  mi  or ischemic stroke,C3538987;C3538987;C3538987;C3538987;C4048877;C4048877;C4048877;C4048877;C4318503;C4318503;C4318503;C4318503,8723/10465
proton pump inhibitors,C0358591;C1384478;C3540020,8724/10465
proton - pump inhibitors,C0358591;C1384478;C3540020,8725/10465
proton - pump inhibitor,C0358591;C3536754;C4521480,8726/10465
proton pump inhibitor use,C0358591;C0358591;C0358591;C3536754;C3536754;C3536754;C4521480;C4521480;C4521480,8727/10465
duration of tnmbrdm ( years ),C0449238;C2926735,8728/10465
duration of tnmbrdm  years,C0449238;C2926735,8729/10465
duration of tnmbrd ( years ),C0449238;C2926735,8730/10465
anti platelet therapy,C0005821;C0005821;C0005821,8731/10465
anti - platelet therapy,C0005821;C0005821;C0005821,8732/10465
no antiplatelet therapy,C1096021,8733/10465
antiplatelet therapy,C1096021,8734/10465
antiplatelet therapy §,,8735/10465
diastolic blood pressurea  mmhg,C0012000;C0012000;C0012000,8736/10465
systolic blood pressure — mm hg,,8737/10465
diastolic blood pressure ( mm hg ),C0428883;C1305849,8738/10465
systolic blood pressure  mm hg,C0488055;C0871470;C1306620,8739/10465
systolic blood pressure ( mmhg ),C0488055;C0871470;C1306620,8740/10465
diastolic blood pressure ( mm hg ) :,C0428883;C1305849,8741/10465
systolic blood pressurea  mm hg,C0039155;C0039155;C0039155,8742/10465
diastolic blood pressure  mm hg,C0428883;C1305849,8743/10465
systolic blood pressure ( mm hg ),C0488055;C0871470;C1306620,8744/10465
diastolic blood pressure  mmhg,C0428883;C1305849,8745/10465
diastolic blood pressure - mmhg,C0428883;C1305849,8746/10465
diastolic blood pressure ( mmhg ),C0428883;C1305849,8747/10465
systolic blood pressure - mmhg,C0488055;C0871470;C1306620,8748/10465
systolic blood pressure  mmhg,C0488055;C0871470;C1306620,8749/10465
diastolic blood pressure — mm hg,,8750/10465
mineralocorticoid receptor antagonist,C1579268,8751/10465
mineralocorticoid receptor antagonists,C1373021;C1579268,8752/10465
diet group ( n = nmbr ),C0012155;C0012155;C0012155;C0012155;C0012155;C0012155;C0012159;C0012159;C0012159;C0012159;C0012159;C0012159;C1519433;C1519433;C1519433;C1519433;C1519433;C1519433;C2983588;C2983588;C2983588;C2983588;C2983588;C2983588;C3668949;C3668949;C3668949;C3668949;C3668949;C3668949,8753/10465
stent group ( n = nmbr ),C0038257;C0038257;C0038257;C0038257;C0038257;C0038257,8754/10465
haq - di scoreff,C3826998;C4321476,8755/10465
haq - di scored,C3826998;C4321476,8756/10465
haq - di score,C3826998;C3826998;C4321476;C4321476,8757/10465
sirolimus,C0072980,8758/10465
everolimus,C0541315,8759/10465
ambulance,C0002422;C3846685,8760/10465
in ambulance,C0002422;C3846685,8761/10465
p value for heterogeneity,C1709380;C1709380,8762/10465
pvalue for heterogeneity,C0019409;C0242960,8763/10465
race  while,C0034510;C1706779;C3853635,8764/10465
racea white,C0007457;C0043157;C0220938,8765/10465
nmbr . nmbr - nmbr . nmbr mg / l,C0053917;C1334884,8766/10465
nmbr . nmbr - nmbr . nmbr mmol / l,C0053917;C1334884,8767/10465
macroalbuminuria  n ( % ),,8768/10465
microalbuminuria  n ( % ),C0730345,8769/10465
womac score,C0449820;C4050231,8770/10465
total score,C2964552,8771/10465
lacunar,C0241970;C1459585,8772/10465
vascular,C0005847;C1558950;C1801960,8773/10465
dbp  mm hg  mean ± sdc,,8774/10465
sbp  mm hg  mean ± sdc,,8775/10465
sbp  mm hg  mean + sdc,C0085805,8776/10465
mean dlqi score ( nmbr % ci ),C3533236;C0444504;C2347634;C2348143,8777/10465
mean pasi score ( nmbr % ci ),C3533236,8778/10465
tc  mmol / l ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,8779/10465
fpg  mmol / l ( mg / dl ),,8780/10465
body weight  mean ± sd  kg,,8781/10465
body weight  mean = sd  kg,C0005910;C1305866,8782/10465
race / ethnicity n ( % ),C0034510;C0034510;C1706779;C1706779;C3853635;C3853635,8783/10465
race / ethnicity  n ( % ),C0034510;C0034510;C1706779;C1706779;C3853635;C3853635,8784/10465
race / ethnicity  no . ( % ),C0034510;C0034510;C1706779;C1706779;C3853635;C3853635,8785/10465
race or ethnicity  n ( % ),C0034510;C1706779;C3853635,8786/10465
arial flutter or fibrillation,C0016385;C2242390,8787/10465
atrial flutter / fibrillation,C0155709,8788/10465
current smoker ( n z nmbr ),C3173209;C3241966,8789/10465
current smoker ( n = nmbr ),C3173209;C3241966,8790/10465
waist circumference  mean ( sd )  cm,C0455829,8791/10465
waist circumference  mean ( sd )  in,C0455829,8792/10465
empagliflozin,C3490348,8793/10465
dapagliflozint,,8794/10465
canagliflozin,C2974540,8795/10465
coronary - artery bypass grafting,C0010055,8796/10465
coronary artery bypass grafting,C0010055,8797/10465
coronary artery bypass graft,C0010055;C1260596,8798/10465
sex : male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,8799/10465
sex  male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,8800/10465
sex  % female,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,8801/10465
sexa male,C0086582;C1706180;C1706428;C1706429,8802/10465
sex : female,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,8803/10465
sex  female,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,8804/10465
sex ( female ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,8805/10465
dbp  mean ( sd )  mm hg,C0536221;C3813197;C4281799,8806/10465
sbp  mean ( sd )  mmhg,C0085805,8807/10465
dbp  mean ( sd )  mmhg,C0536221;C3813197;C4281799,8808/10465
sbp  mean ( sd )  mm hg,C0085805,8809/10465
sbp  mean = sd  mmhg,C0085805,8810/10465
contrast volume ( ml ),C0009924;C0009924;C0009924;C0009924;C1979874;C1979874;C1979874;C1979874,8811/10465
contrast volume  ml,C0009924;C0009924;C0009924;C0009924;C1979874;C1979874;C1979874;C1979874,8812/10465
crp — mg / liter^,,8813/10465
hscrp — mg / liter,,8814/10465
omega - nmbr fa intake nmbrnd third,C1719844;C1719844,8815/10465
omega - nmbr fa intake nmbrst third,C1719844;C1719844,8816/10465
omega - nmbr fa intake nmbr  d third,C1719844;C1719844,8817/10465
mean ( sd ) pre - bronchodilator,C0444504;C2347634;C2348143,8818/10465
mean ( sd ) post - bronchodilator,C0444504;C2347634;C2348143,8819/10465
former smoking,C0205156;C0205156;C0205156;C0750523;C0750523;C0750523,8820/10465
former smoker,C0337671,8821/10465
egfr > nmbr ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,8822/10465
egfr > nmbr ml / min / nmbr - nmbr mnmbr,C1739039;C3811844;C3812682,8823/10465
egfr < nmbr ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,8824/10465
egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),C1739039;C3811844;C3812682,8825/10465
egfr < nmbr ml / min / nmbr - nmbr mnmbr,C1739039;C3811844;C3812682,8826/10465
egfr > nmbr ml / min / nmbr . nmbrmnmbr,C1739039;C3811844;C3812682,8827/10465
egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),C1739039;C3811844;C3812682,8828/10465
egfr < nmbr ml / min / nmbr . nmbr mnmbr *,C1739039;C3811844;C3812682,8829/10465
egfr £ nmbr ml / min / nmbr . nmbrmnmbr,,8830/10465
egfr < nmbr ml / min / nmbr . nmbr mnmbr §,,8831/10465
egfr < nmbr ml / min / nmbr . nmbrmnmbr,C1739039;C3811844;C3812682,8832/10465
primary outcomes,C0205225;C0439612;C0439631,8833/10465
primary outcome !,C0205225;C0439612;C0439631,8834/10465
primary outcome,C0205225;C0439612;C0439631,8835/10465
nmbr vessel,C0053917;C1334884,8836/10465
nmbr vessels,C0053917;C1334884,8837/10465
non - st - segment elevation mi,C1518422,8838/10465
non - st - segment elevation acs,C1518422;C1518422,8839/10465
rate ratio ( nmbr % ci ),C0871208;C0871208;C1521828;C1521828,8840/10465
rate ratio ( nmbr % cl ),C0871208;C0871208;C1521828;C1521828,8841/10465
extensive colitisy,C0205231,8842/10465
extensive colitis,C0205231;C0205231,8843/10465
lipid - lowering therapy — no . ( % ),,8844/10465
lipid - lowering therapy - no . ( % ),C0585943,8845/10465
patients with at least one concomitant disease *,C0030705,8846/10465
patients with at least one concomitant disease | |,C0030705,8847/10465
hyperlipidemia ( % ) §,,8848/10465
hyperlipidemia  %,C0020473;C0428465;C4555212,8849/10465
hyperlipidaemia ( % ),C0020473;C0428465;C4555212,8850/10465
hyperlipidemia ( % ),C0020473;C0428465;C4555212,8851/10465
diagnosed diabetes ( n = nmbr ),C0011900;C0011900,8852/10465
undiagnosed diabetes ( n = nmbr ),C1408353;C1408353,8853/10465
salmeterol ( n[nmbr ),C0073992,8854/10465
salmeterol ( n [nmbr ),C0073992,8855/10465
physician ' s judgment that vka inappropriate],C0031831;C0804815,8856/10465
physician ' s judgment that vka inappropriate,C0031831;C0804815,8857/10465
female simva,C0043210;C0086287;C1705497;C1705498,8858/10465
male simva,C0086582;C1706180;C1706428;C1706429,8859/10465
western europe ( n = nmbr ),C0043129,8860/10465
eastern europe ( n = nmbr ),C0015177,8861/10465
elevated creatine kinase - mb ( > nmbr u / l ),C0151576;C0205250;C0205250;C3163633;C3163633,8862/10465
elevated creatine kinase mb ( > nmbr u / l ),C0151576;C0205250;C0205250;C3163633;C3163633,8863/10465
current tobacco use,C0521116;C0521116;C0521116;C0521116;C1705970;C1705970;C1705970;C1705970,8864/10465
no current tobacco use,C0521116;C0521116;C0521116;C0521116;C1705970;C1705970;C1705970;C1705970,8865/10465
bare metal,C0025552,8866/10465
bare - metal,C0025552,8867/10465
corticosteroid or azathioprine / nmbr - mercaptopurine,C0001617;C3536709,8868/10465
corticosteroid - azathioprine / nmbr - mercaptopurine,C0001617;C0001617;C3536709;C3536709,8869/10465
dapagliflozin nmbr mg,C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951,8870/10465
dapagliflozin nmbrmg,C2353951,8871/10465
empagliflozin nmbr mg,C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348,8872/10465
ertugliflozin nmbr mg,C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805,8873/10465
ics / lama,C0815320;C0815320;C4551720;C4551720,8874/10465
ics / laba,C0815320;C4551720,8875/10465
ics + laba,C0815320;C4551720,8876/10465
duration of disease — yr,,8877/10465
duration of disease — mo,,8878/10465
eze + statin,C0360714,8879/10465
pbo + statin,C0031962,8880/10465
ze + statin,C0360714,8881/10465
coronary endpoint,C0018787;C0018787,8882/10465
coronary end point,C0018787;C0018787,8883/10465
patients with baseline crp concentration £ nmbr mg / l,,8884/10465
patients with baseline crp concentration < nmbr mg / l,C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705;C0030705,8885/10465
none 一 no . ( % ),,8886/10465
score  no . ( % ),C0449820;C4050231,8887/10465
score 一 no . ( % ),,8888/10465
female simva ( „ = nmbr },,8889/10465
male simva ( „ = nmbr },,8890/10465
aspirin — no . ( % ),,8891/10465
aspirin 一 no . ( % ),,8892/10465
adas — cog score,,8893/10465
adas - cog score *,C3539026;C3539026,8894/10465
troponin nmbr at baseline *,C0041199;C0041199;C0041199;C0041199,8895/10465
troponin nmbr at baseline,C0041199;C0041199;C0041199;C0041199,8896/10465
lower limb fracture,C0023216;C0441994;C1548802;C2003888,8897/10465
upper limb fractures,C1140618,8898/10465
upper limb fracture,C0178316,8899/10465
lower limb fractures,C0023216,8900/10465
inflix  yes,C0666743,8901/10465
inflix  no,C0666743,8902/10465
east europe,C1707877,8903/10465
e . europe,C0015176,8904/10465
western europe,C0043129,8905/10465
w . europe,C0015176,8906/10465
eastern europe,C0015177,8907/10465
w est europe,C3811127;C3890902,8908/10465
eastern european,C0239309,8909/10465
general health,C0424575;C4018875,8910/10465
mental health,C0025353,8911/10465
canakinumab dose ( per mo ),C2718773;C2718773;C2718773,8912/10465
canakinumab dose ( per month ),C2718773;C2718773;C2718773,8913/10465
age ( years ) : < nmbr,C0001779,8914/10465
age ( years ) : > nmbr,C0001779,8915/10465
chd status §,,8916/10465
chd status,C0280604;C3542407,8917/10465
rheumatoid factor positive,C0035448;C0035448;C0035448;C0035448;C0035448;C0201660;C0201660;C0201660;C0201660;C0201660,8918/10465
rheumatoid factor - positive,C0035448;C0035448;C0035448;C0035448;C0035448;C0201660;C0201660;C0201660;C0201660;C0201660,8919/10465
priorheartfailure  %,,8920/10465
prior heart failure yes,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,8921/10465
prior heart failure  %,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,8922/10465
gender  male,C0079399;C1522384,8923/10465
gender male,C0079399;C0079399;C0079399;C0079399;C1522384;C1522384;C1522384;C1522384,8924/10465
metabolic syndrome * n = nmbr,C0524620,8925/10465
metabolic syndrome ( n = nmbr ),C0524620,8926/10465
nonmetabolic syndrome ( n = nmbr ),C0039082,8927/10465
bmi ( kg / mnmbr ),C0578022,8928/10465
bmi  kg / mnmbr,C0578022,8929/10465
bmi  kg / mnmbr  n,C0578022,8930/10465
bmi ( kg / mnmbr ) *,C0578022,8931/10465
baseline bmi < nmbr kg / mnmbr,C0168634;C1442488,8932/10465
baseline bmi > nmbr kg / mnmbr,C0168634;C1442488,8933/10465
duration of assigned regimen before surgery post - randomisation characteristic *,C0449238;C0449238;C0449238;C0449238;C2926735;C2926735;C2926735;C2926735,8934/10465
duration of assigned regimen before surgery post - randomisation characteristic * *,C0449238;C0449238;C0449238;C0449238;C2926735;C2926735;C2926735;C2926735,8935/10465
asa use at baseline,C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C3853627;C3853627;C3853627;C3853627;C3853627;C3853627,8936/10465
no asa use at baseline,C0004057;C0004057;C0004057;C0004057;C0004057;C0004057;C3853627;C3853627;C3853627;C3853627;C3853627;C3853627,8937/10465
ics use at baseline,C0815320;C4551720,8938/10465
female eze / simva ( „ = nmbr },,8939/10465
male eze / simva ( „ = nmbr },,8940/10465
body mass index  kg / mnmbr  mean + sd,C0005893;C0578022;C1305855,8941/10465
body mass index  kg / mnmbr  mean ( sd ),C0005893;C0578022;C1305855,8942/10465
body mass index  kg / mnmbr  mean ± sd,,8943/10465
abdominal obesity *,C0311277,8944/10465
abdominal obesity,C0311277,8945/10465
cohort nmbr ( n = nmbr ),C0009247;C0009247;C0599755;C0599755,8946/10465
cohort nmbr ( n = nmbr ) f,C0009247;C0009247;C0599755;C0599755,8947/10465
age  median ( nmbrth - nmbrth percentiles )  y,C0001779,8948/10465
age  median ( nmbrth — nmbrth percentiles )  y,,8949/10465
baseline hbanmbrc  %,C0168634;C1442488,8950/10465
baseline hbanmbrc ( % ),C0168634;C1442488,8951/10465
no aminosalicylates  n,C0368663,8952/10465
aminosalicylates * *,C0368663,8953/10465
aminosalicylates  n,C0368663,8954/10465
vildagliptin nmbr mg qd,C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906,8955/10465
vildagliptin nmbr mg bid,C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906,8956/10465
< nmbr kg / mnmbr ( n — nmbr ),,8957/10465
> nmbr kg / mnmbr ( n — nmbr ),,8958/10465
baseline ldl - c > nmbr . nmbr to < nmbr . nmbr mmol / lc,C0168634;C1442488,8959/10465
baseline ldl - c nmbr . nmbr to < nmbr . nmbr mmol / lc,C0168634;C0168634;C1442488;C1442488,8960/10465
methotrexate use,C0025677;C0025677;C0025677,8961/10465
methotrexate user,C0025677;C0025677,8962/10465
bare metal stent,C2825200,8963/10465
bare - metal stent,C2825200,8964/10465
other ( n = nmbr ),,8965/10465
other ( n — nmbr ),,8966/10465
amputationsa,,8967/10465
amputation,C0002688;C0332840;C1546539,8968/10465
p — value for interaction,,8969/10465
p - value for interaction *,C1709380,8970/10465
p value for interactiont,C1709380,8971/10465
p value for interaction,C1709380,8972/10465
p - value for interaction,C1709380,8973/10465
p value for interaction^,C1709380,8974/10465
p value fo interactio,C1709380,8975/10465
waisthip ratio,C0205682;C0205682,8976/10465
waist - hip ratio,C0205682,8977/10465
tnglycendes < median,,8978/10465
tngtycerides a median,,8979/10465
tngtycendes a median,,8980/10465
tngtycerides < median,,8981/10465
furosemide,C0016860,8982/10465
torsemide,C0076840,8983/10465
drinker ( % ) a,C0556338,8984/10465
drinker ( % ),C0556338,8985/10465
uncertain,C0087130;C4085655,8986/10465
uncerlain,,8987/10465
mean diastolic blood pressure  mm hg,C0428886;C0488053;C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,8988/10465
mean systolic blood pressure  mm hg,C0428886;C0488053;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,8989/10465
maximum cimt < median,C0806909;C1552615;C2826546,8990/10465
maximum cimt a med an,C0806909;C1552615;C2826546,8991/10465
at clinic diastolic pressure > nmbr mm hg,C0002424;C0442592,8992/10465
at clinic systolic pressure > nmbr mm hg,C0002424;C0442592,8993/10465
at clinic systolic pressure < nmbr mm hg,C0002424;C0442592,8994/10465
at clinic diastolic pressure < nmbr mm hg,C0002424;C0442592,8995/10465
thiazolidinediones,C1257987;C3541957,8996/10465
thiazolidinedioneb,,8997/10465
thiazolidinedione no,C0289779;C1257987;C3537039,8998/10465
thiazolidinedione,C0289779;C1257987;C3537039,8999/10465
thiazolidinedione yes,C0289779;C0289779;C0289779;C1257987;C1257987;C1257987;C3537039;C3537039;C3537039,9000/10465
crcl < nmbr ml / min,C1846718,9001/10465
crcl > nmbr ml / min,C1846718,9002/10465
ecrcl < nmbr ml / min,,9003/10465
stroke or transient ischemic attack,C0038454;C4554100,9004/10465
stroke / transient ischemic attack,C0038454;C0038454;C4554100;C4554100,9005/10465
hdl cholesterol  mmol / l  women  mean ± sd,,9006/10465
hdl cholesterol  mmol / l  men  mean ± sd,,9007/10465
disease duration > nmbr years ( n = nmbr ),C0872146,9008/10465
disease duration b nmbr years ( n = nmbr ),C0872146;C0872146,9009/10465
bmi ( kg / rrr ),C0578022,9010/10465
bmi ( kg / m ),C0578022,9011/10465
anterior ( n  % ),C0205094,9012/10465
inferior ( n  % ),C0542339;C0678975,9013/10465
blood pressure — mm hg,,9014/10465
blood pressure  mm hg,C0005823;C1271104;C1272641,9015/10465
blood pressure — mmhg,,9016/10465
blood pressure  mm,C0005823;C1271104;C1272641,9017/10465
blood pressure ( mm hg ),C0005823;C1271104;C1272641,9018/10465
blood pressure ( mmhg ),C0005823;C1271104;C1272641,9019/10465
blood pressure  mmhg,C0005823;C1271104;C1272641,9020/10465
non - st - elevation mi,C1518422,9021/10465
non - st — elevation mi,,9022/10465
non - st - elevation ml,C1518422;C1518422;C1518422,9023/10465
nmbr - nmbr . nmbr : overweight,C0053917;C1334884,9024/10465
nmbr - nmbr - nmbr  overweight,C0053917;C1334884,9025/10465
intention - to - treat with st - segment - elevation myocardial infarction,C0162425;C1283828,9026/10465
intention - to - treat without st - segment - elevation myocardial infarction,C0162425;C1283828,9027/10465
no history of cancer,C0455471,9028/10465
history of cancer,C0455471,9029/10465
antidiabetic agent,C0935929,9030/10465
antidiabetic agents,C0935929,9031/10465
age > = nmbr years old,C0001779,9032/10465
age < nmbr years old,C0001779,9033/10465
ics use at baseline : no,C0815320;C4551720,9034/10465
ics use at baseline : yes,C0815320;C4551720,9035/10465
crp $ nmbr mg / l  n,C3890735;C3890735;C4048285;C4048285,9036/10465
crp < nmbr mg / l  n,C3890735;C4048285,9037/10465
stent thrombosis *,C3897493,9038/10465
stent thrombosis,C3897493,9039/10465
high - dosage ics plus laba with baseline blood eosinophils > nmbr cells per pl ( n = nmbr ),C0205250;C0205250;C0205250;C0205250;C1299351;C1299351;C1299351;C1299351;C2700149;C2700149;C2700149;C2700149;C3887512;C3887512;C3887512;C3887512;C3889660;C3889660;C3889660;C3889660;C4321237;C4321237;C4321237;C4321237;C4522209;C4522209;C4522209;C4522209,9040/10465
high - dosage ics plus laba with baseline blood eosinophils anmbr cells per pl ( n = nmbr ),C0205250;C0205250;C0205250;C0205250;C1299351;C1299351;C1299351;C1299351;C2700149;C2700149;C2700149;C2700149;C3887512;C3887512;C3887512;C3887512;C3889660;C3889660;C3889660;C3889660;C4321237;C4321237;C4321237;C4321237;C4522209;C4522209;C4522209;C4522209,9041/10465
high - dosage ics plus laba with baseline blood eosinophils < nmbr cells per pl ( n = nmbr ),C0205250;C0205250;C0205250;C0205250;C1299351;C1299351;C1299351;C1299351;C2700149;C2700149;C2700149;C2700149;C3887512;C3887512;C3887512;C3887512;C3889660;C3889660;C3889660;C3889660;C4321237;C4321237;C4321237;C4321237;C4522209;C4522209;C4522209;C4522209,9042/10465
not hispanic or latino ( n = nmbr ),C1518424,9043/10465
not hispanic or latino ( n — nmbr ),,9044/10465
< nmbr mg / dl simva,C0053917;C1334884,9045/10465
> nmbr mg / dl simva,C0053917;C1334884,9046/10465
cardiovasculardeath,,9047/10465
cardiovascular death !,C0007226;C0007226;C0007226;C0007226;C3887460;C3887460;C3887460;C3887460,9048/10465
cardiovascular death,C0007226;C0007226;C0007226;C0007226;C3887460;C3887460;C3887460;C3887460,9049/10465
mean body - mass index  kg / mnmbr,C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,9050/10465
mean body mass index  kg / mnmbr,C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,9051/10465
mean body mass index ( kg / mnmbr ) *,C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,9052/10465
mean body mass index ( kg / mnmbr ),C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143,9053/10465
anmbr + enmbr ( n = nmbr ),,9054/10465
anmbr / nmbr ( n = nmbr ),C0053917;C1334884,9055/10465
nmbr - nmbr ( n = nmbr ),C0053917;C1334884,9056/10465
mean sd nmbr - h asbp  mm hg,C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143;C2348143,9057/10465
mean ± sd nmbr - h adbp  mm hg,,9058/10465
egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr,C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,9059/10465
egfr nmbr – nmbr ml / min / nmbr . nmbr mnmbr,,9060/10465
egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr,C1739039;C1739039;C3811844;C3811844;C3812682;C3812682,9061/10465
nmbr - nmbr / month,C0053917;C0053917;C1334884;C1334884,9062/10465
nmbr - nmbr months,C0053917;C1334884,9063/10465
with corticosteroid treatment < nmbr,C0001617;C0001617;C0001617;C0001617;C0001617;C0001617;C0001617;C3536709;C3536709;C3536709;C3536709;C3536709;C3536709;C3536709,9064/10465
with corticosteroid treatment > nmbr,C0001617;C0001617;C0001617;C0001617;C0001617;C0001617;C0001617;C3536709;C3536709;C3536709;C3536709;C3536709;C3536709;C3536709,9065/10465
postmenopausal  no hrt,C0232970,9066/10465
postmenopausal and no ht,C0232970,9067/10465
poslmenopausal  no ht,,9068/10465
postmenopausal and no hrt,C0232970,9069/10465
poslmenopausal  ht,,9070/10465
depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827,9071/10465
depression^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827,9072/10465
no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827,9073/10465
concomitant medications,C0521115;C0521115;C0521115;C0521115,9074/10465
concomitant medication,C0521115;C0521115;C0521115,9075/10465
nmbr blocker,C0053917;C1334884,9076/10465
( nmbr - blockers,C0053917;C1334884,9077/10465
nmbr blockers,C0053917;C1334884,9078/10465
( nmbr blocker,C0053917;C1334884,9079/10465
/ nmbr - blockers,C0053917;C1334884,9080/10465
 nmbr - blockers,C0053917;C1334884,9081/10465
no prior stroke / tia,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,9082/10465
prior stroke / tia,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,9083/10465
prior stroke or tia,C0332152;C0332152;C2826257;C2826257,9084/10465
cv entry criteria,C3538987;C4048877;C4318503,9085/10465
entry criteria,C1705654,9086/10465
fevnmbr / fvc  % a,C3714541,9087/10465
fevnmbr / fvc  % *,C3714541,9088/10465
placebo  % > ( n / n ),C0032042;C1696465;C1706408,9089/10465
placebo  % ( n / n ),C0032042;C1696465;C1706408,9090/10465
mayo < nmbr  n,C0454788;C1077578,9091/10465
mayo $ nmbr  n,C0454788;C0454788;C1077578;C1077578,9092/10465
weight in kg  median ( iqr ),C0005910;C0005910;C0005910;C0043100;C0043100;C0043100;C1305866;C1305866;C1305866;C1705104;C1705104;C1705104,9093/10465
weight - kg  median ( iqr ),C0005910;C0005910;C0005910;C0043100;C0043100;C0043100;C1305866;C1305866;C1305866;C1705104;C1705104;C1705104,9094/10465
weight ( kg )  median ( iqr ),C0005910;C0043100;C1305866;C1705104,9095/10465
prior myocardial infarction — no . ( % ),,9096/10465
prior myocardial infarction 一 no . ( % ),,9097/10465
baseline ics use : no,C0168634;C0168634;C1442488;C1442488,9098/10465
baseline ics use : yes,C0168634;C0168634;C1442488;C1442488,9099/10465
tg  median ( min  max ),C0337445,9100/10465
mtss  median ( min  max ),,9101/10465
jsn  median ( min  max ),,9102/10465
all - cause mortality or hf hospitalization,C0444868;C0444868;C0444868;C0444868;C3539085;C3539085;C3539085;C3539085,9103/10465
all - cause mortality or hf hospitalization^,C0444868;C0444868;C0444868;C0444868;C3539085;C3539085;C3539085;C3539085,9104/10465
fbs < nmbr mg / dl,C3812213,9105/10465
fbs > = nmbr mg / dl,C3812213,9106/10465
amlodipine / valsartan nmbr / nmbr mg,C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523;C1962523,9107/10465
amlodipine / wlsartan inmbr / nmbr mg,C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696;C0051696,9108/10465
all - cause mortality,C0444868;C0444868;C0444868;C0444868;C3539085;C3539085;C3539085;C3539085,9109/10465
all cause mortality,C0444868;C0444868;C0444868;C0444868;C3539085;C3539085;C3539085;C3539085,9110/10465
renal insufficiency / failure,C0035078;C1963154;C0035078;C0035078;C1565489;C1565489,9111/10465
renal insufficiency or failure,C0035078;C1565489,9112/10465
anticoagulants,C0003280,9113/10465
anti - coagulants,C0848112,9114/10465
anticoagulant,C0003280;C0848112;C3536711,9115/10465
oral corticosteroids,C0442027;C0442027;C0442027;C0442027;C0442027;C4521986;C4521986;C4521986;C4521986;C4521986,9116/10465
oral corticosteroid,C0442027;C0442027;C4521986;C4521986,9117/10465
prior lower gi clinical event,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,9118/10465
prior upper gi clinical event,C0332152;C0332152;C2826257;C2826257,9119/10465
complex anatomy ( n - nmbr  nmbr ),C0439855;C0439855;C0439855;C1704241;C1704241;C1704241,9120/10465
noncomplex anatomy ( n - nmbr  nmbr ),C0002808;C0700276;C1384516,9121/10465
all cana,C1418845,9122/10465
all cancer,C0006826;C0998265;C1306459,9123/10465
ace inhibitors / arb,C0003015,9124/10465
ace inhibitor or arb,C0003015;C4541021,9125/10465
ace inhibitors and arb,C0003015,9126/10465
ace inhibitors or arb,C0003015,9127/10465
ace inhibitors or arbs,C0003015,9128/10465
ace inhibitors / arbs,C0003015,9129/10465
physician ' s global assessment,C4050369,9130/10465
physician ' s global assessment !,C4050369,9131/10465
previous or current im use : no,C0205156;C1552607,9132/10465
previous or current cs use : no,C0205156;C1552607,9133/10465
nyha class  n ( % ) i,C1882083,9134/10465
nyha class  n ( % ),C1882083,9135/10465
nyha class  n ( % ) ii,C1882083,9136/10465
nyha class  ( % ),C1882083,9137/10465
baseline heart rate ( beat / min ),C0168634;C1442488,9138/10465
baseline heart rate ( beats / min ),C0168634;C1442488,9139/10465
concomitant medications  %,C0521115;C0521115;C0521115;C0521115,9140/10465
concomitant medication | |,C0521115;C0521115;C0521115,9141/10465
metabolic syndrome  ! n ( % ),C0524620,9142/10465
metabolic syndrome  n ( % ),C0524620,9143/10465
body weight ( kg ),C0005910;C1305866,9144/10465
body weight  %,C0005910;C1305866,9145/10465
body weight  kg,C0005910;C1305866,9146/10465
body weight — kg,,9147/10465
bodyweight ( kg ),C0005910;C1305866,9148/10465
body weighta  kg,C0242821;C0460148;C1268086;C4082212,9149/10465
fev_ ( l ) :,C3714541,9150/10465
fvc  l,C3714541,9151/10465
fvc ( l ) ,C3714541,9152/10465
fvc ( l ) *,C3714541,9153/10465
fvc ( l ),C3714541,9154/10465
no fracture history,C0016658;C0016658;C0016658;C0016658;C0016658;C0016658,9155/10465
fracture history,C0016658;C0016658;C0016658;C0016658;C0016658;C0016658,9156/10465
nmbr to < nmbr ml / min,C0053917;C1334884,9157/10465
> nmbr to < nmbr ml / min,C0053917;C1334884,9158/10465
nmbr - < nmbr ml / min,C0053917;C1334884,9159/10465
nmbr - nmbr ml / min,C0053917;C1334884,9160/10465
met criterion at blt ( n [ % ] ),C0428210;C0428210;C1550543;C1550543;C4317104;C4317104,9161/10465
met criterion at bl ( n [ % ] ),C0428210;C0428210;C0428210;C0428210;C1550543;C1550543;C1550543;C1550543;C4317104;C4317104;C4317104;C4317104,9162/10465
( % ) ( nmbr . nmbr ),,9163/10465
( % ) ( nmbr - nmbr ),,9164/10465
post - bronchodilator fevnmbr reversibility  % a,C2599594,9165/10465
postbronchodilator fevnmbr reversibility  %,C2599594,9166/10465
post - bronchodilator fevnmbr reversibility  %,C2599594,9167/10465
cigarette smoking,C0239059;C0700219,9168/10465
cigarette smoker,C0337667,9169/10465
daily dose nmbr mg n = nmbr,C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070;C2348070,9170/10465
daily dose > nmbr mg n = nmbr,C2348070,9171/10465
female ( n = nmbr  nmbr ),C0043210;C0086287;C1705497;C1705498,9172/10465
male ( n = nmbr  nmbr ),C0086582;C1706180;C1706428;C1706429,9173/10465
hemoglobin ( g rnmbr ),C0019046,9174/10465
hemoglobin ( g nmbr ! ),C0019046,9175/10465
with lipid - lowering agents,C0086440,9176/10465
without lipid - lowering agents,C0086440,9177/10465
macroalbuminuria,,9178/10465
macroalbuminuriaf,,9179/10465
microalbuminuria,C0730345,9180/10465
macro - albuminuria,C2984010,9181/10465
micro - albuminuria,C0085672;C1553035;C3811161;C4049106,9182/10465
egfr ( ml / min per nmbr - nmbr mnmbr ),C1739039;C3811844;C3812682,9183/10465
egfr ( ml / min per nmbr - nmbr mnmbr ) t,C1739039;C3811844;C3812682,9184/10465
macroalbuminuria — no . / total no . ( % ),,9185/10465
microalbuminuria — no . / total no . ( % ),,9186/10465
chd simva,C0280604;C3542407,9187/10465
no chd simva,C0280604;C3542407,9188/10465
> nmbr . nmbr mu / l $ mmol / l,C0053917;C1334884,9189/10465
< nmbr . nmbr mu / l $ mmol / l,C0053917;C1334884,9190/10465
stage nmbra : > = nmbr and < nmbr,C0205390;C1300072;C1306673,9191/10465
stage nmbrb : > = nmbr and < nmbr,C0205390;C1300072;C1306673,9192/10465
canakinumab  hscrp > nmbr - nmbr mg / l at nmbr months ( n = nmbr ),C2718773,9193/10465
canakinumab  hscrp < nmbr - nmbr mg / l at nmbr months ( n = nmbr ),C2718773,9194/10465
post - bronchodilator screening fevnmbr ml,C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594;C2599594,9195/10465
pre - bronchodilator screening fevnmbr ml,C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602;C2599602,9196/10465
duration of hypercholesterolaemia  mean ± sd ( year ),,9197/10465
duration of hypercholesterolemia  mean ± sd ( years ),,9198/10465
< nmbr with no historical count > nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,9199/10465
< nmbr with historical count > nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,9200/10465
baseline hbalc > nmbr . nmbr % ( nmbr mmol / mol ) nmbr,C0168634;C1442488,9201/10465
baseline hbalc < nmbr . nmbr % ( nmbr mmol / mol ) nmbr,C0168634;C1442488,9202/10465
difference from placebo ( nmbr % ci ),C1705241;C1705241;C1705241;C1705242;C1705242;C1705242,9203/10465
difference from placebo * ( nmbr % ci ),C1705241;C1705241;C1705241;C1705242;C1705242;C1705242,9204/10465
central eosinophil count ( cells per pl ),C0205099;C0205099;C1879652;C1879652,9205/10465
central eosinophil count ( cells per pl ) t,C0205099;C0205099;C1879652;C1879652,9206/10465
other anti - platelet agents,C0040616,9207/10465
other antiplatelet agents,C0085826,9208/10465
other forms of atherosclerosis^,C0348078;C0348078;C0376315;C0376315,9209/10465
other forms of atherosclerosis ’,,9210/10465
race or ethnic group  no . ( % ),C0034510;C1706779;C3853635,9211/10465
race or ethnic group — no . ( % ) f,,9212/10465
prior smoker,C0337671,9213/10465
prior stroke,C0332152;C0332152;C2826257;C2826257,9214/10465
no prior stroke,C0332152;C0332152;C2826257;C2826257,9215/10465
gender  n ( % ),C0079399;C1522384,9216/10465
gender  no . ( % ),C0079399;C1522384,9217/10465
coronary heart disease  n ( % ) b,C0010054;C0010068;C1956346,9218/10465
coronary heart disease  n ( % ) t,C0010054;C0010068;C1956346,9219/10465
mean ± s . d . fpg,,9220/10465
mean ( s . d . ) fpg,C0444504;C2347634;C2348143,9221/10465
troponin i ( pg / ml ),C0077401,9222/10465
troponin t ( pg / ml ),C0077404;C1420827,9223/10465
> nmbr ml / min / nmbr . nmbrmnmbr,C0053917;C1334884,9224/10465
≥ nmbr ml / min / nmbr . nmbr mnmbr,,9225/10465
< nmbr ml / min / nmbr . nmbrmnmbr,C0053917;C1334884,9226/10465
< nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,9227/10465
> nmbr ml / min / nmbr . nmbr mnmbr,C0053917;C1334884,9228/10465
ischemia - driven revascularization,C0022116;C4321499,9229/10465
ischemia driven revascularization,C0022116;C4321499,9230/10465
timi minor,,9231/10465
timi major,,9232/10465
history of major microvascular disease  n ( % ),C0683519;C0683519;C0683519;C0683519;C0730226;C0730226;C0730226;C0730226;C0850708;C0850708;C0850708;C0850708;C0944983;C0944983;C0944983;C0944983,9233/10465
history of major macrovascular disease  n ( % ),C0683519;C0683519;C0683519;C0683519;C0730226;C0730226;C0730226;C0730226;C0850708;C0850708;C0850708;C0850708;C0944983;C0944983;C0944983;C0944983,9234/10465
pre - bronchodilation fvc,C0439566,9235/10465
post - bronchodilation fvc,C0439576,9236/10465
nmbr . nmbr ( nmbr . nmbr – nmbr . nmbr ),,9237/10465
nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr ),C0053917;C1334884,9238/10465
nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr ),C0053917;C1334884,9239/10465
history of macrovascular disease ( % ),C0683519;C0730226;C0850708;C0944983,9240/10465
history of microvascular disease ( % ),C0683519;C0730226;C0850708;C0944983,9241/10465
patient characteristics,C0815172,9242/10465
patients ' characteristics,C0815172,9243/10465
treatment with anti - platelet drugs,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704,9244/10465
treatment with antiplatelet drugs,C3469597,9245/10465
concomitant medications  * n ( % ),C0521115;C0521115;C0521115;C0521115,9246/10465
concomitant medication  n ( % ),C0521115;C0521115;C0521115,9247/10465
concomitant medications  n ( % ),C0521115;C0521115;C0521115;C0521115,9248/10465
fpg  mean ( sd )  mg / dl,,9249/10465
fpg  mean ( sd )  mg / dlt,,9250/10465
one - vessel disease,C3275121,9251/10465
two - vessel disease,C0581375,9252/10465
ethnicity,C0015031;C0243103,9253/10465
ethnicity ,C0015031;C0243103,9254/10465
ind / glyb n = nmbr,C4049864,9255/10465
ind / gly n = nmbr,C4049864;C4049864,9256/10465
non - hispanic / latino,C1518424,9257/10465
not hispanic or latino,C1518424,9258/10465
not hispanic / latino,C1518424,9259/10465
north american,C0425358;C2700615,9260/10465
north america,C0028405,9261/10465
south africa,C0037712,9262/10465
south american,C0425359,9263/10465
sou ti africa,C0039247;C0040302;C1553045;C1704756,9264/10465
south america,C0037713,9265/10465
northamerica,,9266/10465
bloodpressure  mean ( sd )  m m hg,C0005823;C1271104;C1272641,9267/10465
blood pressure  mean ( sd )  mm hg,C0005823;C1271104;C1272641,9268/10465
tiotropium / olodaterol nmbr . nmbr / nmbr mg,C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,9269/10465
tiotropium + olodaterol nmbr . nmbr / nmbr mg,C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,9270/10465
tiotropium + olodaterol nmbr . nmbr / nmbr pg,C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,9271/10465
diastolic bp  mmhg ( sd ),C0428883,9272/10465
systolic bp  mmhg ( sd ),C0871470,9273/10465
postamendment,,9274/10465
preamendment,C1548596,9275/10465
fasting glucose — mg / dl,,9276/10465
fasting glucose ( mg / dl ),C0015663,9277/10465
fasting glucose ( mg / dl ) ,C0015663,9278/10465
mean systolic bp  mmhg  mean = sd,C0444504;C2347634;C2348143,9279/10465
mean diastolic bp  mmhg  mean = sd,C0444504;C2347634;C2348143,9280/10465
number of prior aeds  n ( % ) b,C0237753;C0237753;C0449788;C0449788,9281/10465
number of prior aeds  n ( % ),C0237753;C0237753;C0449788;C0449788,9282/10465
mean ( sd ) sdai *,C0444504;C2347634;C2348143,9283/10465
mean ( sd ) cdai *,C0444504;C2347634;C2348143,9284/10465
age > nmbr yearsnmbr,C0001779,9285/10465
age < nmbr yearsnmbr,C0001779,9286/10465
baseline systolic blood pressure ( mm hg ),C4274438,9287/10465
baseline diastolic blood pressure ( mm hg ),C4274392,9288/10465
adp antagonist,C0523452,9289/10465
tnf antagonist,C1448177,9290/10465
comorbidities,C0009488,9291/10465
co - morbidities,C0009488,9292/10465
vildagliptin nmbr mg bid n = nmbr,C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906,9293/10465
vildagliptin nmbr mg qd n = nmbr,C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906;C1570906,9294/10465
migraine with aura,C0154723,9295/10465
migraine without aura,C0338480,9296/10465
previous cancer,C0205156;C0205156;C0205156;C1552607;C1552607;C1552607,9297/10465
previous cancerc,C0205156;C1552607,9298/10465
lipid - lowering drugs,C0086440,9299/10465
lipid - lowerinq druq,C0023779,9300/10465
lipid - lowering drug,C0086440,9301/10465
des type,C0011702;C0011702;C4551552;C4551552,9302/10465
acs type,C0742343;C0742343;C4318612;C4318612,9303/10465
fevnmbr ( post - albuterol )  l,,9304/10465
fevnmbr  pre - albuterol  l,,9305/10465
fevnmbr ( pre - albuterol )  l,,9306/10465
fevnmbr  post - albuterol  l,,9307/10465
p blockers ( % ),C0369773;C2603361,9308/10465
p - blocker ( % ),C0369773;C2603361,9309/10465
severe or very severe,C0205082;C4050465;C4050466,9310/10465
severe / very severea,C0205082;C0205082;C4050465;C4050465;C4050466;C4050466,9311/10465
difference ( nmbr % cl ),C1705241;C1705242,9312/10465
difference ( nmbr % ci ) *,C1705241;C1705242,9313/10465
nmbr months,C0053917;C1334884,9314/10465
nmbr mentis,C0053917;C1334884,9315/10465
nmbr mortis,C0053917;C1334884,9316/10465
> nmbr months,C0053917;C1334884,9317/10465
< nmbr months,C0053917;C1334884,9318/10465
nmbr montlts,C0053917;C1334884,9319/10465
seated sbp  mean ( sd )  mmhg,C0277814;C1283233,9320/10465
seated dbp  mean ( sd )  mmhg,C0277814;C0277814;C0277814;C1283233;C1283233;C1283233,9321/10465
alcohol abuse,C0085762;C4050601,9322/10465
alcohol use,C0001948,9323/10465
> nmbr microg / l,C0053917;C1334884,9324/10465
< nmbr microg / l,C0053917;C1334884,9325/10465
tobacco abuse,C0040336,9326/10465
tobacco use,C0040335;C0543414;C0841002;C3853727,9327/10465
hospital stay ( days ),C3489408,9328/10465
hospital stay  days,C3489408,9329/10465
fevnmbr — % of predicted value,,9330/10465
fevnmbr ( % of predicted value ),,9331/10465
maternal history  n ( % ),C0559473,9332/10465
paternal history  n ( % ),C0424909,9333/10465
plp - c  mean ( sd )  mg / dl,C0034266;C1175541;C1257874;C1705623,9334/10465
ldl - c  mean ( sd )  mg / dl,,9335/10465
hdl - c  mean ( sd )  mg / dl,C3715113,9336/10465
nmbr drinks / wk,C0053917;C0053917;C1334884;C1334884,9337/10465
> nmbr drinks / week,C0053917;C0053917;C1334884;C1334884,9338/10465
nmbr + drinks / wk,C0053917;C0053917;C1334884;C1334884,9339/10465
> nmbr drinks / wk,C0053917;C0053917;C1334884;C1334884,9340/10465
prior hypertension yes,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,9341/10465
prior hypertensiona yes,C0332152;C0332152;C0332152;C2826257;C2826257;C2826257,9342/10465
drug - related ae *,C0013227;C0013227;C1254351;C1254351,9343/10465
drug - related teaes *,C0013227;C0013227;C1254351;C1254351,9344/10465
subgroup p valuef,C1079230;C1515021,9345/10465
subgroup p value 本,,9346/10465
white ethnic origin,C0007457;C0043157;C0220938,9347/10465
while ethnic origin,,9348/10465
> nmbr yr since menopause,C0053917;C1334884,9349/10465
< nmbr yr since menopause,C0053917;C1334884,9350/10465
ls mean difference ( nmbr % ci ),C0023668;C0023668;C0023668;C0023668;C0023668;C0023668,9351/10465
( mean difference  nmbr % ci ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,9352/10465
( mean % difference  nmbr % ci ),C0444504;C0444504;C2347634;C2347634;C2348143;C2348143,9353/10465
reversibility : < nmbr %,C0449261,9354/10465
reversibility : > nmbr %,C0449261,9355/10465
male eze / simva,C0086582;C1706180;C1706428;C1706429,9356/10465
all ez / simva,C0206578,9357/10465
female eze / simva,C0043210;C0086287;C1705497;C1705498,9358/10465
glycated hemoglobin - % ’,,9359/10465
glycated hemoglobin  %,C0017853,9360/10465
glycated hemoglobin ( % ),C0017853,9361/10465
glycated hemoglobin — %,,9362/10465
glycated haemoglobin ( % ),C0017853,9363/10465
anmbrc ( mmol / mol ),,9364/10465
hbanmbrc  mmol / mol,,9365/10465
hbanmbrc ( mmol / mol ),,9366/10465
arterial hypertension *,C0020538,9367/10465
arterial hypertension,C0020538,9368/10465
intervention,C0184661;C0886296;C1273869,9369/10465
interruption,C0332453;C1512900,9370/10465
waist circumference ( cm ),C0455829,9371/10465
waist circumference — cm,,9372/10465
waist circumference  ( cm ),C0455829,9373/10465
waist circumference  cm,C0455829,9374/10465
dbp ( mm hg )  median ( iqr ),C0536221;C3813197;C4281799,9375/10465
sbp ( mm hg )  median ( iqr ),C0085805,9376/10465
total cholesterol  mg / dl,C0201950;C0543421,9377/10465
total cholesterol — mg / dl,,9378/10465
total cholesterol ( mg / dl ),C0201950;C0543421,9379/10465
toial cholcsierol ( mg / dl ),,9380/10465
total cholesterol  mg / dl^,C0201950;C0543421,9381/10465
no change,C0392747;C0443172;C1705241;C4319952,9382/10465
% change,C0392747;C0443172;C1705241;C4319952,9383/10465
> nmbr ml / min,C0053917;C1334884,9384/10465
£ nmbr ml / min,,9385/10465
< nmbr ml / min,C0053917;C1334884,9386/10465
smoking history ( pack - years ),C1519384,9387/10465
smoking history  pack - years,C1519384,9388/10465
smoking history ( pack - yr ),C1519384,9389/10465
dm + ( aliskiren vs . placebo ),C0011816;C3250443,9390/10465
dm - ( aliskiren vs . placebo ),C0011816;C3250443,9391/10465
without beta blocker,C0001645,9392/10465
with beta blocker,C0001645,9393/10465
timi risk score !,C0035647;C0035647;C4552904;C4552904,9394/10465
timi risk score,C0035647;C0035647;C4552904;C4552904,9395/10465
timi risk score  %,C0035647;C0035647;C4552904;C4552904,9396/10465
angiotensin - converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021,9397/10465
angiotensin - converting - enzyme inhibitor,C0003015;C2757044;C3536837;C4541021,9398/10465
total asthma symptom score,C3533163;C3533163,9399/10465
total asthma symptom score :,C3533163;C3533163,9400/10465
diastolic bp  mmhg  mean ± sd,,9401/10465
systolic bp  mmhg  mean ± sd,,9402/10465
uric acid fertile nmbr ( > nmbr . nmbr mg / dl ),C0041980;C0041980,9403/10465
uric acid tertile nmbr ( < nmbr . nmbr mg / dl ),C0041980;C0041980,9404/10465
uric acid tertile nmbr ( > nmbr . nmbr mg / dl ),C0041980;C0041980,9405/10465
> nmbr . nmbr mmol / liter,C0053917;C1334884,9406/10465
> nmbr . nmbr mg / liter,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,9407/10465
< nmbr . nmbr mg / liter,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,9408/10465
< nmbr . nmbr mmol / liter,C0053917;C1334884,9409/10465
< nmbr . nmbr pmol / liter,C0053917;C1334884,9410/10465
age ( years ) - < median ( n = nmbr  nmbr ),C0001779,9411/10465
age ( years ) - > = median ( n = nmbr  nmbr ),C0001779,9412/10465
macrovascular disease  n ( % ),C0012634,9413/10465
microvascular disease  n ( % ),C0443258,9414/10465
vorapaxar ( n = nmbr . nmbr ),C2974521,9415/10465
vorapaxar ( n = nmbr nmbr ),C2974521,9416/10465
vorapaxar ( n = nmbr  nmbr ),C2974521,9417/10465
risk difference,C0035647;C0035647;C4552904;C4552904,9418/10465
lsm difference,C1705241;C1705242,9419/10465
aspirin ( n = nmbr  nmbr ),C0004057,9420/10465
aspirin ( n = nmbr nmbr ),C0004057,9421/10465
rosuvastatin,C0965129,9422/10465
rosuvastatin +,C0965129,9423/10465
metformin use,C0025598;C0025598;C0025598,9424/10465
no metformin use,C0025598;C0025598;C0025598,9425/10465
copd severity  n ( % ) a,C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,9426/10465
copd severity  n ( % ),C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,9427/10465
copd severity  n ( % ) *,C0024117;C0024117;C1412502;C1412502;C3714496;C3714496,9428/10465
prior revascularization,C0332152;C2826257,9429/10465
pci revascularization,C4049621,9430/10465
ldl - c : hdl - c,,9431/10465
ldl - c / hdl - c,C3715113,9432/10465
ldl - c / hdl - cx,C3715113,9433/10465
oral agents,C0442027;C0442027;C0442027;C4521986;C4521986;C4521986,9434/10465
two agents,C0205448;C0205448;C0205448,9435/10465
ras agents,C0034678;C0034678;C0034678;C0525678;C0525678;C0525678,9436/10465
mean ( sd ) fevnmbr ( l ) pre - bronchodilator,C0444504;C2347634;C2348143,9437/10465
mean ( sd ) fevnmbr ( l ) post - bronchodilator,C0444504;C2347634;C2348143,9438/10465
< nmbr years simva ( n = nmbr },C0053917;C1334884,9439/10465
> nmbr years simva ( „ = nmbr },,9440/10465
bmi > nmbr kg / mnmbr,C0578022,9441/10465
bmi < nmbr kg / mnmbr,C0578022,9442/10465
bmi  xnmbr kg / mnmbr,C0578022,9443/10465
bmi < nmbrkg / mnmbr,C0578022,9444/10465
bmi > = nmbrkg / mnmbr,C0578022,9445/10465
bmi  median ( sd )  kg / mnmbr,C0578022,9446/10465
bmi  mean ( sd )  kg / mnmbr,C0578022,9447/10465
physical function,C0516981;C4049916,9448/10465
physical functioning,C0516981;C4049916,9449/10465
ldl - c ( mg / dl ),,9450/10465
hdl - c ( mg / dl ),C3715113,9451/10465
hdl - c  mg / dl,C3715113,9452/10465
ldl - c  mg / dl,,9453/10465
regular aspirin use,C0205272;C0205272;C0205272,9454/10465
no regular aspirin use,C0205272;C0205272;C0205272,9455/10465
> nmbr beats / min,C0053917;C1334884,9456/10465
< nmbr beats / min,C0053917;C1334884,9457/10465
antiplatelets,,9458/10465
antiplatelet,,9459/10465
characteristics,C1521970,9460/10465
characteristic,C1521970,9461/10465
hypokalemia,C0020621;C4553966,9462/10465
hvookalemia,,9463/10465
hyperkalemiab,,9464/10465
hungary,C0020174,9465/10465
surgery,C0038894;C0038895;C0543467;C1274039,9466/10465
baseline uacr < nmbr mg / g,C0168634;C1442488,9467/10465
baseline uacr > nmbr mg / g,C0168634;C1442488,9468/10465
insulin plus nmbr oral agent,C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C0021641;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1533581;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C1579433;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501;C3714501,9469/10465
insulin plus > nmbr oral agent,C0021641;C1533581;C1579433;C3714501,9470/10465
long - acting nitrates,C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317,9471/10465
long acting nitratef,C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317,9472/10465
long - acting nitrate,C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C0205166;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317;C1706317,9473/10465
ischaemic aetiology,C0475224;C0475224;C0475224,9474/10465
ischemic aetiology,C0475224;C0475224;C0475224,9475/10465
systolic blood pressure  mean ( sd )  mm hga,C0488055;C0871470;C1306620,9476/10465
systolic blood pressure  mean ( sd )  mm hg,C0488055;C0871470;C1306620,9477/10465
hscrp < nmbr . nmbr mg / l,,9478/10465
hscrp > nmbr . nmbr mg / l,,9479/10465
hscrp > nmbr . nmbr mga .,,9480/10465
hs - crp > nmbr . nmbr mg / l,C3890735;C4048285,9481/10465
hs - crp < nmbr . nmbr mg / l,C3890735;C4048285,9482/10465
hs - crp < nmbr . nmbr g / l,C3890735;C4048285,9483/10465
creatinine clearance  ml / min,C0812399,9484/10465
creatine clearance  ml / min,C0373595,9485/10465
creatinine clearance ( ml / min ),C0812399,9486/10465
total cholesterolnmbr < nmbr mg / dl,C0439175;C0439810,9487/10465
total cholesterolnmbr > nmbr mg / dl,C0439175;C0439810,9488/10465
rosuvastatin  n ( rate ),C0965129,9489/10465
rosuvastatin n ( rate ) *,C0965129,9490/10465
rosuvastatin n ( rate ),C0965129,9491/10465
tiotropium / olodaterol nmbr / nmbr mg,C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,9492/10465
tiotropium + olodaterol nmbr / nmbr mg,C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,9493/10465
tiotropium + olodaterol nmbr / nmbr pg,C4032878;C4032878;C4032878;C4032878;C4032878;C4032878,9494/10465
diastolic blood pressure,C0428883;C1305849,9495/10465
diastolic blood pressure ,C0428883;C1305849,9496/10465
systolic blood pressure,C0488055;C0871470;C1306620,9497/10465
systolic blood pressure ,C0488055;C0871470;C1306620,9498/10465
cardiac failure *,C0018801;C0018802,9499/10465
cardiac failure §,,9500/10465
cardiac failure,C0018801;C0018802,9501/10465
major cardiovascular event,C0205082;C0205164;C4318856;C4521762,9502/10465
major cardiovascular event *,C0205082;C0205164;C4318856;C4521762,9503/10465
major cardiovascular events,C0205082;C0205164;C4318856;C4521762,9504/10465
no concomitant immunosuppressive and / or prior anti - tnf use,C0521115,9505/10465
concomitant immunosuppressive and / or prior anti - tnf use,C0521115,9506/10465
triglycerides - mg / dl * *,C0041004,9507/10465
triglycerides ( mg / dl ) * *,C0041004,9508/10465
nmbr - nmbr months  n ( % ),C0053917;C1334884,9509/10465
nmbr - < nmbr months  n ( % ),C0053917;C1334884,9510/10465
received nmbr prior biologic therapies  n,C1514756;C1514756,9511/10465
received nmbr prior biologic therapy  n,C1514756;C1514756,9512/10465
immunosuppressants onlyff,C0021081,9513/10465
immunosuppressants only,C0021081;C0021081,9514/10465
mtx > nmbr mg / week,C0025677;C1417487,9515/10465
mtx £ nmbr mg / week,,9516/10465
active smoking,C0205177;C0205177;C0205177;C3853793;C3853793;C3853793;C3888249;C3888249;C3888249,9517/10465
active smoker,C0205177;C3853793;C3888249,9518/10465
cardiovascular risk factors  no . ( % ),C0850624,9519/10465
cardiovascular risk factors  n ( % ),C0850624,9520/10465
demographic,C0011298,9521/10465
demographics,C0011298;C1704791,9522/10465
demography,C0011298,9523/10465
no stroke ( n = nmbr ),C0038454;C4554100,9524/10465
any stroke ( n = nmbr ),C0038454;C4554100,9525/10465
left main,C0205091;C0205091;C0443246;C0443246;C1552822;C1552822,9526/10465
back pain,C0004604;C1963071;C4553945,9527/10465
neck pain,C0007859;C1963180;C4553909,9528/10465
rest pain,C0234253,9529/10465
< nmbr mg / dl eze / simva,C0053917;C1334884,9530/10465
> nmbr mg / dl eze / simva,C0053917;C1334884,9531/10465
no st depression or elevation,C0520887,9532/10465
st depression or elevation,C0520887,9533/10465
medication use at baseline  n ( % ),C0240320;C0240320,9534/10465
medications at baseline  n ( % ),C0013227;C0013227;C0802604;C0802604;C2598133;C2598133;C4284232;C4284232,9535/10465
history of atrial fibrillation or fl utter,C0729790,9536/10465
history of atrial fibrillation / flutter,C0729790;C0729790;C1998417,9537/10465
statin without other llt,C0360714,9538/10465
statin with other llt,C0360714,9539/10465
< qnmbr ( nmbr ) — number / n ( % ),,9540/10465
> qnmbr ( nmbr ) — number / n ( % ),,9541/10465
time from qualifying mi  %,C0040223;C3541383,9542/10465
time from qualifying mi  yrs,C0040223;C3541383,9543/10465
prior history of ml or ischemic stroke,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,9544/10465
prior history of mi or ischaemic stroke,C0332152;C0332152;C0332152;C0332152;C0332152;C0332152;C2826257;C2826257;C2826257;C2826257;C2826257;C2826257,9545/10465
hazard ratio ( nmbr % confi dence interval ),C2985465,9546/10465
hazard ratio ( nmbr % confidence interval ),C2985465,9547/10465
hazard ratio ( nmbr % confidence interval ) *,C2985465,9548/10465
with antiplatelets,,9549/10465
without antiplatelets,,9550/10465
range  ( min  max ),C1514721;C2348147;C3542016,9551/10465
range : min  max,C1514721;C2348147;C3542016,9552/10465
range ( min  max ),C1514721;C2348147;C3542016,9553/10465
aml nmbr mg / hctz nmbr mg,C0023465;C0023465;C0023467;C0023467,9554/10465
om nmbr mg / hctz nmbr mg,C0028971;C0028971;C1705272;C1705272,9555/10465
insulin therapy,C0021641;C0021641;C0021641;C1533581;C1533581;C1533581;C1579433;C1579433;C1579433;C3714501;C3714501;C3714501,9556/10465
noninsulin therapy,C0039798;C0087111;C1363945,9557/10465
mean ± sd  n,,9558/10465
mean ± sd ( yr ),,9559/10465
mean ± sd ( n ),,9560/10465
stage nmbr : > nmbr ml / min / nmbr . nmbr mnmbr,C0205390;C0205390;C1300072;C1300072;C1306673;C1306673,9561/10465
stage nmbr : < nmbr ml / min / nmbr . nmbr mnmbr,C0205390;C0205390;C1300072;C1300072;C1306673;C1306673,9562/10465
median ( qnmbr  qnmbr ),C0549183;C0876920;C2347635;C2348144;C2939193,9563/10465
median ( qnmbr : qnmbr ),C0549183;C0876920;C2347635;C2348144;C2939193,9564/10465
bmi category ( % ),C0578022;C0578022,9565/10465
age category ( % ),C0001779;C0001779,9566/10465
supplementary oxygen,C0030054,9567/10465
supplemental oxygen,C4534306,9568/10465
fvc ( liters ),C3714541,9569/10465
fvc — liters,,9570/10465
> nmbr years of age,C0053917;C1334884,9571/10465
< nmbr years of age,C0053917;C1334884,9572/10465
$ nmbr exacerbations,C0053917;C1334884,9573/10465
nmbr exacerbation,C0053917;C1334884,9574/10465
> nmbr exacerbations,C0053917;C1334884,9575/10465
nmbr exacerbations,C0053917;C1334884,9576/10465
history of mi ( n = nmbr  nmbr ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,9577/10465
no history of mi ( n = nmbr  nmbr ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,9578/10465
vka therapy,C0039798;C0087111;C1363945,9579/10465
dual therapy,C0205173;C0205173;C0205173;C1554184;C1554184;C1554184,9580/10465
egfr  mean ( sd )  ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,9581/10465
egfr  mean = sd  ml / min / nmbr . nmbr mnmbr,C1739039;C3811844;C3812682,9582/10465
nt - probnp ， pmol / h,,9583/10465
nt - probnp  pmol / l^,C0669479;C0754710,9584/10465
nt - probnp  pmol / l,C0669479;C0754710,9585/10465
antihypertensive,C0003364,9586/10465
antihypertensives,C0003364,9587/10465
gender  n ( % ) male,C0079399;C1522384,9588/10465
gender  n [ % ] male,C0079399;C1522384,9589/10465
ldl - c ( mmol / l  mean ),,9590/10465
hdl - c ( mmol / l  mean ),C3715113,9591/10465
all patients ( « = nmbr nmbr ),,9592/10465
all patients ( n = nmbr  nmbr ),C0030705,9593/10465
eastern europe ( % ),C0015177,9594/10465
western europe ( % ),C0043129,9595/10465
om nmbrmg / aml nmbr mg,C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C0028971;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272;C1705272,9596/10465
om nmbr mg / aml nmbr mg,C0028971;C0028971;C0028971;C0028971;C1705272;C1705272;C1705272;C1705272,9597/10465
ischaemic heart disease,C0010054;C0151744,9598/10465
ischemic heart disease,C0010054;C0151744,9599/10465
hbanmbrc  mean ( sd )  %,,9600/10465
hbanmbrc  mean = sd  %,,9601/10465
hbanmbrc  median ( sd )  %,,9602/10465
asia pacific,C0003980,9603/10465
asia - pacific,C0003980,9604/10465
asia / pacific,C0003980,9605/10465
previous coronary revascularization,C0205156;C1552607,9606/10465
previous coronary revascularisation,C0205156;C1552607,9607/10465
corticosteroid use at baseline - no,C0239126;C0239126,9608/10465
corticosteroid use at baseline - yes,C0239126;C0239126;C0239126;C0239126;C0239126;C0239126,9609/10465
fevnmbr reversibility  % *,C0449261,9610/10465
fevnmbr reversibility  % b,C0449261,9611/10465
serum triglycerides — mmol / liter,,9612/10465
serum triglycerides — pmol / liter,,9613/10465
angina pectoris,C0002962,9614/10465
angina pectoris 本,,9615/10465
angina pectoris *,C0002962,9616/10465
angina pectorisf,C0002962,9617/10465
alc > = nmbr . nmbr %,C1424945;C3811058,9618/10465
alc < nmbr . nmbr %,C1424945;C3811058,9619/10465
major bleeding,C0205082;C0205164;C4318856;C4521762,9620/10465
minor bleeding,C0026193;C0205165,9621/10465
a from baselineb,,9622/10465
a from baseline,C0168634;C1442488,9623/10465
bmi : < nmbr . nmbr kg / mnmbr,C0578022,9624/10465
bmi : > nmbr . nmbr kg / mnmbr,C0578022,9625/10465
mayo score  mean ( sd ),C0454788;C0454788;C1077578;C1077578,9626/10465
mayo score ( mean ± sd ),,9627/10465
total ( n = nmbr nmbr ),C0439175;C0439810,9628/10465
total  n = nmbr nmbr,C0439175;C0439810,9629/10465
total ( n = nmbr  nmbr ),C0439175;C0439810,9630/10465
> median ( nmbr . nmbr years ) — number / n ( % ),,9631/10465
< median ( nmbr . nmbr years ) — number / n ( % ),,9632/10465
difference vs placebo * *,C1705241;C1705242,9633/10465
difference vs placebo ',C1705241;C1705242,9634/10465
difference vs . placebo,C1705241;C1705242,9635/10465
difference vs placebo,C1705241;C1705242,9636/10465
avm % △ ( se ),,9637/10465
met % △ ( se ),,9638/10465
chronic kidney diseased,C2364010,9639/10465
chronic kidney disease,C1561643;C4553188,9640/10465
estimated difference %,C0750572;C0750572,9641/10465
estimated difference,C0750572;C0750572,9642/10465
u . s . site,C0041703;C0041703;C0041703,9643/10465
u . s . sites,C0041703,9644/10465
history of diabetes ( n = nmbr ),C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,9645/10465
no history of diabetes ( n = nmbr ),C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,9646/10465
< nmbr months  median ( min  max ),C0053917;C1334884,9647/10465
> nmbr months  median ( min  max ),C0053917;C1334884,9648/10465
posterior circulation,C0205095;C0205095,9649/10465
anterior circulation,C0205094;C0205094,9650/10465
insulin yes,C0021641;C0021641;C0021641;C1533581;C1533581;C1533581;C1579433;C1579433;C1579433;C3714501;C3714501;C3714501,9651/10465
insulin use,C0240016,9652/10465
insulin based,C0021641;C1533581;C1579433;C3714501,9653/10465
non - black race and ss > nmbr ( n = nmbr vs nmbr ),C1518422,9654/10465
non - black race and ss < nmbr ( n = nmbr vs nmbr ),C1518422,9655/10465
family history of diabetes ( % ) *,C1313937,9656/10465
family history of diabetes ( - ),C1313937,9657/10465
family history of diabetes ( + ),C1313937,9658/10465
duration of diabetes  years,C0449238;C0449238;C2926735;C2926735,9659/10465
duration ofdiabetes — yr,,9660/10465
duration of diabetes ( years ),C0449238;C0449238;C2926735;C2926735,9661/10465
duration of diabetes — yr,,9662/10465
duration of diabetes  yrs,C0449238;C0449238;C2926735;C2926735,9663/10465
duration of diabetes ( y ),C0449238;C0449238;C2926735;C2926735,9664/10465
duration of diabetes ( years ) t,C0449238;C0449238;C2926735;C2926735,9665/10465
duration diabetes ( years ),C0449238;C0449238;C2926735;C2926735,9666/10465
at index event,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,9667/10465
index event,C0600653;C0600653;C0918012;C0918012;C1552854;C1552854;C1637833;C1637833;C2986546;C2986546,9668/10465
moderate ckd,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,9669/10465
moderate ’,,9670/10465
moderatey,,9671/10465
no moderate ckd,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,9672/10465
moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335,9673/10465
weight < nmbr . nmbr kg  n,C0005910;C0043100;C1305866;C1705104,9674/10465
weight $ nmbr . nmbr kg  n,C0005910;C0005910;C0005910;C0005910;C0005910;C0005910;C0043100;C0043100;C0043100;C0043100;C0043100;C0043100;C1305866;C1305866;C1305866;C1305866;C1305866;C1305866;C1705104;C1705104;C1705104;C1705104;C1705104;C1705104,9675/10465
history of microvascular disease,C0683519;C0730226;C0850708;C0944983,9676/10465
history of macrovascular disease,C0683519;C0730226;C0850708;C0944983,9677/10465
disease duration  years,C0872146,9678/10465
disease duration ( years ),C0872146,9679/10465
disease duration ( yr ),C0872146,9680/10465
glycated hemoglobin  nonstandardized level — %,,9681/10465
glycated hemoglobin  standardized level — %,,9682/10465
baseline characteristics,C4684572,9683/10465
baseline characteristic,C0168634;C1442488,9684/10465
patients without chronic,C0030705,9685/10465
patients with chronic,C0030705,9686/10465
baseline egfr < nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,9687/10465
baseline egfr < nmbr ml / min / nmbr . nmbr mnmbrc,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,9688/10465
baseline egfr > nmbr ml / min / nmbr . nmbr mnmbr,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,9689/10465
ldl - c  mean ( sd ),,9690/10465
tchdl - c  mean ( sd ),,9691/10465
hdl - c  mean ( sd ),C3715113,9692/10465
symptomatic pad,C0231220;C0231220;C0231220;C0231220;C0231220;C0231220,9693/10465
symptomatic padt,C0231220,9694/10465
statin during admission,C0360714;C0360714,9695/10465
no statin during admission,C0360714;C0360714,9696/10465
rosuvastatin events / patients ( % ),C0965129;C0965129,9697/10465
rosuvastatin  events / patients ( % ),C0965129,9698/10465
average weekly mtx dose ( mg / week ),C1510992;C2825518,9699/10465
average weekly mtx dose ( mg / week ) t,C1510992;C2825518,9700/10465
all teaes *,,9701/10465
all teaes,,9702/10465
mild teaes,C2945599,9703/10465
sbp  mean ± sd ( mmhg ),,9704/10465
dbp  mean ± sd ( mmhg ),,9705/10465
death ( all - cause ),C0011065;C1306577;C4082313;C4552775,9706/10465
death ( all cause ),C0011065;C1306577;C4082313;C4552775,9707/10465
qnmbr : > nmbr . nmbr kg ( n = nmbrvsnmbr ),,9708/10465
qnmbr : < nmbr . nmbr kg ( n = nmbrvsnmbr ),,9709/10465
> = nmbr years ( placebo n = nmbr  nmbr  saxagliptin n = nmbr  nmbr ),,9710/10465
< nmbr years ( placebo n = nmbr  nmbr  saxagliptin n = nmbr  nmbr ),C0053917;C1334884,9711/10465
without psoriasis ( zi = nmbr  nmbr ),C0033860,9712/10465
without psoriasis ( n = nmbr  nmbr ),C0033860,9713/10465
heart rate > nmbr bpm,C0018810,9714/10465
heart rate < nmbr bpm,C0018810,9715/10465
inferior,C0542339;C0678975,9716/10465
non - anterior,C1518422,9717/10465
nonanterior,,9718/10465
not anterior,C1518422,9719/10465
anterior,C0205094,9720/10465
hyperlipidaemia,C0020473;C0428465;C4555212,9721/10465
hyperlipidemia,C0020473;C0428465;C4555212,9722/10465
hyperlipidemia^,C0020473;C0428465;C4555212,9723/10465
left - sided colitisz,C0205091;C0443246,9724/10465
left sided colitis,C2887821,9725/10465
left - sided colitis,C2887821,9726/10465
nadroparin ( n = nmbr ),C0206232,9727/10465
no nadroparin ( n = nmbr ),C0206232,9728/10465
social functioning,C0037395,9729/10465
social function,C0037395,9730/10465
eze / simva,,9731/10465
ez / simva,C0206578,9732/10465
aniagonisi,,9733/10465
antagonist,C0231491,9734/10465
all - cause death n,C0015127;C0015127;C0015127;C0015127;C1524003;C1524003;C1524003;C1524003,9735/10465
all - cause death,C0015127;C0015127;C0015127;C0015127;C1524003;C1524003;C1524003;C1524003,9736/10465
family history of cancera,C0241889,9737/10465
family history of cancerf,C0241889,9738/10465
indacaterol nmbr mg,C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260;C1722260,9739/10465
indacaterol nmbr pg,C1722260;C1722260;C1722260;C1722260;C1722260;C1722260,9740/10465
p  regional difference,C0369773;C2603361,9741/10465
p  regional difference *,C0369773;C2603361,9742/10465
liraglutide nmbr . nmbr mg  n = nmbr,C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,9743/10465
liraglutide nmbr . nmbr mg n = nmbr,C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,9744/10465
liraglutide nmbr - nmbr mg ( n = nmbr ),C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,9745/10465
liraglutide nmbr . nmbr mg ( n = nmbr ),C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408;C1456408,9746/10465
fevnmbr pre - bronchodilator,C2599602,9747/10465
fevnmbr post - bronchodilator,,9748/10465
ace inhibitors / arbs  n ( % ),C0003015,9749/10465
ace - inhibitors / arbs  n ( % ),C0003015,9750/10465
increase creatinine  < nmbr . nmbr mg / dl,C0442805;C0442805,9751/10465
increase creatinine  > nmbr . nmbr mg / dl,C0442805;C0442805,9752/10465
> nmbr . nmbr ( % ),C0053917;C1334884,9753/10465
< nmbr . nmbr ( % ),C0053917;C1334884,9754/10465
baseline lipid and lipoprotein values,C0168634;C1442488,9755/10465
baseline lipid / lipoprotem values,C0168634;C1442488,9756/10465
baseline lipid / lipoprotein values,C0168634;C1442488,9757/10465
previous stroke *,C0205156;C0205156;C1552607;C1552607,9758/10465
previous stroke,C0205156;C0205156;C1552607;C1552607,9759/10465
hypertension — no . ( % ),,9760/10465
hypertension — no . ( % ) |,,9761/10465
overall ( n = unmbr ),C0282416;C1561607,9762/10465
overall ( n = nmbr ),C0282416;C1561607,9763/10465
history of diabetes :,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,9764/10465
history of diabetes,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,9765/10465
beta - blockers  n ( % ),C0001645,9766/10465
beta - blockers  ( % ),C0001645,9767/10465
history of hypertension *,C0455527,9768/10465
history of hypertension,C0455527,9769/10465
ischemic heart disease  ( % ),C0010054;C0151744,9770/10465
ischemic heart disease  n ( % ),C0010054;C0151744,9771/10465
ischaemic heart disease  n ( % ),C0010054;C0151744,9772/10465
patients receiving enl  no . ( % ),C0030705,9773/10465
patients receiving lcz  no . ( % ),C0030705,9774/10465
urinary albumin : creatinine ratioa ( mg / g ),C2362049,9775/10465
urinary albumin : creatinine ratio ( mg / g ),C2362049,9776/10465
indian ( american ) or alaska native,C1524069,9777/10465
indian ( american ) or alaskan native,C1524069,9778/10465
saxagliptin nmbr mg,C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934;C1611934,9779/10465
saxagliptin nmbrmg,C1611934,9780/10465
mssbp < nmbrmmhg,,9781/10465
mssbp > nmbrmmhg,,9782/10465
infarct localisation,C0021308;C0021308,9783/10465
infarct localization,C0021308;C0021308,9784/10465
placebo group ( n = nmbr ),C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408,9785/10465
placebo group ( n = nmbr ) f,C0032042;C0032042;C0032042;C0032042;C0032042;C0032042;C1696465;C1696465;C1696465;C1696465;C1696465;C1696465;C1706408;C1706408;C1706408;C1706408;C1706408;C1706408,9786/10465
sjc ( nmbr joints ),,9787/10465
sjc ( / nmbr joints ),,9788/10465
tjc ( / nmbr joints ),,9789/10465
tjc ( nmbr joints ),,9790/10465
oral anticoagulants,C0354604,9791/10465
oral anticoagulant,C0354604,9792/10465
ischemia,C0022116;C4321499,9793/10465
ischaemic,C0475224,9794/10465
disease characteristics,C0599878,9795/10465
disease characteristics *,C0599878,9796/10465
nyha functional class,C1882083;C1882083;C1882083,9797/10465
ara functional class,C0325983;C0325983;C0325983;C0325983;C0325983;C0325983;C0325983;C0325983;C0325983;C2316832;C2316832;C2316832;C2316832;C2316832;C2316832;C2316832;C2316832;C2316832;C3890184;C3890184;C3890184;C3890184;C3890184;C3890184;C3890184;C3890184;C3890184;C4282437;C4282437;C4282437;C4282437;C4282437;C4282437;C4282437;C4282437;C4282437;C4321455;C4321455;C4321455;C4321455;C4321455;C4321455;C4321455;C4321455;C4321455,9798/10465
teaes ( > nmbr % in any treatment group ) *,,9799/10465
teaes ( > nmbr % in any treatment group ),,9800/10465
history myocardial infarction,C0155668;C1275835,9801/10465
history of myocardial infarction,C1275835,9802/10465
acq - nmbr score *,C2919686;C2919686;C2919686;C2919686,9803/10465
npi - nmbr score *,C1412208;C1412208;C1412208;C1412208;C1549728;C1549728;C1549728;C1549728;C3539727;C3539727;C3539727;C3539727,9804/10465
acq - nmbr scoret,C2919686;C2919686,9805/10465
nmbr - h ppg ( mmol / l ),C0053917;C1334884,9806/10465
nmbr - h ppg ( mmol / l ) *,C0053917;C1334884,9807/10465
nmbr - h pg ( mmol / l ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,9808/10465
fvc post - bronchodilator,C3714541,9809/10465
fvc pre - bronchodilator,C3714541,9810/10465
baseline su dose < nmbr / nmbr maximal,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,9811/10465
baseline su dose > nmbr / nmbr maximal,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,9812/10465
mean sd ldl - c  mg / dl,C0444504;C2347634;C2348143,9813/10465
mean sd hdl - c  mg / dl,C0444504;C2347634;C2348143,9814/10465
laa closure,C0185003;C1521802,9815/10465
pfo closure,C0185003;C1521802,9816/10465
cdai < nmbr . nmbr *,C0683448;C1413248;C3273706,9817/10465
sdai < nmbr . nmbr *,C3871128,9818/10465
nyha class — no . ( % ) $,,9819/10465
nyha class — no . ( % ),,9820/10465
drug - eluting,C0013227;C1254351,9821/10465
drug eluting,C0013227;C1254351,9822/10465
homa - p,,9823/10465
homa - ir,C0022065;C0022071;C1448132,9824/10465
no . of patients with psa,,9825/10465
no . of patients with ra,,9826/10465
no . of patients with as,,9827/10465
ng ( n = nmbr  nmbr ),C0017887;C0028074,9828/10465
no ( n = nmbr  nmbr ),,9829/10465
nmbr ( n = nmbr  nmbr ),C0053917;C1334884,9830/10465
sf - nmbrvnmbr mcs  mean [sd],C0037712,9831/10465
sf - nmbrvnmbr pcs  mean [sd],C0037712;C0037712,9832/10465
regular ppi use,C0205272;C0205272;C0205272,9833/10465
no regular ppi use,C0205272;C0205272;C0205272,9834/10465
hospitalization for acs,C0019993;C0019993,9835/10465
hospitalization for,C0019993,9836/10465
hospitalization for hf,C0019993;C0019993;C0019993;C0019993,9837/10465
pbo + mtx to mtx,C0031962;C0031962,9838/10465
czp + mtx to mtx,C0054841;C0054841;C1861828;C1861828;C1872109;C1872109,9839/10465
tg  mg / dl  mean ± sd,,9840/10465
tc  mg / dl  mean ± sd,,9841/10465
tc  mg / dl  mean + sd,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122,9842/10465
aiirocumab,,9843/10465
alirocumab,C3491162,9844/10465
hispanic or latino ethnic groupf,C0086409,9845/10465
hispanic or latino ethnic group !,C0086409,9846/10465
hispanic or latino ethnic groupb,C0086409,9847/10465
hispanic or latino ethnic group *,C0086409,9848/10465
prior aspirin,C0332152;C2826257,9849/10465
no prior aspirin,C0332152;C2826257,9850/10465
medication  n ( % ),C0013227;C3244316;C4284232,9851/10465
medications  n ( % ),C0013227;C0802604;C2598133;C4284232,9852/10465
medication — no . ( % ),,9853/10465
medications . no . ( % ),C0013227;C0802604;C2598133;C4284232,9854/10465
medications  no . ( % ),C0013227;C0802604;C2598133;C4284232,9855/10465
eze + statin n = nmbr,C0360714,9856/10465
pbo + statin n = nmbr,C0031962,9857/10465
incidence *,C0021149;C0220856,9858/10465
incidence  %,C0021149;C0220856,9859/10465
incidencea,,9860/10465
asia  pacific and other,C0003980,9861/10465
asia pacific or other,C0003980,9862/10465
asia pacific and other,C0003980,9863/10465
apo b : apo a - i ratio,C0003593;C3252643,9864/10465
apob : apoal ratio,C0003593;C3252643,9865/10465
apob : apoa - l ratio,C0003593;C3252643,9866/10465
saxa + met n = nmbr,,9867/10465
dapa + met n = nmbr,,9868/10465
patients with uncomplicated events,C0030705;C0030705,9869/10465
patients with complicated events,C0030705;C0030705,9870/10465
sf - nmbr mcs  mean ± sd,,9871/10465
sf - nmbr pcs  mean ± sd,,9872/10465
systolic blood pressure subgroups,C0488055;C0871470;C1306620,9873/10465
diastolic blood pressure subgroups,C0428883;C1305849,9874/10465
losartan  n / n ( % ),C0126174,9875/10465
valsartan  n / n ( % ),C0216784,9876/10465
persistent,C0205322;C0332996,9877/10465
persistent af,C0205322;C0205322;C0332996;C0332996,9878/10465
ukpds nmbr - year risk score < nmbr %,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,9879/10465
ukpds nmbr - year risk score > nmbr %,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,9880/10465
sirolimus - eluting,C0072980,9881/10465
everolimus - eluting,C0541315,9882/10465
immunosuppressants,C0021081,9883/10465
immunosuppressant^^,C0021081,9884/10465
hdl - c  mg / dl  mean ± sd,,9885/10465
ldl - c  mg / dl  mean + sd,,9886/10465
ldl - c  mg / dl  mean ± sd,,9887/10465
hdl - c  mg / dl  mean + sd,C3715113,9888/10465
medication use,C0240320,9889/10465
medication,C0013227;C3244316;C4284232,9890/10465
education *,C0013621;C0013622;C0013658;C0039401,9891/10465
medications *,C0013227;C0802604;C2598133;C4284232,9892/10465
medications,C0013227;C0802604;C2598133;C4284232,9893/10465
sgrq total score * ( units ),C2964552,9894/10465
sgrq total score  units,C2964552,9895/10465
sgrq total score ( units ),C2964552,9896/10465
weight  median ( sd )  kg,C0005910;C0043100;C1305866;C1705104,9897/10465
weight  mean ( sd ) kg,C0005910;C0043100;C1305866;C1705104,9898/10465
weight  median ( iqr )  kg,C0005910;C0043100;C1305866;C1705104,9899/10465
weight  mean ( sd )  kg,C0005910;C0043100;C1305866;C1705104,9900/10465
diclofenac nmbr mg ( n nmbr nmbr )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091,9901/10465
diclofenac nmbr mg ( n nmbr nmbr )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091;C0012091,9902/10465
total no .,C0439175;C0439810,9903/10465
total body,C0229960,9904/10465
ind / gly ( n = nmbr ),C4049864;C4049864,9905/10465
ind + pbo ( n = nmbr ),C4049864,9906/10465
ind + gly ( n = nmbr ),C4049864;C4049864,9907/10465
score of $ nmbr  no . ( % ),C0449820;C0449820;C4050231;C4050231,9908/10465
score of # nmbr  no . ( % ),C0449820;C0449820;C4050231;C4050231,9909/10465
body - mass index ( kg / m ' ),C0005893;C0578022;C1305855,9910/10465
body - mass index ( kg / m - ) !,C0005893;C0578022;C1305855,9911/10465
body - mass index ( kg / m - ),C0005893;C0578022;C1305855,9912/10465
time to treatment initiation ( min ,C3494202;C3494202;C3494202,9913/10465
time to treatment initiation ( min ),C3494202;C3494202;C3494202,9914/10465
patients with microalbuminuria at baseline,C0030705,9915/10465
patients with macroalbuminuria at baseline,C0030705,9916/10465
atrial fibrillation !,C0004238;C0344434;C1963067,9917/10465
atrial fibrillation  %,C0004238;C0344434;C1963067,9918/10465
atrial fibrillation,C0004238;C0344434;C1963067,9919/10465
atrial fibrillation ( % ),C0004238;C0344434;C1963067,9920/10465
prior tnf antagonist treatment - no,C1514463,9921/10465
prior tnf antagonist treatment - yes,C1514463;C1514463;C1514463,9922/10465
pt baseline ( week nmbr ),C0032743;C0032743;C0699718;C0699718,9923/10465
db baseline ( week nmbr ),C1418892;C1418892,9924/10465
odds ratio ( nmbr % ci ),C0028873,9925/10465
odds ratio ( nmbr % cl ),C0028873,9926/10465
ethnicity  n ( % ),C0015031;C0243103,9927/10465
ethnicity  no . ( % ),C0015031;C0243103,9928/10465
ethnicity - no . ( % ),C0015031;C0243103,9929/10465
pacemaker  n ( % ),C0030163;C0810633;C1546728;C3275122;C3853703,9930/10465
pacemaker  ( % ),C0030163;C0810633;C1546728;C3275122;C3853703,9931/10465
physical examination,C0031809;C1744699,9932/10465
physical examinations,C0031809,9933/10465
ileum and colon,C0020885,9934/10465
ileum or colon,C0020885,9935/10465
killip class > ii ( % ),C2697845,9936/10465
killip class  n ( % ),C1881332,9937/10465
qrs < nmbr msec,,9938/10465
qrs > nmbr ms *,,9939/10465
hbanmbrc  %  mean ( sd ) b,,9940/10465
hbanmbrc  %  mean ( sd ),,9941/10465
hbanmbrc  %  mean ± sd,,9942/10465
< nmbr % blood eosinophils at baseline,C0053917;C0053917;C1334884;C1334884,9943/10465
> nmbr % blood eosinophils at baseline,C0053917;C0053917;C1334884;C1334884,9944/10465
czp nmbr mg ( n nmbr ),C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,9945/10465
czp nmbr mg ( nnmbr ),C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C0054841;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1861828;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109;C1872109,9946/10465
age ( median  iqr )  y,C0001779,9947/10465
age  median ( iqr )  y,C0001779,9948/10465
atrial fibrillation / flutter,C0155709,9949/10465
atrial fibrillation or flutter,C0004238;C0344434;C1963067,9950/10465
metformin,C0025598,9951/10465
no metformin,C0025598,9952/10465
q wave,C0429089;C1305738,9953/10465
q wave mi,C0861151,9954/10465
q - wave mi,C0861151,9955/10465
hand fracture,C0435632,9956/10465
hip fracture,C0019557;C0149531;C4552776,9957/10465
canagliflozin ( n = nmbr ),C2974540,9958/10465
empagliflozin ( n = nmbr ),C3490348,9959/10465
smoking history,C1519384,9960/10465
smoking history ,C1519384,9961/10465
post - bronchodilator fevnmbr / fvc  %,C2599594,9962/10465
postbronchodilator fevnmbr / fvc  %,C2599594,9963/10465
smoker ( % ),C0337664,9964/10465
smoker ( % ) a,C0337664,9965/10465
ast  u / l,C1415181;C3891303,9966/10465
alt  u / l,C1266129;C4553172,9967/10465
non - hdl - c  mmol / l,C1518422,9968/10465
non - hdl - c ( mmol / l ),C1518422,9969/10465
menopause and ht,C0025320;C0567312,9970/10465
menopause and hrt,C0025320;C0567312,9971/10465
minimum - maximum,C1524031;C1524031;C1524031;C1552614;C1552614;C1552614;C2826545;C2826545;C2826545,9972/10465
minimum : maximum,C1524031;C1552614;C2826545,9973/10465
patients < nmbr %,C0030705,9974/10465
patients > nmbr %,C0030705,9975/10465
women ( n = nmbr vs nmbr ),C0043210,9976/10465
men ( n = nmbr vs nmbr ),C0025266,9977/10465
men ( n = nmbr nmbr ),C0025266,9978/10465
diastolic — mean ( sd ) ( mm hg ),,9979/10465
systolic — mean ( sd ) ( mm hg ),,9980/10465
active cancer,C0205177;C0205177;C0205177;C3853793;C3853793;C3853793;C3888249;C3888249;C3888249,9981/10465
no active cancer,C0205177;C0205177;C0205177;C3853793;C3853793;C3853793;C3888249;C3888249;C3888249,9982/10465
ac tve cancer,C0001246;C0001246;C0001246;C0003354;C0003354;C0003354;C1412573;C1412573;C1412573;C2000891;C2000891;C2000891;C3539770;C3539770;C3539770,9983/10465
physical activity  kcal / wk,C0015259;C0026606,9984/10465
physical activity  kcal / wk *,C0015259;C0026606,9985/10465
loop or thiazide diuretic,C0445022,9986/10465
loop or thiazide diuretic #,C0445022,9987/10465
alcohol use  drinks / wk,C0001948,9988/10465
alcohol use  drinks / wk *,C0001948,9989/10465
total population,C3258257,9990/10465
total population n,C3258257,9991/10465
interruption ( n = nmbr ),C0332453;C1512900,9992/10465
intervention ( n = nmbr ),C0184661;C0886296;C1273869,9993/10465
non - st - segment elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010;C1518422,9994/10465
non — st - segment — elevation myocardial infarction,,9995/10465
% risk reduction ( nmbr % ci ),C1137094,9996/10465
risk reduction ( nmbr % cl ),C1137094,9997/10465
use of beta - blocker,C1524063,9998/10465
use of beta - blockers,C1524063,9999/10465
hf hospitalization,C0018488;C1313497;C1538440;C3273279,10000/10465
hf hospitalization n,C0018488;C1313497;C1538440;C3273279,10001/10465
hospitalization,C0019993,10002/10465
r elative risk ( nmbr % ci ),C0205090;C0205090;C0684010;C0684010;C2603358;C2603358,10003/10465
relative risk ( nmbr % ci ),C0242492,10004/10465
relative risk ( nmbr % cl ),C0242492,10005/10465
> nmbr . nmbr ( n — nmbr ),,10006/10465
< nmbr . nmbr ( n — nmbr ),,10007/10465
mi > nmbr months *,C3810814,10008/10465
mi < nmbr months *,C3810814,10009/10465
> nmbr months — number / n ( % ),,10010/10465
< nmbr months — number / n ( % ),,10011/10465
all n = nmbr  nmbr,C0369718;C0441922,10012/10465
all n = nmbr nmbr,C0369718;C0441922,10013/10465
any clinical or lesion rf for st,C0205210,10014/10465
no clinical or lesion rfs for st,C0205210,10015/10465
neuropathy,C0442874,10016/10465
nephropathy,C0022658,10017/10465
hbanmbrc > nmbr % ( n nmbr nmbr ),,10018/10465
hbanmbrc < = nmbr % ( n nmbr nmbr ),,10019/10465
am △ 士 s . e .,,10020/10465
ama 士 s . e .,,10021/10465
im or cs use : no,,10022/10465
im and cs use : no,,10023/10465
hdlnmbr - c,,10024/10465
ldlnmbr - c,,10025/10465
at randomization,C0034656,10026/10465
randomization,C0034656,10027/10465
to randomization,C0034656,10028/10465
> nmbr years simva,C0053917;C1334884,10029/10465
< nmbr years simva,C0053917;C1334884,10030/10465
simvastatin nmbr mg ( n = nmbr ) *,C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554,10031/10465
simvastatin nmbr mg ( n = nmbr ),C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554;C0074554,10032/10465
hispanic or latino ( n — nmbr ),,10033/10465
hispanic or latino ( n = nmbr ),C0086409,10034/10465
copd exacerbation : yes,C0740304,10035/10465
copd exacerbation : no,C0740304,10036/10465
hdl cholesterol > nmbr - nmbr mmol / l,C0023822;C0392885,10037/10465
ldl cholesterol < nmbr - nmbr mmol / l,C0023824;C0202117,10038/10465
ldl cholesterol > nmbr - nmbr mmol / l,C0023824;C0202117,10039/10465
hdl cholesterol < nmbr - nmbr mmol / l,C0023822;C0392885,10040/10465
sex  female  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,10041/10465
sex ( male )  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,10042/10465
sex  male  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,10043/10465
sex  male  no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384,10044/10465
adjusted p - value for interaction,C0456081,10045/10465
unadjusted p - value for interaction,C1439367,10046/10465
no chd eze / simva,C0280604;C3542407,10047/10465
chd eze / simva,C0280604;C3542407,10048/10465
aspirin use ( p = nmbr - nmbrt ),C0004057;C0004057;C0004057,10049/10465
aspirin use ( p = nmbr - nmbr 十 ),,10050/10465
dapagliflozin nmbr mg ( n = nmbr ),C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951;C2353951,10051/10465
ertugliflozin nmbr mg ( n = nmbr ),C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805;C4079805,10052/10465
empagliflozin nmbr mg ( n = nmbr ),C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348;C3490348,10053/10465
prior coronary artery bypass grafting,C0332152;C2826257,10054/10465
prior coronary artery bypass graft,C0332152;C0332152;C2826257;C2826257,10055/10465
cholesterol ( mmol / l ),C0008377,10056/10465
cholesterol  mmol / l,C0008377,10057/10465
fevnmbr  litres ( pre ipratropium )  mean ( sd ),,10058/10465
fevnmbr  litres ( post ipratropium )  mean ( sd ),,10059/10465
insulin ( pmol / l ),C0021641;C1533581;C1579433;C3714501,10060/10465
insulin  pmol / l,C0021641;C1533581;C1579433;C3714501,10061/10465
proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - < median ( n = nmbr  nmbr ),C1100660,10062/10465
proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - > = median ( n = nmbr  nmbr ),C1100660,10063/10465
( mmol / l],C1532563,10064/10465
mmol / mol,C3829066,10065/10465
mmol / l,C1532563,10066/10465
wc ( cm ),C0013123;C2825512,10067/10465
rr ( cl ),,10068/10465
patient ' s global assessment,C4054229,10069/10465
patient ' s global assessment !,C4054229,10070/10465
patient ' s global assessment of,C4054229,10071/10465
no epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429,10072/10465
epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429,10073/10465
nitrates  ( % ),C0028125,10074/10465
nitrates  n ( % ),C0028125,10075/10465
cox hr ( nmbr % ci ),C1565830,10076/10465
cmh rr ( nmbr % ci ),C4554402,10077/10465
coronary revascularization,C0877341,10078/10465
coronary revascularisation,C0877341,10079/10465
n - nmbr pufa ( n = nmbr ),C0369718;C0369718;C0441922;C0441922,10080/10465
n - nmbr - pufa ( n = nmbr ),C0369718;C0369718;C0441922;C0441922,10081/10465
antihypertensive agents,C0003364,10082/10465
antihypertensive agents *,C0003364,10083/10465
mean ( sd )  y,C0444504;C2347634;C2348143,10084/10465
mean ( sd ) bmi,C0444504;C2347634;C2348143,10085/10465
non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = nmbr  nmbr ),C1535899,10086/10465
non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = nmbr  nmbr ),C1535899,10087/10465
aldosterone blocker,C0002006,10088/10465
aldosterone blockers,C0002006,10089/10465
adjusted hr ( nmbr % ci ),C0456081,10090/10465
adjusted hr ( nmbr % cl ),C0456081,10091/10465
cohort nmbr ( uacr < nmbr . nmbr mg / g ),C0009247;C0009247;C0599755;C0599755,10092/10465
cohort nmbr ( uacr > nmbr . nmbr mg / g ),C0009247;C0009247;C0599755;C0599755,10093/10465
no extensive colitis  n,C0205231;C0205231,10094/10465
extensive colitis  n,C0205231;C0205231,10095/10465
prior migraine,C0332152;C2826257,10096/10465
prior migraine *,C0332152;C2826257,10097/10465
primary endpoint death / mi / idr / st,C2986535;C2986535;C2986535;C2986535;C2986535;C2986535;C2986535;C2986535,10098/10465
primary end point : death / mi / idr / st,C2986535,10099/10465
difference from placebo,C1705241;C1705241;C1705241;C1705242;C1705242;C1705242,10100/10465
difference from placeboa,C1705241;C1705242,10101/10465
difference from placebo ¥,,10102/10465
standing after nmbr minute change from baseline,C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472,10103/10465
standing after nmbr minutes change from baseline,C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472;C0231472,10104/10465
american indian or alaskan native,C0002460,10105/10465
american indian / alaska native,C0002460,10106/10465
american indian or alaska native,C0002460,10107/10465
multiracial,C1881928,10108/10465
multi - racial,C0439064;C0439064;C0439064;C0439064;C3266262;C3266262;C3266262;C3266262,10109/10465
aqlq ( s ) + nmbr scored,C4055434,10110/10465
aqlq ( s ) + nmbr scorets,C4055434,10111/10465
antiarrhythmic,C0003195;C3537142,10112/10465
anti arrhythmic,C0003195;C3537142,10113/10465
ct findings,C0007673;C0007673;C0007673;C3540513;C3540513;C3540513;C3813556;C3813556;C3813556;C3888140;C3888140;C3888140,10114/10465
ecg findings,C0438154,10115/10465
lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C1096202;C1439335,10116/10465
lipoprotein ( a ) ( mmol / l ),C0065058;C0125953;C1096202;C1439335,10117/10465
baseline . mean _ sd  mg / dl,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,10118/10465
baseline . mean _ sd . mg / mg,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,10119/10465
baseline . mean _ sd . mg / dl,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,10120/10465
≤ nmbr u / kg / day,,10121/10465
> nmbr u / kg / day,C0053917;C1334884,10122/10465
valsartan,C0216784,10123/10465
bosentan,C0252643,10124/10465
losartan,C0126174,10125/10465
history of stroke,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,10126/10465
history of stroke *,C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,10127/10465
patients without syndesmophytes at baseline,C0030705,10128/10465
patients with syndesmophytes at baseline,C0030705,10129/10465
lipid - lowering,C0023779,10130/10465
lipid lowering,C0023779;C0023779,10131/10465
stratum ii,C1710602;C4082587,10132/10465
stratum i,C0021966;C0221138,10133/10465
aaponmbr at rest  mm hg,C0035253;C1622890,10134/10465
paonmbr at rest  mm hg,C0035253;C1622890,10135/10465
mean ( s . d . ) systolic blood pressure  mm hg,C0444504;C2347634;C2348143,10136/10465
mean ( s . d . ) diastolic blood pressure  mm hg,C0444504;C2347634;C2348143,10137/10465
> nmbr to < nmbr h  n ( % ),C0053917;C1334884,10138/10465
nmbr to < nmbr h  n ( % ),C0053917;C1334884,10139/10465
coronary artery disease^,C0010054;C0010068;C1956346,10140/10465
coronaiy artery disease,C0852949,10141/10465
coronary artery disease,C0010054;C0010068;C1956346,10142/10465
> o - nmbr - i - i,C0483204;C0483204;C0483204;C0483204,10143/10465
> o - nmbr - ii,C0483204;C0483204;C0483204;C0483204,10144/10465
egfr  ml / min / nmbr . nmbr mnmbr  mean ( sd ),C1739039;C3811844;C3812682,10145/10465
egfr  ml / min / nmbr . nmbr mnmbr  mean ± sd,,10146/10465
baseline fevnmbr,C0168634;C1442488,10147/10465
baseline fevnmbr #,C0168634;C1442488,10148/10465
nmbr ( n nmbr nmbr ),C0053917;C1334884,10149/10465
nmbr mg ( n nmbr nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,10150/10465
respiratory rate  breaths / min,C0231832;C0489258,10151/10465
respiratory rate ( breaths / min ),C0231832;C0489258,10152/10465
karnofsky score < nmbr,C0206065;C0206065,10153/10465
karnofsky score 竺 nmbr,,10154/10465
ldl - csmedian,,10155/10465
ldl - c > median,,10156/10465
non - hdl - c *,C1518422,10157/10465
non - hdl - c,C1518422,10158/10465
duration of pci — min,,10159/10465
duration of pci  min,C0449238;C2926735,10160/10465
mean ( s . d . ) bmi  kg / mnmbr,C0444504;C2347634;C2348143,10161/10465
mean ± s . d . bmi  kg / mnmbr,,10162/10465
baselinec,,10163/10465
( baseline ),C0168634;C1442488,10164/10465
baselineb,,10165/10465
baseline ,C0168634;C1442488,10166/10465
baseline,C0168634;C1442488,10167/10465
< nmbr . nmbr % ( nmbr mmol / mol ),C0053917;C1334884,10168/10465
≥ nmbr . nmbr % ( ≥ nmbr mmol / mol ),,10169/10465
inferior ( % ),C0542339;C0678975,10170/10465
anterior { % ),C0205094,10171/10465
age group  no . ( % ),C0027362;C2348001,10172/10465
age group  n ( % ),C0027362;C2348001,10173/10465
qualifying mi < nmbr yrs prior,C1514624,10174/10465
qualifying mi $ nmbr yrs prior,C1514624;C1514624,10175/10465
hawaiian / pacific islander,C0337920,10176/10465
hawaiian pacific islander,C0337920,10177/10465
bl mean ( mmhg ),C0005918;C0005918;C0005918;C0006413;C0006413;C0006413;C1552663;C1552663;C1552663;C2827109;C2827109;C2827109,10178/10465
bl mean ( cm ),C0005918;C0005918;C0005918;C0006413;C0006413;C0006413;C1552663;C1552663;C1552663;C2827109;C2827109;C2827109,10179/10465
no or unknown,,10180/10465
no / unknown,C0439673;C3541433;C4050014,10181/10465
loop diuretic,C0354100;C3536704,10182/10465
loop diuretics,C0354100,10183/10465
non diuretics,C1518422,10184/10465
esam ( ng / ml ),C1424976,10185/10465
ngal ( ng / ml ),C0215955;C1416806;C2346625,10186/10465
fevnmbr / fvc,C3714541,10187/10465
fevnmbr / fvc %,C3714541,10188/10465
history of diabetes ( a ),C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,10189/10465
history of diabetes ( % ),C0019664;C0019664;C0019665;C0019665;C0262512;C0262512;C0262926;C0262926;C1705255;C1705255;C2004062;C2004062,10190/10465
age : < nmbr years ( n = nmbr ),C0001779,10191/10465
age < nmbr years ( n = nmbr ),C0001779,10192/10465
age  years  mean ( range ),C0001779,10193/10465
age  years : median ( range ),C0001779,10194/10465
metabolic syndrome ( % ) b,C0524620,10195/10465
metabolic syndrome ( % ),C0524620,10196/10465
peripheral artery disease — no . ( % ),,10197/10465
peripheral - artery disease — no . ( % ),,10198/10465
aiorvasiaiin,,10199/10465
atorvastatin,C0286651,10200/10465
epa ( mol % ),,10201/10465
aa  mol %,C0282379;C1235746;C1882141;C4554792,10202/10465
epa  mol %,,10203/10465
cardiovasculardeath / myocardial infarction / stroke,C0027051;C0027051;C0428953;C0428953;C2926063;C2926063;C3810814;C3810814;C4552959;C4552959,10204/10465
cardiovascular death / myocardial infarction / stroke,C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051;C0027051,10205/10465
m o nito ring treatment,C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0369637;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923;C0441923,10206/10465
monitoring treatment,C0150369;C0150369;C0150369;C0150369;C0150369;C0150369;C0150369;C1283169;C1283169;C1283169;C1283169;C1283169;C1283169;C1283169,10207/10465
baseline focal seizure frequency / nmbr days  median ( qnmbr  qnmbr ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,10208/10465
baseline focal seizure frequency / nmbr days  median ( qnmbr - qnmbr ),C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,10209/10465
thiazide diuretics,C0012802,10210/10465
thiazide diuretic,C0012802;C3536861,10211/10465
diabetes present nmbr ( nmbr . nmbr ),C0011847;C0011847;C0011847;C0011847;C0011849;C0011849;C0011849;C0011849,10212/10465
diabetes absent nmbr ( nmbr . nmbr ),C0011847;C0011847;C0011847;C0011847;C0011849;C0011849;C0011849;C0011849,10213/10465
baseline medication,C0168634;C0168634;C0168634;C1442488;C1442488;C1442488,10214/10465
baseline cv medications,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,10215/10465
baseline medications,C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488,10216/10465
calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611,10217/10465
calcium antagonist,C0006684,10218/10465
calcium antagonists,C0006684,10219/10465
at qualifying event,C1514624;C1514624,10220/10465
qualifying event,C1514624;C1514624,10221/10465
nmbr - nmbr . nmbr : obese class ii,C0053917;C1334884,10222/10465
nmbr - nmbr . nmbr : obese class i,C0053917;C1334884,10223/10465
white race — no . ( % ) f,,10224/10465
white race — no . ( % ) : t,,10225/10465
white race — no . ( % ) :,,10226/10465
ileocolon,,10227/10465
lleocolon,,10228/10465
tiotropium nmbrmg ( n = nmbr,C0213771,10229/10465
tiotropium nmbr mg ( n = nmbr ),C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771;C0213771,10230/10465
multi - vessel coronary artery disease,C1299432,10231/10465
multivessel coronary artery disease,C0010054;C0010068;C1956346,10232/10465
mean ± sd msdbp  mm hg,,10233/10465
mean sd mssbp  mm hg,C0444504;C2347634;C2348143,10234/10465
mean age  y ( sd ),C0444504;C2347634;C2348143,10235/10465
mean age ( y ) ( sd ),C0444504;C2347634;C2348143,10236/10465
age in nmbr classes,C0001779;C0001779;C0001779;C0001779;C0001779;C0001779;C0001779;C0001779,10237/10465
egfr in nmbr classes,C1739039;C1739039;C1739039;C1739039;C1739039;C1739039;C1739039;C1739039;C3811844;C3811844;C3811844;C3811844;C3811844;C3811844;C3811844;C3811844;C3812682;C3812682;C3812682;C3812682;C3812682;C3812682;C3812682;C3812682,10238/10465
heart rate  bpm,C0018810,10239/10465
heart rate — bpm,,10240/10465
heart rate ( bpm ),C0018810,10241/10465
biguanide ( metformin ),C0005382;C3537187;C4317165,10242/10465
biguanides ( metformin ),C0005382;C0360396;C3540012,10243/10465
naive : no,,10244/10465
naive : yes,,10245/10465
no steroids ( n = nmbr vs nmbr ),C0038317,10246/10465
steroids ( n = nmbr vs nmbr ),C0038317,10247/10465
secondary ' outcomes,C0027627;C0175668;C0205436,10248/10465
secondary outcomes,C0027627;C0175668;C0205436,10249/10465
clopidogrel,C0070166,10250/10465
clopiodogrel,,10251/10465
antiplatelet - onl group ( n = nmbr ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429,10252/10465
antiplatelet - only group ( n = nmbr ),C0205171;C0205171;C0205171;C0205171;C0205171;C0205171;C1720467;C1720467;C1720467;C1720467;C1720467;C1720467,10253/10465
myopathyt,,10254/10465
myopathy,C0026848,10255/10465
baseline hdl - c in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,10256/10465
baseline trl - c in nmbr classes,C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C0168634;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488;C1442488,10257/10465
with diabetes,C0011847;C0011849,10258/10465
without diabetes,C0011847;C0011849,10259/10465
treated vessel,C1522326,10260/10465
treated vessel !,C1522326,10261/10465
estimated glomerular filtration rate - ml / min / nmbr . nmbrmnmbrtt,C3811844;C3811844,10262/10465
estimated glomerular filtration rate ( ml / min / nmbr . nmbrmnmbr ),C3811844,10263/10465
inferior or posterior,C0542339;C0678975,10264/10465
inferior / posterior,C0542339;C0678975,10265/10465
weight > nmbr kg,C0005910;C0043100;C1305866;C1705104,10266/10465
weight < nmbr kg,C0005910;C0043100;C1305866;C1705104,10267/10465
systolic ( mean  sd ),C0039155,10268/10465
diastolic ( mean  sd ),C0012000,10269/10465
tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr,C0053917;C1334884,10270/10465
tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr,C0053917;C1334884,10271/10465
patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr at baseline,C0030705;C0030705;C0030705,10272/10465
patients with egfr < nmbr ml / min / nmbr . nmbrmnmbr at baseline,C0030705;C0030705;C0030705,10273/10465
baseline hbanmbrc > nmbr . nmbr %,C0168634;C1442488,10274/10465
baseline hbanmbrc < nmbr . nmbr %,C0168634;C1442488,10275/10465
nmbr . nmbr - nmbr . nmbr % f,C0053917;C1334884,10276/10465
nmbr . nmbr - nmbr . nmbr % t,C0053917;C1334884,10277/10465
number of stents,C0237753;C0449788,10278/10465
number of patients,C2360800,10279/10465
tjc ( nmbr joints )  mean ( sd ),,10280/10465
sjc ( nmbr joints )  mean ( sd ),,10281/10465
body mass index  median ( iqr ) b,C0005893;C0578022;C1305855,10282/10465
body mass index  median ( iqr ),C0005893;C0578022;C1305855,10283/10465
all other,,10284/10465
all others,C1955473;C3539125,10285/10465
secondary *,C0027627;C0175668;C0205436,10286/10465
secondary pci,C0027627;C0175668;C0205436,10287/10465
no . of prior aeds  n ( % ),,10288/10465
no . of prior aeds  c n ( % ),,10289/10465
( mean change  nmbr % ci ),C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,10290/10465
( mean % change  nmbr % ci ),C0444504;C0444504;C0444504;C0444504;C2347634;C2347634;C2347634;C2347634;C2348143;C2348143;C2348143;C2348143,10291/10465
hazard ratiof,C0598697,10292/10465
hazard ratio,C2985465,10293/10465
prior myocardial infarction yes,C0155668;C0155668;C0155668,10294/10465
prior myocardial infarction  %,C0155668,10295/10465
dpp - nmbr inhibitor,C1414174;C1414174,10296/10465
dpp - nmbr inhibitors,C1414174;C1414174,10297/10465
ldl - c / hdl - c ratio,C0428621,10298/10465
ldl - c : hdl - c ratio,,10299/10465
modified has - bled $ nmbr,C0392747;C3889737,10300/10465
modified has - bled < nmbr,C0392747;C3889737,10301/10465
subgroup,C1079230;C1515021,10302/10465
subgroups,C1079230,10303/10465
old stroke *,C1536121,10304/10465
new stroke *,C0205314;C0205314,10305/10465
low risk,C3272281;C3538919,10306/10465
lower risk,C3272281;C3538919,10307/10465
high - intensity statin,C4081854,10308/10465
high - intensity statin *,C4081854,10309/10465
no high - intensity statin,C4081854,10310/10465
smoker  ! n ( % ),C0337664,10311/10465
smokers  n ( % ),C0337664,10312/10465
ics use yes / no  %,C0815320;C4551720,10313/10465
ics use  yes / no %,C0815320;C4551720,10314/10465
ics use  yes / no  %,C0815320;C4551720,10315/10465
present smokerc,C0150312;C0449450,10316/10465
present smoker,C0150312;C0449450,10317/10465
p - value ( int ),C1709380,10318/10465
p value ( int ),C1709380,10319/10465
alteplase,C0032143,10320/10465
reteplase,C0256103,10321/10465
western europe / australia,C0043128;C0043129,10322/10465
western europe and australia,C0043129,10323/10465
geographical region,C0017446,10324/10465
geographic region,C0017446,10325/10465
tiotropium nmbr mg respimat ® ( n z nmbr ),,10326/10465
tiotropium nmbr mg respimat ® ( n = nmbr ),,10327/10465
body - mass index > nmbr  n ( % ),C0005893;C0578022;C1305855,10328/10465
body mass index > nmbr  n ( % ),C0005893;C0578022;C1305855,10329/10465
pbo + mtx n = nmbr,C0031962;C0031962,10330/10465
czp + mtx n = nmbr,C0054841;C0054841;C1861828;C1861828;C1872109;C1872109,10331/10465
ef < nmbr % hfref ( n = nmbr  nmbr % ),,10332/10465
ef > nmbr % hfpef ( n = nmbr  nmbr % ),,10333/10465
macroalbuminuria at baseline ( nmbr % of patients treated ),C0168634;C1442488,10334/10465
microalbuminuria at baseline ( nmbr % of patients treated ),C0730345;C0730345,10335/10465
any coronary artery disease,C0010054;C0010068;C1956346,10336/10465
only coronary artery disease,C0205171;C0205171;C0205171;C1720467;C1720467;C1720467,10337/10465
estimated gfr < nmbr ml / min / nmbr . nmbr mnmbr,C0750572;C0750572,10338/10465
estimated gfr > nmbr ml / min / nmbr . nmbr mnmbr,C0750572;C0750572,10339/10465
female patients  n ( % ),C0150905,10340/10465
male patients  n ( % ),C0150904,10341/10465
history  pack - years,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,10342/10465
history ( pack - years ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,10343/10465
duration of diabetes > nmbr years,C0449238;C0449238;C2926735;C2926735,10344/10465
duration of diabetes < nmbr years,C0449238;C0449238;C2926735;C2926735,10345/10465
structural heart disease §,,10346/10465
structural heart disease,C1290384,10347/10465
no family history of chd ( n = nmbr  nmbr ),C0241889;C0241889,10348/10465
family history of chd ( n = nmbr  nmbr ),C0241889;C0241889,10349/10465
subcortical wml load diameter  mm  mean ( sd ),C0815275;C0815275;C0815275,10350/10465
subcortical wml load diameter  mm   mean ( sd ),C0815275;C0815275;C0815275,10351/10465
etoricoxib nmbr mg ( n nmbr nmbr )  . . . n . . . ( . % . . ) . . . . . . . . . . .,C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314,10352/10465
etoricoxib nmbr mg ( n nmbr nmbr )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314;C0972314,10353/10465
glycoprotein iib / iiia inhibitor,C0016011,10354/10465
glycoprotein iib / iiia inhibitors,C0016011,10355/10465
with acei / arb,C3888198,10356/10465
without acei / arb,C3888198,10357/10465
corticosteroid or immunosuppressant,C0001617;C3536709,10358/10465
corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727,10359/10465
corticosteroid and immunosuppressant,C0001617;C3536709,10360/10465
egfr < nmbr ml / min,C1739039;C3811844;C3812682,10361/10465
egfr > nmbr ml / min,C1739039;C3811844;C3812682,10362/10465
st - segment — elevation myocardial infarction,,10363/10465
st - segment elevation myocardial infarction,C1536220,10364/10465
patients with psoriasis ( n = nmbr ),C0030705,10365/10465
patients without psoriasis ( n = nmbr ),C0030705,10366/10465
egfr < nmbr ml / min / nmbr . nmbr mz,C1739039;C3811844;C3812682,10367/10465
egfr > nmbr ml / min / nmbr . nmbr mz,C1739039;C3811844;C3812682,10368/10465
age > nmbr years ( median ),C0001779,10369/10465
age < nmbr years ( median ),C0001779,10370/10465
no . pts,C1419129;C2698747,10371/10465
no . men,C0025266,10372/10465
nmbr mg qw nmbr . nmbr pt yrs,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,10373/10465
nmbr mg biw nmbr . nmbr pt yrs,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,10374/10465
fasting plasma glucose ( mg / dl ),C0015663;C0015663,10375/10465
fasting plasma glucose — mg / dl,,10376/10465
antidiabetic medications,C0935929,10377/10465
antidiabetic medication,C0935929,10378/10465
ldl - c ( median  iqr )  mg / dl,,10379/10465
hdl - c ( median  iqr )  mg / dl,C3715113,10380/10465
nonischemic cardiomyopathy,C0878544,10381/10465
ischaemic cardiomyopathy,C0349782,10382/10465
ischemic cardiomyopathy,C0349782,10383/10465
no ilb / iiia inhibitors,C4697913,10384/10465
ilb / iiia inhibitors,C4697913,10385/10465
nontatal ml,C0439526;C1705224;C3887665,10386/10465
nonfatal ml,C0439526;C1705224;C3887665,10387/10465
no of events women men *,C0441471;C3541888,10388/10465
no of events womenmen *,C0441471;C3541888,10389/10465
demographic features,C0683970,10390/10465
demographic feature,C0683970,10391/10465
non - epa ( n = nmbr ),C1518422,10392/10465
non - us ( n = nmbr ),C1518422,10393/10465
heart failure *,C0018801;C0018802;C4554158,10394/10465
heart failure,C0018801;C0018802;C4554158,10395/10465
heart failurea,C0018787,10396/10465
acetylsalicylic acid,C0004057,10397/10465
acetyl - salicylic acid,C0004057,10398/10465
difference ( % ),C1705241;C1705242,10399/10465
difference ( se ),C1705241;C1705242,10400/10465
exercise > once weekly,C0015259;C1522704,10401/10465
exercise > once weekly ?,C0015259;C1522704,10402/10465
nmbr - nmbr days ( % ),C0053917;C1334884,10403/10465
nmbr - nmbr yr ( % ),C0053917;C1334884,10404/10465
number stent > nmbr,C0237753;C0449788,10405/10465
number ste  t > nmbr,C0237753;C0237753;C0237753;C0237753;C0449788;C0449788;C0449788;C0449788,10406/10465
most common concomitant aeds  d n ( % ),C0205393;C0205393;C0205393,10407/10465
most common concomitant aeds  n ( % ),C0205393;C0205393;C0205393,10408/10465
> nmbr % to < nmbr % ( > nmbr to nmbr mmol / mol ),C0053917;C1334884,10409/10465
> nmbr % to < nmbr % ( > nmbr to < nmbr mmol / mol ),C0053917;C1334884,10410/10465
baricitinib nmbr mg ( n = nmbr ),C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947,10411/10465
baricitinib nmbr mg qd ( n = nmbr ),C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947;C4044947,10412/10465
alcohol consumption,C0001948,10413/10465
alcohol consumption !,C0001948,10414/10465
sri response  %,C1420401;C1420401;C1420401;C1420401,10415/10465
acr response  %,C1412134;C1412134;C1412134;C1412134;C1515941;C1515941;C1515941;C1515941,10416/10465
endpoint / baseline,C2349179;C2349179;C2826544;C2826544,10417/10465
endpoint / baselinec,C2349179;C2826544,10418/10465
ranozaline,,10419/10465
ranolazine,C0073633,10420/10465
left anterior descending coronary artery,C0226032,10421/10465
l eft anterior descending coronary artery,C0439394;C1706495;C3642217,10422/10465
renal subgroup,C0022646;C0022646,10423/10465
female subgroup,C0043210;C0043210;C0086287;C0086287;C1705497;C1705497;C1705498;C1705498,10424/10465
ss < nmbr ( n = nmbrvsnmbr ),C2699257;C2699257;C3891295;C3891295;C4551874;C4551874,10425/10465
ss > nmbr ( n = nmbrvs nmbr ),C2699257;C2699257;C3891295;C3891295;C4551874;C4551874,10426/10465
transient ischemic attack,C0007787;C0917805,10427/10465
transient ischaemic attack,C0007787;C0917805,10428/10465
nmbr mg ew n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,10429/10465
nmbr mg eow n = nmbr,C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,10430/10465
phgada ( mm ),,10431/10465
ptgada ( mm ),,10432/10465
patient ' s assessment of pain !,C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0030705,10433/10465
patient ' s assessment of pain,C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0679830;C0030705,10434/10465
lama ( only monotherapy ),C0999593;C1416775,10435/10465
laba ( only monotherapy ),,10436/10465
insulin glargine ( n = nmbr ),C0907402,10437/10465
insulin glargine ( n = nmbrll ),C0907402,10438/10465
secukinumab  nmbr mg ( n = nmbr ),C3179547,10439/10465
secukinumab nmbr mg ( n = nmbr ),C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547;C3179547,10440/10465
paroxysmal,C0205311,10441/10465
paroxysmal af,C0235480,10442/10465
history of major microvascular disease — no . ( % ),,10443/10465
history of major macrovascular disease — no . ( % ),,10444/10465
non - hdl cholesterol,C0729627;C1535899,10445/10465
non - hdl choleslerol,C1518422,10446/10465
insulin treated,C0021641;C1533581;C1579433;C3714501,10447/10465
insulin - treated,C0021641;C1533581;C1579433;C3714501,10448/10465
msdbp  mmhg ( sd ),,10449/10465
mssbp  mmhg ( sd ),,10450/10465
no prior statin ( n = nmbr  nmbr ),C0332152;C2826257,10451/10465
prior statin ( n = nmbr  nmbr ),C0332152;C2826257,10452/10465
fevnmbr ( liters ),,10453/10465
fevnmbr — liters,,10454/10465
systolic,C0039155,10455/10465
diastolic,C0012000,10456/10465
czp + mtx^mtx,C0054841;C0054841;C1861828;C1861828;C1872109;C1872109,10457/10465
pbo + mtx^mtx,C0031962;C0031962,10458/10465
history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,10459/10465
no history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062,10460/10465
stage nmbr : > = nmbr,C0205390;C0205390;C1300072;C1300072;C1306673;C1306673,10461/10465
stage nmbr : < nmbr,C0205390;C0205390;C1300072;C1300072;C1306673;C1306673,10462/10465
ato nmbr mg and sim nmbr^nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,10463/10465
ato nmbr mg and sim nmbr - nmbr mg ( n = nmbr ),C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C0053917;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884;C1334884,10464/10465
